Purinergic Signalling: Therapeutic Developments.

Introduction

Purinergic signalling, i.e., nucleotides as extracellular signalling molecules, was proposed in 1972 ( Burnstock, 1972 ). However, this concept was not well accepted until the 1990’s when receptor subtypes for purines and pyrimidines were cloned and characterised, which includes four subtypes of the P1 (adenosine) receptor, seven subtypes of P2X ion channel receptors, and eight subtypes of the P2Y G protein-coupled receptor ( Ralevic and Burnstock, 1998 ). Early studies were largely concerned with the physiology, pharmacology and biochemistry of purinergic signalling ( Burnstock, 2007 ). Adenosine 5′-triphosphate (ATP) is a cotransmitter with classical transmitters in both the peripheral and central nervous systems. In addition, purines are powerful extracellular messengers to non-neuronal cells, including secretory, exocrine and endocrine, endothelial, immune, musculo-skeletal and inflammatory cells ( Burnstock and Knight, 2004 ). Purinergic signalling is rapid in neurotransmission, neuromodulation and in secretion, but is also long-term in proliferation, differentiation, migration and death in development and regeneration ( Burnstock, 2016f ).

More recently, the focus has been on the pathophysiology and therapeutic potential of both P1 ( Chen et al., 2013 ; de Lera Ruiz et al., 2014 ; Layland et al., 2014 ; Liu and Xia, 2015 ; Borea et al., 2016 ) and P2 ( Burnstock and Kennedy, 2011 ; Bartlett et al., 2014 ; Ford et al., 2015 ; Burnstock, 2016e ) receptors. Reviews focussed on different aspects of purinergic pathophysiology are also available, including inflammatory and immune disorders ( Arulkumaran et al., 2011 ; Junger, 2011 ; Hansson et al., 2016 ); cancer ( Burnstock and Di Virgilio, 2013 ; Di Virgilio and Adinolfi, 2017 ); gout and fibrosis ( Gicquel et al., 2017 ); P2X7 receptors (R) as therapeutic targets ( Romagnoli et al., 2008 ); medicinal chemistry of purinoceptors ( Jacobson and Muller, 2016 ); pain ( Burnstock and Sawynok, 2010 ; Alves et al., 2013 ; Kuan and Shyu, 2016 ; Sawynok, 2016 ) and adenosine kinase inhibitors ( Kowaluk and Jarvis, 2000 ). A number of purine-related compounds have been patented. Therapeutic developments for disorders of different systems in the body will now follow. Reviews concerned with the early literature will be quoted, so the focus of this review will be concerned largely with the most recent findings.

Disorders of the Central Nervous System (CNS)

Investigations into purinergic signalling and its roles in disorders of the CNS have been reported, for instance following surgery, stroke, accidents and ischemia, neurodegenerative diseases (such as Parkinson’s, Alzheimer’s and Huntington’s diseases), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), epilepsy and neuropsychiatric disorders (including schizophrenia, depression and anxiety). Reviews covering this topic are available ( Burnstock, 2008b ; Burnstock et al., 2011 ), including the recent attention to the development of centrally penetrant P2X7R antagonists for the treatment of CNS disorders ( Burnstock and Verkhratsky, 2012 ; Puchalowicz et al., 2014 ; Sperlagh and Illes, 2014 ; Burnstock, 2015b ; Cisneros-Mejorado et al., 2015b ).

Neurodegenerative Diseases

Neurodegeneration in the CNS is associated with inflammation and damage to both neurons and glia ( Rama Rao and Kielian, 2015 ). Reviews are available that include coverage of early papers concerned with neurodegenerative diseases ( Puchalowicz et al., 2014 ; Santiago et al., 2014 ; Fasullo and Endres, 2015 ; Förster and Reiser, 2015 ; Burnstock, 2016a ; Fumagalli et al., 2016 ). Recent attention has been directed toward the use of P2X7R antagonists for the treatment of neurodegenerative diseases ( Metzger et al., 2017 ). However, adenosine acting via A 2A R has also been claimed as a promising therapeutic agent for the prevention and treatment of neurodegenerative diseases ( Cunha, 2016 ; Harmse et al., 2016 ; Olatunji et al., 2016 ).

Alzheimer’s Disease (AD)

There is progressive cognitive impairment in AD, with prominent deficits in short term memory. The potential of purinergic drugs for the treatment of AD has attracted much interest in recent years. Previous studies have led to the proposal that both P2X7R and P2Y 4 R antagonists are potential therapeutic targets for the treatment of AD ( Erb et al., 2015 ; Miras-Portugal et al., 2015 ; Woods et al., 2016 ). It has been suggested that the blockade of P2Y 1 R may have therapeutic potential against cognitive disturbances in AD ( Guzman and Gerevich, 2016 ). β-Amyloid increased release of ATP, which potentiated excitatory synaptic activity via P2XR, effects that were blocked by P2X antagonists ( Sáez-Orellana et al., 2016 ). The glycosylphosphatidylinositol-anchored prion protein binds to and modulates the expression of P2X4R, which may be involved in AD ( Carneiro et al., 2016 ). Recently, a potential role has been proposed for ATP-sensitive potassium channel (K ATP ) modulation as a therapeutic strategy against AD ( Salgado-Puga et al., 2017 ).

Adenosine A 3 R agonists suppress amyloid-β protein precursor internalisation and amyloid-β generation ( Li S. et al., 2015 ). Hippocampal adenosine A 2A R up-regulation is necessary to trigger memory dysfunction in AD ( Cunha, 2015 ).

Parkinson’s Disease (PD)

The involvement of adenosine A 2A R in PD and their interactions with dopamine receptors has attracted most attention (see Jenner, 2014 ). A 2A R antagonists have been proposed for the treatment of PD ( Jenner, 2014 ; Mori, 2014 ; Pinna, 2014 ; Navarro et al., 2016 ). K ATP ( Dragicevic et al., 2015 ) and P2X1R ( Gan et al., 2015 ; Navarro et al., 2016 ; Yang Z. et al., 2016 ) in PD have also been reported, perhaps indicating new therapeutic targets. Clinical trials istradefylline, an A 2A R antagonist, have taken place and it may have a beneficial effect in conjunction with commonly used anti-Parkinson’s therapies ( Tao and Liang, 2015 ; Uchida et al., 2015 ; Vorovenci and Antonini, 2015 ), although in a later study, istradefylline was shown to enhance amyloid-β generation and γ-secretase activity ( Lu et al., 2016 ). Oligomerisation kinetics of A 2A and dopamine D 2 R have important implications for PD ( Casadó-Anguera et al., 2016 ; Ferré et al., 2016 ; Guixà-González et al., 2016 ). Clinical trials for A 2A antagonists for PD are assessed in a review ( Navarro et al., 2016 ). A 2A R inhibition stopped rotenone-induced motor impairment in a rat model of PD ( Fathalla et al., 2016 ). A 1 as well as A 2A R antagonists were recommended as promising candidates for treatment of PD in a recent paper ( Essawy et al., 2017 ).

P2X7R antagonists have also been implicated in this disease ( Jörg et al., 2014 ; Wang et al., 2017 ). A P2X7R antagonist, brilliant blue G, was recently shown to be protective in a lipopolysaccharide (LPS) animal model of PD ( Wang et al., 2017 ).

Huntington’s Disease (HD)

Earlier studies reported that A 2A R agonists could be therapeutically useful for HD and that P2X7R antagonists inhibited neuronal apoptosis and attenuated body weight loss and motor co-ordination deficit in HD patients. Adenosine A 2A R inhibition reversed working memory deficits of HD at early stages models and it was proposed that A 2A R antagonists may therapeutically reverse the cognitive deficits in HD patients ( Li W. et al., 2015 ). In earlier publications, A 1 R agonists were suggested to be therapeutic targets ( Ferrante et al., 2014 ; Lee and Chern, 2014 ). It has been claimed that K ATP channels may be potential targets for treatment of HD ( Gupta and Sharma, 2014 ). Inhibition of equilibrative nucleoside transporter 1 enhances the adenosine level and may be a potential therapeutic approach for treating HD ( Kao et al., 2017 ).

Amyotrophic Lateral Sclerosis

Involvement of A 2A R, P2X4R and P2X7R in ALS has been reported ( Volonté et al., 2016 ). A 1 R have also been implicated in ALS ( Nascimento et al., 2015 ). Preconditioning with latrepirdine, an adenosine 5′-monophosphate (AMP)-activated protein kinase activator, was beneficial in the SOD1 mouse model of ALS ( Coughlan et al., 2015 ). A 2A R activation facilitated neuromuscular transmission in SOD1 mice during the pre-symptomatic but not symptomatic phase of the disease ( Nascimento et al., 2014 ). Pharmacological inhibition of A 2A R protects against degeneration of spinal motor neurons in the mouse SOD1G93A ALS model ( Ng et al., 2015 ).

P2X7R expression was significantly reduced, leading to Ca 2+ disturbances in peripheral blood mononuclear cells in ALS patients ( Liu J. et al., 2016 ). Low concentrations of endogenous ATP acting on P2X7R induced motor neuron death ( Gandelman et al., 2013 ). Spinal cord pathology was reduced by P2X7R inhibitors in the mouse SOD1 ALS model ( Apolloni et al., 2014 ).

Multiple Sclerosis

P2X7R and the P2YR-like GPR17 are involved in MS ( Plemel et al., 2014 ; Burnstock, 2015c ; Ou et al., 2016 ). There is upregulation of ecto-5′-nucleotidase (CD73) in experimental autoimmune encephalomyelitis, which is an MS animal model ( Lavrnja et al., 2015 ). Genetic variants in P2X7R affect susceptibility to MS ( Gu et al., 2015 ; Sadovnick et al., 2017 ).

Brain Injury, Neuroprotection, and Neuroregeneration

Brain Injury

The importance of inflammation in the responses to brain injury has been reviewed and the involvement of P1R and P2R ( Fiebich et al., 2014 ; Beamer et al., 2016 ) and of P2X7R in particular ( Burnstock, 2016b ; Giuliani A.L. et al., 2017 ). The roles of purinergic signalling in neurodegeneration as a consequence of brain injury, neuroprotection and neuroregeneration have been discussed in reviews ( Hu et al., 2014 ; Burnstock, 2016a ). Ectonucleotidase activities and nucleotide levels in serum are altered by brain stab injury ( Parabucki et al., 2014 ; Laketa et al., 2015 ). P2X7R antagonists appear to be effective as a treatment for radiation injury ( Xu et al., 2015 ). Astrocytic p -connexin 43 stimulates neuronic autophagy through P2X7R activation in the hippocampus, resulting in brain injury-induced cognitive deficit repair ( Sun L. et al., 2015 ). P2X7R antagonists have been implicated as a novel target to prevent secondary neurological injury after traumatic brain injury ( Kimbler et al., 2012 ) and after spinal cord injury ( Peng et al., 2009 ). P2X7R antagonists could be therapeutically effective to treat stroke patients ( Kuan et al., 2015 ). P2X7R stimulation in acute ischaemic stroke is beneficial by restricting early oedema formation and perhaps by modulating responses of glia ( Kaiser et al., 2016 ). Hypoxic-ischaemic brain injury increases intracellular Ca 2+ in oligodendrocytes, which is partly mediated by P2X7R ( Fern et al., 2014 ). P2X7R antagonists may provide a new target for the treatment of cerebral ischaemia ( Bai and Li, 2013 ; Yu Q. et al., 2013 ) and for the prevention of ischaemic damage to oligodendrocytes ( Domercq et al., 2010 ). P2X7 antagonists or inhibition of pannexin-1 channels reduced brain damage following ischaemia ( Cisneros-Mejorado et al., 2015a ; Mahi et al., 2015 ).

Activation of upregulated P2Y 1 R results in neuroblast migration to sites of brain damage ( Cao et al., 2015 ). Microglial P2Y 12 R activation follows neuronal injury ( Swiatkowski et al., 2016 ). A 2A R activation was suggested for the treatment of brain injury and subsequent neuroinflammation ( Dai and Zhou, 2011 ). A 2A R on cells derived from bone marrow modulate white matter lesions following chronic cerebral hypoperfusion ( Ran et al., 2015 ). Diadenosine tetraphosphate (Ap 4 A) may be a good candidate for traumatic spinal cord injury treatment ( Reigada et al., 2017 ). Adenosine kinase facilitated astrogliosis after traumatic brain injury and its inhibition in reactive astrocytes ameliorated astrogliosis-induced cell death ( Jin et al., 2016 ).

ATP and adenosine concentrations in the brain were significantly raised during brain ischaemia to stimulate P1R and P2R ( Cisneros-Mejorado et al., 2015b ; Pedata et al., 2016 ). P2X4R expressed by microglia are involved in post-ischaemic brain inflammation ( Cheng et al., 2014 ). P2X4R are required for neuroprotection via ischemic preconditioning ( Ozaki et al., 2016 ). Neuronal K ATP channels play a role in hypoxic preconditioning where they decrease neonatal hypoxic-ischaemic brain injury; it has been proposed that openers of K ATP channels may prove to be therapeutically beneficial ( Sun H.S. et al., 2015 ). Intranasal administration of guanosine reduced ischaemic brain damage in rats ( Ramos et al., 2016 ). Ambiguously, both A 2A R agonists and antagonists may protect against ischaemic brain injury ( Pedata et al., 2014 ). A 1 R contribute to immune responses following neonatal hypoxic ischaemic brain injury ( Winerdal et al., 2016 ). A valuable review of the involvement of P1R, P2XR and P2YR in brain ischemia is available ( Pedata et al., 2016 ).

Neuroprotection and Neuroregeneration

This topic is explored in recent reviews ( Rodrigues et al., 2015 ; Burnstock, 2016a ; Illes et al., 2016 ). Inhibition of P2XR and P2YR as well as activation of P1R following ATP breakdown to adenosine released from CNS cells, have been shown to be neuroprotective. Activation of the pannexin 1/P2X7R complex contribute to the neuroprotection that occurs after ischaemic pre- and post-conditioning ( Mahi et al., 2015 ). Docosahexaenoic acid in the diet is thought to be a purinergic modulator via P2XR where it protects against neurodegenerative diseases ( Molz et al., 2015 ). Neuroprotection mediated by microglia is associated with P2X7R activation and release of tumour necrosis factor-α ( Masuch et al., 2016 ). Blockade of P2X7R provides neuroprotection against stroke, traumatic brain injury and subarachnoid haemorrhage ( Zhao H. et al., 2016 ). P2X7R antagonists improve recovery after spinal cord injury ( Wang et al., 2004 ). From a recent study on P2Y 2 R knockout (KO) mice and murine cell lines, it was concluded that P2Y 2 R play a neuroprotective role in neurological disorders, especially AD ( de Diego-Garcia et al., 2017 ). Neuroprotection is claimed to be mediated by P2Y 13 nucleotide receptors in neurons ( Pérez-Sen et al., 2015 ). Activation of P2Y 2 R evokes regeneration of glial cells and nerves and the P2YR-like GPR17 evokes oligodendrocyte regeneration. Neural stem cell activation leads to neuroregeneration, probably via P2X4R and P2X7R. Reviews focused on the roles played by P2X4R and P2X7R ( Miras-Portugal et al., 2015 ) and A 2A R ( Ribeiro et al., 2016 ) in neurodegeneration and neuroprotection have been published.

Psychiatric Disorders

Several antipsychotic drugs (e.g., chlorpromazine, fluspirilene, and haloperidol) were found to antagonise responses mediated by P2XR. These antipsychotic drugs act therapeutically by inhibiting dopaminergic hyperactivity by suppressing P2X-mediated effects (see Burnstock, 2015b ). Brain penetrant P2X7R antagonists are being developed as drug targets for psychiatric diseases ( Bhattacharya and Biber, 2016 ). Reviews about purinergic signalling in psychiatric disorders, such as addiction, depression, schizophrenia, bipolar disorder and autism, have been previously published ( Yamada et al., 2014 ; Lindberg et al., 2015 ; Krügel, 2016 ). The possibility has been raised that P1R agonists might be beneficial in the therapy of psychiatric disorders ( Cieslak et al., 2016 ).

Schizophrenia

Adenosine neuromodulation in schizophrenia has received the most attention (see Rial et al., 2014 ; Ciruela et al., 2015 ; Turcin et al., 2016 ). Deletion of A 2A R from astrocytes interferes with glutamate homeostasis resulting in cognitive and psychomotor impairment in schizophrenia ( Matos et al., 2015 ). It has been suggested that P2X7R and pannexin 1 channels are involved (see Burnstock and Verkhratsky, 2012 ; Avendano et al., 2015 ).

Bipolar Disorder

P2X7R, mediating neuroinflammation via microglial activity, contribute to bipolar disorder (see Gubert et al., 2013 , 2016 ; Barron et al., 2014 ). Serum concentrations of uric acid increase in different clinical phases of bipolar disorder ( Albert et al., 2015 ) and in those patients treated with lithium ( Muti et al., 2015 ). The purinergic system may become dysregulated during manic episodes and it has been proposed that raised uric acid levels could be a useful indicator of bipolar disorder manic phases ( Bartoli et al., 2017a ). Purinergic modulators that reduce levels of uric acid may be therapeutically beneficial ( Bartoli et al., 2017b ). However, a decrease in serum adenosine levels in bipolar disorder patients was reported ( Gubert et al., 2016 ).

Depression and Anxiety

Reviews describing the roles of both P1 (A 1 and A 2A ) and P2X7R in mood disorders are available ( Yamada et al., 2014 ; Ortiz et al., 2015 ). Antidepressant effects of P2X7 antagonists have been reported ( Pereira et al., 2013 ; Zhang K. et al., 2016 ). P2X2R in the medial prefrontal cortex mediate the antidepressant-like actions of ATP released from astrocytes ( Cao et al., 2013 ). Brilliant blue G, a P2X7R antagonist, had antidepressant and anti-inflammatory actions in mice after LPS administration ( Ma et al., 2014 ). The P2X7R antagonist, A-804598, affected neuroimmune and behavioural features of stress ( Catanzaro et al., 2014 ). Stress-related mood disorders activate the inflammasome via release of ATP and stimulation of P2X7R ( Iwata et al., 2016 ). Co-expression of wild-type P2X7R with the polymorphism variant Gln460Arg alters receptor function associated with mood disorders ( Aprile-Garcia et al., 2016 ). Increased K ATP channel activity due to a mutation led to reduced anxiety in mice ( Lahmann et al., 2014 ). K ATP channels are involved in the pathogenesis of depression and may be a therapeutic target for this disorder ( Fan et al., 2016 ). Altered levels of several ATP-dependent chromatin remodelling factors may be linked to high trait anxiety ( Wille et al., 2016 ).

A 2A R antagonists were reported to have antidepressant activity ( Yamada et al., 2014 ). Creatine and ketamine had antidepressant effects, probably mediated by activation of A 1 R and A 2A R ( Cunha et al., 2015 ). Caffeine, acting as an A 2A R antagonist, prevented depression triggered by chronic stress ( Kaster et al., 2015 ; Dziubina et al., 2016 ). Striatal and extrastriatal A 2A R in the forebrain regulate fear responses in mice ( Wei et al., 2014 ). A 2A R mediated increased interleukin (IL)-1β in the brain contributed to anxiety ( Chiu et al., 2014 ). Fear and anxiety in a mouse model of post-traumatic stress disorder were alleviated by administration of a derivative of adenosine, WS0701 ( Huang et al., 2014 ). A 1 R agonists have been used to treat anxiety, but have troublesome side-effects so positive allosteric modulators have been developed as potent anxiolytic agents ( Vincenzi et al., 2016 ). An antidepressant-like effect of inosine in mice has been reported ( Gonçalves et al., 2017 ).

Autism

Adenosine in addition to suramin, a non-selective ATP antagonist, are reported to improve behaviour in autistic individuals ( Masino et al., 2013 ; Naviaux et al., 2014 , 2015 ; Hamidpour et al., 2016 ).

Addiction

Targeting A 2A R may offer strategies for combating drug addiction. Striatopallidal A 2A R signalling in the dorsomedial striatum has been suggested as a therapeutic target in drug addiction by reducing habit formation ( Li et al., 2016 ). Caffeine potentiates the addictive effects of drugs of abuse, including cocaine and amphetamine derivatives ( Ferrée, 2016 ).

Treatment of rodents with a P2X3R antagonist diminished opioid tolerance ( Tai et al., 2010 ) and tolerance to morphine-induced antinociception ( Ma et al., 2015 ). Lead-induced neuroinflammation via P2X7R may be responsible for the intensification of morphine tolerance ( Baranowska-Bosiacka et al., 2016 ). Opiate-induced changes in brain adenosine levels may be associated with opiate addiction and withdrawal ( Wu et al., 2013 ).

Adenosine, acting via A 2A R, regulates addiction induced by cocaine. Women are more sensitive to cocaine and are therefore more vulnerable to becoming addicted. Adenosine antagonists may be an effective treatment ( Broderick and Malave, 2014 ). A 2A -D 2 receptor-receptor interactions in the dorsal striatum are differentially affected by cocaine, which contributes to compulsive drug seeking ( Pintsuk et al., 2016 ).

Interactions between striatal A 2A and glutamate (mGlu5) receptors modulate the drug-seeking effects of methamphetamine ( Wright S.R. et al., 2016 ). Methamphetamine produces alterations in adenosine receptor expression in the nucleus accumbens ( Kavanagh et al., 2015 ). A 2A R antagonism in dorsomedial striatum reduces methamphetamine addiction ( Furlong et al., 2015 ). Adenosine A 2A R integrate the rewarding and motivational behaviours of methamphetamine ( Chesworth et al., 2016 ). Behavioural sensitisation provides a model in animals for drug craving that underlies human addiction and sensitisation to amphetamine was reduced by P2Y 1 R antagonists in the mesocortico-limbic dopaminergic system ( Krügel et al., 2013 ).

A 2A R agonist treatment can help counteract nicotine addiction ( Jastrzebska et al., 2014 ). A 2A R are a potential target for the treatment of alcohol abuse ( Micioni Di Bonaventura et al., 2012 ; Houchi et al., 2013 ). Regulation in adenosine signalling in striatal circuits in alcohol addiction was reviewed ( Nam et al., 2013 ). A 1 R signalling contributes to the regulation of basolateral amygdala excitability and to the pathophysiology of alcohol addiction ( Rau et al., 2014 ). A review of alcohol addiction discusses the role of adenosine ( Michalak and Biala, 2016 ). P2X4R modulate synaptic signalling associated with alcohol addiction ( Franklin et al., 2014 ; Khoja et al., 2016 ).

Epilepsy

Early focus was on the role of P1R in epileptic seizures, but P2X4R and P2YR, but especially P2X7R antagonists have been recently explored as neuroleptic agents (see Burnstock, 2015b ; Engel et al., 2016 ; Rassendren and Audinat, 2016 ; Beamer et al., 2017 ; Cieslak et al., 2017 ). Seizure-induced increases in microglial process numbers were reduced and kainate-induced seizure behaviours were exacerbated in P2Y 12 KO mice ( Eyo et al., 2014 ). Antiepileptic consequences of deep brain stimulation may be mediated by P1R activation ( Miranda et al., 2014 ). P2X3R expression was upregulated in epileptic rats and humans and it was postulated that P2X3R antagonists might be therapeutically effective ( Zhou X. et al., 2016 ). The release of adenosine and ATP during on-going epileptiform activity was measured with microelectrode biosensors ( Frenguelli and Wall, 2016 ). ATP levels were increased during epileptic seizures, which were not of neuronal origin ( Lietsche et al., 2016 ). There is an insightful Editorial about purinergic signalling-induced neuroinflammation in epilepsy ( Engel, 2016 ).

A role for post-transcriptional control of the P2X7R expression has been proposed and therapeutic targeting of microRNA-22 was suggested to prevent development of epilepsy and inflammation ( Jimenez-Mateos et al., 2015 ). Purinergic signalling, via P2X7R, regulates neonatal seizures associated with hypophosphatasia, an inherited metabolic bone disease characterised by spontaneous seizures ( Sebastián-Serrano et al., 2016 ). P2X7R antagonists were effective against hypoxia-induced neonatal seizures in mice ( Rodriguez-Alvarez et al., 2017 ).

Migraine

The role of ATP in migraine was initially suggested to involve vascular events (see Burnstock and Verkhratsky, 2012 ; Haanes and Edvinsson, 2014 ). Later, P2X3R in nociceptive brain areas, including the thalamus and trigeminal nucleus, were investigated and their interaction with P2Y 1 R in trigeminal neurons ( Hullugundi et al., 2014 ; Marchenkova et al., 2016 ). The therapeutic potential of antagonists to P2X7R for migraine treatment has been proposed ( Gölöncsér and Sperlágh, 2014 ), as well as P2X3R and P2X2/3R antagonists ( Kilinc et al., 2015 ; Yegutkin et al., 2016 ). Reviews have been published about the roles and therapeutic potential of purinergic signalling in the aetiology of migraine ( Cieslak et al., 2015 ; Yegutkin et al., 2016 ).

Neuropathic Pain

P1R and P2R involvement in neuropathic pain has been discussed in reviews ( Burnstock and Sawynok, 2010 ; Burnstock et al., 2011 ; Burnstock, 2014a , 2016c ). The discovery by Inoue and colleagues that antagonists to P2X4R on microglia are effective against neuropathic pain was particularly important (see Tsuda, 2016 ). Antagonists to P2X7R and P2Y 12 R also act on microglia to reduce neuropathic pain (see Tsuda and Inoue, 2016 ; Tsuda, 2017 ). A 3 R agonists delay the development of neuropathic pain ( Janes et al., 2016 ). Glial P2Y 2 R are potential targets for the management of trigeminal-related pain ( Magni et al., 2015 ). Pannexin 1 and P2X7R interactions have been suggested to play a role in chronic pain ( Bravo et al., 2015 ). P2X7R antagonists have been recommended for the treatment of central post-stroke pain ( Kuan et al., 2015 ). A review discusses the use of P2XR subtype antagonists for the treatment of central neuropathic pain ( Kuan and Shyu, 2016 ). Purinergic signalling in the spinal dorsal horn and anterior cingulate cortex appear to be involved in neuropathic pain ( Tsuda et al., 2017 ). P2X3 and P2X2/3R blockade has also been claimed to reduce chronic pain ( Cantin et al., 2012 ; Xu et al., 2012 ; Giniatullin and Nistri, 2013 ).

Brain Tumours

Neuroblastoma, a rare childhood tumour, expresses P2X7R, which mediate proliferation. The P2X7R appears to be a regulator of neuroblastoma metabolic activity, angiogenesis and growth and may be a target for neuroblastoma treatment ( Amoroso et al., 2015 ; Gomez-Villafuertes et al., 2015 ). The action of the antitumor agent, temozolomide, was increased by the antiproliferative actions of P2X7R agonists and antagonists to A 3 R and P2Y 1 R on human glioblastoma ( D’Alimonte et al., 2015 ). P2X4R may also be involved in human neuroblastoma ( Gualix et al., 2015 ).

P2X7R were over-expressed in human malignant gliomas and P2X7R antagonists decreased tumour cell numbers ( Fang et al., 2015 ; Morrone et al., 2016 ; McLarnon, 2017 ). Extracellular nucleotides control glioma growth via P2X7R and P2Y 6 R activation ( Braganhol et al., 2015 ). P2X7 and A 2A R activation leads to release of cytokines by macrophages, which was prevented by antagonists to these receptors ( Bergamin et al., 2015 ). P2X7R antagonists blocked the cell cytotoxicity caused by irradiation for glioma ( Gehring et al., 2015 ). Purine nucleoside phosphorylase is released from rat C6 glioma cells, contributing to the purinergic system homeostasis and exhibiting a pathophysiological role ( Giuliani P. et al., 2017 ).

It was claimed that K ATP channels are associated with tumorigenesis of human glioma ( Ru et al., 2014 ). A 3 R blockade enhances the actions of antitumour drugs used against human glioblastoma stem-like cells ( Torres A. et al., 2016 ). A 1 and A 2B R also sensitise glioblastoma stem cells to chemotherapy ( Daniele et al., 2014 ). P2Y 2 R interactions with caveolin-1 represents a novel target for human astrocytoma cells ( Martinez et al., 2016 ).

Sleep Disorders

P2Y 11 R appear to be associated with narcolepsy ( Kornum et al., 2011 ). Reduced endothelial dilation to ATP in cerebral arteries occurred in a rat model of obstructive sleep apnoea ( Crossland et al., 2013 ). Adenosine is a key player in the regulation and maintenance of sleep-wake dependent neural activity changes, where dysregulation can lead to sleep-wake disorders ( Holst et al., 2016 ). The A 2A R antagonist, SCH58261 , overcame the blood–brain barrier dysfunction as a result of sleep restriction ( Hurtado-Alvarado et al., 2016 ).

Cardiovascular Diseases

Reviews about this topic are available ( Erlinge and Burnstock, 2008 ; Headrick et al., 2013 ; Burnstock and Ralevic, 2014 ; Burnstock, 2015a ; Burnstock and Pelleg, 2015 ; Ralevic, 2015 ; Sousa and Diniz, 2017 ).

Heart Diseases

Heart Failure

In chronic heart failure adenosine accumulates, probably as a result of lowered adenosine deaminase (ADA) gene expression and raised CD73 activity. Adenosine therapy mediated by A 1 R and A 3 R is cardioprotective for chronic heart failure ( Greene et al., 2016 ; Voors et al., 2017 ). A 1 R agonists attenuate cardiac hypertrophy and prevent heart failure in a mouse model (left-ventricular pressure-overload) and in a rat model (neonatal cardiac myocyte) ( Chuo et al., 2016 ). A 2B R agonists exert stronger cardioprotective effects against cardiac ischaemia/reperfusion injury compared to A 2A R activation in rats ( Ke et al., 2015 ). CD73 and A 2B R agonists have been considered as therapeutic agents for myocardial ischaemia. Genetic deletion of CD39 results in increased myocardial ischaemia-reperfusion injury ( Smith et al., 2016 ). Inflammatory responses initiated during ischemia-mediated immune injury may be regulated by adenosine ( Boros et al., 2016 ).

Early studies were concerned with the role of adenosine in ischaemic and reperfusion injuries. However, there is also interest in the role of ATP. Application of ATP, prior to or just after cardiac ischaemia is cardioprotective ( Ren et al., 2016 ). ATP released from the ischaemic myocardium causes reflex responses mediated by cardiac sympathetic afferent nerves ( Dong et al., 2016 ). P2YR are important therapeutic targets in myocardial protection during ischemia/reperfusion ( Djerada et al., 2017 ). P2Y 6 R could be a therapeutic target to regulate cardiac hypertrophy ( Clouet et al., 2016 ). There is increased expression of P2Y 2 and P2X1R in the hearts of rats with congestive heart failure.

P2X4R are needed for neuroprotection via ischemic preconditioning ( Ozaki et al., 2016 ). P2X3R expression increased in dorsal root ganglion (DRG) and superior cervical ganglia neurons, resulting in exaggerated sympathoexcitatory reflexes. NONRATT021972 siRNA decreases the upregulation of P2X7R and improves cardiac function after myocardial ischemia ( Tu et al., 2016 ). Mitochondrial K ATP channels provide protection against myocardial ischemia/reperfusion injury ( Wang et al., 2015 ; Shimizu and Calvert, 2016 ). K ATP channels maintain high energy phosphates and myocardial perfusion in heart failure ( Jameel et al., 2016 ).

Myocardial Infarction

A clinical trial (Acute Myocardial Infarction Study of Adenosine) concluded that infusion for 3 h of adenosine resulted in a reduction of infarct size ( Yetgin et al., 2015 ; Bulluck et al., 2016 ). Protection against myocardial infarction was mediated by A 1 R in the rabbit heart. The A 3 R agonist IB-MECA produced cardioprotection against myocardial infarction ( Tian et al., 2015 ). Microglial P2X7R in the rat hypothalamic paraventricular nuclei regulate the sympathoexcitatory responses in acute myocardial infarction ( Du D. et al., 2015 ). Loss of mouse P2Y 4 R protects against myocardial infarction ( Horckmans et al., 2015 ). CD39 reduced infarct size following ischaemia-reperfusion injury ( Smith et al., 2016 ). P2Y 12 R antagonists have been recommended for long-term protection of patients, post-myocardial infarction ( Alexopoulos et al., 2016 ). The K ATP channel opener, natakalim, improves ventricular remodelling of congestive heart failure after myocardial infarction ( Jin, 2016 ).

Atrial Fibrillation

Adenosine reduces post-operative atrial fibrillation (AF). Up-regulation of A 2A R involves abnormal calcium handling in AF. Prevention of A 2A R activation in patients with AF may sustain uniform beat-to-beat responses at higher beating frequencies ( Molina et al., 2016 ). Adenosine-guided pulmonary vein isolation following a randomised clinical trial was recommended to treat paroxysmal AF ( Macle et al., 2015 ), although this has been queried in a more recent clinical trial ( Ghanbari et al., 2016 ). ATP-induced AF has also been investigated ( Hasebe et al., 2016 ). The efficacy of the P2Y 12 antagonists ticagrelor and prasugrel are not affected in AF ( Ondrakova et al., 2016 ). The roles of adenosine and ATP in atrial arrhythmias and fibrillation have been discussed ( Jared Bunch, 2015 ; Belhassen and Michowitz, 2016 ).

Supraventricular Tachycardia

Acute therapy by ATP for paroxysmal supraventricular tachycardia was used in the late 1940’s. In patients with paroxysmal supraventricular tachycardia bolus injection of Adenocard (adenosine) is clinically prescribed to slow conduction time via the atrioventricular node, via A 1 R ( Sachdeva and Gupta, 2013 ). Treatment of paroxysmal supraventricular tachycardia by adenosine and ATP is discussed ( Lerman, 2015 ). To provoke vasovagal reaction in syncope patients ATP and adenosine are administered together with the head-up tilt table test ( Fragakis et al., 2015 ).

Cardiomyopathy

Cardiomyopathy can be an inherited disease, but can occur as a result of vitamin B deficiency, amyloidosis, alcoholism or viral infections. ATP synthase disruption contributes to diabetic cardiomyopathy ( Ni et al., 2016 ). P2X7R involvement in dilated cardiomyopathy has been reported ( Martinez et al., 2015 ).

Cardiac Fibrosis and myocarditis

P2Y 11 R agonists reduce cardiac fibrosis ( Certal et al., 2015 ). Extracellular nucleotide regulation of signalling in cardiac fibrosis has been discussed ( Novitskaya et al., 2016 ). The P2X7R antagonist, A740003, reduces experimental autoimmune myocarditis, suggesting a treatment for clinical myocarditis ( Zempo et al., 2015 ).

Angina

ATP injections to treat angina pectoris associated with coronary disease were used during the 1940s, while AMP was used to treat angina. ATP treatment for patients with coronary insufficiency was also used early. Intracoronary administration of adenosine results in angina pain. Intracoronary administration of adenosine in patients with unstable angina produced decreased myonecrosis and improved coronary blood flow ( Kizilirmak et al., 2015 ). In vascular pain, which encompasses pelvic and ischaemic pain, migraine and angina, it is thought that release of ATP from endothelial cells during reactive hyperaemia after vasospasm diffuses through the microvascular wall to activate P2X3R on perivascular sensory nerves to send impulses that travel to pain centres in the brain via the spinal cord ( Joseph et al., 2015 ). P2X2/3R expressed on airway nociceptive sensory nerves mediate cardiovascular reflexes in conscious rats ( Hooper et al., 2016 ).

Cardiac Transplants

Responses of the transplanted human heart to adenosine show supersensitivity. Protection of cardiac grafts from cold ischaemia/reperfusion injury is caused by donor pretreatment with AMP-activated protein kinase ( Yang C. et al., 2016 ). Treatment with P2XR antagonists prolongs cardiac transplant survival.

Vascular Diseases

Hypertension

It has been proposed in a recent review ( Burnstock, 2017 ) that there are five different ways that purinergic signalling can contribute to the development of hypertension:

ATP released as a cotransmitter from sympathetic nerves together with noradrenaline (NA) contributes, via P2X1R, to the vasoconstriction that results from increased sympathetic vasomotor activity in hypertension. Therefore, P2X1R antagonists should be useful for the treatment of hypertension, especially since there is a substantial increase in ATP relative to NA released from sympathetic nerves in spontaneously hypertensive rats ( Brock and Van Helden, 1995 ; Goonetilleke et al., 2013 ).

Release of ATP from endothelial cells by shear stress as a result of changes in blood flow acts on P2YR and P2X4R on endothelial cells to release nitric oxide (NO) resulting in vasodilation. Introduction of P2Y 1 , P2Y 2 , and P2X4 agonists would cause increased vasodilation in hypertension.

Brain stem and hypothalamic neurons mediate sympathetic nerve activity. Recent studies show that P2X3R antagonists are antihypertensive, due to reduced sympathetic nerve activity as a result of increased peripheral P2X3R-mediated carotid body chemoreceptor reflexes ( Pijacka et al., 2016 ).

P2X7R in the kidney contribute to the pathophysiology of hypertension and P2X7R antagonists may have promise as clinical antihypertensive agents.

In hypertensive patients adenosine activates the vascular renin-angiotensin system. P1R agonists have been suggested for the treatment of hypertension ( Ho M.F. et al., 2016 ).

Recently, P2Y 6 R were shown to age-dependently promote vascular remodelling in a mouse model, an effect inhibited by MRS2578, suggesting that P2Y 6 R are a therapeutic target for the prevention of age-related hypertension ( Sunggip et al., 2017 ).

Atherosclerosis

ATP signalling influences the development of atherosclerosis ( Burnstock, 2008a ; Ferrari et al., 2015 ). Endothelial and smooth muscle cell proliferation are promoted by adenosine and ATP in atherosclerosis via P2Y 1 , P2Y 2 , and P1R. In a human model, adenosine, via A 2A R, modulates foam cell formation ( Reiss and Cronstein, 2012 ). A 2B and A 3 antagonists reduce atherosclerotic plaque development. There are increased concentrations of circulating adenosine 5′-diphosphate (ADP) and ATP in atherosclerosis ( Jalkanen et al., 2015 ). Uridine 5′-triphosphate (UTP), via P2Y 2 R, induces expression of vascular cell adhesion molecule-1 in coronary artery endothelial cells, which leads to the monocyte recruitment associated with atherosclerosis development. Upregulated P2Y 2 R mediate intimal hyperplasia in collared rabbit carotid artery. P2Y 1 R antagonists are a therapeutic target for neointima formation ( Liu R. et al., 2015 ). Endothelial P2X4R play a more important role in intense proliferation in atherosclerosis than P2Y 2 R. ATP, by inducing leukocyte recruitment in mice, contributes to atherogenesis, via P2Y 2 , P2Y 6 , P2X4, and P2X7R. P2X7R are over-expressed in atherosclerosis and P2X7R deficiency leads to less plaque formation ( Stachon et al., 2016 ). CD39 mRNA-coated stents may be a treatment for atherosclerosis ( Abraham et al., 2015 ).

Atherosclerosis of coronary vessels is called coronary artery disease or coronary artery syndrome. P2Y 12 R antagonists combined with aspirin are beneficial for patients with acute coronary syndrome ( De Luca et al., 2016 ; Rollini et al., 2016 ). A 2A R on coronary arteries have also been claimed to be involved in coronary artery disease ( Gariboldi et al., 2017 ).

Vascular Injury, Angiogenesis and Restenosis

An initiating event in the pathogenesis of vascular diseases is often vascular injury. Injured cells release ATP, which, together with adenosine, evoke endothelial and smooth muscle cell growth, proliferation, migration and death. Adenosine, following breakdown of ATP, is protective against ischaemic injury. P2Y 12 R antagonists are prescribed as prevention against ischaemic stroke ( Liu F. et al., 2015 ). P2Y 2 R mediate regulation of endothelial inflammation and angiogenesis ( Gidlöf et al., 2015 ).

Sustained control of proliferation of endothelial and smooth muscle cells as a result of P1 and P2YR activation during vascular remodelling in restenosis after angioplasty has been reported and therapeutic possibilities are being explored ( Burnstock, 2002 ). Activation of A 2B R stimulates angiogenesis in human microvascular endothelial cells ( Du X. et al., 2015 ). Adenosine, via A 2A R, stimulates wound healing and angiogenesis following tissue injury in mice. CD39 administration decreases injury-induced platelet deposition and recruitment of leukocytes and inhibits neointimal hyperplasia. A review discusses the vascular actions of P2XR in renal injury ( Howarth et al., 2015 ).

Thrombosis, Inflammation, and Stroke

Nucleotides are extracellular mediators of vascular inflammation and thrombosis. Clopidogrel, a P2Y 12 antagonist, inhibits aggregation in platelets and is widely prescribed for thrombosis and stroke ( Sarafoff et al., 2012 ). Other P2Y 12 antagonists have been developed, including ticlopidine, cangrelor, ticagrelor, prasugrel, elinogrel, BX 667, and PSB 0739. P2Y 1 R antagonists also have antithrombotic actions and have been recommended as a complement to current P2Y 12 anti-platelet strategies. The P2Y 6 R may be a therapeutic target for systemic inflammatory responses. Review articles are available about purinergic signalling in thrombosis and inflammation, including the use of different oral or intravenous P2Y 12 R antagonists ( Tang et al., 2015 ; Nylander and Schulz, 2016 ; Rollini et al., 2017 ). P2X7R are pro-thrombotic and genetic KO of the gene for the P2X7R was shown to be protective in a mouse carotid artery thrombosis model ( Furlan-Freguia et al., 2011 ). Adenosine, via A 2A R and A 3 R, had antithrombotic effects ( Cristalli et al., 1994 ; Hofer et al., 2013 ).

Migraine

Migraine pain involves two distinct cerebrovascular phases: an initial vasoconstriction (with no pain), followed by vasodilation (reactive hyperaemia) associated with pain. A purinergic hypothesis for migraine was proposed in 1981 ( Burnstock, 1981 ). It was suggested that after the initial vasospasm ATP and adenosine (following breakdown of ATP) may mediate the vasodilation during reactive hyperaemia associated with pain. It was also hypothesised that stimulation of P2X3R on sensory nerve terminals located on the adventitia of the cerebral microvasculature by ATP contributed to the migraine pain. Data has also been presented recently that is consistent with the purinergic hypothesis of migraine pain ( Yegutkin et al., 2016 ). P2X3R antagonists have been proposed as potential candidates for migraine treatment ( Waeber and Moskowitz, 2003 ). The non-steroidal anti-inflammatory compound, naproxen, currently in use for migraine pain, blocks P2X3R-mediated responses in trigeminal neurons of the rat. Migraine could involve a chronic disorder of the sympathetic nervous system, where increased release of the sympathetic cotransmitter ATP contributes to the initial vasospasm.

Adenosine may also be involved in migraine. Adenosine infusion resulted in symptoms that were migraine-like and withdrawal of the P1R antagonists theophylline and caffeine also resulted in migraine-like symptoms. Clinical trials with the adenosine uptake inhibitor dipyridamole, that results in increased extracellular adenosine, were halted due to the increase of migraine attacks in all patients. Overactive P2YR on glial cells may contribute to pain transduction during migraine. Reviews have been published about the role of purinergic signalling in the aetiology of migraine and the potential of purinergic compounds ( Cieslak et al., 2015 ; Jacobs and Dussor, 2016 ).

Diabetic Vascular Disease

There is pre-junctional A 1 R-mediated sympathetic neurotransmission and ATP-mediated endothelial vasodilatation in mesenteric arteries of streptozotocin (STZ) diabetic rats ( Burnstock and Novak, 2013 ). There is enhanced A 2A R-mediated increase in coronary flow in type 1 diabetic mice ( Labazi et al., 2016 ). UTP, ATP and adenosine evoked vasodilation is reduced in the circulation of skeletal muscle of type 2 diabetic patients. Erythrocyte release of ATP is diminished in type 2 diabetics, supporting the view that a defect in the physiology of erythrocytes may contribute to diabetic vascular disease. Erythrocytes are less deformable in type 2 diabetes leading to lowered levels of deformation-induced ATP release. Low erythrocyte ATP release may contribute to the prevention and treatment of diabetic peripheral vascular disease ( Richards et al., 2015 ). P2X7R expression by monocytes might play a role in the pathological changes of type 2 diabetes mellitus ( Wu et al., 2015 ).

Aortic Valve Disease

ATP inhibits mineralisation of the aortic valve seen in calcific aortic valve disease ( Côté et al., 2012 ). Increased levels of ectonucleotidase are found in calcific aortic valve disease and inhibition of ectonucleotidase with ARL67156 prevented disease development in rats.

Blood Cell Diseases

Adenosine is a potential therapeutic target for the prevention and treatment of sickle cell disease ( Fu and Davies, 2015 ). The circulating levels of adenosine are elevated in pregnant women with sickle cell disease ( Ashimi et al., 2015 ). Amyloid-β peptide inhibits ATP release from erythrocytes, suggesting that in AD, vascular amyloid peptide may play a role.

Diseases of the Airways

Reviews covering the early literature are available ( Burnstock et al., 2012a ; McGovern and Mazzone, 2014 ).

Inflammation occurs in most diseases of the airways, including chronic obstructive pulmonary disease (COPD), dyspnea, asthma, cystic fibrosis (CF), allergy, infection and injury. Purine nucleotide release from airway epithelial cells is raised in inflammatory processes and has an important role in the pathophysiology of chronic lung disease. P2X7R are a therapeutic target in lung hypersensitivity reactions seen in chronic inflammatory responses. P2X7R modulate lung inflammatory, fibrotic and functional changes in silicosis, an occupational lung disease ( Monção-Ribeiro et al., 2014 ). P2X4R mediate acute airway inflammation by regulating dendritic cell function ( Wiesler et al., 2016 ). Vagal parasympathetic reflex bronchoconstriction has a role in inflammatory airway disease. Mucin hypersecretion is stimulated in various respiratory diseases and silencing of MUC8 by siRNA increased P2Y 2 R-induced airway inflammation ( Cha et al., 2015 ). P2Y 2 R have also been claimed to downregulate MUC5AC gene expression ( Jeong et al., 2016 ). Nucleotides released during airway inflammation activate P2Y 6 R leading to further release of inflammatory cytokines ( Hao et al., 2014 ). Anti-inflammatory effects of adenosine in the lung have been described involving immune cells.

Asthma

A role of adenosine in asthma has been considered for many years, because it is a powerful bronchoconstrictor in asthmatic, but not healthy lungs and P1R antagonists have been used for the treatment of asthma (see Cicala and Ialenti, 2013 ). It was suggested earlier that the bronchoconstriction evoked by adenosine in asthma was as a result of indirect actions by release of leukotrienes, histamine or endothelin (see Burnstock et al., 2012a ). In early reports, A 2A , A 2B , and A 3 R were all claimed to mediate inhibition of allergic airway inflammation and mast cells were shown to be involved. Expression of adenosine receptors on monocytes from patients with asthma contributes to the progression of the disease ( Yuryeva et al., 2015 ). A 2A R are involved in the immunological pathogenesis of asthma ( Wang et al., 2016 ).

The roles of nucleotides in asthma has gained attention. In human lung mast cells, ATP is an important modulator of histamine release. Attenuated P2X7R function gives protection from asthma and was suggested to be age related. ATP in sputum was significantly elevated in patients with asthma, which was correlated with the percentage of neutrophils in sputum ( Soma et al., 2016 ). Impaired P2X1R-mediated adhesion in eosinophils from asthmatic patients has been reported ( Wright A. et al., 2016 ). P2Y 6 R activation was effective for treatment of a mouse model of asthma ( Chetty et al., 2016 ).

In allergic asthma, inhalation of allergens, such as pollen spores or house dust mite allergen, or triggers such as viral infection or air pollution, trigger inflammation. For an immune response to be triggered by allergens, activation of dendritic cells is required. In allergic asthmatics, bronchoconstriction following inhaled adenosine was mediated by A 1 R. Selective antagonists to A 2B R improve inflammatory conditions in allergic asthma ( Basu et al., 2017 ). ATP plays a role in inflammation in allergic asthma by recruitment and activation of inflammatory cells. P2Y 1 R are involved in allergic airway inflammation, probably by regulating maturation of dendritic cells. It has also been proposed that P2Y 2 R in the respiratory epithelium are important sensors for airborne allergens. P2X7R have been implicated in the pathophysiology of allergy-induced lung inflammation. Activating P2X7R on hematopoietic cells, namely eosinophils or dendritic cells, may be a therapeutic approach to treat allergic asthma. Oxatomide, an anti-allergic antihistamine, is claimed to also act as a P2X7R antagonist ( Yoshida et al., 2015 ). P2R act as modulators of rat eosinophil recruitment in allergic inflammation ( Alberto et al., 2016 ). Asthmatic patients exhibit hypersensitivity to aerosolised ATP, but the effects of ATP are not mediated by adenosine ( Basoglu et al., 2017 ).

Chronic Obstructive Pulmonary Disease (COPD)

COPD emphysema and chronic bronchitis. COPD is caused by gas or noxious particles, particularly in tobacco smoke, trigging a lung inflammatory response that when in the larger airways is called chronic bronchitis while in the alveoli is called emphysema.

The role of adenosine receptors in COPD has been the main emphasis to date. Combined stimulation of A 2B and glucocorticoid receptors in epithelial cells of human airways induces genes that have anti-inflammatory potential for COPD ( Greer et al., 2013 ). A 2B R on human mast cells were claimed to be a strategic target for COPD and inhaled A 2A R agonists have been used for the treatment of COPD. A 1 , A 2B , and A 3 R antagonists have also been used to treat COPD ( Basu et al., 2017 ).

ATP is implicated in COPD as well as adenosine. COPD is characterised by up-regulation of ATP in bronchoalveolar lavage fluid, which promotes inflammation and tissue degradation. ATP-induced pulmonary vasodilation occurs in patients with COPD. Activation of P2X7R signalling by cigarette smoke appears to play a role in the pathogenesis of emphysema. Cigarette smoke induces neutrophil ATP release via P2X7 and probably P2Y 2 R activation. Aerosolised ATP exacerbates the symptoms of COPD ( Basoglu et al., 2015 ). A valuable review about purinergic signalling and COPD has been published recently ( Pelleg et al., 2016 ).

Airway Infections

Antibiotics, including erythromycin, are used widely for the treatment of lower and upper respiratory tract infections. Erythromycin blocks the P2XR-mediated Ca 2+ influx and could represent one mechanism by which it exerts its effects. The airway epithelium has a role in activating the innate immune response during lung bacterial infections to fight the infection. Over-expression of the ectonucleotidase, CD39, promotes bacteria-induced inflammation, mediated largely by P2X7R in mouse airways. It has been proposed that P2X7R agonists together with low molecular weight anti-tuberculosis medicines could be used to treat multi-drug-resistant tuberculosis (TB) ( Soares-Bezerra et al., 2015 ), although caution was advised as a polymorphism of the P2X7R was reported to increase the risk of recurrence of TB ( Fernando et al., 2007 ). In infectious inflammatory diseases the roles of P2X7R and ectonucleotidases have been reviewed ( Morandini et al., 2014 ). Polymorphisms of the P2X7R gene are associated with the prognosis and risk of human TB ( Zheng X. et al., 2017 ). Data has been presented to support the view that P2X7R antagonists should be used to treat the aggressive forms of TB ( Amaral et al., 2014 ). Selective, orally bioavailable and potent ATP synthase inhibitors show activity against both non-replicating and replicating TB ( Singh et al., 2015 ). P2X7R contain the spread of Toxoplasma gondii in vivo ( Corrêa et al., 2017 ). The role of purinergic signalling in a mouse model of pneumococcal meningitis has been explored ( Zierhut et al., 2017 ). The authors showed that although P2X7R activated the NLRP3 inflammasome/IL-1β pathway that mediates inflammation in pneumococcal meningitis, neither suramin nor brilliant blue G affected the disease, possibly because of meningitis-associated down-regulation of brain P2X7R expression and/or a decrease in ATP levels in cerebrospinal fluid.

Adenosine protects against Streptococcus pneumoniae infection of the lungs by pulmonary neutrophil recruitment regulation ( Bou Ghanem et al., 2015 ). Macrophages that engulf bacteria produce adenosine that suppresses sensitisation in response to early-life infections ( Pei and Linden, 2016 ). Chemokine release and leukocyte recruitment are modulated by nucleotides in inflamed airways via an action on P2YR on immune and epithelial cells. Mucociliary clearance is the initial defence against infections of the airways. Airway epithelium releases ATP into the surface liquid layer that controls mucus clearance via P2R and, following breakdown to adenosine, also through P1R. Pulmonary TB patients had higher ADA activity in bronchoalveolar lavage fluid and in the sputum.

Infection with the malaria protozoan parasite, Plasmodium falciparum , induces ATP release from erythrocytes. Rupture of erythrocytes releases ATP during the blood-stage of P. chabaudi malaria that increases P2X7R expression on CD4 + T cells. Platelet ADA, CD39, and CD73 expression was reduced in Trypanosoma evansi infected rats. A review about purinergic signalling and malaria-infected erythrocytes is available ( Huber, 2012 ). Haemolysis produced by leukotoxin, a bacterial virulence factor, was increased by ATP release and P2XR activation of human erythrocytes.

P2X7R activation regulates inflammatory responses during acute viral infection ( Lee et al., 2012 ) and is involved in the exacerbated immune response seen during influenza virus infection ( Leyva-Grado et al., 2017 ). ATP, released by activated macrophages and damaged cells, modulates lung inflammation in pneumonia in cattle. Both pulmonary microvascular endothelial cells and epithelial cells expressed P2X7R mRNA.

The pneumovirus respiratory syncytial virus commonly causes childhood lower respiratory tract diseases. It reduces alveolar clearance, probably via UTP, released by the bronchoalveolar epithelium following infection, suggesting that P2Y 2 R antagonists may be therapeutically important for the treatment of severe respiratory syncytial virus bronchiolitis ( Vanderstocken et al., 2012 ). Rhinoviral stimuli and ATP signalling contribute to human bronchial smooth muscle production of IL-33 by severe asthmatics ( Calvén et al., 2015 ). ATP is involved in the expression and release of a major airway mucin, MUC5AC, mainly via P2Y 2 R and it was suggested that modulation of this pathway could be useful clinically for mucus hypersecretion following viral infections ( Shishikura et al., 2016 ).

Lung Injury

Acute respiratory stress syndrome and lung injury can lead to respiratory failure. There is a protective effect of ATP-MgCl 2 in ischaemia-reperfusion lung injury. Alveolar macrophages contribute substantially to chronic lung inflammation development, including silicosis, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, sarcoidosis, and asbestosis.

Alveolar macrophages express P2X7R, which stimulate the IL-1 to IL-5 proinflammatory cytokine cascade and may be clinically relevant in lung hypersensitivity reactions occurring due to chronic inflammation. P2X7R are involved in the pathophysiology of LPS-induced lung injury and LPS-induced inflammation occurs independently of P2Y 1 R ( Liverani, 2017 ). There is up-regulation of pulmonary P2X4 and P2X7R in both acute and chronic lung injury and P2X7R deletion, but not P2X4 deletion, was lung protective ( Hafner et al., 2017 ). The initial inflammatory cells recruited during lung injury are pulmonary neutrophils and P2X7R antagonists reduced neutrophil infiltration and proinflammatory cytokine levels ( Mishra et al., 2016 ).

Neuroendocrine body cells lining the lung epithelium at intervals, release ATP in response to distension, which then stimulates P2X3R to activate vagal sensory fibres that originate in the nodose ganglion ( Brouns et al., 2003 ). This mechanism may control reflex responses to noxious gases and hyperventilation. Ventilator-induced lung injury may involve ATP release from neuroepithelial cell bodies in response to stretch and therefore may be therapeutically relevant.

Pulmonary fibrosis can be caused by injury. In patients with idiopathic pulmonary fibrosis A 2B R signalling may promote the production of inflammatory and fibrotic mediators. Extracellular adenosine levels are closely associated with the progression of pulmonary fibrosis ( Luo F. et al., 2016 ). Adenosine production by CD73 enhanced radiation-induced lung fibrosis ( Wirsdörfer et al., 2016 ). LPS caused increased expression of A 1 , A 2A , and A 2B and P2YR, and decreased expression of A 3 R, while mechanical ventilation reduced P2Y 4 mRNA levels. Both A 2A and A 2B R were claimed to attenuate acute lung injury. Upregulated A 2A R activation is likely to improve the healing process after acute LPS-induced lung injury ( Friebe et al., 2014 ). A protective role for A 2B R signalling has been reported to counter ischaemic lung injury ( Densmore et al., 2017 ). Protective effects of A 3 R activation in attenuating reperfusion lung injury has also been reported. Inhibition of adenosine kinase attenuates acute lung injury ( Köhler et al., 2016 ). Inhaled A 2B R agonists have been recommended for the treatment of acute lung injury ( Hoegl et al., 2015 ). Adenosine is detrimental in lung recovery following hyperoxic lung injury ( Davies et al., 2016 ). Reviews have been written about adenosine receptors as potential therapeutic targets for acute respiratory stress syndrome and acute lung injury ( Schepp and Reutershan, 2008 ; Eckle et al., 2009 ).

Cystic Fibrosis (CF)

Cystic fibrosis is hereditary as a result of a loss of function gene mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Some outstanding reviews about purinergic signalling in CF have been published ( Burnstock et al., 2012a ; Della Latta et al., 2013 ). The regulation of ion transport by UTP and ATP in CF and normal human airway epithelium was proposed early, in retrospect probably via P2Y 2 and/or P2Y 4 R. P2R compounds for the treatment of CF to restore Cl - secretion and/or inhibit Na + absorption are being investigated. Lipoxin A 4 , which stops inflammation, is inadequately produced in patients with CF, but it stimulates apical ATP release, which activates P2Y 11 R resulting in epithelial repair ( Higgins et al., 2014 ). With the R117H mutation associated with mild forms of CF, there are faults with the gating conformational changes in the CFTR transmembrane domains, although the function of the nucleotide binding domains are unchanged ( Yu et al., 2016 ). Gating of the R117H-CFTR was shown to be almost completely rectified by combined treatment with an ATP analogue [ N 6 -(2-phenylethyl)-2′-deoxy-ATP], VX-770 (Ivacaftor, currently used to treat CF) and nitrate ions (NO 3 - ). The authors concluded that future therapeutic developments might include the complementary use of ATP analogues with VX-770.

Cl - secretion across CF airway epithelia is restored by ATP by triggering calcium entry via P2XR. It was suggested that P2X4/6 heteromultimer receptors might be involved. CFTR activity is necessary for ATP release following erythrocyte deformation. CFTR is reduced or absent in CF and mechanical deformation of erythrocytes does not induce ATP release. Increasing nucleotide release via motion could have therapeutic implications for CF patients. Women with CF showed reduced survival compared with males. Oestrogen may lower breathing-induced release of ATP and ATP receptor-mediated [Ca 2+ ] i increase that induces Cl - secretion. Anti-oestrogens may therefore be beneficial in the treatment of CF.

A 1 R agonists release [Ca 2+ ] i and activate Cl - and K + currents in CF epithelial cells of the airways. A 1 and A 2A R participate in regulation of Cl - secretion in CF airway epithelial cells. Bronchoalveolar lavage from CF patients contained high concentrations of adenosine, correlating with higher 5′-nucleotidase and lower ADA activity. Adenosine regulates CFTR via A 2B R. The exhaled breath condensate biomarker, adenosine, tracks changes in lung function in CF ( Esther et al., 2013 ). There is increased airway adenosine metabolism in early CF ( Esther et al., 2015 ).

Lung Cancer

Human lung A549 epithelial-like adenocarcinoma cells express P2UR (i.e., P2Y 2 and/or P2Y 4 ) that mediate increases in [Ca 2+ ] i . In A549 cells there is calcium-dependent UTP and ATP release (with subsequent increase in adenosine levels). Erythromycin selectively inhibits influx of Ca 2+ induced via P2X4R stimulation in A549 lung tumour cells. A549 cells express P2Y 2 , P2Y 4 , and P2Y 6 , and P2X4R. ATP induces dose-dependent inhibition of growth of cell lines, including human mesothelioma (MER082), human papillary lung adenocarcinoma (H441), human squamous cell lung carcinoma (H520), human large cell lung carcinoma (H460), human small cell lung carcinoma (GLC4) and the PC14 lung adenocarcinoma cell line. ATP was released from Calu-3 cells derived from human lung adenocarcinoma, probably in response to P2Y 2 R activation. UTP, ATP and uridine diphosphate stimulate proliferation of lung tumour A549 cells through P2Y 2 and P2Y 6 R.

Autocrine ATP release and P2X7R activation affects the migration of human lung cancer cells ( Takai et al., 2014 ). A significant increase in survival of non-small cell lung cancer patients with high P2X7R expression was identified compared to patients with low P2X7R expression ( Boldrini et al., 2015 ). Nucleotides released by radiochemotherapy induce chemotaxis, adhesion and proliferation of human lung cancer cells and metastasis was inhibited in immunodeficient mice by purinergic receptor antagonists ( Schneider et al., 2015 ). An association of P2X7, P2X4, and P2Y 1 R with distant metastatic lung tumours was observed and increased degradation of ATP and ADP by CD39, which influence tumour growth and metastasisation ( Hofman et al., 2015 ). ATP promotes cell survival by inducing a long lasting and sustained increase in [Ca 2+ ] i in lung cancer cells ( Song et al., 2016 ). ATP binding cassette E1 promotes growth, invasion and metastasis of lung adenocarcinoma cells ( Tian Y. et al., 2016 ). Ecto-5′-nucleotidase (CD73) inhibitors are currently under clinical trial to treat non-small cell lung cancer ( Zhu et al., 2017 ).

A 2B R on host immune cells may participate in promoting angiogenesis and suppressing immunity and A 2B R KO mice showed reduced growth in a Lewis lung carcinoma isograft model. ATP increased the cytotoxicity of cisplatin, a common anti-cancer drug for the treatment of lung cancer, in the H460 carcinoma cell line. An A 3 R agonist inhibited cell proliferation by stopping the cell cycle and by apoptosis in A549 cells. Antagonism of A 2A R expressed by lung adenocarcinoma tumour cells inhibited their growth ( Mediavilla-Varela et al., 2013 ). A 2A R expression and CD73 have opposing prognostic effects in non-small cell lung cancer ( Inoue et al., 2017 ).

Cachexia often occurs in lung cancer patients. In clinical trials, infusion of ATP in advanced non-small cell lung cancer patients contributed beneficially by increasing body weight, muscle strength and quality of life, as well as enhancing survival ( Agteresch et al., 2003 ). ATP has been claimed to reduce radiation-induced damage in patients with non-small cell lung cancer ( Swennen et al., 2008 ).

Chronic Cough

The therapeutic promise of P2X3R antagonists for the treatment of chronic cough was first recognised by Ford and Undem (2013) . P2X3R are expressed by airway afferent nerves and mediate hypersensitivity of the cough reflex, which is dramatically reduced by the oral P2X3 antagonist, AF-219 ( Abdulqawi et al., 2015 ). Central A 1 R were shown to suppress cough ( El-Hashim et al., 2016 ).

Pleurisy

Inosine contributed with adenosine to exert, via A 2 R, anti-inflammatory effects in pleural inflammation ( da Rocha Lapa et al., 2012 ).

Lung Allograft

Ecto-5′-nucleotidase (CD73) reduced rejection of airway allografts by stimulating A 2A R, which is a negative modulator of lymphocyte recruitment into the allograft. P2X7R antagonists prolong mouse lung allograft survival ( Liu et al., 2014 ).

Diseases of the Special Senses

Purinergic signalling is involved in the physiology of the nasal organs, ear, eye and tongue. Purinergic drugs are being explored for corneal injury, retinal detachment, glaucoma, dry eye, retinitis, uveitis, rhinosinusitis, diabetic retinopathy, macular degeneration, noxious odour damage, Ménière’s disease, sensorineural deafness, tinnitus and taste defects ( Burnstock, 2006 ; Housley et al., 2009 ).

Eye

The early literature up to 2006 was reviewed ( Burnstock, 2006 ) and there are more recent reviews covering the treatment of ocular diseases by purinergic drugs ( Guzman-Aranguez et al., 2014 ; Sanderson et al., 2014 ; Beckel et al., 2016 ; Lee et al., 2016 ; Reichenbach and Bringmann, 2016 ).

Glaucoma is characterised by progressive degeneration of retinal ganglion cells and visual loss. Elevated intraocular pressure reduction is the treatable risk factor for glaucoma. P2X7R antagonists are being explored for the treatment of glaucoma ( Krizaj et al., 2014 ; Pérez de Lara et al., 2015 ; Sakamoto et al., 2015 ). There is elevation of extracellular ATP and upregulation of NTPDase1 in animal models of chronic glaucoma ( Lu et al., 2015 ). Cromakalim, a K ATP channel opener, lowers intraocular pressure ( Roy Chowdhury et al., 2015 , 2016 ). Evidence for the use of adenosine receptor antagonists for the treatment of glaucoma has also been presented ( Zhong et al., 2013 ; Agarwal and Agarwal, 2014 ). Ap 4 A improves adrenergic anti-glaucomatous therapeutic effectiveness ( Loma et al., 2015 ) and has recently been claimed to be an effective compound for the treatment of glaucoma ( Fonseca et al., 2017 ).

Treatment for dry eye by a long lasting P2Y 2 R agonist, diquafosol, was developed by Inspire Pharmaceuticals, Inc. and is currently in use in Japan and Korea (see Lau et al., 2014 ).

A P2Y 2 R agonist, INS37217, enhances subretinal fluid reabsorption and is recommended for the treatment of retinal detachment ( Maminishkis et al., 2002 ; Meyer et al., 2002 ).

P2X7R antagonist and A 3 R agonists have been implicated for the treatment of diabetic neuropathy and retinopathy ( Sugiyama, 2014 ; Reichenbach and Bringmann, 2016 ), photoreceptor neurodegeneration ( Hu et al., 2015 ; Ho T. et al., 2016 ), retinitis ( Corso et al., 2016 ) and uveitis ( Zhao R. et al., 2016 ).

The roles of P2Y 2 and P2X7R in corneal wound healing have been reviewed ( Minns and Trinkaus-Randall, 2016 ; Minns et al., 2016 ). P2X7R activation in oxysterol cytotoxicity may be a target for the treatment of age-related macular degeneration ( Olivier et al., 2016 ).

Ear

In the auditory system ATP depressed sound-evoked action potentials in the auditory nerve by stimulating P2YR. Acoustic over-stimulation can cause permanent hearing loss due to damage and death of cochlea hair cells. Noise exposure promotes the release of ATP into endolymph. ATP regulates hearing sensitivity and could be useful to treat sensorineural deafness, Ménières disease and tinnitus. UTP infusion into the deafened guinea pig inner ear rescued auditory neurons ( Fransson et al., 2009 ). P2XR-mediated control of cochlear gap junctions may be protective by reducing hearing sensitivity to noise stress ( Zhu and Zhao, 2012 ), perhaps via P2X2R ( Yan et al., 2013 ; Mittal et al., 2016 ). Susceptibility to hearing loss and noise-induced neural injury in the mouse cochlea is regulated by A 2A R ( Vlajkovic et al., 2017 ).

Olfactory Organs

Purinergic receptors are expressed in the nasal mucosa, including P2X3R on olfactory neurons. There is enhanced odour sensitivity in the presence of antagonists to P2R suggesting that endogenous ATP at a low level normally decreases odour responsiveness. Chemosensory trigeminal neurons express P2X2R, which contribute to control of odour recognition ( Housley et al., 2009 ). Activation of P2X3R negatively modulates the odour response, indicating a protective strategy for olfactory sensory neurons ( Yu, 2015 ). Olfactory nerves and secretory cells in the vomeronasal organ express purinoceptors. Heat-shock protein induction by noxious odour damage is inhibited by P2R antagonists in vivo . The inhibitory effect of ATP in odour responses may contribute to the reduction of odour sensitivity following exposure to noxious fumes and could be a new mechanism for neuroprotection ( Yu and Zhang, 2014 ). ATP release following injury leads to post-injury neuroregeneration and may result in the development of therapies to restore loss of smell ( Hayoz et al., 2012 ). P2Y 1 R increase neuronal network activity in the developing olfactory bulb ( Fischer et al., 2012 ). Purinergic signalling serves as a paracrine signal in regulating the neurogenesis of mouse olfactory epithelium ( Gao L. et al., 2010 ). It has been claimed that purinoceptors are a therapeutic target to alleviate or restore loss of olfactory sensory neurons by the mycotoxin, satratoxin ( Jia et al., 2011 ). Activation of A 2 R may be a novel therapeutic approach for enhancing nasal mucociliary clearance in chronic rhinosinusitis ( Hua et al., 2013 ).

Tongue

ATP is a key neurotransmitter in the taste system, acting largely via P2X2/3 heteromultimer receptors ( Kinnamon and Finger, 2013 ; Vandenbeuch et al., 2015 ). Consequently, disruption of taste function may be an unintentional consequence of therapeutic trials of pain, chronic cough and other conditions using purinergic P2X3R antagonists ( Vandenbeuch et al., 2013 ).

Immune System and Inflammation

P2X7, P2Y 1 , and P2Y 2 R on immune and inflammatory cells are important in immunomodulation and inflammation, and the purinergic contribution to neuroinflammation underlying neuropathology has been discussed in several recent reviews ( Jacob et al., 2013 ; Takenouchi et al., 2014 ; Di Virgilio and Vuerich, 2015 ; Beamer et al., 2016 ). The role of P2X7R in particular in diseases related to neuroinflammation and the use of P2X7R centrally penetrant antagonists has been highlighted ( Baudelet et al., 2015 ; Di Virgilio, 2015 ; Gentile et al., 2015 ; Burnstock, 2016b ; Danquah et al., 2016 ; Karmakar et al., 2016 ; Rech et al., 2016 ; Corrêa et al., 2017 ; Giuliani A.L. et al., 2017 ; Jiang et al., 2017 ; Zheng B. et al., 2017 ). It has been claimed that activation of P2X1R on neutrophils and platelets is involved in regulation of thrombo-inflammation ( Oury et al., 2015 ). P2Y 12 R activation modulates sepsis-induced inflammation ( Liverani et al., 2016 ). Adenosine, acting mainly via A 2A R, is also involved in neoplastic and inflammatory and immune-mediated disease states ( Antonioli et al., 2014a ; da Rocha Lapa et al., 2014 ; Cekic and Linden, 2016 ; Ingwersen et al., 2016 ; Zhang X. et al., 2016 ; Faas et al., 2017 ).

Infection

Reviews have been published concerned with purinergic signalling in immune cell trafficking at sites of infection ( Ferrari et al., 2016b ) and P2X7R in infectious inflammatory diseases ( Morandini et al., 2014 ). Apoptosis of macrophages via ATP-stimulated P2X7R leads to the killing of the mycobacteria they contain, which may lead to new strategies to combat bacterial infections. The cytotoxic effects of ATP on macrophages are through P2X7R, while the bactericidal actions of ATP (and UTP) may be though P2Y 2 R. There is a valuable article about purinergic signalling in infection and autoimmune diseases ( Savio and Coutinho-Silva, 2016 ). The P2X7R is a potential target for the treatment of Clostridium perfringens type C infection ( Nagahama et al., 2015 ). P2X7R activation modulates cell death during Porphyromonas gingivalis infection ( Almeida-da-Silva et al., 2016 ). P2X7 and P2X4R activation is protective during severe Escherichia coli infection ( Greve et al., 2017 ). P2X7R develop the inflammatory response associated with sepsis ( Santana et al., 2015 ) and might serve as a therapeutic target to ameliorate brain damage in sepsis ( Savio et al., 2016 ). A 2A R have also been recommended as a therapeutic target to treat sepsis ( Sivak et al., 2016 ). The role of purinergic signalling in the immune response in sepsis has been reviewed ( Ledderose et al., 2016 ). ATP protects against sepsis through P2X7R on macrophages by enhancing intracellular bacterial killing ( Csóka et al., 2015 ). Chlamydiae are intracellular bacterial pathogens and these infections are influenced by inflammasomes and purinergic signalling ( Pettengill et al., 2016 ). Purines modulate the inflammatory response in rats infected by Cryptococcus neoformans ( de Azevedo et al., 2016 ). ADP facilitates monocyte recruitment in bacterial infection ( Zhang X. et al., 2016 ). ATP synthase has been proposed as a target to kill Mycobacterium tuberculosis ( Tantry et al., 2017 ). Purinergic enzymatic activities in lymphocytes and cardiomyocytes modulated the inflammatory responses of mice infected by T. cruzi ( do Carmo et al., 2017 ). Adenosine restored LPS-inhibited chemotaxis via A 1 R, making this a promising therapeutic strategy for infectious diseases ( Xu et al., 2017 ).

Infection by Schistosoma mansoni , a parasitic blood fluke, results in thymic atrophy. The cloning and characterisation of a P2XR (schP2X) from S. mansoni was the first non-vertebrate ATP-gated ion channel, which could be an alternative drug target to treat schistosomiasis (see Burnstock and Kennedy, 2011 ). Purinergic signalling influences the immune response to infection by Leishmania , a protozoan parasite ( Chaves et al., 2014 ; Figueiredo et al., 2016 ). Purinergic signalling is involved in Trichomonas vaginalis parasite infection ( Menezes and Tasca, 2016 ). The dysfunction of P1, P2Y and P2X7R and NTPDases are likely to contribute to morbidity due to human schistosomiasis ( Silva, 2016 ). P2X7R are important in parasite control as they regulate T effector cells and inflammation during L. amazonensis infection ( Figliuolo et al., 2017a ). A commentary about ATP as an initiator of immunity to parasitic infections has been published ( Nelson et al., 2017 ).

P2X7R modulate the antiviral and inflammatory processes that occur during Dengue virus-2 infection ( Corrêa et al., 2016 ) and exacerbate the immune response that occurs during influenza virus infection ( Leyva-Grado et al., 2017 ). P2X4R antagonists reduce herpetic pain ( Matsumura et al., 2016 ). Both P2X4 and P2X7R are involved in hepatitis C virus infection ( Manzoor et al., 2016 ). Purinoceptors are putative targets for the treatment of HIV-1 infection ( Pacheco et al., 2014 ). Ribavirin, an adenosine analogue, exhibited potent antiviral activities ( Hao et al., 2017 ).

Endocrine Diseases

Purinoceptors are expressed widely by endocrine glands ( Burnstock and Knight, 2004 ). Actions of purines have been described in the pituitary gland, with implications for pathological as well as physiological states. 5′-Nucleotidase activity in platelets is changed by hyper- and hypothyroidism and could be a further mechanism by which alterations in thyroid hormones are related to vascular diseases. The role of purinergic signalling in thyroid hormone activities in health and disease has been reviewed ( Silveira et al., 2013 ). In the ovary, follicular atresia involves cellular degeneration that is due to apoptosis evoked by P2X7R activation in both somatic and germinal follicular cells. Adiponectin, secreted by adipocytes, is anti-inflammatory, protecting against fatty liver disorder, insulin-resistant type 2 diabetes and atherosclerosis. A review including the limited knowledge of purinergic signalling in the endocrine system has been published ( Burnstock, 2014b ).

Diabetes

Fibroblast P2YR are impaired in type 2 diabetes, which leads to lower glucose uptake, indicating that P2YR could be therapeutically useful as antidiabetic drugs. Analogues of the P2Y 1 R agonist, 2-methylthio ADP, have been developed for the treatment of type 2 diabetes ( Yelovitch et al., 2012 ). P2YR activation potentiates insulin secretion making it a promising therapeutic target for type 2 diabetes ( Zhang et al., 2015b ; DeOliveira et al., 2017 ). Adenosine, acting via A 2A R, increases pancreatic β-cell proliferation, and has been suggested as a therapeutic target for diabetes ( Schulz et al., 2016 ). Uridine adenosine tetraphosphate may be a therapeutic target for diabetes ( Matsumoto et al., 2015 ).

There is an enhancement of P2X7R-induced apoptosis on the retinal microvasculature in early diabetes. P2X7R located on glucagon-containing α cells in pancreatic islets in STZ-induced diabetic animals increase and they migrate centrally to replace missing insulin-containing β cells. P2X7R antagonists have been proposed as a therapeutic target to cause immunosuppression and tolerance induction in pancreatic islet transplantation ( Aikin, 2013 ; Vergani et al., 2013 ). NONRATT021972 siRNA decreases the expression of P2X7 mRNA and protein in DRG, reducing mechanical and thermal hyperalgesia in type 2 diabetic rats ( Liu et al., 2016 c). Type 1 diabetes impairs P2X7R signalling in osteocytes that affects osteoblast function and maintenance of bone health ( Seref-Ferlengez et al., 2016 ). STZ-induced type 1 diabetes was prevented in P2X7R KO mice ( Vieira et al., 2016 ). Diabetic sympathetic neuropathy in type 2 diabetic rats was reduced by decreasing the expression of P2X7R in superior cervical ganglia ( Wu et al., 2016 ). P2X7R are expressed in pancreatic cancer cells. P2X7R antagonists are likely to be effective therapeutic agents ( Giannuzzo et al., 2016 ).

P2X3R antagonists have been proposed for the treatment of diabetic neuropathic pain ( Guo et al., 2015 ; Zhang et al., 2015b ; Peng et al., 2017 ; Rao et al., 2017 ). Recently P2X7R have also been claimed to be involved in painful diabetic neuropathy in rats ( Liu et al., 2017 ). P2X7R polymorphisms are associated with severe diabetic neuropathic pain scores ( Ursu et al., 2014 ). A 1 R agonists improve mechanical allodynia in a painful diabetic neuropathy mouse model ( Katz et al., 2015 ).

There is up-regulation of hippocampal A 2A R in STZ-diabetes and A 2A R antagonists gave neuroprotection. A 2A R are a therapeutic target for diabetic retinopathy ( Ibrahim et al., 2011 ). Reduced expression of A 1 R in pancreatic α-cells could result in the development of type 1 diabetes ( Yip et al., 2013 ). There is increased expression of A 2B R in women with gestational diabetes mellitus ( Wojcik et al., 2014 ). In diabetic rats, A 2B R agonists improve erectile function ( Wen et al., 2015 ). It was suggested that reduction in A 3 R expression/function may slow the progression of diabetic neuropathy ( Yan H. et al., 2016 ). Blockade of ATP synthase interaction with cyclophilin D has been proposed as a promising therapeutic target to treat diabetic encephalopathy ( Yan S. et al., 2016 ).

K ATP channels have neuroprotective effects in patients with type 2 diabetes ( Liu R. et al., 2016 ; Rubaiy, 2016 ). P2Y 1 and P2Y 2 R mediate relaxation of the rat corpus cavernosum and may improve erectile function in men with diabetes ( Gür et al., 2009 ).

An A 2A R agonist was shown to enhance healing of chronic diabetic foot ulcers in a clinical trial ( Squadrito et al., 2014 ; Montesinos et al., 2015 ). Adenosine kinase inhibitors attenuate inflammation in diabetic retinopathy ( Elsherbiny et al., 2013a ). Retinal inflammation in diabetic retinopathy is mediated by ADA2 and the anti-inflammatory activity of A 2A R signalling is impaired with increased ADA2 activity ( Elsherbiny et al., 2013b ).

Several reviews about purinergic signalling in diabetes and its therapeutic potential are available ( Burnstock and Novak, 2013 ; Cieslak and Roszek, 2014 ; Antonioli et al., 2015 ; Fotino et al., 2015 ; Kishore et al., 2015 ; Merighi et al., 2015 ; Vindeirinho et al., 2016 ). The involvement of purinergic signalling in diabetic nephropathy is discussed later in the Section on Kidney.

Obesity

ATP released as a cotransmitter from sympathetic nerves, stimulates brown adipocytes. ATP stimulates lipogenesis in rat adipocytes, regulating fat stores not via established hormones. Adipocytes express two different P2YR subtypes and P2Y 11 R activation inhibited insulin-stimulated lepton production and lipolysis stimulation. P2Y 4 R mediate inhibition of cardiac fat formation ( Lemaire et al., 2016 ). The anti-obesity effects of sesamol, a potent anti-inflammatory compound, is mediated by AMP-activated protein kinase ( Go et al., 2017 ). Blocking P2Y 6 R activation in the CNS with the antagonist MRS2578 inhibits feeding in mice ( Steculorum et al., 2017 ).

Some ATP effects are as a result of adenosine, after breakdown of ATP, which is also involved in the activities of adipocytes. Adenosine increased lipolysis and induced thermogenesis in brown adipocytes via A 2A R ( Gnad et al., 2014 ). They showed that A 2A R antagonists counteract high fat-induced obesity in mice. Administration of A 2A R agonists to obese mice caused improvements in glucose homeostasis and adipose tissue inflammation, suggesting that this may show promise for therapeutic treatment of obesity ( DeOliveira et al., 2017 ).

There is disturbance of adiponectin secretion in obese patients and adiponectin release is controlled by ATP ( Yamauchi and Kadowaki, 2013 ). A combination of Ca 2+ and ATP augments vesicular release of adiponectin ( Komai et al., 2014 ). Both ATP and adenosine have roles in the regulation of leptin secretion from adipocytes ( Szkudelski, 2007 ). There is abnormal fat distribution in P2X7R KO mice ( Beaucage et al., 2014 ). Manipulation of P2XR signalling may represent a novel therapeutic target in metabolically unhealthy obesity under inflammatory conditions ( Pandolfi et al., 2016 ). There is protection of rats on high fat diet by adenosine ( Lee, 2015 ). Perivascular adipose tissue of heavy smokers has increased expression of P2X7R and inflammasome components leading to increased release of inflammatory cytokines ( Rossi et al., 2014 ).

Gut Disorders

Purinergic signalling plays an important role in a variety of gut activities ( Liñán-Rico et al., 2015 ; Burnstock, 2016d ; Chaudhury et al., 2016 ). ATP is a cotransmitter in non-adrenergic, non-cholinergic inhibitory nerves involved in peristalsis, a synaptic transmitter in submucosal and myenteric ganglia, it mediates mucosal secretion and vascular control of the gastrointestinal tract. Both interstitial cells of Cajal and enteric glial cells express P2R.

Investigations of purinoceptors as therapeutic candidates for gut disorders are underway ( Antonioli et al., 2013 ; Ochoa-Cortes et al., 2014 ; Burnstock, 2016d ).

Inflammatory Bowel Disease (IBD)

Nucleotides and their receptors are involved in the pathogenesis of IBD, of which ulcerative colitis (UC) and Crohn’s disease are the main types. P2Y 6 R are highly expressed on the T cells infiltrating IBD, suggesting that P2Y 6 R may play a role in the pathogenesis of IBD. P2X7R agonists are involved in colonic motor dysfunction associated with bowel inflammation in rats ( Antonioli et al., 2014b ) and are over-expressed in gut mucosa of patients with IBD. P2X7R KO mice are protected against gut inflammation ( Figliuolo et al., 2017b ). ATP activates mast cells, which further promote the inflammatory process ( Kurashima and Kiyono, 2016 ). Oestrogen receptor β activation plays a therapeutic role in IBD by down-regulation of P2X3 and P2X7R ( Ma B. et al., 2016 ). The roles of P2X7R in IBD are discussed in reviews ( Kurashima et al., 2015 ; Diezmos et al., 2016 ).

P2X7R-expressing enteric neurons are differentially affected in UC based on their chemical codes ( da Silva et al., 2015 ). In a later paper, it was shown that UC affected secretory and vasodilatory neurons, enteric sensory neurons and enteric glia of the submucosal plexus expressing P2X7R ( da Silva et al., 2017 ). The P2X7R antagonist, A438079, down-regulated the production of proinflammatory cytokines and attenuated murine colitis, indicating that P2X7R mediate inflammatory responses during UC ( Wan P. et al., 2016 ). Activation of P2X7R triggers the death of mucosal regulatory T cells ( Figliuolo et al., 2017b ). There was P2XR enhancement in an animal model of UC. MicroRNA-16 and microRNA-206 have pro-inflammatory roles in UC by down-regulating A 2A and A 3 R expression ( Tian T. et al., 2016 ; Wu et al., 2017 ).

There is increased expression of P2X7R in the inflamed mucosa in Crohn’s disease, suggesting that P2X7R antagonists may be targets for treatment of Crohn’s disease ( Neves et al., 2014 ; Eser et al., 2015 ; Wan P. et al., 2016 ; Figliuolo et al., 2017b ). P2X3R antagonists are being explored as therapeutic agents against colic and UC pain ( Eser et al., 2015 ), as well as antibodies against P2X3R ( Deiteren et al., 2015 ; Diezmos et al., 2016 ; Shcherbatko et al., 2016 ).

The potential of P2X3R to treat irritable bowel syndrome has been suggested. In diarrhoea-predominant irritable bowel syndrome there is increased expression of P2Y 1 and P2Y 2 R, which was associated with abdominal pain ( Luo Y. et al., 2016 ). P2X7R in DRG play a role in transmission of the nociceptive signal from the gut ( Liu S. et al., 2015 ). A review about purinergic mediators in the control of intestinal inflammation and irritable bowel syndrome is available ( Kurashima et al., 2015 ).

Motility Disorders

Purinergic signalling is involved in gastrointestinal motility disorders, including diarrhoea and constipation ( Jiménez et al., 2014 ). Purinergic fast inhibitory junction potentials are impaired in Hirschsprung’s disease ( Jiménez et al., 2015 ). P2X4 and P2X7R activity was potentiated in enteric glia isolated from mice treated long-term with morphine ( Bhave et al., 2017 ).

A review focuses on the pathophysiological roles of P2YR in inflammation ( Wan H.X. et al., 2016 ). Aged mice have a lower ability to deal with inflammation evoked by Candida albicans infection, due to a lower gut density of A 2A R, which reduce inflammation ( Rodrigues et al., 2016 ).

Colorectal Cancer

Apoptosis is induced by extracellular ATP and ATP also reduced growth of primary cultures of colorectal carcinomas, possibly via P2Y 2 R (see Burnstock and Di Virgilio, 2013 ; Wan H.X. et al., 2016 ). Purinergic responses of HT-29 cells, a colonic adenocarcinoma cell line, are mediated by P2Y 2 and/or P2Y 4 R. Enhanced expression of A 2B R on colorectal cancer cells that are proliferating suggests that antagonists to A 2B R may be a promising therapeutic target for colorectal cancer ( Ma et al., 2010 ; Molck et al., 2016 ). 8-Chloro adenosine inhibited growth of colorectal cancer cell lines 80514 and HCT116 in vivo and in vitro . A phase II, multi-centre study of CF101, an A 3 R agonist, showed stabilisation of tumour in 35% of refractory metastatic colorectal cancer patients. P2X7R antagonists reduce tumour occurrence in a colitis-associated cancer mouse model ( Hofman et al., 2015 ). There is high expression of the ectonucleotidase CD39 in human rectal adenocarcinoma ( Zhang et al., 2015a ).

Diseases of the Kidney

Reviews are available ( Burnstock et al., 2014a ; Menzies et al., 2017 ; Oyarzun et al., 2017 ), including one that focuses on the roles played by ATP released as a cotransmitter from sympathetic nerves in renal diseases ( Burnstock and Loesch, 2017 ).

Purinoceptors are richly expressed in the glomerulus, renal vascular system and nephron in the kidney, including subtypes involved in the regulation of glomerular filtration, renin secretion and transport of nutrients, ions, water and toxins. The distribution of NTPDases 1 and 2 parallels the distribution of P2R in the kidney, influencing physiological and pathophysiological renal events (see Burnstock et al., 2014a ). Adenosine and ATP have protective effects against renal ischaemic-reperfusion injury, and have been investigated for transplantation-induced erythrocytosis and chronic renal failure treatment. It has been suggested that nephron luminal P2R are part of an epithelial ‘secretory’ defence mechanism against harmful particles or bacteria. Increased expression of P2X7R in glomerulonephritis, hypertension, polycystic kidney disease (PKD) and diabetes may be therapeutically relevant as a novel treatment of kidney failure.

Renal Injury and Failure

ATP contributes to kidney remodelling and progression toward chronic renal failure (with associated sympathetic overactivity). P2X7R are expressed weakly in healthy glomerulus, but after glomerular injury (e.g., in hypertension and diabetes) are upregulated, mostly in podocytes, but also in mesangial and endothelial cells ( Vonend et al., 2004 ). P2X7R play a role in altered intracellular calcium homeostasis in peripheral blood mononuclear cells of chronic kidney disease patients ( Lajdova et al., 2012 ). P2X7R mediate deleterious renal epithelial-fibroblast cross-talk. P2X7R antagonists may be therapeutic targets to prevent and treat morbidity and mortality in kidney injury ( Zarjou and Agarwal, 2011 ). P2X7R antagonists were protective against ischaemic acute kidney injury in mice ( Yan et al., 2015 ). Arterial calcification is a feature in chronic kidney disease patients and ATP signalling is involved (see Fish et al., 2013 ). Cyclosporine is a potent immunosuppressive agent, but with limitations because of its side effect of nephrotoxicity. However, treatment with ATP following pre-treatment with verapamil greatly reduces nephrotoxicity. ATP is an important contributor to innate immunity regulation in primary idiopathic nephrotic syndrome. There is increased renal fibrosis in P2X4R-deficient mice following unilateral ureteric obstruction ( Kim et al., 2014 ).

Adenosine mediates haemodynamic changes in adult renal failure. A 2B R-mediated IL-6 induction contributes to renal fibrogenesis and this receptor has therapeutic potential for treatment of chronic kidney disease ( Grenz et al., 2012 ). Dendritic cells and macrophages activated by A 2A R agonists attenuate acute renal injury ( Li et al., 2012 ; Truong et al., 2016 ). There is a review describing A 2A R in acute kidney injury ( Vincent and Okusa, 2015 ).

Polycystic Kidney Disease (PKD)

The genetic disorder PKD results in abnormal proliferation of tubular cells of the adult nephron, leading to progressive dilation of tubules and formation of fluid-filled cysts that destroy by compression neighbouring tissue. In the cysts ATP is released at high concentrations. The Caenorhabditis elegans nematode is an animal model for investigating basic molecular mechanisms underlying human autosomal dominant PKD; the C. elegans PKD-2 and LOV-1 proteins are homologues of human polycystin (PC)-1 and PC-2 proteins. Nucleotide release is involved in both fluid flow and pressure responses and its role in altered mechanosensory transduction in PKD is considered in a review ( Patel and Honoré, 2010 ).

Cysts in the collecting ducts of the cpk/cpk mouse model of congenital PKD express P2X7R, where they mediate cyst development. P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 , P2X5, and P2X7R were found on the lining epithelial cells of renal cysts in the rat Han:SPRD cy/+ model of autosomal dominant PKD. Expression of mRNA and protein for P2Y 2 , P2Y 6 , and P2X7R increased substantially as the disease developed. ATP inhibits renal cyst growth, via P2X7R. The P2X7R antagonists, oxidised ATP and A-438079, reduced cyst formation via extracellular signal-regulated kinase-dependent pathways in a zebrafish model of PKD ( Chang et al., 2011 ). Nucleotides in the lumen fluid of cysts stimulate P2YR resulting in increased growth of Madin Darby canine kidney-derived cysts. Knocking out PKD-1 gene expression increased A 3 R in human renal cells ( Aguiari et al., 2009 ). There is a review about the functional and therapeutic importance of purinergic signalling in PKD ( Ilatovskaya et al., 2016 ).

Ischaemia

Proximal tubular ATP declines rapidly in ischaemic acute renal failure. There was early recognition that there was restoration after ischaemia by perfusion of ATP-MgCl 2 and A 3 R KO mice were shown to be protected against ischaemic renal failure. The ectonucleotidase CD73 protects the kidney from ischaemia-reperfusion injury via production of adenosine and free radical reduction ( Jian et al., 2012 ). The role of adenosine in protection from renal ischaemia-reperfusion injury has been investigated and discussed in reviews ( Yap and Lee, 2012 ; Roberts et al., 2013 ; Sashindranath et al., 2017 ).

Nephritis

Glomerulonephritis is one of the leading causes of end-stage renal disease. Increased expression of pro-apoptotic P2X7R has been demonstrated in both experimental and human glomerulonephritis, which suggests that P2X7R antagonists may have therapeutic potential ( Deplano et al., 2013 ). It was shown later that P2X7R-deficiency attenuated renal injury in experimental glomerulonephritis ( Taylor et al., 2009 ). P2X7R blockade attenuates lupus nephritis by inhibiting inflammasome activation ( Zhao et al., 2013 ) and protects against cisplatin-induced nephrotoxicity ( Zhang et al., 2014 ). The P2R antagonist, pyridoxal-phosphate-6-azophenyl-2′,4′-disulfonate (PPADS), effectively inhibits mesangial cell proliferation in a rat mesangial proliferative glomerulonephritis model. Tubuloglomerular feedback is greatly reduced in Thy-1 nephritic rats, but exogenous 5′-nucleotidase improved it. In P2Y 1 R KO mice, there is protection against fibrosis and death by renal failure as a result of experimental crescentic glomerulonephritis. Adenosine uptake inhibitors attenuated glomerulonephritis in mice. A 2A R agonists may treat macrophage-mediated experimental glomerulonephritis. A 2A R agonists reduced inflammation in mouse kidneys, suggesting a therapeutic approach for human lupus nephritis.

Hypertension

Hypertension is a feature of chronic renal disease; this is due largely to sympathetic overactivity as a result of afferent signals from the kidney and triggering sympathetic tone resetting by activation of hypothalamic centres ( Orth et al., 2001 ). ATP is a cotransmitter released from sympathetic nerves, whose activity is increased in hypertension.

There is an enhanced P2R-mediated vasoconstriction of both efferent and afferent arterioles in chronic angiotensin II-induced hypertensive rats, with predominant P2X1 and P2X7R control of glomerular haemodynamics ( Franco et al., 2017 ). In connexin 30 KO mice, epithelial sodium channels that are unable to respond to changes in sodium levels as a result of reduced paracrine ATP feedback regulation may play a role in salt-sensitive hypertension. Mice lacking P2Y 2 R have salt-resistant hypertension. The P2X7R is expressed weakly in healthy kidney glomerulus, but expression is significantly increased in hypertension ( Vonend et al., 2004 ; Menzies et al., 2015 ). P2X7R antagonists inhibited the development of renal injury and salt-sensitive hypertension in Dahl salt-sensitive rats ( Ji et al., 2012 ). Activation of A 1 R in mouse proximal tubules, modulated deoxycorticosterone acetate-salt hypertension.

Diabetic Nephropathy

Adenosine receptor agonists protect STZ-diabetic rats from nephropathy ( Taskiran et al., 2016 ). A review discusses the role of A 2B R antagonists as therapeutic treatment of diabetic nephropathy ( Quezada et al., 2013 ). CD73 generation of adenosine attenuates diabetic nephropathy ( Tak et al., 2014 ). A 3 R antagonists reduced fibrosis in diabetic nephropathy ( Kretschmar et al., 2016 ). AMP-activated protein kinase has been proposed as a potential treatment of diabetic nephropathy ( Cameron et al., 2016 ). Chronic A 2A R stimulation prevents proteinuria and glomerular damage in experimental diabetes ( Persson et al., 2015 ).

P2X7R agonists evoke renal inflammation and injury induced by high-fat diet in type 2 diabetes, suggesting that P2X7R antagonists might be of therapeutic interest ( Solini et al., 2013 ). P2X7R expression was increased in the STZ diabetic rat model ( Vonend et al., 2004 ). It has been suggested that P2X7R antagonists may be a useful coadjuvant treatment to delay the progression of diabetic nephropathy ( Rodrigues et al., 2014 ). Data has been presented to suggest that activation of P2X7R contributes to the high prevalence of kidney disease found in diabetics ( Rodrigues et al., 2014 ; Menzies et al., 2017 ). Deletion of the P2Y 2 R reduced the development of nephrogenic diabetes insipidus polyuria induced by lithium. Blockade of P2Y 12 R in the renal collecting duct alleviates nephrogenic diabetes insipidus ( Zhang et al., 2015c ).

Nephrotoxicant Injury

Drug-induced nephrotoxicity was reduced by ATP-MgCl 2 . A 1 R antagonists are protective against cisplatin-induced acute kidney injury in rats ( Gill et al., 2009 ). Adenosine antagonists are protective against acute renal failure. A 1 R antagonists also reduce nephrotoxicity induced by the immunosuppressive agent cyclosporine. Cyclosporine increases plasma adenosine levels in kidney transplant patients. A 3 R antagonism is effective against acute tacrolimus toxicity.

Cancer

P2X7R are strongly expressed on human embryonic kidney tumours, associated with increased proliferation ( Adinolfi et al., 2012 ). The anthraquinone, emodin, inhibits human embryonic kidney cancer cell invasiveness by antagonising P2X7R ( Jelassi et al., 2013 ). A prognostic indicator for post-operative cancer-specific survival of clear-cell renal cell carcinoma patients is P2X7R expression ( Liu Z. et al., 2015 ).

Diseases of the Lower Urinary Tract

The early literature has been thoroughly reviewed ( Burnstock, 2014d ; Keay et al., 2014 ).

Urinary Bladder

In contrast to laboratory animals, where the purinergic component of bladder parasympathetic cotransmission is about 50%, in healthy human bladder it is approximately 2% although ATP receptors are expressed by the smooth muscle. In pathological conditions, however, such as neurogenic bladder, outflow obstruction and interstitial cystitis (IC), the purinergic component can be as much as 40% and is consequently a therapeutic target. Botulinum neurotoxin type A (BTXA) is often used to treat bladder incontinence, where it inhibits ATP release as well as acetylcholine (ACh) release both from parasympathetic nerves and urothelial cells. Bladder epithelial cell release of ATP from patients with IC was substantially higher compared to healthy controls. Dysfunction in micturition involves P2X3R in rats with chronic spinal cord-injury, suggesting that P2X3R antagonists could be used to treat neurogenic bladder dysfunction.

Overactive Bladder (OAB) Syndrome

There are valuable reviews that discuss the roles of purinergic signalling in OAB ( Meng et al., 2012 ; Sacco et al., 2015 ). OAB syndrome, which increases in old age, is characterised by frequency, nocturia and urgency, with or without urge incontinence. Women with an OAB exhibit higher ATP levels in their urine compared to controls, suggesting that this could be used as a prognostic marker for detrusor overactivity ( Cheng et al., 2013 ; Silva-Ramos et al., 2013 ). The increased urine ATP concentration is due to increased release of ATP from proliferating urothelium and reduced metabolism of ATP ( Silva-Ramos et al., 2013 ). P2X3R are present in the human bladder and, when upregulated, may play a role in the pathophysiology of OAB.

Patients with metabolic syndrome, where the risk of developing cardiovascular disease and diabetes is increased, exhibit a higher incidence of OAB. P2X3R expression is increased in subepithelial sensory nerves resulting in increased bladder activity. OAB is common among PD patients and inhibition of overactivity by A 2A R antagonists occurs, probably by acting in the CNS to regulate the micturition reflex ( Kitta et al., 2012 ). Uridine diphosphate via P2Y 6 R regulates abnormal smooth muscle activity in the OAB and increases contractions due to P2X1R activation ( Yu W. et al., 2013 ). P2Y 6 -deficiency increases micturition frequency and reduces contractility in the mouse urinary bladder ( Kira et al., 2017 ).

Unstable Bladder

Unstable bladder (also referred to as detrusor instability or detrusor hyperreflexia) is either neurogenic or idiopathic in origin. Neurogenic detrusor instability can occur as a result of a stroke, or pelvic or spinal cord injury, as well as in PD and MS. Neurogenic bladders are hyper-responsive to ATP, via P2X3R.

Expression of P2X2R in both urothelium and detrusor muscle of suprasacral spinal cord injury patients are similar to P2X2R expression in bladder tissue from idiopathic overactive bladder patients. ATP levels increased in the rat spinal cord-injured bladder that activates P2X3 and P2X2/3R on afferent nerve fibres resulting in neurogenic bladder overactivity ( Munoz et al., 2012 ). P2YR agonists ADP, UTP and uridine diphosphate originating in the urothelium augment the contractile overactivity following spinal cord injury. Sympathetic nerve hyperactivity may play a role in reflex sympathetic dystrophy where increased ATP would be released as a cotransmitter to activate P2X1R on smooth muscle resulting in increased contractions of the bladder and P2X3R on sensory nerve fibre terminals resulting in bladder reflexes and nociception. Inhibition of P2X7R expressed at spinal cord injury sites improved the dysfunction of neurogenic bladder ( Munoz et al., 2017 ).

Urothelial cell ATP release (both resting and evoked) was substantially more from rat bladders following chronic spinal cord injury, contributing to bladder hyperactivity development. In a mouse bladder overactivity model, bradykinin facilitated the release of ATP from nerve terminals via prejunctional receptors ( Fabiyi and Brading, 2006 ).

In the absence of P2X3R in KO mice, there is bladder hyperactivity ( Cockayne et al., 2000 ; Vlaskovska et al., 2001 ). AF-219, a P2X3 and P2X2/3R antagonist that is metabolically stable and orally bioavailable, is being investigated as a treatment for urinary tract dysfunction ( Ford and Cockayne, 2011 ).

Idiopathic detrusor instability patients show abnormal bladder purinergic transmission, which may contribute to the symptoms of OAB ( Andersson and Hedlund, 2002 ; O’Reilly et al., 2002 ). There is greater potency of ATP via P2X1R for generating detrusor contractions in unstable bladder patients. Urothelial release of ATP from human bladders from patients with detrusor overactivity occurs in both idiopathic and neurogenic conditions ( Kumar et al., 2010 ). Oxybutynin, administered chronically, results in a shift from muscarinic to purinergic transmission in the rat bladder wall. Expression of P2X3R is increased on suburothelial sensory nerve fibres in idiopathic detrusor overactivity patients ( Liu H. et al., 2013 ).

Interstitial Cystitis (IC)/Bladder Pain Syndrome

The possible roles of ATP and adenosine in IC/bladder pain syndrome are discussed in a review ( Veselá et al., 2012a ). Hypoosmotic mechanical stimulation of urothelial cells released ATP that was substantially increased in cyclophosphamide-induced inflamed bladder ( Smith et al., 2005 ). In rats with cystitis induced by hydrochloric acid, purinergic receptors were lost, although release of ATP from mucosal cells was increased.

Contractions of the rat bladder mediated by parasympathetic nerve stimulation and release of ATP and ACh, were reduced in cyclophosphamide-induced cystitis ( Veselá et al., 2012b ), while P2XR function in sensory neurons was enhanced. The purinergic component was abolished in the neurogenic bladder following desensitisation with α,β-methylene ATP (α,β-meATP). ATP release due to stretch from bladder urothelium from IC patients was greater compared to healthy urothelium and P2X3R expression was upregulated. Urothelial cells from cats with feline IC responded to α,β-meATP, indicating increased expression of urothelial P2XR. There is mechanical hypersensitivity of the bladder in feline IC together with greater release of ATP from the urothelium; P2X1R expression is reduced and P2Y 2 R expression is lost.

A 1 R blockade during the initial phase of IC/bladder pain syndrome was suggested as a treatment for this condition ( Aronsson et al., 2012 ). The A 1 R in rat urinary bladder is decreased in cyclophosphamide-induced cystitis ( Veselá et al., 2011 ).

In neutrophils and macrophages in the submucosa of the bladder from mice with cyclophosphamide-induced haemorrhagic cystitis, expression of P2X7R is increased ( Martins et al., 2012 ). Treatment with A-438079, a P2X7R antagonist, or genetic ablation of this receptor reduced nociceptive behaviour.

Outflow Obstruction

P2X1R expression in smooth muscle of the bladder was increased in the human obstructed bladder. In animal models of outlet obstruction, in vivo release of ATP from urothelial cells was increased compared to controls ( Akino et al., 2011 ). Contractions to ATP were reduced in obstructed urinary bladder of rats ( Sjuve Scott et al., 2004 ). There is P2X3R up-regulation in interstitial cells of Cajal in an experimental rat model of partial bladder outflow obstruction ( Li et al., 2013 ). In the pig, partial bladder outlet obstruction resulted in reduced contractions in response to electrical field stimulation as well as to purinergic agonists ( Milicic et al., 2006 ), but in the rat partial outlet obstruction model, contractions to ATP were increased after 2 weeks and 3 months ( Murakami et al., 2008 ). Patients with bladder outflow obstruction release higher amounts of ATP into the urine ( Silva-Ramos et al., 2016 ).

Botulinum Toxin A (BTXA) and ATP Release

BTXA is increasingly being used to treat detrusor overactivity. In an early paper, it was shown that BTXA inhibited ATP as well as ACh release from parasympathetic nerves. Recently, BTX has been shown to inhibit ATP release from the urothelium ( Chancellor et al., 2008 ; Ikeda Y. et al., 2012 ; Cruz, 2013 ). Daytime frequency, urgency, nocturia and pain were decreased by injection of BTXA into the human bladder. BTX is used to treat OAB syndrome and bladder hypersensory states ( Apostolidis et al., 2005 ; Atiemo et al., 2005 ).

Chronic Alcohol Consumption and Bladder Function

Chronic consumption of ethanol impairs purinoceptor-mediated relaxation of detrusor smooth muscle of the rat ( Calvert et al., 2002 ). Ethanol also alters neuronal P2XR.

Diabetic Bladder

Damage to human urinary bladder autonomic nerves and disturbances in micturition in diabetes have been recognised for many years. Urothelial release of ATP has been reported to play a role in bladder dysfunction in type 2 diabetes ( Wang Z. et al., 2013 ). There is a transient increase in sensitivity of the STZ rat whole bladder preparation to α,β-meATP. The cholinergic component of nerve-mediated contractions was reduced in diabetic rat and rabbit bladders, but the purinergic component was increased ( Mumtaz et al., 2006 ).

In STZ mice, the urinary bladder had weaker nerve-mediated contractions in response to electrical field stimulation in contrast to normal mouse bladder. Ca 2+ regulation of ATP release may be impaired in diabetes. Increased adenosine- and ATP-mediated relaxant responses, together with increased ATP-mediated contractile responses were observed in bladders from 8-week STZ diabetic rats. The enhanced contractions of STZ-diabetic rat bladders to nerve stimulation and ATP peaked between 6 and 9 weeks, but dropped to control levels by 12–20 weeks ( Daneshgari et al., 2006 ). There is also an increase in release of ATP in STZ female rat bladders ( Munoz et al., 2008 ). There is upregulation of P2X1R in the bladder of STZ-induced diabetes in the early phase, but downregulation of the P2X2R ( Liu et al., 2008 ). Bladder overactivity occurring 2 months after induction of diabetes with STZ was accompanied by enhanced expression of P2Y 2 and P2Y 4 R ( Suadicani et al., 2009 ).

Bacterial Infection

Bacterial infection of the bladder causes urgency, urinary incontinence and overactivity. Urine ATP concentrations were reduced during episodes of bacteriuria ( Walsh et al., 2013 ). An ATP assay method has been employed for many years to test for bacteriuria in urine.

Bladder Cancer

The growth of bladder cancer cells is reduced by ATP, both in vivo and in vitro ( Shabbir et al., 2008 ; Shabbir and Burnstock, 2009 ). Doxorubicin, used to treat bladder cancer, has side effects, such as increased urgency and urinary frequency. Quercetin, a plant-derived flavonoid, prevents bladder cancer in cells lines, by suppressing cell proliferation and inducing arrest of the cell cycle or cell death by inhibiting the activity of ecto-nucleotidases ( Rockenbach et al., 2013 ). In humans with bladder papillary carcinoma urothelial differentiation was correlated with the expression and localisation of P2X3 and P2X5R ( Sterle et al., 2014 ). High CD73 immunoreactivity was associated with reduced bladder tumour progression ( Wettstein et al., 2015 ). P2X7R protein favoured survival of patients with bladder urothelial cell carcinoma ( Hu J. et al., 2016 ).

Bladder Pain

In 1995, P2X3 homomultimer and P2X2/3 heteromultimer receptors were cloned and were localised on sensory nerve endings. Purinergic mechanosensory transduction was proposed ( Burnstock, 1999 ), suggesting that release of ATP from urothelial cells as a result of distension stimulates P2X3 and P2X2/3R on suburothelial sensory nerve endings to activate high threshold nociceptive nerve fibres that reach the cortex pain centres ( Burnstock, 2009 ). Distension of the bladder stimulates discharge in the nociceptive sensory nerves, which can be mimicked by ATP and can be inhibited by P2X3R antagonists ( Vlaskovska et al., 2001 ). Stimulation of bladder P2X3R sensitises bladder afferent nerves, mimicking the sensitising effect of cyclophosphamide-induced cystitis. P2X3R are a potential target for therapeutic treatment of bladder pain. P2Y 2 R are also expressed on bladder sensory nerves and are claimed to mediate increased stimulation of P2XR-mediated activity, playing a role in bladder pain syndrome (IC) ( Chen et al., 2010 ).

Urethra

The principal non-adrenergic, non-cholinergic inhibitory transmitter to the urethra is NO, but a small component of purinergic neurotransmission is also involved ( Andersson, 2001 ). ATP causes urethral relaxation, probably via P2Y 1 R, in pigs, guinea-pigs, rabbits and hamsters. The responses to non-adrenergic, non-cholinergic nerve stimulation were blocked by α,β-meATP, indicating that the P2X1R subtype was involved.

Sensory nerve fibres supplying the urethra may release ATP during axon reflex activity. Prostaglandins, produced following stimulation of P2YR, contribute to contractions of the urethra in pathophysiological conditions. In the rat, SC19220 (a prostaglandin E1 antagonist), lowered detrusor tone leading to increased bladder capacity and decreased voiding efficiency. Some sensory functions in the urethra are mediated by afferent fibres that express P2X3R ( Canda et al., 2006 ). A review that discusses the therapeutic opportunities offered by K ATP channels in the urethra is available ( Kyle, 2014 ).

Ureter

The ureter motor innervation is sparse, perhaps because peristaltic activity is not neurogenic, but myogenic. The dominant nerves in the ureter are sensory, confined mainly to the suburothelial plexus. These nerves contribute to vesicoureteral reflux that activates reflexes that modulate urine delivery to the bladder.

ATP constricts the pig ureter, while intravesical adenosine evoked relaxation via A 2B R. In the ureter, ATP, α,β-meATP and adenosine evoked transient decreases in the frequency of peristalsis. In the rat ureter expression of P2X1R was shown on smooth muscle, while P2X5 and perhaps P2X7R are expressed on urothelium and P2X6R in the layer beneath the urothelium. P2X3R are localised on subepithelial sensory nerves that mediate nociception produced by release of ATP following distension of urothelial cells ( Knight et al., 2002 ; Rong and Burnstock, 2004 ). Some ureter purinoceptors are likely to participate in long-term (trophic) events during development and regeneration, such as cell proliferation, differentiation, migration and cell death. The human ureter releases ATP in response to distension and human ureteric suburothelial sensory nerves express P2X3R ( Calvert et al., 2008b ). In a review of the pharmacology and physiology of the human ureter, it was proposed that purinergic receptors may prove to be analgesic targets to treat ureteral colicky pain and to facilitate ureteral stone passage ( Canda et al., 2007 ).

Seven days after unilateral ureteral obstruction of wild-type mice, it was shown that there was increased expression of P2X7R associated with fibrogenic responses and inflammation in the cortex. However, in P2X7R KO mice, the alterations seen in the wild-type mice were not present. It was suggested that P2X7R antagonists may play a role in preventing renal interstitial fibrosis. In A 2A R KO mice with unilateral ureteral obstruction, there was a substantially increased progression of renal interstitial fibrosis ( Xiao et al., 2013 ).

Diseases of the Liver

In the liver, the two epithelial cell types that secrete bile, i.e., hepatocytes and cholangiocytes, express purinoceptor in the plasma membrane. Modulation of the release of ATP and purinergic signalling may be novel strategies to manage cholestasis and other bile flow disorders. Both quiescent and activated hepatic stellate cells (HSC) express purinergic receptors: P2Y 2 and P2Y 4 R on quiescent and P2Y 6 R on activated HSC. P2YR on satellite cells could be a therapeutic target to treat or prevent liver fibrosis. Reviews concerned with purinergic signalling in liver disease are available ( Burnstock et al., 2014b ; Vaughn et al., 2014 ).

Liver Injury, Inflammation, Immune Regulation and Repair

Purinergic signalling regulates the immune response in the liver. In A 1 R KO mice α-naphthylisothiocyanate-induced cholestatic liver injury was decreased. CD39-deficient mice treated with adenosine, probably via A 2A R, were protected from reperfusion injury ( Sun et al., 2011 ). A 1 R antagonists abolished ischaemic preconditioning. After the resection of bile-duct-ligated cirrhotic livers, an A 2A R agonist improved liver function ( Iskandarov et al., 2016 ). Inhalation of high concentrations of hydrogen protects against ischaemia/reperfusion injury through A 2A R activation ( Li H. et al., 2017 ). Adenosine, via A 2B or A 3 R, accelerates the cell cycle during partial hepatectomy-induced liver regeneration in rats ( Mendieta-Condado et al., 2007 ). In mice, ATL-146e, a selective A 2A R agonist, prevented concanavalin A-induced acute liver injury.

P2Y 2 R activation in mice makes a major contribution to endotoxin-induced acute liver injury ( Samuel et al., 2010 ). In mice with acute liver injury, P2Y 2 R mediate neutrophil infiltration, regulating immune responses associated with death of hepatocytes. P2Y 2 R antagonists might be useful to treat inflammatory liver disease ( Ayata et al., 2012 ). A review discusses the role of purinergic signalling in sterile liver injury ( Oliveira et al., 2013 ).

Infusion of ATP-MgCl 2 was shown early to improve hepatic function and survival following hepatic ischaemia and after reperfusion. During ischaemia there is a substantial loss of ATP from hepatocytes. Resistance of hepatocytes to hypoxia is promoted by P2Y 2 R. In mice, CD39 deletion from natural killer (NK) cells reduced hepatic ischaemia/reperfusion injury, indicating that during liver regeneration ATP modulates NK cell function. UTP acting via P2Y 2 and/or P2Y 4 R before induction of ischaemia attenuates post-ischaemic hepatocyte apoptosis resulting in a reduction of liver damage ( Ben-Ari et al., 2009 ). Platelet aggregation triggered by ADP may have a role in ischaemia reperfusion injury ( Schulte am Esch et al., 2010 ).

ATP released from sympathetic nerves and from hepatocytes, may participate in the regulation of liver repair. In P2Y 2 R KO mice, hepatocellular proliferation is impaired, indicating that ATP has a trophic role in liver regeneration and growth after injury ( Thevananther et al., 2008 ). ATP release following partial hepatectomy in rats regulates liver regeneration. Apyrase (CD39/NTPDase1) reduces extracellular ATP allowing NK cells to play a role in the regulation of the immune response and to improve liver regeneration ( Graubardt et al., 2013 ). After partial hepatectomy, liver regeneration is enhanced by the K ATP opener, diazoxide ( Nakagawa et al., 2012 ).

Hepatocyte lipoapoptosis contributes to hepatic inflammation in lipotoxic liver injury. Pannexin1 may contribute to hepatic inflammation by increasing ATP release in lipotoxic liver injury ( Xiao et al., 2012 ). Acetaminophen (APAP), used to reduce pain and fever, may damage hepatocytes. In mouse APAP-induced inflammation models, full injury following an overdose involved P2X7R activation ( Amaral et al., 2013 ). P2X7R activate hepatic caspase-1 as well as the migration of neutrophils into the liver, suggesting that ATP may play a major role in the development of inflammasomes following overdose of APAP ( Hoque et al., 2012 ). A438079, a P2X7R antagonist, is protective against APAP-induced liver injury ( Xie et al., 2013 ). P2X4R are involved in liver regeneration after partial hepatectomy in mice ( Besnard et al., 2016 ). P2X1R-regulated IL-22 secretion is required for liver regeneration ( Kudira et al., 2016 ).

Fibrosis and Hepatic Stellate Cells (HSC)

Liver fibrosis followed by cirrhosis is a common cause of liver failure. HSC are the main fibrogenic cells of the liver, which express nucleotide receptors that are functional ( Kruglov et al., 2007 ) and mediate phospholipase D activity ( Benitez-Rajal et al., 2006 ).

Adenosine A 2B R play pro-fibrotic roles in human HSC ( Zhong et al., 2007 ). During fibrosis, HSC proliferate and undergo senescence and A 2A R mediate both these key processes, suggesting that A 2A R antagonists are potential antifibrotics ( Ahsan, 2011 ). A 2A R contribute to the pathogenesis of hepatic fibrosis and A 2A R antagonists may reduce ethanol-induced stellate cell activation and fibrosis ( Szuster-Ciesielska et al., 2012 ; Chiang et al., 2013 ). MRS1754, an A 2B R antagonist, reduced hepatic collagen deposition during fibrosis progression ( Stoll et al., 2012 ).

Activation of P2Y 2 and P2Y 6 R regulates procollagen-1 transcription and may be targets to treat or prevent liver fibrosis, thereby avoiding cirrhosis and chronic liver failure. PPADS, a P2R antagonist, inhibited HSC proliferation and prevented the development of non-biliary liver fibrosis ( Dranoff et al., 2007 ). NTPDase2 is a preferential ATPase that greatly influences inflammation and biliary type fibrogenesis. Ecto-5′-nucleotidase (CD73) gene expression in HSC and portal fibroblasts increased during myofibroblastic differentiation and is a therapeutic target for antifibrotic therapy ( Fausther et al., 2012 ).

Human platelet ATP release contributes to reduced type I collagen production and HSC activation in vitro ( Ikeda N. et al., 2012 ). In progressive fibrosis, eicosapentaenoic acid replenishes hepatic levels of ATP leading to a reduction of steatosis and inflammation ( Jia et al., 2012 ). Blockade of the P2X7R-NLRP3 inflammasome axis is considered to be a potential therapeutic target for liver fibrosis ( Jiang et al., 2017 ).

Cirrhosis

Liver injury induced by alcohol is associated with enhanced inflammatory responses and adenosine, acting via A 2A R, may prove to be an effective strategy for reducing liver injury ( Pritchard et al., 2011 ). During fulminant hepatitis, A 2A R contribute to the anti-inflammatory actions that limit liver damage ( Choukèr et al., 2008 ). In cirrhosis, platelet dysfunction is partly mediated by purinergic signalling. Cerebral A 1 R are involved in liver cirrhosis ( Boy et al., 2008 ). Ectonucleotidase NTPDase 2 is down-regulated in biliary cirrhosis. It has also been claimed that endogenous A 1 R activation may protect mice against liver injury induced by acute ethanol by reducing oxidative stress and decreasing the accumulation of lipid ( Yang et al., 2013 ). ATP-MgCl 2 was used early to improve survival following massive hepatectomy in cirrhotic rats and adenosine partially reversed cirrhosis induced by carbon tetrachloride. In alcoholic liver disease, ATP and uric acid mediate inflammatory cross-talk between immune cells and hepatocytes ( Petrasek et al., 2015 ). A 2A R are involved in the pathogenesis of hepatic cirrhosis ( Chan et al., 2006 ).

Hepatitis

In vitro infection by duck hepatitis B virus, Rous sarcoma virus, and hepatitis delta virus was inhibited by suramin. Sympathetic nerves influence immune-mediated experimental hepatitis ( Neuhuber and Tiegs, 2004 ) and ATP released as a cotransmitter with NA is probably involved. In autoimmune hepatitis P2X7R regulate NKT cells ( Kawamura et al., 2006 ). P2X7R activation participates in hepatitis delta and hepatitis B virus infection of human hepatocytes ( Taylor and Han, 2010 ). Leptin-induced GLUT4 function in stellate cells in non-alcoholic steatohepatitis is mediated by P2X7R ( Chandrashekaran et al., 2016 ). Chronic hepatitis C virus infection evokes progressive liver disease, exhibiting cirrhosis, insulin resistance, fibrosis and finally liver cancer. P2X4 and P2X7R may be a major component of the purinergic signalling complex in hepatitis C virus-induced liver pathogenesis ( Manzoor et al., 2016 ). In rats, A 2A R stimulation inhibited hepatocyte lipotoxicity and non-alcoholic steatohepatitis ( Imarisio et al., 2012 ). Adenosine, via A 2A R, controls NKT-cell-dependent hepatitis induction ( Subramanian et al., 2014 ). Purinergic mechanisms involved in autoimmune hepatitis have been reviewed ( Kapila et al., 2013 ).

Liver Transplantation

Human liver can be maintained successfully under hypothermic conditions for a maximum of 10 h using adenosine at high concentrations, although overcoming ischaemic damage is a major obstacle. However, infusion of ATP can preserve cells injured sublethally by enhancing their recovery following ischaemic injury and purinergic receptor antagonists prevent cold preservation-induced cell death. Upregulation of CD39 post-adenoviral infection prolongs transplant graft survival. After transplantation regeneration of the donor liver is important and ATP, via P2Y 2 R, activates hepatocyte cell cycle progression and proliferation in vitro and modulates growth factor activities in vivo ( Thevananther et al., 2004 ). A 2A R stimulation down regulated adhesion molecules, proinflammatory cytokines and ultimately improved liver function following liver transplantation in rats ( Tang et al., 2010 ). In post-transplant allografts, purinergic signalling is used to predict as well as monitor progression of fibrosis and rejection. Blood from acute rejection patients showed raised intracellular levels of ATP in CD4 + lymphocytes ( Qu et al., 2017 ).

Liver Cancer

Primary liver malignant tumours are subdivided in to hepatocarcinoma, bile duct carcinoma (cholangiocarcinoma) and hepatocholangiocarcinoma. ATP increases calcium uptake by rat hepatoma cells, probably via P2Y 2 or P2Y 4 R subtypes. There is upregulation of P2Y 2 R in human hepatocellular carcinoma cells ( Tak et al., 2016 ), which mediates proliferation and migration of the cells ( Xie et al., 2014 ). Carcinoma-specific expression of P2Y 11 R make a major contribution to ATP-induced signalling that controls cell migration in human hepatocellular carcinoma cells ( Khalid et al., 2017 ). CD39 KO mice showed an increased incidence of spontaneous and induced hepatocellular carcinoma. Intra-arterial injection of an inhibitor of ATP production was suggested as a novel liver cancer therapy. The effects of ATP infusions in vivo on rat hepatocarcinomas have been investigated ( Frontini et al., 2011 ). P2X3R over-expression is involved in poor recurrence-free survival in hepatocellular carcinoma patients and identifies the P2X3R as a potential therapeutic target ( Maynard et al., 2015 ). Inhibition by adenosine of hepatoma cell growth was reported early.

The A 3 R agonist, CF101, inhibited liver metastasis (following colon carcinoma) ( Bar-Yehuda et al., 2008 ). CF102, another selective A 3 R agonist, has anti-inflammatory and anti-tumour effects on the liver and was studied in a clinical trial for hepatocellular carcinoma patients ( Stemmer et al., 2010 ). A 2B R are strongly expressed in human hepatoma cellular carcinoma ( Xiang et al., 2006 ). Mouse regulatory T cell CD39 expression mediated inhibition of NK cell activity and promoted hepatic metastatic tumour growth ( Sun et al., 2013 ). Liver metastasis from colorectal cancer is one of the main causes of cancer-related morbidity and ATP-chemotherapy may effectively treat initially unresectable colorectal liver metastasis ( Hur et al., 2012 ). In hepatocellular carcinoma, up-regulation of ATP-binding cassette transporter genes is mediated by cellular microRNAs ( Borel et al., 2012 ).

Diseases of the Reproductive System

Reviews are available about purinergic signalling in the reproductive system in both health and disease ( Burnstock, 2014c ; Gorodeski, 2015 ).

Disorders of the Male Reproductive Tract

Erectile Dysfunction

Abnormalities in purinergic signalling, including impaired ATP-mediated cavernosal relaxation, may contribute to erectile dysfunction associated with prostate enlargement and diabetes and may provide a target for therapy ( Hupertan et al., 2012 ; Wen and Xia, 2012 ). Normal penile erectile function involves a fine balance between contraction and relaxation in the corpus cavernosum smooth muscle. The strong relaxation induced by ATP via P2YR on human corpus cavernosum is comparable to that produced by NO, thus ATP together with an NO donor may prove to be effective for erectile disorders ( Hupertan et al., 2012 ). ATP released from sympathetic nerves leads to relaxation of cavernosum smooth muscle via P2Y 4 R, whereas ADP, after breakdown of ATP released from endothelial cells, acts via P2Y 1 R on endothelial cells to produce relaxation via NO ( Calvert et al., 2008a ). P2XR might also be involved ( Gur et al., 2007 ; Phillips et al., 2014 ).

In anaesthetised dogs, ATP and adenosine induce penile tumescence, probably via A 2 R; pelvic nerve stimulation also produced tumescence. Impaired adenosine signalling via A 1 R contributes to erectile dysfunction ( Ning et al., 2012a ). Elevated adenosine signalling, via A 2B R, may contribute to priapism, where there is persistent penile erection lasting at least 4 h without sexual excitation ( Dai et al., 2009 ; Ning et al., 2012b ). A review highlights adenosine signalling in penile tissue as a potential therapeutic target to treat erectile disorders ( Wen and Xia, 2012 ). Impaired erectile function occurs in CD73 KO mice resulting in decreased endogenous adenosine. Corpus cavernosum from men suffering from vasculogenic erectile dysfunction show lower ectonucleotidase CD39 activity resulting in ATP accumulation. Human corpus cavernosum relaxation by P2R agonists was substantially reduced in erectile dysfunction patients ( Faria et al., 2010 ). ATP release from cavernosal tissue increased in patients following prostatectomy. Activating ATP-mediated pathways may restore erectile function in diabetics where there is impaired NO bioavailability. It has been suggested that P2X3 antagonists may improve recovery of erectile function ( Li C.L. et al., 2015 ).

Male Fertility and Contraception

ATP increases the fertilising potential of sperm in humans and is used to treat spermatozoa during in vitro fertilisation. In P2X1R KO mice fertility was diminished with decreased number of spermatozoa in the ejaculate ( Mulryan et al., 2000 ). This raises the possibility that P2X1R antagonists would provide a safe and effective contraceptive ( White et al., 2013 ). In rat testes, during spermatogenesis there is differential, stage-dependent immunostaining for P2XR subtypes ( Glass et al., 2001 ), suggesting purinergic targets for both fertility and contraception. ATP triggers the acrosome reaction via P2X7R in human spermatozoa ( Torres-Fuentes et al., 2015 ). Purinergic signalling plays a role in the maturation of sperm cells in the testes. When the selective P2X1 and P2X3R desensitiser, α,β-meATP, was injected into the cauda epididymis, fertility in male rats was impaired. Adenosine stimulates human sperm motility via A 2 R.

Prostatic Hyperplasia

Purinergic compounds have been suggested for the therapeutic treatment of benign prostatic hyperplasia ( Andersson et al., 2002 ). Injection of BTX into the prostate, which reduces ATP and ACh release, treats bladder obstruction hyperactivity, by decreasing prostate size and as such improving urine flow rate ( Chuang and Chancellor, 2006 ).

Disorders of the Female Reproductive Tract

Regulating the proliferation of ovarian granulosa cells as well as steroidogenesis contributes to ovarian pathophysiology, since in rats with polycystic ovarian syndrome, theca hyperplasia occurs ( Salvetti et al., 2009 ). The hydrolysis of ADP and ATP was reduced by ovariectomy and oestradiol replacement therapy ( Pochmann et al., 2004 ). Ovarian tumours arise largely from the surface of squamous-to-cuboid mesothelium covering the ovary. ATP stimulated mitogen-activated kinase in neoplastic and pre-neoplastic surface epithelium, suggesting that co-released ATP from sympathetic nerves may contribute to the regulation of cell proliferation in neoplastic epithelial cells from the surface of the ovary ( Choi et al., 2003 ).

In the human fallopian tube, ATP-mediated contractions are increased during acute purulent inflammation, probably as a result of upregulation of P2X1 and P2X2R ( Ziganshin et al., 2008 ). It has been claimed that targeting P2X7R may lead to new treatments to prevent uterine contractions in preterm deliveries. A naturally occurring P2X7 splice variant, the P2X7jR, blocks P2X7R-mediated actions ( Feng et al., 2006 ). It is co-expressed with P2X7R in female reproductive tract epithelia. The P2X7j isoform hetero-oligomerises with the P2X7R and co-expression of P2X7R and P2X7jR blocks ATP-induced pore formation, and abolishes agonist-induced apoptosis. P2Y 2 R agonists may be a non-hormonal alternative therapy for treating vaginal dryness in post-menopausal women. ATP is considered as a therapeutic target to control uterine activity during difficult labours ( Zafrah and Alotaibi, 2017 ).

The P2X7R contributes to the control of cervical infections. P2X7R-mediated activation of cervical epithelial cells inhibits Chlamydia and mycobacteria infection ( Darville et al., 2007 ). ATP regresses endometriosis in a rat model ( Zhang C. et al., 2016 ). Adenosine in the placenta mediates the placental disturbances induced by alcohol, perhaps contributing to the pathogenesis of foetal alcohol syndrome ( Acevedo et al., 1997 ). Adenosine protects vaginal epithelial cells from T. vaginalis cytotoxicity ( Menezes and Tasca, 2016 ). Plasma adenosine is raised in hyperemesis gravidarum (severe morning sickness) and serves as a prejunctional modulator of sympathetic neurotransmission, which limits further progression of this pregnancy-related disease ( Yoneyama et al., 2004 ).

Preeclampsia

ATP infusion in pregnant rats involved an inflammatory response that occurs in preeclampsia ( Spaans et al., 2014a ). Elevated placental adenosine signalling contributes to the pathogenesis of preeclampsia ( Iriyama et al., 2015 ). Hypoxia stimulates ATP release, which is rapidly broken down to adenosine by ectonucleotidases and women with preeclampsia and their foetuses have increased circulating adenosine concentrations. There is elevation of adenosine A 2A R expression in placental biopsies, villous explants and placental microvillous membranes ( von Versen-Höynck et al., 2009 ). In preeclampsia A 2B R on microvascular endothelial cells have also been implicated ( Escudero et al., 2008 ). Reduced adenosine-mediated angiogenesis in preeclamptic pregnancies may be associated with hypertension development in the offspring ( Escudero et al., 2014 ). The interaction between A 2A R and the angiotensin system may be involved in the early growth of the placenta. A 2A R expression is raised in pre-eclampsia, perhaps as a consequence of poor placental perfusion in preeclampsia ( Kurlak et al., 2015 ). Elevation of ADA activity in women with preeclampsia may contribute to their increased levels of uric acid and pro-inflammatory immune activity ( Giorgi et al., 2016 ). Release of ATP increases in preeclampsia following hypoxia and oxidative/nitrative stress, which acts on P2X4R to influence homeostasis of the placenta ( Roberts et al., 2007 ). There is deficient spiral artery remodelling and trophoblast invasion in preeclampsia, both of which may be inhibited by ATP-induced activated macrophages ( Spaans et al., 2014b ). It was concluded from a study of the relationship between the foeto-placental adenosine release and utero-placental circulatory insufficiency in pregnancies featuring preeclampsia, that foetal plasma adenosine increases before utero-placental insufficiency induces generalised foetal hypoxia ( Yoneyama et al., 1996 ).

Malignant Cancer of Reproductive Organs

Prostate Cancer

Prostate cancer is the second most common male cancer and the third leading cause of cancer death. Prostate cancer cells are sensitive to extracellular ATP. ATP and adenosine inhibit the growth of human prostate cancer cells ( Lertsuwan et al., 2017 ), identified at that time to act via P2Y 1 , P2Y 2 and/or P2Y 4 , P2Y 6 and P2Y 11 R subtypes. Activation of P2Y 1 R inhibited growth and induced cell death of prostate cancer PC-3 cells and P2Y 1 R agonists were claimed to be therapeutically promising for prostate cancer ( Wei et al., 2011 ).

However, prostate tumour cells were shown later to also express P2X4, P2X5, and P2X7R in PC-3 cells and P2X4 and P2X5R in DU145 cells. ATP inhibited tumour cell growth, but not by UTP or adenosine, while 2′(3′)- O -(4-benzoylbenzoyl) ATP increased apoptotic cell death in PC-3 cells, probably via P2X7R. CD73 KO mice resist prostate carcinogenesis and CD73 promoted de novo prostate tumorigenesis. Anti-CD73 monoclonal antibodies decreased tumour growth and metastasis in the prostate ( Stagg et al., 2012 ).

There are many polymorphisms of the P2X7R ( Fuller et al., 2009 ), which, as well as resulting in loss of function, alter receptor activity. Cytolytic P2X7R expression was found in 116 prostate cancer pathology specimens ( Slater et al., 2004 ). In normal tissues from patients with no evidence of cancer, P2X7R were not expressed, suggesting that the appearance of P2X7R is an early marker of prostate cancer.

Prostate tumour cell proliferation is inhibited by adenosine. A 3 R activation by IB-MECA inhibited proliferation of prostate cancer cells and induced cell cycle arrest and apoptosis ( Aghaei et al., 2012 ). Activation of A 3 R suppressed prostate cancer metastasis ( Jajoo et al., 2009 ). The ATP synthase β subunit also plays a role in prostate cancer metastasis ( Li W. et al., 2017 ).

Breast Cancer

Inhibition of growth of human breast cancer cells by ATP was shown for the first time in 1993. Chemotherapeutic ATP release from breast tumour cells of mice increased tumour regression through apoptosis and it was suggested that P2Y 2 and/or P2Y 4 R were involved. Oestrogen, acting via oestrogen receptor α, promoted proliferation of breast cancer cells by down-regulating expression of P2Y 2 R and reducing P2Y 2 R-induced increase in [Ca 2+ ] i ( Li et al., 2011 ). P2Y 2 R activation by ATP released from cancer cells induces the invasion of metastatic breast cancer cells ( Eun et al., 2015 ). Up-regulation of P2Y 6 R occurs in the mesenchymal phenotype of breast cancer cells and inhibition of P2Y 6 R may be a useful therapeutic target for metastasis of breast cancer ( Azimi et al., 2016 ; Ma X. et al., 2016 ).

Antibody therapy with anti-CD73 inhibited breast tumour growth and metastasis ( Stagg et al., 2010 ). Bisphosphonates are also effective inhibitors of breast cancer ( Fehm et al., 2012 ). Proteomic analysis of human breast carcinoma revealed upregulation of ATP synthase in tumours and the ATP synthase inhibitor, aurovertin B, inhibited proliferation of several breast cancer cell lines ( Huang et al., 2008 ). Malignant breast carcinoma cells release ATP making the pre-metastatic environment suitable for micro-metastasis in lymph nodes and associated afferent lymph vessels ( Kawai et al., 2008 ).

In breast tumour cells ATP increased [Ca 2+ ] i and high concentrations produced apoptosis via P2X7R. Activation of P2X7R in the human breast cancer cell line, T47D, increased cell migration and development of metastases, suggesting that P2X7R antagonists may have therapeutic roles ( Xia et al., 2015 ). The role of hypoxia in the regulation of tumour progression has been debated. However, P2X7R expression is increased by hypoxia and hypoxia-driven increase in P2X7R enhances tumour cell invasion and migration. Silencing of P2X5R inhibited cell proliferation and may be a new mechanism to target cancer metastasis.

A 1 and A 3 R mRNA are expressed on human breast tumours ( Panjehpour et al., 2012 ). Adenosine induces tumour cell proliferation and migration of T-47D and MCF-7 breast carcinoma cell lines ( Mujoomdar et al., 2004 ). MDA-MB-231, a human breast cancer cell line, expressed A 2B R, which mediated cell proliferation and A 2B R inhibition slowed growth of breast tumours ( Cekic et al., 2012 ). A 3 R agonists reduced bone metastasis of breast cancer, suggesting a therapeutic approach to bone-residing breast cancer ( Varani et al., 2013 ).

Cervical Cancer

HeLa cells from human cervical cancer are used to study purinergic signalling involvement in cancer. Activation of P2Y 2 R with UTP and ATP caused proliferation of HeLa cells. P2Y 4 and P2Y 6 R expression increased during proliferation. Stimulation of P2Y 1 R on HeLa cells triggered epidermal growth factor receptor mitogen signalling and P2Y 1 antagonists reduced proliferation. Permeabilisation of cervical cancer cells to a cytotoxin is activated by P2YR ( Bukhari et al., 2015 ). P2Y 6 R activation induces HeLa cell migration ( Gendaszewska-Darmach and Szustak, 2016 ). Oestrogen reversed the apoptotic activity mediated by P2X7R in normal human cervix, but not in cervical epithelial cancer cells. A truncated P2X7R variant (P2X7-j), expressed in cervical cancer cells, antagonised the P2X7R through hetero-oligomerisation. Gentle mechanical stimulation released ATP from HeLa cells. The presence of ectonucleotidase in human cervical cancer cell regulates the levels of nucleotides, limiting their effects ( Beckenkamp et al., 2014 ).

Ovarian Cancer

ATP raised [Ca 2+ ] i and stimulated growth of SKOV-3 and OVCAR-3 human ovarian carcinoma cells. ATP may act as a messenger to control the ovarian epithelial cell cycle through P2Y 2 R on human ovarian cancer cells. A 2 R antagonists inhibited angiogenic activity of human ovarian cancer cells. The treatment of human ovarian carcinoma with cisplatin in the presence of ATP results in additive cytotoxicity ( Rotte et al., 2010 ). P2X7R were highly expressed in both human ovarian tumours and ovarian cancer cell lines and paracrine release of ATP acts on P2X7R to cause proliferation of ovarian cancer cells ( Vazquez-Cuevas et al., 2014 ).

Uterine Cancer

P2Y 2 R play a role in the control of the cell cycle and in the suppression of proliferation of human endometrial carcinoma cells. The P2X7R has been used as a biomarker for uterine epithelial cancers. There is decreased P2X7R expression on endometrial epithelium in pre-cancerous and cancer cells ( Li et al., 2007 , 2009 ). Activation of P2X7R-dependent apoptosis has a chemotherapeutic growth-preventive effect on pre-cancerous and early cancerous epithelial lesions ( Fu et al., 2009 ; Gorodeski, 2009 ). Loss of CD73 in endometrial cancer allows for tumour progression ( Bowser et al., 2016 ). A higher proportion of ADA2 ∗ 1/ ∗ 1 genotype was observed in women with uterine leiomyomas ( Gloria-Bottini et al., 2016 ).

Skin Diseases

Reviews about purinergic signalling in the skin during health and disease have been published ( Burnstock et al., 2012b ; Geraghty et al., 2016 ). Changes in P2R subtype expression occurs in the epidermis during proliferative disorders, such as psoriasis and scleroderma, and P2Y 2 R may be a novel target to treat these disorders. ATP plays an important role in wound healing, the defence response, innate immunity and inflammation in the skin and might be an important therapeutically in psoriasis and scleroderma.

Psoriasis

Psoriasis is a chronic skin disease involving epidermal hyperproliferation. ATP and parathyroid hormone-related protein increased proliferation in HaCaT cells and may account for the hyperproliferation that occurs in psoriasis. P2Y 2 R contribute to epidermal homeostasis and indicate a possible therapy for psoriasis. P2Y 11 R mediate IL-6 production in human keratinocytes, which is important in psoriasis ( Ishimaru et al., 2013 ). P2X7R signalling induces inflammation leading to differentiation of Th17 lymphocytes, which are involved in the pathogenesis and potential treatment of psoriasis ( Killeen et al., 2013 ). P2X7R play a role in shaping the inflammatory microenvironment in psoriasis ( Lioi et al., 2015 ). Strong P2X7R expression is confined to the basal layer cell membrane, while P2Y 1 R were expressed all through the psoriatic epidermis.

In the blood of psoriasis patients, there are high levels of adenosine. Adenosine raised cyclic AMP levels in lesions of epidermis from psoriasis patients. There is a defective purine nucleotide synthetic pathway in patients with psoriasis and nucleotide metabolism is altered in psoriatic keratinocytes. In psoriasis patients, ADA levels were significantly elevated in both serum and epidermis. It was concluded from a clinical trial that caffeine, a P1R antagonist, is an inexpensive, safe and effective treatment for psoriasis. The role of adenosine as an endogenous mediator of the pathogenesis of psoriasis has been reviewed ( Festugato, 2015 ) and clinical trials for the use of A 3 R agonists for the treatment of psoriasis described ( Borea et al., 2015 ; Kofoed et al., 2015 ). A 2A R are upregulated in psoriasis and A 2A R agonists may counteract inflammation in this disease ( Merighi et al., 2017 ). A 2B R are also expressed by human epidermal keratinocytes and their expression is reduced in psoriasis ( Andrés et al., 2017 ).

Scleroderma

Scleroderma encompasses a spectrum of disorders that cause dermal fibrosis and systemic sclerosis (SSc). SSc is a severe disease of the connective tissue of affected organs, including the skin. Adenosine A 2A R contribute to the pathogenesis of dermal fibrosis and may be a therapeutic target to treat and prevent dermal fibrosis in scleroderma ( Chan and Cronstein, 2010 ). Fibroblasts from SSc patients had a high rate of spontaneous IL-6 release, which was increased by ATP stimulation. SSc fibroblasts expressed mRNA for P2X3, P2X4, P2X7, P2Y 1 , P2Y 2 , P2Y 4 , and P2Y 6 , suggesting a possible therapeutic role for P2R antagonists in SSc patients via modulation of fibroblast function.

Skin Inflammation

The skin is an immune defence organ. Chemical, immune-specific or physical insults evoke increased expression of proinflammatory mediators, in particular keratinocytes release chemokines. Release of ATP is associated with inflammation of the skin, as well as increase in expression of, in particular, P2X7 and perhaps P2Y 1 R, and subsequent release of proinflammatory cytokines. Skin inflammation is reduced by P2X7R antagonists.

In ectonucleotidase (CD39) KO mice, rapid ATP release from keratinocytes is triggered by irritant chemicals causing exacerbated skin inflammation. Ultraviolet (UV) radiation evokes ATP release from keratinocytes and P2Y 6 R mediate UV radiation-induced inflammatory responses ( Takai et al., 2011 ). ATP, when released after trauma or infection, may enhance immunoresponses and P2R agonists may increase vaccine efficacy. A 1 and A 2 R may function as cutaneous neurogenic pro-inflammatory mediators. Human skin keratinocytes infected by Staphylococcus aureus , which releases α-toxin, exhibited a transient reduction in cellular ATP levels ( Suriyaphol et al., 2009 ). P2X3 and P2X2/3 nociceptive receptors on sensory nerve endings are increased in inflamed skin and antagonists to these receptors have been developed as analgesics.

Wound Healing

Topically applied A 2B and particularly A 2A R agonists promote cutaneous wound healing in both healthy and diabetic conditions. A 2A R agonists also promote collagen production by dermal fibroblasts. Adenosine inhibits proliferation of vascular smooth muscle cells via A 2 R activation. A review discusses the involvement of A 2A and A 2B R signalling in wound healing and fibrosis ( Shaikh and Cronstein, 2016 ).

ATP and ADP also play a role in wound healing. ATP, released by damaged cells and physiologically during gentle mechanical stimulation, contributes to wound healing, tissue repair and regeneration. Cutaneous wound healing is accelerated by Mg-ATP, probably by increasing synthesis of vascular endothelial growth factor. Release of ATP from platelets and other cells during wound healing results in an increase in [Ca 2+ ] i in keratinocytes, associated with epidermal growth and differentiation. ATP improves ischaemic skin flap survival after surgery, while P2R antagonists accelerate barrier repair.

There is acute inflammation in the initial phase of wound healing. ATP is involved in the development of inflammation through P2X7R-mediated production and release of cytokines from immune cells. The presence of P2X7R on immune cells mediates killing of intracellular pathogens by stimulating apoptosis of the host macrophage, chemo-attraction and cell adhesion. In contrast, adenosine has anti-inflammatory effects. ATP released following infection and trauma acts as an endogenous adjuvant to increase the immune response and P2R agonists may enhance the efficacy of vaccines.

Wound healing also involves new vessel growth (angiogenesis) and both ATP and adenosine contribute to cell proliferation and migration during angiogenesis. In cultured porcine artery smooth muscle cells, ADP and ATP stimulate DNA synthesis and cell proliferation. ATP and UTP are mitogenic in human vascular smooth muscle cells and P2Y 2 and P2Y 4 R might be involved.

Wound healing is delayed in denervated wounds. In a rat model of this, P2X5, P2X7, P2Y 1 , and P2Y 2 R expression was altered in the epidermis. P2Y 1 R expression was increased in the basal proliferating layer of keratinocytes in the regenerating epidermis, while P2Y 2 R were significantly decreased. ATP and UTP, probably via P2Y 2 R, increased proliferation of the MCS-P5 murine keratinocyte cell line, and enhanced wound healing in mice ( Kehasse et al., 2013 ; Jin et al., 2014 ). ATP release and P2YR signalling mediate electric field-stimulated directional keratinocyte migration ( Riding and Pullar, 2016 ). A review discussed the clinical applications of purinergic compounds to enhance wound healing ( Gendaszewska-Darmach and Kucharska, 2011 ).

Warts

Warts are caused by human papillomavirus infection of epidermis basal keratinocytes. P2X5R staining was increased in warts. P2X7R immunoreactivity was found in hyperkeratotic areas of the stratum corneum and in nuclei of koilocytes in the wart suprabasal layers. The nuclei positive for P2X7R were shrunken, showing much more intense P2X7R staining. The expression of P2X7R in the nucleus of human papillomavirus-infected cells was associated with disruption of the cellular machinery. P2X7R agonists may be used to trigger apoptosis in these virally infected cells. P2X5 and P2X7R are being explored for the treatment of warts.

Allergy

Contact allergen sensitisation involves immune system activation by endogenous danger signals. P2X7R KO mice exhibit resistance to contact hypersensitivity. P2X7R KO dendritic cells do not induce sensitisation in response to contact allergens or release IL-1β in response to ATP. This suggests that P2X7R are crucial for release of ATP from skin in response to contact allergens. Interference with P2X7R signalling could be a therapeutic approach to prevent allergic contact dermatitis.

Hailey–Hailey and Darier Diseases

These are autosomal dominant skin disorders and are characterised by epidermal keratinocyte dissociation (acantholysis) at the epidermis suprabasal layer. In lesions P2Y 2 R are not localised on acantholytic cells, but P2X7R appear in the plasma membranes, potentially mediating apoptosis.

Barrier Function

The skin protects the water-rich internal organs from environmental dryness, with the stratum corneum being critical to the water-impermeable barrier. Topical application of ATP and α,β-meATP via P2XR delayed barrier recovery, damaged by surfactant, organic solvent or tape stripping. P2R antagonists, however, accelerated barrier repair. In mice skin wounds healed faster following treatment with ATP-encapsulated fusogenic lipid vesicles rather than with lipid vesicles. PPADS, a P2XR antagonist, accelerates skin barrier repair and prevented epidermal hyperplasia.

Burns

There is increased concentration of adenosine in burn blister fluid, and depletion of ATP in skin after thermal injury. ATP has a protective effect against skin burns. ATP-MgCl 2 administration following burn injury reversed the damage to the intravascular clearing of lipid emulsions within the reticuloendothelial immune system. Glucose metabolism was affected by ATP in thermally injured skin.

Burn injury produces severe pain and the relieving effects of tetramethylpyrazine, a Chinese medicine, are claimed to be due to it acting as a P2X3R antagonist ( Gao Y. et al., 2010 ). Skin P2X3R expression was increased on sensory nerve terminals in first and second degree burns, but, following treatment with tetramethylpyrazine, P2X3R expression was reduced. P2X3R may play a role in the short-lasting thermal hyperalgesia induced by mild heat injury ( Füredi et al., 2010 ). After a superficial skin burn, adenosine reduced the skin area showing hypersensitivity.

Pain

Skin pain is associated with changes in sympathetic nerve activity and ATP released from rat sympathetic nerves as a cotransmitter with NA may modulate cutaneous nociceptors. P2X3R are expressed on sensory neurons in DRG, nodose and trigeminal ganglia that innervate cutaneous tissues. ATP and ADP stimulate skin afferent nerve terminals and skin cell damage stimulates nociceptive sensory nerves via ATP release. In rat skin with carrageenan-induced inflammation, nociceptors can be selectively activated with α,β-meATP, indicating the involvement of P2X3R. ATP contributes to the enhanced sensitivity of inflamed skin nociceptors, leading to heat hyperalgesia. P2X3R antagonists are anti-nociceptive. UV light evokes hypersensitivity of skin to ATP-induced pain. After subcutaneous bee venom injection, there is reduction of prolonged pain by PPADS, and it was suggested that stimulation of P2XR in the spinal cord contributes to cutaneous pain. The terminals of nociceptive neurons in the skin are targets for P2X3R antagonists. UTP sensitises a subpopulation of cutaneous C-fibre nociceptors to mechanical stimuli. There is increased P2X3R expression on calcitonin gene-related peptide-positive sensory fibres during the growth of tumours, mediating nociception. Increased expression of skin glial cell neurotrophic factor increases the mechanical sensitivity of nociceptive afferents expressing P2X3R.

Ecto-5′-nucleotidase (CD73) is located on nociceptive terminals and epidermal keratinocytes in the epidermis, which, by hydrolysing AMP to adenosine, is suggested to be anti-nociceptive. Blockade of peripheral P2Y 1 R prevents thermal hyperalgesia ( Kwon et al., 2014 ). Mechanical allodynia is induced by α,β-meATP, which sensitises P2X3R on cutaneous nociceptive sensory fibres ( Ren et al., 2015 ).

Reviews with coverage of purinergic signalling and cutaneous pain are available ( Zhu and Lu, 2010 ; Burnstock, 2016c ).

Dermatitis

In irritant dermatitis, there is a pathogenic role for keratinocyte-derived ATP. The necrosis produced by the chemical irritant croton oil was prevented by the pre-treatment with A438079, a selective P2X7R antagonist ( Zanin et al., 2015 ). Topical application of A 2A antagonists prevents radiation dermatitis ( Perez-Aso et al., 2016 ).

Skin Cancer

Different subtypes of P1R and P2R are involved in skin cancer, playing roles in differentiation, apoptosis and proliferation. The roles of purinoceptors are complicated because there are multiple receptor subtypes on the same cell, which can have opposing effects. For example, P2Y 2 R mediate an increase in tumour cell numbers, while P2Y 1 , P2X5, and P2X7R mediate a decrease in cell numbers. In cancers of the skin, proliferation outweighs apoptotic cell death.

UV light is a stimulus for the genesis of cutaneous cancer, including basal and squamous cell carcinoma as well as melanoma, where the UV-B component has the most severe effects. UV-B irradiation decreases the amount of P2X1, P2Y 2 , and P2X7R, which contributes to the malignant transformation of keratinocytes ( Ruzsnavszky et al., 2011 ).

Basal and Squamous Cell Carcinomas

Basal cell and squamous cell carcinoma are tumours that generally occur after the age of 50, squamous cell carcinoma being the more common and aggressive of the two. Nucleoside analogues reduced basal cell carcinoma growth. A human cutaneous squamous cell (epidermal) carcinoma cell line, A431, express P2R that induce increases in [Ca 2+ ] i . ATP-stimulated A431 cells induced production of inositol-trisphosphate, suggesting the involvement of P2YR. P2X5 and P2YR were strongly expressed on both squamous and basal cell carcinomas. P2X7R are expressed in apoptotic cells in superficial multifocal and infiltrative cells and in the necrotic centre of nodular basal cell carcinomas. Expression of P2Y 1 R was confined to the stroma surrounding tumours. P2Y 4 R were present only in basal cell carcinomas. ATP and UTP at low concentrations induced an increase in the number of A431 cells, while high concentrations substantially decreased cell numbers.

ATP via P2X7R caused apoptosis of A431 cells and UTP and adenosine (after ATP breakdown) also induced cell death ( Völkl et al., 2008 ). 2′(3′)- O -(4-Benzoylbenzoyl) ATP, a potent P2X7R agonist, reduced skin carcinoma and papilloma and formation ( Fu et al., 2009 ). ADA in saliva was shown to be a diagnostic marker of tongue squamous cell carcinoma ( Rai et al., 2011 ).

Melanoma

Malignant melanoma, which is highly metastatic, is derived from melanocytes. ATP inhibited the growth of both human and animal melanoma cells in vivo . CD39 is over-expressed in differentiated human melanomas. Expression of P2X7R was increased in superficial spreading melanoma patients, which were later shown to be functional and may be a therapeutic target for melanoma therapy ( White et al., 2005 ). A low pH environment as seen in solid tumours induced ATP release from B16 melanoma cells, which increases proliferation via P2X7R. Oxidised ATP, a P2X7R antagonist, inhibited tumour growth ( Hattori et al., 2012 ). P2Y 1 , P2Y 2 , and P2Y 6 R mRNA and protein expression was observed in human melanomas. The presence of P2Y 1 and P2X7R, which had been suggested to be therapeutic targets for melanoma treatment using ATP, was demonstrated by immunohistochemistry ( White et al., 2009 ). The release of ATP from murine B16 melanoma cells was shown to upregulate CD39 expression on regulatory T cells. Dying tumour cells release ATP, which accumulates at high concentrations and acts as an immune danger signal, although it can also kill adjacent tumour cells directly via P2X7R ( Feng et al., 2011 ). Accelerated melanoma tumour progression in mice lacking P2X7R has been reported ( Adinolfi et al., 2015 ). γ-Irradiation that induces arrest in tumour cell growth and death, induced P2X7R-dependent release of ATP from B16 cells ( Ohshima et al., 2010 ).

In an animal model of melanoma, tumour growth was reduced in CD73 KO mice ( Yegutkin et al., 2011 ). Implanting B16 cells into CD73 KO mice, thereby decreasing the production of adenosine, resulted in reduced tumour growth ( Ring et al., 2011 ). Adenosine potentiated the in vivo actions of chemotherapeutic agents. Antimetastatic therapies based on inhibition of A 1 R activation have been suggested. A 1 , A 2A , A 2B and A 3 R subtypes are expressed in the A375 human malignant melanoma cell line. A 3 R activation resulted in growth inhibition of melanoma cells ( Morello et al., 2011 ). However, another study claimed that adenosine, acting through A 3 R, induced cell proliferation of human malignant melanoma C32 cells ( Soares et al., 2012 ). A 2B R antagonists impaired IL-8 production that is raised in malignant melanoma patients, while A 3 R antagonists decreased vascular endothelial growth factor that promotes human carcinoma cell angiogenesis and metastasis ( Merighi et al., 2009 ). Adenosine is a potent immunoregulatory factor modulating cytotoxic activity and cytokine production of anti-melanoma specific T cells.

In conclusion, P2Y 2 R mediate proliferation, P2X5R mediate differentiation (i.e., are antiproliferative) and P2X7R mediate cell death. Therefore, P2Y 2 R antagonists and P2X5 and P2X7R agonists have therapeutic potential for the treatment of skin cancer.

Musculoskeletal Diseases

Reviews that include discussion of the pathophysiology of musculoskeletal diseases have been published ( Burnstock et al., 2013 ; Young et al., 2013 ; Agrawal and Gartland, 2015 ; Jørgensen et al., 2015 ; Orriss et al., 2016 ). There are multiple purinoceptor subtypes expressed by bone and cartilage, which are potential targets for original therapeutic strategies to inhibit bone resorption in osteoporosis, rheumatoid arthritis (RA), periodontitis and tumour-induced osteolysis.

Muscular Dystrophy

ATP was used early to treat myopathies, although the mechanism of action was not known. Allopurinol has been used for the treatment of Duchenne muscular dystrophy (DMD). It counteracts low purine nucleotide degradation levels that occur in Duchenne muscle, but chronic administration of allopurinol failed to improve DMD symptoms. Lymphoblastoid cells from DMD patients were found to be highly sensitive to ATP stimulation.

The mdx model of DMD, lacking the dystrophin protein, mimics muscle damage and subsequent regeneration. Sequential expression of P2X5, P2Y 1 and P2X2R was described during muscle regeneration in the mdx model ( Ryten et al., 2004 ). It was claimed recently that a P2Y 2 R antagonist may ameliorate cardiomyopathy in DMD ( De Oliveira Moreira et al., 2017 ). P2Y 1 R were expressed on infiltrating immune cells. A purinergic dystrophic phenotype was seen during the earliest stage of developing dystrophic muscle. Dystrophic myoblasts express P2X4 and P2X7R proteins and it was claimed that antagonists to these receptors may be of potential therapeutic benefit. ATP signalling is altered in muscular dystrophy, but was partly recovered after nifedipine treatment ( Valladares et al., 2014 ). It was claimed that dihydropyridines may be used as a therapeutical tool to reduce muscle damage observed in dystrophic muscles. It was suggested that P2XR antagonists alter the adaptive immune component in the muscle infiltrates in DMD and are a promising therapeutic approach to treat DMD ( Gazzerro et al., 2015 ).

Myofascial pain is a feature of DMD and ATP stimulates myofascial nociceptors. P2X7R upregulation occurs in dystrophic mdx mouse muscles and treatment with P2X7R antagonists slows the progression of DMD ( Sinadinos et al., 2015 ). Sensitivity to ATP is higher, release of ATP is greater and expression of P2Y 2 R is increased, but P2Y 1 R expression is decreased in mdx mice. A review about purinergic receptors in DMD was published ( Krasowska et al., 2014 ).

Myasthenia Gravis (MG)

Myasthenia gravis is an autoimmune disease, which affects the neuromuscular junction. Lack of neuronal A 2A R-mediated Ca v 1 (L-type) influx causes tetanic failure in MG ( Noronha-Matos et al., 2011 ). It was suggested that the adenosinergic pathway was dysfunctional in autoimmune MG and that stimulation of CD73 activity and A 2A R may have therapeutic potential for MG ( Oliveira et al., 2015 ).

Fibromyalgia

Fibromyalgia (a musculoskeletal disease) is characterised by allodynia, as well as mood disorders. In fibromyalgia patients, there are decreased levels of ATP in platelets perhaps contributing to the pathogenesis of the disease ( Bazzichi et al., 2008 ).

Osteoporosis

Osteoporosis, characterised by bone mass loss (bone mineral density decrease), leads to a high risk of bone fracture. The P2X7R is considered to be important in relation to the treatment of osteoporosis ( Kvist et al., 2014 ). P2X7R plays a critical role in both cortical and cancellous bone mass augmentation and were shown to stimulate cancellous and periosteal bone formation and inhibit cancellous bone resorption during growth. Single nucleotide polymorphisms of the P2X7R gene are associated with the risk of fractures, decrease in bone mineral density and osteoporosis. P2X7R are involved in the formation of human osteoclasts. P2X7R antagonists are being considered for the treatment of osteoporosis and with remodelling disorders, where bone mass is reduced ( Jørgensen et al., 2011 ). Skeletal pain accompanies osteoporosis and P2X2/3R might have a role in osteoporosis patients under a high bone turnover state ( Iba and Yamashita, 2016 ). P2X5R may be a therapeutic target for treatment for inflammatory bone loss ( Kim et al., 2017 ). Polymorphisms in the P2X4 and P2X7R genes ( Husted et al., 2013 ) and the Leu46Pro polymorphism of the human P2Y 2 R gene were linked to bone mineral density and the risk of osteoporosis in Dutch fracture patients ( Wesselius et al., 2013 ). It was suggested that clopidogrel, a P2Y 12 R antagonist used for stroke and thrombosis, increases the risk of fractures in osteoporotic patients ( Jørgensen et al., 2012 ). P2Y 13 R antagonists have also been proposed for the treatment of osteoporosis ( Wang N. et al., 2013 ).

Adenosine receptors are involved in osteoporosis ( McPhee and Whiting, 1989 ). Trans -differentiation of osteoblasts to adipocytes, which involves A 2B R, may contribute to the pathogenesis of osteoporosis ( Rayalam et al., 2011 ). P1R might be targets for treating osteoporosis and other diseases characterised by excessive bone turnover.

Osteoarthritis (OA)

Osteoarthritis is a degenerative joint disease as a result of wear of the articular cartilage due to abnormal load to the joint or from infection, trauma or due to ageing. The pain from OA is due largely to inflammation. Increased ATP levels and 5′-nucleotidase activity are present in osteoarthritic joint synovial fluid, compared to the joints from RA patients, particularly from osteoarthritic patients where deposition of calcium-containing crystals were also present. ATP contributes to pathologic mineralisation in articular cartilage and therefore P2R antagonists might provide therapeutic tools for crystal-associated arthritis ( Costello et al., 2011 ). ATP levels in knee synovial fluid of patients with OA are related to pain intensity ( Kumahashi et al., 2011 ). P2X3 and P2X2/3R play an important role in the development of articular hyperalgesia of arthritic joints ( Teixeira et al., 2016 ). In the long-term complications following total hip arthroplasty, different polymorphic variants of the P2X7R are associated with high or reduced periprosthetic osteolysis ( Mrazek et al., 2010 ). There are elevated concentrations of ATP in the synovial fluid of dogs with OA ( Torres B.T. et al., 2016 ). Purinergic signalling, via P2R, produces calcium oscillations in migratory chondrogenic progenitor cells isolated from OA cartilage ( Matta et al., 2015 ). Platelets promote cartilage repair and chondrocyte proliferation via release of ADP in a rodent model of OA, suggesting that P2Y 1 or P2Y 12 R agonists may be useful for treatment of OA ( Zhou Q. et al., 2016 ). Treatment with the selective P2X7R antagonist, AZD9056, produced pain-relieving and anti-inflammatory effects in rats with OA ( Hu H. et al., 2016 ).

Adenosine signalling is also involved in OA. Adenosine, produced following breakdown of ATP, is released from chondrocytes and contributes to tissue damage in arthritic conditions. The regulation of LPS-induced IL-6 release involves A 2A R, indicating that adenosine has a regulatory role in controlling osteoclastogenesis and inflammation. Electromagnetic field stimulation up-regulates A 2A R in synovial fibroblasts and adenosine, acting through both A 1 and A 2A R, had anti-inflammatory activity to control joint inflammation ( De Mattei et al., 2009 ). A 2A and A 3 R agonists modulate prostaglandin E 2 and cytokine release in human osteoarthritic fibroblasts ( Ongaro et al., 2012 ). Adenosine receptors also mediate regulation of inflammatory responses in human synoviocytes ( Varani et al., 2010b ). A 2A R agonists are used to reduce joint destruction due to septic arthritis ( Cohen et al., 2004 ). A 2A R deletion resulted in the development of OA in mice, suggesting that A 2A R agonists might be a target for the treatment of OA ( Corciulo et al., 2017 ).

Rheumatoid Arthritis (RA)

The potential involvement in RA of purinergic signalling was recognised first in the 1990’s when concentrations of adenosine, after released ATP was broken down, were reduced in synovial fluid in RA compared to OA. Increased levels of adenosine as a treatment for RA was suggested. UTP and ATP activate calcium-mobilising P2UR to synergistically act with IL-1 to stimulate release of prostaglandin E 2 from human rheumatoid synovial cells. Hypotonic stress promotes ATP release and cell proliferation via transient receptor potential vanilloid 4 activation in RA rat synovial fibroblasts ( Hu et al., 2017 ).

IL-1β is a proinflammatory cytokine that substantially contributes to the progression of RA. ATP, through P2X7R, induced increased levels of IL-1β in RA patient blood samples compared to control samples. Mononuclear cells from these patients were more sensitive to stimulation by ATP, possibly because of P2X7R genetic polymorphism ( Portales-Cervantes et al., 2012 ). P2X7R are involved in the pathogenesis of RA and systemic lupus erythematosus ( Portales-Cervantes et al., 2010 ). P2X7R mRNA and protein are expressed in human rheumatoid synoviocytes. Studies of arthritis animal models suggest an in vivo role for the P2X7R in the progression of this inflammatory disease. There was a lower incidence and reduced severity of the symptoms of arthritis induced by anti-collagen treatment in P2X7R KO mice. Therefore targeting the P2X7R may be a potential treatment for RA. P2X7R antagonists in the collagen-induced animal model of RA reduced destruction of peripheral inflammatory tissue. In a later study, it was claimed that AZD9056, a P2X7R antagonist, was not effective against RA ( Keystone et al., 2012 ). P2X7R antagonists are being investigated for clinical use against inflammatory joint pain ( Beswick et al., 2010 ). A multicentre, double-blind, placebo-controlled clinical trial showed that ATP infusions reduced inflammation and disease symptoms in patients with RA ( Bours et al., 2010 ).

Bovine chondrocytes express P2X1 and P2X3R and following stimulation there was release of inflammatory mediators. Therefore antagonists to these receptors may be therapeutically useful for articular cartilage resorption and diseases involving inflammation. There was an increased platelet response to ADP in RA patients ( Mac Mullan et al., 2010 ).

Sympathetic nerves mediate proinflammatory responses during the initial phase of arthritis induced by type II collagen, probably via cytokines such as interferon-γ released in response to the sympathetic cotransmitters ATP and NA ( Straub et al., 2008 ). α,β-MeATP-sensitive P2XR (probably P2X3) are expressed on rat knee joint peripheral nociceptive afferent fibres and the increased ATP levels in damaged and inflamed tissues, may contribute to nociception and pain. P2X3R were found on nociceptive sensory fibres in lumber facet joints, where low back pain originates ( Ishikawa et al., 2005 ). Changes in P2X3R expression on DRG neurons that label isolectin B4 were seen following the induction of RA ( Averill et al., 2008 ). P2X3R expressed on trigeminal ganglia also contribute to orofacial pressure pain in monoarthritis of the temporomandibular joint. Plasma extravasation in the rat knee joint induced by bradykinin was enhanced by ATP, released as a cotransmitter from sympathetic nerves. Intravenous guanethidine, which inhibits release of sympathetic cotransmitters, proved to be effective in RA patients. Uncaria tomentosa extract affects the metabolism of adenine nucleotides and has been suggested as an adjuvant to treat arthritis ( Castilhos et al., 2015 ).

The evidence showing a role for adenosine in RA has been reviewed ( Varani et al., 2010a ). Increased activity of ADA was seen in synovial fluid from patients with RA as well as in rheumatoid synovial fibroblasts ( Nakamachi et al., 2003 ). The ImmuKnow assay might effectively identify RA patients that are more at risk of developing infections ( Akimoto et al., 2013 ). Signalling via the A 2A R caused modification of the cytokine milieu in RA ( Masahiro et al., 2003 ). Over-expression of A 3 R was observed in peripheral blood mononuclear cells of RA patients. Patients with RA had greater expression A 3 R in the synovium ( Stamp et al., 2012 ). There are increased levels of A 2A and A 3 R on the lymphocytes and neutrophils of RA patients. In the dorsal horn of rats with induced RA, A 1 R agonists decreased activation of c-fos and astrocytes. In a later study of the adjuvant-induced monoarthritis model an A 3 specific agonist prevented bone resorption. ATP, working via A 2 R, also reduced joint injury. A phase II clinical trial provided evidence for A 3 R agonists as a treatment for RA ( Fishman et al., 2008 ; Silverman et al., 2008 ). CGS 21680, an agonist of the A 2A R, reduced progression of murine type II collagen-induced arthritis ( Mazzon et al., 2011 ). A 2A R agonists ameliorate adjuvant-induced arthritis in rats ( Vincenzi et al., 2013 ). Methotrexate (MTX) is often used to treat RA. In human joints with inflammatory disease, MTX treatment involved A 2A R. Adenosine via A 2B R prevented MTX-induced inhibition of osteoclast bone destruction in arthritis induced by adjuvant ( Teramachi et al., 2011 ). In RA patients treated with MTX, studies of polymorphisms of the genes involved in adenosine release concluded that genotyping may help identify patients who would most benefit from MTX treatment ( Wessels et al., 2006 ). Anti-tumour necrosis factor-α has also been used to treat RA, but it raises the risk of reactivating tuberculosis. ADA assay is a specific and sensitive test for the quick diagnosis of rheumatoid effusions ( Zakeri et al., 2012 ).

Tooth Pain

There are many sensory nerves, originating in the trigeminal ganglia, expressing P2X3R in tooth pulp and ATP is released from odontoblasts in response to mechanical stimulation to act on these receptors, resulting in pain ( Shibukawa et al., 2015 ). LPS-induced pulp inflammation increased the expression of P2XR in trigeminal sensory nerves ( Chen et al., 2014 ). Mechanical or cold stimulation of odontoblast processes in dentin tubules, results in ATP release and dental pain ( Liu X. et al., 2015 ). Therefore P2X3R antagonists may be therapeutically useful to reduce toothache.

Bone Cancer Pain

Bone metastases, common in prostate and breast cancer patients, may cause substantial bone loss and pain. Purinergic signalling involvement in bone cancer was initially reported in the 1990’s when P2U (i.e., P2Y 2 /P2Y 4 ) receptors were cloned from osteoclastoma. The expression of P2Y 2 R from human osteoclasts from bone giant cell tumour was later reported. Butyl benzyl phthalate, which interferes with mammalian ion channel receptors, inhibited ATP-induced cell proliferation via P2XR in human osteosarcoma HOS cells ( Liu and Chen, 2010 ). ATP was used in autologous bone marrow transplantation for removing residual tumour cells. In mice, a type of human apyrase, APT102, in addition to aspirin disrupts bone metastasis ( Uluçkan et al., 2008 ). Release of ATP from tumour cells further stimulates osteoclast formation and activity, contributing to bone destruction that often happens around tumour metastases. Bisphosphonates, used to treat osteoporosis, treat bone cancer and may involve apoptosis induced by ApppI, an ATP analogue produced by bisphosphonates ( Sillero et al., 2009 ).

Purinergic signalling plays a role in bone cancer pain. Bone pain can be relieved by radiation therapy, which may be related to the Ca 2+ -signalling cascade, mediated by P2X6R. In a mouse model of cancer pain, increased expression of P2X3R on calcitonin gene-related peptide immunoreactive DRG neurons during tumour growth, it was claimed that ATP had a role in cancer-related pain ( Liu M. et al., 2013 ). In rats, systemic inhibition of P2X3 and P2X2/3R with AF-353 strongly attenuated bone cancer pain-related behaviour ( Kaan et al., 2010 ). In mice, administration of A-317491, a selective P2X3 and P2X2/3R antagonist, attenuated the early stages of bone pain in cancer ( Hansen et al., 2012 ). Functional up-regulation of P2X3R has been described in DRG of bone cancer pain in a rat model ( Wu et al., 2012 ).

In P2X7R KO mice, bone cancer pain-related behaviours had an earlier onset ( Hansen et al., 2011 ). Most human osteosarcomas expressed P2X7R isoforms A and B ( Giuliani et al., 2014 ) and P2X7R are involved in cancer-induced bone pain and P2X7R antagonists were suggested as a useful analgesic target ( Falk et al., 2015 ). P2Y 1 R signalling in the DRG and spinal cord may mediate pain from bone cancer ( Chen et al., 2012 ). Activation of K ATP channels at the spinal cord level reduces pain associated with bone cancer ( Xia et al., 2014 ). Stimulation by AMP-activated protein kinase suppresses neuroinflammation and reduces bone cancer pain ( Song et al., 2015 ).

Myeloma

Multiple myeloma (cancer of plasma cells) involves osteolytic bone lesions, due largely to enhanced osteoclast activity. A 2 R may be therapeutically useful to treat and prevent multiple myeloma-induced bone disease as activation of A 2A R reduces osteoclast function, while activation of A 2B R stimulates osteoblast differentiation ( He et al., 2012 ). 8-Amino-adenosine is another possible therapeutic compound for the treatment of multiple myeloma.

Severe Combined Immunodeficiency

A major cause of severe combined immunodeficiency are genetic defects in the ADA gene. Lack of ADA causes accumulation of adenosine. Bone defects as a result of reduced osteoclastogenesis together with a defect in osteoblast function leading to low bone formation were seen in about a half of early-onset ADA-deficient patients ( Sauer et al., 2009 ). Further, the microenvironment of bone marrow in ADA KO mice had a lower ability to support haematopoiesis. In ADA KO mice, treatment with gene therapy, bone marrow transplantation or enzyme replacement, led to a full recovery. ADA-transduced hematopoietic stem cell gene therapy also enhanced the growth of children with this disease.

Dwarfism (Achondroplasia)

This is a congenital dysplasia of the skeleton as a result in a mutation in the gene encoding fibroblast growth factor receptor type 3 (FGR3). Ap 4 A diminished the expression of the achondroplasic FGFR3 receptor and P2Y 1 , P2Y 2 , P2Y 6 , and P2Y 11 R are expressed by achondroplasic chondrocytes mediating the action of Ap 4 A ( Guzmán-Aránguez et al., 2008 ). Ap 4 A reversed the morphological changes supporting a therapeutic role for Ap 4 A as a possible treatment of dwarfism ( Huete et al., 2011 ).

Paget’s Disease

There is an increase in osteoclast numbers in Paget’s disease, leading to an increase in bone resorption and a high turnover of bone. Bisphosphonates have been employed as a treatment for Paget’s disease and P2X7 antagonists have also been considered ( Agrawal et al., 2010 ).

Ossification of the Posterior Longitudinal Ligament of the Spine

This disease causes neurological damage as a result of ectopic bone formation in spinal ligaments. In this disease, extracellular ATP in ossification of cell cultures of the posterior longitudinal ligament of the spine (OPLL) is increased. P2Y 1 R are highly expressed in OPLL cells. Mechanical stress and ATP increase the levels of osteopontin and alkaline phosphatase mRNA in OPLL cells, effects that can be inhibited by MRS2179, a selective P2Y 1 R antagonist. Over-expression of P2Y 1 R in OPLL-induced mineralisation resulted in ectopic bone formation in the spinal ligament cells of patients with OPLL ( Tanaka et al., 2011 ).

Concluding Comments

Clinical interventions involving purinergic signalling are just beginning. However, the beginning and future of purinergic compounds for the treatment of a wide range of diseases is described in this review. P2Y 12 R antagonists, such as clopidogrel and ticagrelor, are currently in wide use for stroke and thrombosis, as are P2Y 2 R agonists for dry eye and A 1 R agonists for supraventricular tachycardia. The use of P2X7R antagonists for the treatment of inflammatory diseases is promising, but the presence of polymorphic variations of this receptor is holding up the development of selective antagonists appropriate for each disease. P2X3R antagonists are in clinical trials for use against visceral pain, chronic cough and hypertension. A 2A R agonists are in use for the treatment of PD, and perhaps soon in wider use. P2X1R antagonists are being investigated for treatment of bladder disorders and hypertension, while P2X4, P2X7 and A 3 R antagonists are being explored for neuropathic pain. Treatments with inhalation of ectonucleotidases to alter the balance of ATP and adenosine and inhibitors of ATP release, are also a therapeutic approach being explored. The development of novel purinergic compounds by medicinal chemists that are orally available and stable in vivo would be a significant advantage in developing therapeutic approaches, including centrally penetrant P2X7R antagonists ( Able et al., 2011 ).

The majority of the therapeutic approaches for many heart disorders based on purinergic signalling manipulation are not fully understood yet and strategies to overcome the side-effects of treatment need to be considered. The pathophysiological roles of purinergic signalling in blood vessels are clearer and it plays an important role in controlling vascular tone and remodelling. Immunologic factors related to purinergic signalling are attracting more attention and should be considered ( Cekic and Linden, 2016 ). Human embryonic stem cells are able to self-renew and have the potential to differentiate into different cell types, including cardiovascular progenitor cells. This system of differentiation is being investigated for cardiac regenerative therapy ( Huang et al., 2016 ). The single nucleotide polymorphisms in purinergic receptor genes and their association with diseases are being explored for potential use as diagnosis biomarkers (see Caseley et al., 2014 ). Purinoceptors modulate neural stem cell proliferation, differentiation, migration and cell death and could be therapeutic approaches for the treatment of neurological and psychiatric illnesses ( Illes and Rubini, 2017 ). MicroRNAs modulating purinergic signalling are gaining interest as potential original therapeutic targets and disease biomarkers ( Ferrari et al., 2016a ).

Although still in its infancy, clinical use of purinergic compounds has started. Several relevant pharmacological interventions are currently in clinical use. The lack of more established purinergic therapies may be due to there being relatively few receptor subtype-specific agonists and antagonists that are both effective and stable in vivo (see Jacobson and Muller, 2016 ). In some situations, a degree of redundancy is present, with several different subtypes of receptor mediating similar functional effects. Purinergic signalling is implicated in multiple disorders and therefore offers many potential future therapeutic targets. It should be noted, however, that since most purinoceptors are ubiquitous, to selectively target specific cell types may prove to be a challenge. As well as the development of selective agonists and antagonists, therapeutic strategies will probably include compounds that control P2R expression, inhibitors of extracellular ATP breakdown and inhibitors or enhancers of ATP transport. Understanding the interactions of purinergic signalling with other established signalling systems will be necessary.

Author Contributions

The author confirms being the sole contributor of this work and approved it for publication.

Conflict of Interest Statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer SS and handling Editor declared their shared affiliation.

I am greatly indebted to Dr. Gillian E. Knight for the excellent editorial work in the preparation of this manuscript.

References

Abdulqawi R. Dockry R. Holt K. Layton G. Mccarthy B. G. Ford A. P. ( 2015 ). P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 385 1198 – 1205 . 10.1016/S0140-6736(14)61255-1 25467586

Able S. L. Fish R. L. Bye H. Booth L. Logan Y. R. Nathaniel C. ( 2011 ). Receptor localization, native tissue binding and ex vivo occupancy for centrally penetrant P2X7 antagonists in the rat. Br. J. Pharmacol. 162 405 – 414 . 10.1111/j.1476-5381.2010.01025.x 20840537 PMC3031061

Abraham M. K. Nolte A. Reus R. Behring A. Zengerle D. Avci-Adali M. ( 2015 ). In vitro study of a novel stent coating using modified CD39 messenger RNA to potentially reduce stent angioplasty-associated complications. PLOS ONE 10 : e0138375 10.1371/journal.pone.0138375 PMC4575070 26381750

Acevedo C. G. Huambachano A. Perez E. Rojas S. Bravo I. Contreras E. ( 1997 ). Effect of ethanol on human placental transport and metabolism of adenosine. Placenta 18 387 – 392 . 10.1016/S0143-4004(97)80038-0 9250700

Adinolfi E. Capece M. Franceschini A. Falzoni S. Giuliani A. L. Rotondo A. ( 2015 ). Accelerated tumor progression in mice lacking the ATP receptor P2X7. Cancer Res. 75 635 – 644 . 10.1158/0008-5472.CAN-14-1259 25542861

Adinolfi E. Raffaghello L. Giuliani A. L. Cavazzini L. Capece M. Chiozzi P. ( 2012 ). Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res. 72 2957 – 2969 . 10.1158/0008-5472.CAN-11-1947 22505653

Agarwal R. Agarwal P. ( 2014 ). Newer targets for modulation of intraocular pressure: focus on adenosine receptor signaling pathways. Expert Opin. Ther. Targets 18 527 – 539 . 10.1517/14728222.2014.888416 24579961

Aghaei M. Karami-Tehrani F. Panjehpour M. Salami S. Fallahian F. ( 2012 ). Adenosine induces cell-cycle arrest and apoptosis in androgen-dependent and -independent prostate cancer cell lines, LNcap-FGC-10, DU-145, and PC3. Prostate 72 361 – 375 . 10.1002/pros.21438 21656837

Agrawal A. Buckley K. A. Bowers K. Furber M. Gallagher J. A. Gartland A. ( 2010 ). The effects of P2X7 receptor antagonists on the formation and function of human osteoclasts in vitro. Purinergic Signal. 6 307 – 315 . 10.1007/s11302-010-9181-z 21103214 PMC2947658

Agrawal A. Gartland A. ( 2015 ). P2X7 receptors: role in bone cell formation and function. J. Mol. Endocrinol. 54 R75 – R88 . 10.1530/JME-14-0226 25591582

Agteresch H. J. Burgers S. A. Van Der Gaast A. Wilson J. H. Dagnelie P. C. ( 2003 ). Randomized clinical trial of adenosine 5′-triphosphate on tumor growth and survival in advanced lung cancer patients. Anticancer Drugs 14 639 – 644 . 10.1097/00001813-200309000-00009 14501386

Aguiari G. Varani K. Bogo M. Mangolini A. Vincenzi F. Durante C. ( 2009 ). Deficiency of polycystic kidney disease-1 gene (PKD1) expression increases A3 adenosine receptors in human renal cells: implications for cAMP-dependent signalling and proliferation of PKD1-mutated cystic cells. Biochim. Biophys. Acta 1792 531 – 540 . 10.1016/j.bbadis.2009.03.001 19285554

Ahsan M. K. ( 2011 ). The adenosine A2 receptor enhances primary rat HSC proliferation and inhibits senescence by down-regulation of P53 and RB. Hepatology 54 750A – 751A . 10.3389/fphar.2014.00069

Aikin R. A. ( 2013 ). Targeting purinergic receptors in islet transplantation. Diabetes Metab. Res. Rev. 62 1394 – 1395 . 10.2337/db13-0211 PMC3636627 23613563

Akimoto M. Yunoue S. Otsubo H. Yoshitama T. Kodama K. Matsushita K. ( 2013 ). Assessment of peripheral blood CD4+ adenosine triphosphate activity in patients with rheumatoid arthritis. Mod. Rheumatol. 23 19 – 27 . 10.1007/s10165-012-0621-1 22374112

Akino H. Nagase K. Watanabe N. Tanase K. Oyama N. Miwa Y. ( 2011 ). ATP release from blassers is increased in-vivo and suppressed by alpha-1 adrenoceptor blocker in a rat model of bladder outlet obstruction. Eur. Urol. Suppl. 10 303 – 304 . 10.1016/S1569-9056(11)60955-X

Albert U. De Cori D. Aguglia A. Barbaro F. Bogetto F. Maina G. ( 2015 ). Increased uric acid levels in bipolar disorder subjects during different phases of illness. J. Affect. Disord 173 170 – 175 . 10.1016/j.jad.2014.11.005 25462413

Alberto A. V. Faria R. X. De Menezes J. R. Surrage A. Da Rocha N. C. Ferreira L. G. ( 2016 ). Role of P2 receptors as modulators of rat eosinophil recruitment in allergic inflammation. PLOS ONE 11 : e0145392 10.1371/journal.pone.0145392 PMC4718666 26784445

Alexopoulos D. Xanthopoulou I. Moulias A. Lekakis J. ( 2016 ). Long-term P2Y12-receptor antagonists in post-myocardial infarction patients: facing a new trilemma? J. Am. Coll. Cardiol. 68 1223 – 1232 . 10.1016/j.jacc.2016.05.088 27609686

Almeida-da-Silva C. L. Morandini A. C. Ulrich H. Ojcius D. M. Coutinho-Silva R. ( 2016 ). Purinergic signaling during Porphyromonas gingivalis infection. Biomed. J. 39 251 – 260 . 10.1016/j.bj.2016.08.003 27793267 PMC6140136

Alves L. A. Bezerra R. J. Faria R. X. Ferreira L. G. Da Silva Frutuoso V. ( 2013 ). Physiological roles and potential therapeutic applications of the P2X7 receptor in inflammation and pain. Molecules 18 10953 – 10972 . 10.3390/molecules180910953 24013409 PMC6270334

Amaral E. P. Ribeiro S. C. Lanes V. R. Almeida F. M. De Andrade M. R. Bomfim C. C. ( 2014 ). Pulmonary infection with hypervirulent Mycobacteria reveals a crucial role for the P2X7 receptor in aggressive forms of tuberculosis. PLOS Pathog. 10 : e1004188 10.1371/journal.ppat.1004188 PMC4081775 24991816

Amaral S. S. Oliveira A. G. Marques P. E. Quintão J. L. Pires D. A. Resende R. R. ( 2013 ). Altered responsiveness to extracellular ATP enhances acetaminophen hepatotoxicity. Cell Commun. Signal. 11 : 10 10.1186/1478-811X-11-10 PMC3608937 23384127

Amoroso F. Capece M. Rotondo A. Cangelosi D. Ferracin M. Franceschini A. ( 2015 ). The P2X7 receptor is a key modulator of the PI3K/GSK3β/VEGF signaling network: evidence in experimental neuroblastoma. Oncogene 34 5240 – 5251 . 10.1038/onc.2014.444 25619831

Andersson K. E. ( 2001 ). Neurotransmission and drug effects in urethral smooth muscle. Scand. J. Urol. Nephrol. Suppl. 207 26 – 34 . 10.1080/003655901750174854 11409612

Andersson K. E. Chapple C. R. Höfner K. ( 2002 ). Future drugs for the treatment of benign prostatic hyperplasia. World J. Urol. 19 436 – 442 . 10.1007/s00345-002-0253-8 12022712

Andersson K. E. Hedlund P. ( 2002 ). Pharmacologic perspective on the physiology of the lower urinary tract. Urology 60 13 – 20 . 10.1016/S0090-4295(02)01786-7 12493344

Andrés R. M. Terencio M. C. Arasa J. Payá M. Valcuende-Cavero F. Navalón P. ( 2017 ). Adenosine A2A and A2B receptors differentially modulate keratinocyte proliferation: possible deregulation in psoriatic epidermis. J. Invest. Dermatol. 137 123 – 131 . 10.1016/j.jid.2016.07.028 27498346

Antonioli L. Blandizzi C. Csóka B. Pacher P. Haskó G. ( 2015 ). Adenosine signalling in diabetes mellitus - pathophysiology and therapeutic considerations. Nat. Rev. Endocrinol. 11 228 – 241 . 10.1038/nrendo.2015.10 25687993

Antonioli L. Colucci R. Pellegrini C. Giustarini G. Tuccori M. Blandizzi C. ( 2013 ). The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications. Pharmacol. Ther. 139 157 – 188 . 10.1016/j.pharmthera.2013.04.002 23588157

Antonioli L. Csóka B. Fornai M. Colucci R. Kókai E. Blandizzi C. ( 2014a ). Adenosine and inflammation: what’s new on the horizon? Drug Discov. Today 19 1051 – 1068 . 10.1016/j.drudis.2014.02.010 24607729

Antonioli L. Giron M. C. Colucci R. Pellegrini C. Sacco D. Caputi V. ( 2014b ). Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats. PLOS ONE 9 : e116253 10.1371/journal.pone.0116253 PMC4280204 25549098

Apolloni S. Amadio S. Parisi C. Matteucci A. Potenza R. L. Armida M. ( 2014 ). Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis. Dis. Model Mech. 7 1101 – 1109 . 10.1242/dmm.017038 25038061 PMC4142730

Apostolidis A. Popat R. Yiangou Y. Cockayne D. Ford A. P. Davis J. B. ( 2005 ). Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J. Urol. 174 977 – 982 . 10.1097/01.ju.0000169481.42259.54 16094018

Aprile-Garcia F. Metzger M. W. Paez-Pereda M. Stadler H. Acuña M. Liberman A. C. ( 2016 ). Co-Expression of wild-type P2X7R with Gln460Arg variant alters receptor function. PLOS ONE 11 : e0151862 10.1371/journal.pone.0151862 PMC4795689 26986975

Aronsson P. Johnsson M. Vesela R. Winder M. Tobin G. ( 2012 ). Adenosine receptor antagonism suppresses functional and histological inflammatory changes in the rat urinary bladder. Auton. Neurosci. 171 49 – 57 . 10.1016/j.autneu.2012.10.006 23142515

Arulkumaran N. Unwin R. J. Tam F. W. ( 2011 ). A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin. Investig. Drugs 20 897 – 915 . 10.1517/13543784.2011.578068 PMC3114873 21510825

Ashimi O. Parchim N. Zhang Y. Song A. Iriyama T. Sibai B. ( 2015 ). Circulating adenosine levels are elevated in pregnant women with sickle cell disease through 2,3-DPG induction. Am. J. Obstet. Gynecol. 212 S409 – S410 . 10.1016/j.ajog.2014.10.1060

Atiemo H. Wynes J. Chuo J. Nipkow L. Sklar G. N. Chai T. C. ( 2005 ). Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model. Urology 65 622 – 626 . 10.1016/j.urology.2004.10.057 15780404

Avendano B. C. Montero T. D. Chávez C. E. Von Bernhardi R. Orellana J. A. ( 2015 ). Prenatal exposure to inflammatory conditions increases Cx43 and Panx1 unopposed channel opening and activation of astrocytes in the offspring effect on neuronal survival. Glia 63 2058 – 2072 . 10.1002/glia.22877 26096155

Averill S. Inglis J. J. King V. R. Thompson S. W. Cafferty W. B. Shortland P. J. ( 2008 ). Reg-2 expression in dorsal root ganglion neurons after adjuvant-induced monoarthritis. Neuroscience 155 1227 – 1236 . 10.1016/j.neuroscience.2008.06.049 18652880

Ayata C. K. Ganal S. C. Hockenjos B. Willim K. Vieira R. P. Grimm M. ( 2012 ). Purinergic P2Y2 receptors promote neutrophil infiltration and hepatocyte death in mice with acute liver injury. Gastroenterology 143 k1620 – 1629 . 10.1053/j.gastro.2012.08.049 22974709

Azimi I. Beilby H. Davis F. M. Marcial D. L. Kenny P. A. Thompson E. W. ( 2016 ). Altered purinergic receptor-Ca2+ signaling associated with hypoxia-induced epithelial-mesenchymal transition in breast cancer cells. Mol. Oncol. 10 166 – 178 . 10.1016/j.molonc.2015.09.006 26433470 PMC5528926

Bai H. Y. Li A. P. ( 2013 ). P2X7 receptors in cerebral ischemia. Neurosci. Bull. 29 390 – 398 . 10.1007/s12264-013-1338-7 23640286 PMC5561845

Baranowska-Bosiacka I. Listos J. Gutowska I. Hoy-Mokrzynska A. Kolasa-Wolosiuk A. Tarnowski M. ( 2016 ). Effects of perinatal exposure to lead (Pb) on purine receptor expression in the brain and gliosis in rats tolerant to morphine analgesia. Toxicology 339 19 – 33 . 10.1016/j.tox.2015.10.003 26478469

Barron M. L. Werry E. L. Mcgregor I. S. Kassiou M. ( 2014 ). “P2X7 in bipolar and depressive disorders,” in Pathologies of Calcium Channels , eds Weiss N. Koschak A. ( Berlin : Springer ), 635 – 661 .

Bartlett R. Stokes L. Sluyter R. ( 2014 ). The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. Pharmacol. Rev. 66 638 – 675 . 10.1124/pr.113.008003 24928329

Bartoli F. Carrà G. Clerici M. ( 2017a ). Update on bipolar disorder biomarker candidates: what about uric acid/adenosine hypothesis? Expert Rev. Mol. Diagn. 17 105 – 106 . 10.1080/14737159.2017.1270757 27935329

Bartoli F. Crocamo C. Dakanalis A. Brosio E. Miotto A. Capuzzi E. ( 2017b ). Purinergic system dysfunctions in subjects with bipolar disorder: a comparative cross-sectional study. Compr. Psychiatry 73 1 – 6 . 10.1016/j.comppsych.2016.09.011 27837679

Bar-Yehuda S. Stemmer S. M. Madi L. Castel D. Ochaion A. Cohen S. ( 2008 ). The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-κB signal transduction pathways. Int. J. Oncol. 33 287 – 295 . 18636149

Basoglu O. K. Barnes P. J. Kharitonov S. A. Pelleg A. ( 2015 ). Effects of aerosolized adenosine 5′-triphosphate in smokers and patients with COPD. Chest 148 430 – 435 . 10.1378/chest.14-2285 25590209

Basoglu O. K. Pelleg A. Kharitonov S. A. Barnes P. J. ( 2017 ). Contrasting effects of ATP and adenosine on capsaicin challenge in asthmatic patients. Pulm. Pharmacol. Ther. 45 13 – 18 . 10.1016/j.pupt.2017.04.004 28392320

Basu S. Barawkar D. A. Ramdas V. Patel M. Waman Y. Panmand A. ( 2017 ). Design and synthesis of novel xanthine derivatives as potent and selective A2B adenosine receptor antagonists for the treatment of chronic inflammatory airway diseases. Eur. J. Med. Chem. 134 218 – 229 . 10.1016/j.ejmech.2017.04.014 28415011

Baudelet D. Lipka E. Millet R. Ghinet A. ( 2015 ). Involvement of the P2X7 purinergic receptor in inflammation: an update of antagonists series since 2009 and their promising therapeutic potential. Curr. Med. Chem. 22 713 – 729 . 10.2174/0929867322666141212120926 25515510

Bazzichi L. Giannaccini G. Betti L. Fabbrini L. Schmid L. Palego L. ( 2008 ). ATP, calcium and magnesium levels in platelets of patients with primary fibromyalgia. Clin. Biochem. 41 1084 – 1090 . 10.1016/j.clinbiochem.2008.06.012 18634773

Beamer E. Fischer W. Engel T. ( 2017 ). The ATP-gated P2X7 receptor as a target for the treatment of drug-resistant epilepsy. Front. Neurosci. 11 : 21 10.3389/fnins.2017.00021 PMC5288361 28210205

Beamer E. Gölöncsér F. Horváth G. Bekö K. Otrokocsi L. Koványi B. ( 2016 ). Purinergic mechanisms in neuroinflammation: an update from molecules to behavior. Neuropharmacology 104 94 – 104 . 10.1016/j.neuropharm.2015.09.019 26384652

Beaucage K. L. Xiao A. Pollmann S. I. Grol M. W. Beach R. J. Holdsworth D. W. ( 2014 ). Loss of P2X7 nucleotide receptor function leads to abnormal fat distribution in mice. Purinergic Signal. 10 291 – 304 . 10.1007/s11302-013-9388-x 24222214 PMC4040179

Beckel J. M. Lu W. Civan M. M. Mitchell C. H. ( 2016 ). Treatment of retinal disorders with purinergic drugs: beyond receptors. J. Ocul. Pharmacol. Ther. 32 488 – 489 . 10.1089/jop.2016.29020.jbe 27754823

Beckenkamp A. Santana D. B. Bruno A. N. Calil L. N. Casali E. A. Paccez J. D. ( 2014 ). Ectonucleotidase expression profile and activity in human cervical cancer cell lines. Biochem. Cell Biol. 92 95 – 104 . 10.1139/bcb-2013-0051 24697693

Belhassen B. Michowitz Y. ( 2016 ). Unmasking right atrial fibrillation: a new indication of adenosine triphosphate test? Heart Rhythm 13 364 – 365 . 10.1016/j.hrthm.2015.10.020 26476150

Ben-Ari Z. Pappo O. Yitzhaki S. Cheporko Y. Shainberg A. Zinman T. ( 2009 ). Uridine-5′-triphosphate protects against hepatic- ischemic/reperfusion injury in mice. Transplantation 87 1155 – 1162 . 10.1097/TP.0b013e31819e3cdc 19384161

Benitez-Rajal J. Lorite M. J. Burt A. D. Day C. P. Thompson M. G. ( 2006 ). Phospholipase D and extracellular signal-regulated kinase in hepatic stellate cells: effects of platelet-derived growth factor and extracellular nucleotides. Am. J Physiol. Gastrointest. Liver Physiol. 291 G977 – G986 . 10.1152/ajpgi.00041.2006 17030901

Bergamin L. S. Braganhol E. Figueiró F. Casali E. A. Zanin R. F. Sévigny J. ( 2015 ). Involvement of purinergic system in the release of cytokines by macrophages exposed to glioma-conditioned medium. J. Cell Biochem. 116 721 – 729 . 10.1002/jcb.25018 25546398

Besnard A. Gautherot J. Julien B. Tebbi A. Garcin I. Doignon I. ( 2016 ). The P2X4 purinergic receptor impacts liver regeneration after partial hepatectomy in mice through the regulation of biliary homeostasis. Hepatology 64 941 – 953 . 10.1002/hep.28675 27301647

Beswick P. J. Billinton A. Chambers L. J. Dean D. K. Fonfria E. Gleave R. J. ( 2010 ). Structure-activity relationships and in vivo activity of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor. Bioorg. Med. Chem. Lett. 20 4653 – 4656 . 10.1016/j.bmcl.2010.05.107 20579878

Bhattacharya A. Biber K. ( 2016 ). The microglial ATP-gated ion channel P2X7 as a CNS drug target. Glia 64 1772 – 1787 . 10.1002/glia.23001 27219534

Bhave S. Gade A. Kang M. Hauser K. F. Dewey W. L. Akbarali H. I. ( 2017 ). Connexin-purinergic signaling in enteric glia mediates the prolonged effect of morphine on constipation. FASEB J. 31 2649 – 2660 . 10.1096/fj.201601068R 28280004 PMC5434649

Boldrini L. Giordano M. Alì G. Melfi F. Romano G. Lucchi M. ( 2015 ). P2X7 mRNA expression in non-small cell lung cancer: MicroRNA regulation and prognostic value. Oncol. Lett. 9 449 – 453 . 25436007 10.3892/ol.2014.2620 PMC4247004

Borea P. A. Gessi S. Merighi S. Varani K. ( 2016 ). Adenosine as a multi-signalling guardian angel in human diseases: when, where and how does it exert its protective effects? Trends Pharmacol. Sci. 37 419 – 434 . 10.1016/j.tips.2016.02.006 26944097

Borea P. A. Varani K. Vincenzi F. Baraldi P. G. Tabrizi M. A. Merighi S. ( 2015 ). The A3 adenosine receptor: history and perspectives. Pharmacol. Rev. 67 74 – 102 . 10.1124/pr.113.008540 25387804

Borel F. Han R. Visser A. Petry H. Van Deventer S. J. Jansen P. L. ( 2012 ). Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 55 821 – 832 . 10.1002/hep.24682 21932399

Boros D. Thompson J. Larson D. F. ( 2016 ). Adenosine regulation of the immune response initiated by ischemia reperfusion injury. Perfusion 31 103 – 110 . 10.1177/0267659115586579 25987550

Bou Ghanem E. N. Clark S. Roggensack S. E. Mciver S. R. Alcaide P. Haydon P. G. ( 2015 ). Extracellular adenosine protects against Streptococcus pneumoniae lung infection by regulating pulmonary neutrophil recruitment. PLOS Pathog. 11 : e1005126 10.1371/journal.ppat.1005126 PMC4552087 26313746

Bours M. J. Peeters R. H. Landewé R. B. Beijer S. Arts I. C. Dagnelie P. C. ( 2010 ). Adenosine 5′-triphosphate infusions reduced disease activity and inflammation in a patient with active rheumatoid arthritis. Rheumatology (Oxford) 49 2223 – 2225 . 10.1093/rheumatology/keq177 20547656

Bowser J. L. Blackburn M. R. Shipley G. L. Molina J. G. Dunner K. Jr. Broaddus R. R. ( 2016 ). Loss of CD73-mediated actin polymerization promotes endometrial tumor progression. J. Clin. Invest. 126 220 – 238 . 10.1172/JCI79380 26642367 PMC4701552

Boy C. Meyer P. T. Kircheis G. Holschbach M. H. Herzog H. Elmenhorst D. ( 2008 ). Cerebral A1 adenosine receptors (A1AR) in liver cirrhosis. Eur. J. Nucl. Med. Mol. Imaging 35 589 – 597 . 10.1007/s00259-007-0586-z 18000666

Braganhol E. Kukulski F. Lévesque S. A. Fausther M. Lavoie E. G. Zanotto-Filho A. ( 2015 ). Nucleotide receptors control IL-8/CXCL8 and MCP-1/CCL2 secretions as well as proliferation in human glioma cells. Biochim. Biophys. Acta 1852 120 – 130 . 10.1016/j.bbadis.2014.10.014 25445541

Bravo D. Maturana C. J. Pelissier T. Hernández A. Constandil L. ( 2015 ). Interactions of pannexin 1 with NMDA and P2X7 receptors in central nervous system pathologies: possible role on chronic pain. Pharmacol. Res. 101 86 – 93 . 10.1016/j.phrs.2015.07.016 26211949

Brock J. A. Van Helden D. F. ( 1995 ). Enhanced excitatory junction potentials in mesenteric arteries from spontaneously hypertensive rats. Pflügers Arch. Eur. J. Physiol. 430 901 – 908 . 10.1007/BF01837403 8594542

Broderick P. A. Malave L. B. ( 2014 ). Cocaine shifts the estrus cycle out of phase and caffeine restores it. J. Caffeine Res. 4 109 – 113 . 10.1089/jcr.2014.0015 25538863 PMC4267733

Brouns I. Van Genechten J. Burnstock G. Timmermans J.-P. Adriaensen D. ( 2003 ). Ontogenesis of P2X3 receptor-expressing nerve fibres in the rat lung, with special reference to neuroepithelial bodies. Biomed. Res. 14 80 – 86 .

Bukhari M. Deng H. Jones N. Towne Z. Woodworth C. D. Samways D. S. ( 2015 ). Selective permeabilization of cervical cancer cells to an ionic DNA-binding cytotoxin by activation of P2Y receptors. FEBS Lett. 589 1498 – 1504 . 10.1016/j.febslet.2015.04.044 25937122 PMC4497545

Bulluck H. Sirker A. Loke Y. K. Garcia-Dorado D. Hausenloy D. J. ( 2016 ). Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: an updated meta-analysis of randomized controlled trials. Int. J. Cardiol. 202 228 – 237 . 10.1016/j.ijcard.2015.09.005 26402450 PMC4669305

Burnstock G. ( 1972 ). Purinergic nerves. Pharmacol. Rev. 24 509 – 581 . 4404211

Burnstock G. ( 1981 ). Pathophysiology of migraine: a new hypothesis. Lancet 317 1397 – 1399 . 10.1016/S0140-6736(81)92572-1 6113355

Burnstock G. ( 1999 ). Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction. J. Anat. 194 335 – 342 . 10.1046/j.1469-7580.1999.19430335.x 10386771 PMC1467933

Burnstock G. ( 2002 ). Purinergic signalling and vascular cell proliferation and death. Arterioscler. Thromb. Vasc. Biol. 22 364 – 373 . 10.1161/hq0302.105360 11884276

Burnstock G. ( 2006 ). Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol. Rev. 58 58 – 86 . 10.1124/pr.58.1.5 16507883

Burnstock G. ( 2007 ). Purine and pyrimidine receptors. Cell. Mol. Life Sci. 64 1471 – 1483 . 10.1007/s00018-007-6497-0 17375261 PMC11149472

Burnstock G. ( 2008a ). Dual control of vascular tone and remodelling by ATP released from nerves and endothelial cells. Pharmacol. Rep. 60 12 – 20 . 18276981

Burnstock G. ( 2008b ). Purinergic signalling and disorders of the central nervous system. Nat. Rev. Drug Discov. 7 575 – 590 . 10.1038/nrd2605 18591979

Burnstock G. ( 2009 ). Purinergic mechanosensory transduction and visceral pain. Mol. Pain 5 : 69 10.1186/1744-8069-5-69 PMC2789721 19948030

Burnstock G. ( 2014a ). The erasmus lecture 2012, Academia Europaea. The concept of cotransmission: focus on ATP as a cotransmitter and its significance in health and disease. Eur. Rev. 22 1 – 17 . 10.1017/S1062798713000586

Burnstock G. ( 2014b ). Purinergic signalling in endocrine organs. Purinergic Signal. 10 189 – 231 . 10.1007/s11302-013-9396-x 24265070 PMC3944044

Burnstock G. ( 2014c ). Purinergic signalling in the reproductive system in health and disease. Purinergic Signal. 10 157 – 187 . 10.1007/s11302-013-9399-7 24271059 PMC3944041

Burnstock G. ( 2014d ). Purinergic signalling in the urinary tract in health and disease. Purinergic Signal. 10 103 – 155 . 10.1007/s11302-013-9395-y 24265069 PMC3944045

Burnstock G. ( 2015a ). Blood cells: an historical account of the roles of purinergic signalling. Purinergic Signal. 11 411 – 434 . 10.1007/s11302-015-9462-7 26260710 PMC4648797

Burnstock G. ( 2015b ). Physiopathological roles of P2X receptors in the central nervous system. Curr. Med. Chem. 22 819 – 844 . 25005189 10.2174/0929867321666140706130415

Burnstock G. ( 2015c ). Purinergic signalling in neuroregeneration. Neural Regen. Res. 10 1919 10.4103/1673-5374.165300 PMC4730803 26889167

Burnstock G. ( 2016a ). An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration. Neuropharmacology 104 4 – 17 . 10.1016/j.neuropharm.2015.05.031 26056033

Burnstock G. ( 2016b ). P2X ion channel receptors and inflammation. Purinergic Signal. 12 59 – 67 . 10.1007/s11302-015-9493-0 26739702 PMC4749528

Burnstock G. ( 2016c ). Purinergic receptors and pain - an update. Front. Med. Chem. 9 : 3 – 55 . 10.2174/9781681082493116090003

Burnstock G. ( 2016d ). “Purinergic signalling in the gut,” in The Enteric Nervous System. 30 Years Later Vol. 891 eds Brierley S. Costa M. ( Berlin : Springer ), 91 – 112 .

Burnstock G. ( 2016e ). Purinergic signalling: pathophysiology and therapeutic potential. J. Drug Res. Dev. 2 10.16966/2470-1009.122 24067872

Burnstock G. ( 2016f ). Short- and long-term (trophic) purinergic signalling. Philos. Trans. R. Soc. B Biol. Sci. 371 : 20150422 10.1098/rstb.2015.0422 PMC4938022 27377731

Burnstock G. ( 2017 ). Purinergic signalling in the cardiovascular system. Circ. Res. 120 207 – 228 . 10.1161/CIRCRESAHA.116.309726 28057794

Burnstock G. Arnett T. R. Orriss I. R. ( 2013 ). Purinergic signalling in the musculoskeletal system. Purinergic Signal. 9 541 – 572 . 10.1007/s11302-013-9381-4 23943493 PMC3889393

Burnstock G. Brouns I. Adriaensen D. Timmermans J. P. ( 2012a ). Purinergic signalling in the airways. Pharmacol. Rev. 64 834 – 868 . 10.1124/pr.111.005389 22885703

Burnstock G. Di Virgilio F. ( 2013 ). Purinergic signalling in cancer. Purinergic Signal. 9 491 – 540 . 10.1007/s11302-013-9372-5 23797685 PMC3889385

Burnstock G. Evans L. Bailey M. ( 2014a ). Purinergic signalling in the kidney in health and disease. Purinergic Signal. 10 71 – 101 . 10.1007/s11302-013-9400-5 24265071 PMC3944043

Burnstock G. Kennedy C. ( 2011 ). “P2X receptors in health and disease,” in Purine and Pyrimidine Receptor Pharmacology , eds Jacobson K. A. Linden J. ( Burlington : Academic Press ), 333 – 372 . 10.1016/B978-0-12-385526-8.00011-4 21586364

Burnstock G. Knight G. E. ( 2004 ). Cellular distribution and functions of P2 receptor subtypes in different systems. Int. Rev. Cytol. 240 31 – 304 . 10.1016/S0074-7696(04)40002-3 15548415

Burnstock G. Knight G. E. Greig A. V. H. ( 2012b ). Purinergic signalling in healthy and diseased skin. J. Invest. Dermatol. 132 526 – 546 . 10.1038/jid.2011.344 22158558

Burnstock G. Krügel U. Abbracchio M. P. Illes P. ( 2011 ). Purinergic signalling: from normal behaviour to pathological brain function. Prog. Neurobiol. 95 229 – 274 . 10.1016/j.pneurobio.2011.08.006 21907261

Burnstock G. Loesch A. ( 2017 ). Sympathetic innervation of the kidney in health and disease: emphasis on the role of purinergic cotransmission. Auton. Neurosci. 204 4 – 16 . 10.1016/j.autneu.2016.05.007 27270214

Burnstock G. Novak I. ( 2013 ). Purinergic signalling and diabetes. Purinergic Signal. 9 307 – 324 . 10.1007/s11302-013-9359-2 23546842 PMC3757143

Burnstock G. Pelleg A. ( 2015 ). Cardiac purinergic signalling in health and disease. Purinergic Signal. 11 1 – 46 . 10.1007/s11302-014-9436-1 25527177 PMC4336308

Burnstock G. Ralevic V. ( 2014 ). Purinergic signaling and blood vessels in health and disease. Pharmacol. Rev. 66 102 – 192 . 10.1124/pr.113.008029 24335194

Burnstock G. Sawynok J. ( 2010 ). “ATP and adenosine receptors and pain,” in Pharmacology of Pain , eds Beaulieu P. Lussier D. Porreca F. Dickenson A. H. ( Seattle : IASP Press ), 303 – 326 .

Burnstock G. Vaughn B. Robson S. ( 2014b ). Purinergic signalling in the liver in health and disease. Purinergic Signal. 10 51 – 70 . 10.1007/s11302-013-9398-8 24271096 PMC3944046

Burnstock G. Verkhratsky A. ( 2012 ). Purinergic Signalling and the Nervous System. Berlin : Springer .

Calvén J. Akbarshahi H. Menzel M. Ayata C. K. Idzko M. Bjermer L. ( 2015 ). Rhinoviral stimuli, epithelial factors and ATP signalling contribute to bronchial smooth muscle production of IL-33. J. Transl. Med. 13 281 10.1186/s12967-015-0645-3 PMC4552418 26318341

Calvert R. C. Banks F. C. Thompson C. S. Mikhailidis D. P. Morgan R. J. ( 2002 ). Chronic ethanol consumption impairs adrenoceptor- and purinoceptor-mediated relaxations in isolated rat detrusor smooth muscle. BJU. Int 89 793 – 794 . 10.1046/j.1464-410X.2002.t01-4-02801.x 11966655

Calvert R. C. Khan M. A. Thompson C. S. Mikhailidis D. P. Burnstock G. ( 2008a ). A functional study of purinergic signalling in the normal and pathological rabbit corpus cavernosum. BJU Int. 101 1043 – 1047 . 10.1111/j.1464-410X.2007.07385.x 18190636

Calvert R. C. Thompson C. S. Burnstock G. ( 2008b ). ATP release from the human ureter on distension and P2X3 receptor expression on suburothelial sensory nerves. Purinergic Signal. 4 377 – 381 . 10.1007/s11302-008-9123-1 18819020 PMC2583211

Cameron K. O. Kung D. W. Kalgutkar A. S. Kurumbail R. G. Miller R. Salatto C. T. ( 2016 ). Discovery and preclinical characterization of 6-chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic acid (PF-06409577), a direct activator of adenosine monophosphate-activated protein kinase (AMPK), for the potential treatment of diabetic nephropathy. J. Med. Chem. 59 8068 – 8081 . 10.1021/acs.jmedchem.6b00866 27490827

Canda A. E. Cross R. L. Chapple C. R. ( 2006 ). Pharmacology of the lower urinary tract and management of overactive bladder. J. Turk. Ger. Gynecol. Assoc. 7 146 – 158 .

Canda A. E. Turna B. Cinar G. M. Nazli O. ( 2007 ). Physiology and pharmacology of the human ureter: basis for current and future treatments. Urol. Int. 78 289 – 298 . 10.1159/000100830 17495484

Cantin L. D. Bayrakdarian M. Buon C. Grazzini E. Hu Y. J. Labrecque J. ( 2012 ). Discovery of P2X3 selective antagonists for the treatment of chronic pain. Bioorg. Med. Chem. Lett. 22 2565 – 2571 . 10.1016/j.bmcl.2012.01.124 22370269

Cao L. Pu J. Scott R. H. Ching J. Mccaig C. D. ( 2015 ). Physiological electrical signals promote chain migration of neuroblasts by up-regulating P2Y1 purinergic receptors and enhancing cell adhesion. Stem Cell Rev. 11 75 – 86 . 10.1007/s12015-014-9524-1 25096637 PMC4333314

Cao X. Li L. P. Wang Q. Wu Q. Hu H. H. Zhang M. ( 2013 ). Astrocyte-derived ATP modulates depressive-like behaviors. Nat. Med. 19 773 – 777 . 10.1038/nm.3162 23644515

Carneiro M. V. Americo T. A. Guimarães M. Z. Linden R. ( 2016 ). The prion protein selectively binds to and modulates the content of purinergic receptor P2X4R. Biochem. Biophys. Res. Commun. 472 293 – 298 . 10.1016/j.bbrc.2016.02.122 26946358

Casadó-Anguera V. Bonaventura J. Moreno E. Navarro G. Cortés A. Ferré S. ( 2016 ). Evidence for the heterotetrameric structure of the adenosine A2A-dopamine D2 receptor complex. Biochem. Soc. Trans. 44 595 – 600 . 10.1042/BST20150276 27068975

Caseley E. A. Muench S. P. Roger S. Mao H. J. Baldwin S. A. Jiang L. H. ( 2014 ). Non-synonymous single nucleotide polymorphisms in the P2X receptor genes: association with diseases, impact on receptor functions and potential use as diagnosis biomarkers. Int. J. Mol. Sci. 15 13344 – 13371 . 10.3390/ijms150813344 25079442 PMC4159798

Castilhos L. G. Rezer J. F. Ruchel J. B. Thorstenberg M. L. Jaques J. A. Schlemmer J. B. ( 2015 ). Effect of Uncaria tomentosa extract on purinergic enzyme activities in lymphocytes of rats submitted to experimental adjuvant arthritis model. BMC Complement. Altern. Med. 15 : 189 10.1186/s12906-015-0694-4 PMC4474424 26088322

Catanzaro J. M. Hueston C. M. Deak M. M. Deak T. ( 2014 ). The impact of the P2X7 receptor antagonist A-804598 on neuroimmune and behavioral consequences of stress. Behav. Pharmacol. 25 582 – 598 . 10.1097/FBP.0000000000000072 25083574

Cekic C. Linden J. ( 2016 ). Purinergic regulation of the immune system. Nat. Rev. Immunol. 16 177 – 192 . 10.1038/nri.2016.4 26922909

Cekic C. Sag D. Li Y. Theodorescu D. Strieter R. M. Linden J. ( 2012 ). Adenosine A2B receptor blockade slows growth of bladder and breast tumor. J. Immunol. 188 198 – 205 . 10.4049/jimmunol.1101845 22116822 PMC3819109

Certal M. Vinhas A. Pinheiro A. R. Ferreirinha F. Costa M. A. Correia-De-Sá P. ( 2015 ). Novel anti-fibrotic effect of the UTP-sensitive P2Y11 receptor in rat cardiac myofibroblasts. Auton. Neurosci. 192 72 10.1016/j.ceca.2015.08.004 26324417

Cha H. J. Jung M. S. Ahn D. W. Choi J. K. Ock M. S. Kim K. S. ( 2015 ). Silencing of MUC8 by siRNA increases P2Y2-induced airway inflammation. Am. J. Physiol. Lung. Cell Mol. Physiol. 308 L495 – L502 . 10.1152/ajplung.00332.2014 25575516

Chan E. S. Cronstein B. N. ( 2010 ). Adenosine in fibrosis. Mod. Rheumatol. 20 114 – 122 . 10.1007/s10165-009-0251-4 19949965 PMC3129242

Chan E. S. Montesinos M. C. Fernandez P. Desai A. Delano D. L. Yee H. ( 2006 ). Adenosine A2A receptors play a role in the pathogenesis of hepatic cirrhosis. Br. J. Pharmacol. 148 1144 – 1155 . 10.1038/sj.bjp.0706812 16783407 PMC1752015

Chancellor M. B. Fowler C. J. Apostolidis A. De Groat W. C. Smith C. P. Somogyi G. T. ( 2008 ). Drug insight: biological effects of botulinum toxin A in the lower urinary tract. Nat. Clin. Pract. Urol. 5 319 – 328 . 10.1038/ncpuro1124 18461049 PMC3119263

Chandrashekaran V. Das S. Seth R. K. Dattaroy D. Alhasson F. Michelotti G. ( 2016 ). Purinergic receptor X7 mediates leptin induced GLUT4 function in stellate cells in nonalcoholic steatohepatitis. Biochim. Biophys. Acta 1862 32 – 45 . 10.1016/j.bbadis.2015.10.009 26474534 PMC4988689

Chang M. Y. Lu J. K. Tian Y. C. Chen Y. C. Hung C. C. Huang Y. H. ( 2011 ). Inhibition of the P2X7 receptor reduces cystogenesis in PKD. J. Am. Soc. Nephrol. 22 1696 – 1706 . 10.1681/ASN.2010070728 21636640 PMC3171940

Chaudhury A. Dendi V. S. Mirza W. ( 2016 ). Colligative property of ATP: implications for enteric purinergic neuromuscular neurotransmission. Front. Physiol. 7 : 500 10.3389/fphys.2016.00500 PMC5083878 27840610

Chaves M. M. Marques-Da-Silva C. Monteiro A. P. Canetti C. Coutinho-Silva R. ( 2014 ). Leukotriene B4 modulates P2X7 receptor-mediated Leishmania amazonensis elimination in murine macrophages. J. Immunol. 192 4765 – 4773 . 10.4049/jimmunol.1301058 24729618

Chen J. Wang L. Zhang Y. Yang J. ( 2012 ). P2Y1 purinoceptor inhibition reduces extracellular signal-regulated protein kinase 1/2 phosphorylation in spinal cord and dorsal root ganglia: implications for cancer-induced bone pain. Acta Biochim. Biophys. Sin. (Shanghai) 44 367 – 372 . 10.1093/abbs/gms007 22349022

Chen J. F. Eltzschig H. K. Fredholm B. B. ( 2013 ). Adenosine receptors as drug targets - what are the challenges? Nat. Rev. Drug Discov. 12 265 – 286 . 10.1038/nrd3955 23535933 PMC3930074

Chen X. Molliver D. C. Gebhart G. F. ( 2010 ). The P2Y2 receptor sensitizes mouse bladder sensory neurons and facilitates purinergic currents. J. Neurosci. 30 2365 – 2372 . 10.1523/JNEUROSCI.5462-09.2010 20147562 PMC2828760

Chen Y. Zhang L. Yang J. Zhang L. Chen Z. ( 2014 ). LPS-induced dental pulp inflammation increases expression of ionotropic purinergic receptors in rat trigeminal ganglion. Neuroreport 25 991 – 997 . 10.1097/WNR.0000000000000193 25055139

Cheng R. D. Ren J. J. Zhang Y. Y. Ye X. M. ( 2014 ). P2X4 receptors expressed on microglial cells in post-ischemic inflammation of brain ischemic injury. Neurochem. Int. 67 9 – 13 . 10.1016/j.neuint.2014.01.011 24486458

Cheng Y. Mansfield K. J. Allen W. Millard R. J. Burcher E. Moore K. H. ( 2013 ). Correlation between cystometric volumes, ATP release, and pH in women with overactive bladder versus controls. Neurourol. Urodyn. 32 969 – 973 . 10.1002/nau.22344 23129360

Chesworth R. Brown R. M. Kim J. H. Ledent C. Lawrence A. J. ( 2016 ). Adenosine 2A receptors modulate reward behaviours for methamphetamine. Addict. Biol. 21 407 – 421 . 10.1111/adb.12225 25612195

Chetty A. Sharda A. Warburton R. Chen T. Xue C. Castellot J. ( 2016 ). Effect of a purinergic P2Y6 receptor agonist on airway remodeling and responsiveness in a mouse model of asthma. Am. J. Respir. Crit. Care Med. 193 A2173 .

Chiang D. J. Roychowdhury S. Bush K. Mcmullen M. R. Pisano S. Niese K. ( 2013 ). Adenosine 2A receptor antagonist prevented and reversed liver fibrosis in a mouse model of ethanol-exacerbated liver fibrosis. PLOS ONE 8 : e69114 10.1371/journal.pone.0069114 PMC3715448 23874883

Chiu G. S. Darmody P. T. Walsh J. P. Moon M. L. Kwakwa K. A. Bray J. K. ( 2014 ). Adenosine through the A2A adenosine receptor increases IL-1β in the brain contributing to anxiety. Brain Behav. Immun. 41 218 – 231 . 10.1016/j.bbi.2014.05.018 24907587 PMC4167209

Choi K. C. Tai C. J. Tzeng C. R. Auersperg N. Leung P. C. ( 2003 ). Adenosine triphosphate activates mitogen-activated protein kinase in pre-neoplastic and neoplastic ovarian surface epithelial cells. Biol. Reprod. 68 309 – 315 . 10.1095/biolreprod.102.006551 12493727

Choukèr A. Thiel M. Lukashev D. Ward J. M. Kaufmann I. Apasov S. ( 2008 ). Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway. Mol. Med. 14 116 – 123 . 10.2119/2007-00075.Chouker 18163162 PMC2156187

Chuang Y. C. Chancellor M. B. ( 2006 ). The application of botulinum toxin in the prostate. J. Urol. 176 2375 – 2382 . 10.1016/j.juro.2006.07.127 17085104

Chuo C. H. Devine S. M. Scammells P. J. Krum H. Christopoulos A. May L. T. ( 2016 ). VCP746, a novel A1 adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model. Clin. Exp. Pharmacol. Physiol. 43 976 – 982 . 10.1111/1440-1681.12616 27377874

Cicala C. Ialenti A. ( 2013 ). Adenosine signaling in airways: toward a promising antiasthmatic approach. Eur. J. Pharmacol. 714 522 – 525 . 10.1016/j.ejphar.2013.06.033 23850943

Cieslak M. Czarnecka J. Roszek K. ( 2016 ). The roles of purinergic signaling in psychiatric disorders. Acta Biochim. Pol. 63 1 – 9 . 10.18388/abp.2015_1004 26495439

Cieslak M. Czarnecka J. Roszek K. Komoszynski M. ( 2015 ). The role of purinergic signaling in the etiology of migraine and novel antimigraine treatment. Purinergic Signal. 11 307 – 316 . 10.1007/s11302-015-9453-8 25957584 PMC4529850

Cieslak M. Roszek K. ( 2014 ). Purinergic signaling in the pancreas and the therapeutic potential of ecto-nucleotidases in diabetes. Acta Biochim. Pol. 61 655 – 662 . 25522227

Cieslak M. Wojtczak A. Komoszynski M. ( 2017 ). Role of the purinergic signaling in epilepsy. Pharmacol. Rep. 69 130 – 138 . 10.1016/j.pharep.2016.09.018 27915186

Ciruela F. Fernández-Dueñas V. Contreras F. Arnau J. M. Menchón J. M. Vallano A. ( 2015 ). “Adenosine in the neurobiology of schizophrenia: potential adenosine receptor-based pharmacotherapy,” in Psychiatry and Neuroscience Update: Bridging the Divide , eds Gargiulo P. Á Arroyo H. L. M. ( Cham : Springer International Publishing ), 375 – 388 .

Cisneros-Mejorado A. Gottlieb M. Cavaliere F. Magnus T. Koch-Nolte F. Scemes E. ( 2015a ). Blockade of P2X7 receptors or pannexin-1 channels similarly attenuates postischemic damage. J. Cereb. Blood Flow Metab. 35 843 – 850 . 10.1038/jcbfm.2014.262 25605289 PMC4420860

Cisneros-Mejorado A. Perez-Samartin A. Gottlieb M. Matute C. ( 2015b ). ATP signaling in brain: release, excitotoxicity and potential therapeutic targets. Cell. Mol. Neurobiol. 35 1 – 6 . 10.1007/s10571-014-0092-3 25096398 PMC11488175

Clouet S. Di Pietrantonio L. Daskalopoulos E. P. Esfahani H. Horckmans M. Vanorlé M. ( 2016 ). Loss of mouse P2Y6 nucleotide receptor is associated with physiological macrocardia and amplified pathological cardiac hypertrophy. J. Biol. Chem. 291 15841 – 15852 . 10.1074/jbc.M115.684118 27231349 PMC4957065

Cockayne D. A. Hamilton S. G. Zhu Q.-M. Dunn P. M. Zhong Y. Novakovic S. ( 2000 ). Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 407 1011 – 1015 . 10.1038/35039519 11069181

Cohen S. B. Gill S. S. Baer G. S. Leo B. M. Scheld W. M. Diduch D. R. ( 2004 ). Reducing joint destruction due to septic arthrosis using an adenosine 2A receptor agonist. J. Orthop. Res. 22 427 – 435 . 10.1016/j.orthres.2003.08.011 15013106

Corciulo C. Lendhey M. Wilder T. Schoen H. Cornelissen A. S. Chang G. ( 2017 ). Endogenous adenosine maintains cartilage homeostasis and exogenous adenosine inhibits osteoarthritis progression. Nat. Commun. 8 : 15019 10.1038/ncomms15019 PMC5437286 28492224

Corrêa G. Almeida L. C. Moreira-Souza A. C. Savio L. E. Takiya C. M. Marques-Da-Silva C. ( 2017 ). Inflammatory early events associated to the role of P2X7 receptor in acute murine toxoplasmosis. Immunobiology 222 676 – 683 . 10.1016/j.imbio.2016.12.007 28069296

Corrêa G. Lindenberg C. D. A. Fernandes-Santos C. Gandini M. Petitinga P. F. Coutinho-Silva R. ( 2016 ). The purinergic receptor P2X7 role in control of Dengue virus-2 infection and cytokine/chemokine production in infected human monocytes. Immunobiology 221 794 – 802 . 10.1016/j.imbio.2016.02.003 26969484

Corso L. Cavallero A. Baroni D. Garbati P. Prestipino G. Bisti S. ( 2016 ). Saffron reduces ATP-induced retinal cytotoxicity by targeting P2X7 receptors. Purinergic Signal. 12 161 – 174 . 10.1007/s11302-015-9490-3 26739703 PMC4749535

Costello J. C. Rosenthal A. K. Kurup I. V. Masuda I. Medhora M. Ryan L. M. ( 2011 ). Parallel regulation of extracellular ATP and inorganic pyrophosphate: roles of growth factors, transduction modulators, and ANK. Connect. Tissue Res. 52 139 – 146 . 10.3109/03008207.2010.491928 20604715

Côté N. El Husseini D. Pepin A. Guauque-Olarte S. Ducharme V. Bouchard-Cannon P. ( 2012 ). ATP acts as a survival signal and prevents the mineralization of aortic valve. J. Mol. Cell Cardiol. 52 1191 – 1202 . 10.1016/j.yjmcc.2012.02.003 22366713

Coughlan K. S. Mitchem M. R. Hogg M. C. Prehn J. H. ( 2015 ). “Preconditioning” with latrepirdine, an adenosine 5′-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice. Neurobiol. Aging 36 1140 – 1150 . 10.1016/j.neurobiolaging.2014.09.022 25443289

Cristalli G. Vittori S. Thompson R. D. Padgett W. L. Shi D. Daly J. W. ( 1994 ). Inhibition of platelet aggregation by adenosine receptor agonists. Naunyn Schmiedebergs Arch. Pharmacol. 349 644 – 650 . 7969516 10.1007/pl00004904

Crossland R. F. Durgan D. J. Lloyd E. E. Phillips S. C. Reddy A. K. Marrelli S. P. ( 2013 ). A new rodent model for obstructive sleep apnea: effects on ATP-mediated dilations in cerebral arteries. Am. J. Physiol. Regul. Integr. Comp. Physiol. 305 R334 – R342 . 10.1152/ajpregu.00244.2013 23761641 PMC3833398

Cruz F. ( 2013 ). Targets for botulinum toxin in the lower urinary tract. Neurourol. Urodyn. 33 31 – 38 . 10.1002/nau.22445 23775898

Csóka B. Németh Z. H. Törö G. Idzko M. Zech A. Koscsó B. ( 2015 ). Extracellular ATP protects against sepsis through macrophage P2X7 purinergic receptors by enhancing intracellular bacterial killing. FASEB J. 29 3626 – 3637 . 10.1096/fj.15-272450 26060214 PMC4550379

Cunha M. P. Pazini F. L. Rosa J. M. Ramos-Hryb A. B. Oliveira Á Kaster M. P. ( 2015 ). Creatine, similarly to ketamine, affords antidepressant-like effects in the tail suspension test via adenosine A1 and A2A receptor activation. Purinergic Signal. 11 215 – 227 . 10.1007/s11302-015-9446-7 25702084 PMC4425723

Cunha R. ( 2015 ). Hippocampal adenosine A2A receptor up-regulation isnecessary and sufficient to trigger memory dysfunction inAlzheimer’s disease. J. Neurochem. 134 322 .

Cunha R. A. ( 2016 ). How does adenosine control neuronal dysfunction and neurodegeneration? J. Neurochem. 139 1019 – 1055 . 10.1111/jnc.13724 27365148

da Rocha Lapa F. Da Silva M. D. De Almeida Cabrini D. Santos A. R. ( 2012 ). Anti-inflammatory effects of purine nucleosides, adenosine and inosine, in a mouse model of pleurisy: evidence for the role of adenosine A2 receptors. Purinergic Signal. 8 693 – 704 . 10.1007/s11302-012-9299-2 22456813 PMC3486164

da Rocha Lapa F. Júnior S. J. M. Cerutti M. L. Santos A. R. S. ( 2014 ). “Pharmacology of adenosine receptors and their signaling role in immunity and inflammation,” in Pharmacology and Therapeutics , ed. Gowder S. J. T. ( Rijeka : InTech ), 85 – 130 .

da Silva M. V. Marosti A. R. Mendes C. E. Palombit K. Castelucci P. ( 2015 ). Differential effects of experimental ulcerative colitis on P2X7 receptor expression in enteric neurons. Histochem. Cell Biol. 143 171 – 184 . 10.1007/s00418-014-1270-6 25201348

da Silva M. V. Marosti A. R. Mendes C. E. Palombit K. Castelucci P. ( 2017 ). Submucosal neurons and enteric glial cells expressing the P2X7 receptor in rat experimental colitis. Acta Histochem. 119 481 – 494 . 10.1016/j.acthis.2017.05.001 28501138

Dai S. S. Zhou Y. G. ( 2011 ). Adenosine 2A receptor: a crucial neuromodulator with bidirectional effect in neuroinflammation and brain injury. Rev. Neurosci. 22 231 – 239 . 10.1515/RNS.2011.020 21476942

Dai Y. Zhang Y. Phatarpekar P. Mi T. Zhang H. Blackburn M. R. ( 2009 ). Adenosine signaling, priapism and novel therapies. J. Sex. Med. 6(Suppl. 3) , 292 – 301 . 10.1111/j.1743-6109.2008.01187.x 19267852

D’Alimonte I. Nargi E. Zuccarini M. Lanuti P. Di Iorio P. Giuliani P. ( 2015 ). Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells. Purinergic Signal. 11 331 – 346 . 10.1007/s11302-015-9454-7 25976165 PMC4529851

Daneshgari F. Liu G. Imrey P. B. ( 2006 ). Time dependent changes in diabetic cystopathy in rats include compensated and decompensated bladder function. J. Urol. 176 380 – 386 . 10.1016/S0022-5347(06)00582-9 16753447

Daniele S. Zappelli E. Natali L. Martini C. Trincavelli M. L. ( 2014 ). Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy. Cell. Death Dis. 5 e1539 10.1038/cddis.2014.487 PMC4260745 25429616

Danquah W. Meyer-Schwesinger C. Rissiek B. Pinto C. Serracant-Prat A. Amadi M. ( 2016 ). Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation. Sci. Transl. Med. 8 366ra162 10.1126/scitranslmed.aaf8463 27881823

Darville T. Welter-Stahl L. Cruz C. Sater A. A. Andrews C. W. Jr. Ojcius D. M. ( 2007 ). Effect of the purinergic receptor P2X7 on Chlamydia infection in cervical epithelial cells and vaginally infected mice. J. Immunol. 179 3707 – 3714 . 10.4049/jimmunol.179.6.3707 17785807

Davies J. Li H. Karmouty-Quintana H. Chen N. Y. Weng T. Molina J. ( 2016 ). Extracellular adenosine is detrimental in lung recovery following hyperoxic lung injury in a murine model of bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 193 A3850 .

de Azevedo M. I. Ferreiro L. Da Silva A. S. Tonin A. A. Monteiro D. U. Casali E. A. ( 2016 ). Participation of purines in the modulation of inflammatory response in rats experimentally infected by Cryptococcus neoformans . Microb. Pathog. 99 36 – 40 . 10.1016/j.micpath.2016.07.015 27469575

de Diego-Garcia L. Ramírez-Escudero M. Sebastián-Serrano A. Diaz-Hernández J. I. Pintor J. Lucas J. J. ( 2017 ). Regulation of proteasome activity by P2Y2 receptor underlies the neuroprotective effects of extracellular nucleotides. Biochim. Biophys. Acta 1863 43 – 51 . 10.1016/j.bbadis.2016.10.012 27768902

de Lera Ruiz M. Lim Y. H. Zheng J. ( 2014 ). Adenosine A2A receptor as a drug discovery target. J. Med. Chem. 57 3623 – 3650 . 10.1021/jm4011669 24164628

De Luca L. Capranzano P. Patti G. Parodi G. ( 2016 ). Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: review of the literature and practical considerations. Am. Heart J. 176 44 – 52 . 10.1016/j.ahj.2016.03.006 27264219

De Mattei M. Varani K. Masieri F. F. Pellati A. Ongaro A. Fini M. ( 2009 ). Adenosine analogs and electromagnetic fields inhibit prostaglandin E2 release in bovine synovial fibroblasts. Osteoarthritis Cartilage 17 252 – 262 . 10.1016/j.joca.2008.06.002 18640059

Deiteren A. Van Der Linden L. De Wit A. Ceuleers H. Buckinx R. Timmermans J. P. ( 2015 ). P2X3 receptors mediate visceral hypersensitivity during acute chemically-induced colitis and in the post-inflammatory phase via different mechanisms of sensitization. PLOS ONE 10 : e0123810 10.1371/journal.pone.0123810 PMC4401691 25885345

Della Latta V. Cabiati M. Rocchiccioli S. Del Ry S. Morales M. A. ( 2013 ). The role of the adenosinergic system in lung fibrosis. Pharmacol. Res. 76 182 – 189 . 10.1016/j.phrs.2013.08.004 23994158

Densmore J. C. Schaid T. R. Jeziorczak P. M. Medhora M. Audi S. Nayak S. ( 2017 ). Lung injury pathways: adenosine receptor 2B signaling limits development of ischemic bronchiolitis obliterans organizing pneumonia. Exp. Lung Res. 43 38 – 48 . 10.1080/01902148.2017.1286697 28266889 PMC5831175

De Oliveira Moreira D. Santo Neto H. Marques M. J. ( 2017 ). P2Y2 purinergic receptors are highly expressed in cardiac and diaphragm muscles of mdx mice, and their expression is decreased by suramin. Muscle Nerve 55 116 – 121 . 10.1002/mus.25199 27220808

DeOliveira C. C. Paiva Caria C. R. Ferreira Gotardo E. M. Ribeiro M. L. Gambero A. ( 2017 ). Role of A1 and A2A adenosine receptor agonists in adipose tissue inflammation induced by obesity in mice. Eur. J. Pharmacol. 799 154 – 159 . 10.1016/j.ejphar.2017.02.017 28202393

Deplano S. Cook H. T. Russell R. Franchi L. Schneiter S. Bhangal G. ( 2013 ). P2X7 receptor-mediated Nlrp3-inflammasome activation is a genetic determinant of macrophage-dependent crescentic glomerulonephritis. J. Leukoc. Biol. 93 127 – 134 . 10.1189/jlb.0612284 23089744

Diezmos E. F. Bertrand P. P. Liu L. ( 2016 ). Purinergic signaling in gut inflammation: the role of connexins and pannexins. Front. Neurosci. 10 : 311 10.3389/fnins.2016.00311 PMC4925662 27445679

Di Virgilio F. ( 2015 ). P2X receptors and inflammation. Curr. Med. Chem. 22 866 – 877 . 10.2174/0929867322666141210155311 25524252

Di Virgilio F. Adinolfi E. ( 2017 ). Extracellular purines, purinergic receptors and tumor growth. Oncogene 36 293 – 303 . 10.1038/onc.2016.206 27321181 PMC5269532

Di Virgilio F. Vuerich M. ( 2015 ). Purinergic signaling in the immune system. Auton. Neurosci. 191 117 – 123 . 10.1016/j.autneu.2015.04.011 25979766

Djerada Z. Feliu C. Richard V. Millart H. ( 2017 ). Current knowledge on the role of P2Y receptors in cardioprotection against ischemia-reperfusion. Pharmacol. Res. 118 5 – 18 . 10.1016/j.phrs.2016.08.009 27520402

do Carmo G. M. Doleski P. H. De Sá M. F. Grando T. H. Bottari N. B. Leal D. B. ( 2017 ). Purinergic enzymatic activities in lymphocytes and cardiomyocytes of mice acutely infected by Trypanosoma cruzi modulating the inflammatory responses. Exp. Parasitol. 175 44 – 50 . 10.1016/j.exppara.2017.02.002 28167210

Domercq M. Perez-Samartin A. Aparicio D. Alberdi E. Pampliega O. Matute C. ( 2010 ). P2X7 receptors mediate ischemic damage to oligodendrocytes. Glia 58 730 – 740 . 10.1002/glia.20958 20029962

Dong F. Yang X. J. Jiang T. B. Chen Y. ( 2016 ). Ischemia triggered ATP release through Pannexin-1 channel by myocardial cells activates sympathetic fibers. Microvasc. Res. 104 32 – 37 . 10.1016/j.mvr.2015.11.005 26596404

Dragicevic E. Schiemann J. Liss B. ( 2015 ). Dopamine midbrain neurons in health and Parkinson’s disease: emerging roles of voltage-gated calcium channels and ATP-sensitive potassium channels. Neuroscience 284 798 – 814 . 10.1016/j.neuroscience.2014.10.037 25450964

Dranoff J. A. Kruglov E. A. Abreu-Lanfranco O. Nguyen T. Arora G. Jain D. ( 2007 ). Prevention of liver fibrosis by the purinoceptor antagonist pyridoxal-phosphate-6-azophenyl-2′,4′-disulfonate (PPADS). In Vivo 21 k957 – 965 . 18210741

Du D. Jiang M. Liu M. Wang J. Xia C. Guan R. ( 2015 ). Microglial P2X7 receptor in the hypothalamic paraventricular nuclei contributes to sympathoexcitatory responses in acute myocardial infarction rat. Neurosci. Lett. 587 22 – 28 . 10.1016/j.neulet.2014.12.026 25524407

Du X. Ou X. Song T. Zhang W. Cong F. Zhang S. ( 2015 ). Adenosine A2B receptor stimulates angiogenesis by inducing VEGF and eNOS in human microvascular endothelial cells. Exp. Biol. Med. 240 1472 – 1479 . 10.1177/1535370215584939 PMC4935298 25966978

Dziubina A. Szmyd K. Zygmunt M. Sapa J. Dudek M. Filipek B. ( 2016 ). Evaluation of antidepressant-like and anxiolytic-like activity of purinedione-derivatives with affinity for adenosine A2A receptors in mice. Pharmacol. Rep. 68 1285 – 1292 . 10.1016/j.pharep.2016.07.008 27689756

Eckle T. Koeppen M. Eltzschig H. K. ( 2009 ). Role of extracellular adenosine in acute lung injury. Physiology 24 298 – 306 . 10.1152/physiol.00022.2009 19815856

El-Hashim A. Z. Mathew S. Spina D. ( 2016 ). The A1 adenosine receptor is a novel inhibitory receptor that regulates the cough reflex via a central mechanism of action. Am. J. Respir. Crit. Care Med. 193 A6003 – A6003 .

Elsherbiny N. M. Ahmad S. Naime M. Elsherbini A. M. Fulzele S. Al-Gayyar M. M. ( 2013a ). ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. Life Sci. 93 78 – 88 . 10.1016/j.lfs.2013.05.024 23770229

Elsherbiny N. M. Naime M. Ahmad S. Elsherbini A. M. Mohammad S. Fulzele S. ( 2013b ). Potential roles of adenosine deaminase-2 in diabetic retinopathy. Biochem. Biophys. Res. Commun. 436 355 – 361 . 10.1016/j.bbrc.2013.05.023 23685153

Engel T. ( 2016 ). Purinergic signaling-induced neuroinflammation and status epilepticus. Expert. Rev. Neurother. 16 735 – 737 . 10.1586/14737175.2016.1164036 26953622

Engel T. Alves M. Sheedy C. Henshall D. C. ( 2016 ). ATPergic signalling during seizures and epilepsy. Neuropharmacology 104 140 – 153 . 10.1016/j.neuropharm.2015.11.001 26549853

Erb L. Cao C. Ajit D. Weisman G. A. ( 2015 ). P2Y receptors in Alzheimer’s disease. Biol. Cell 107 1 – 21 . 10.1111/boc.201400043 25179475 PMC4286471

Erlinge D. Burnstock G. ( 2008 ). P2 receptors in cardiovascular regulation and disease. Purinergic Signal. 4 1 – 20 . 10.1007/s11302-007-9078-7 PMC2245998 18368530

Escudero C. Casanello P. Sobrevia L. ( 2008 ). Human equilibrative nucleoside transporters 1 and 2 may be differentially modulated by A2B adenosine receptors in placenta microvascular endothelial cells from pre-eclampsia. Placenta 29 816 – 825 . 10.1016/j.placenta.2008.06.014 18703227

Escudero C. Roberts J. M. Myatt L. Feoktistov I. ( 2014 ). Impaired adenosine-mediated angiogenesis in preeclampsia: potential implications for fetal programming. Front. Pharmacol. 5 : 134 10.3389/fphar.2014.00134 PMC4046493 24926270

Eser A. Colombel J. F. Rutgeerts P. Vermeire S. Vogelsang H. Braddock M. ( 2015 ). Safety and efficacy of an oral inhibitor of the purinergic receptor P2X7 in adult patients with moderately to severely active Crohn’s disease: a randomized placebo-controlled, double-blind, phase IIa study. Inflamm. Bowel Dis. 21 2247 – 2253 . 10.1097/MIB.0000000000000514 26197451

Essawy S. S. Tawfik M. K. Korayem H. E. ( 2017 ). Effects of adenosine receptor antagonists in MPTP mouse model of Parkinson’s disease: mitochondrial DNA integrity. Arch. Med. Sci. 13 659 – 669 . 10.5114/aoms.2017.67284 28507584 PMC5420638

Esther C. R. Jr. Olsen B. M. Lin F. C. Fine J. Boucher R. C. ( 2013 ). Exhaled breath condensate adenosine tracks lung function changes in cystic fibrosis. Am. J. Physiol. Lung. Cell Mol. Physiol. 304 L504 – L509 . 10.1152/ajplung.00344.2012 23355385 PMC3627937

Esther C. R. Muhlebach M. M. Turkovic L. Rosenow T. Boucher R. C. Stick S. M. ( 2015 ). Increased airway adenosine metabolism and oxidative stress in early cystic fibrosis lung disease. Am. J. Respir. Crit. Care Med. 191 A1032 .

Eun S. Y. Ko Y. S. Park S. W. Chang K. C. Kim H. J. ( 2015 ). P2Y2 nucleotide receptor-mediated extracellular signal-regulated kinases and protein kinase C activation induces the invasion of highly metastatic breast cancer cells. Oncol. Rep. 34 195 – 202 . 10.3892/or.2015.3972 26063340

Eyo U. B. Peng J. Swiatkowski P. Mukherjee A. Bispo A. Wu L. J. ( 2014 ). Neuronal hyperactivity recruits microglial processes via neuronal NMDA receptors and microglial P2Y12 receptors after status epilepticus. J. Neurosci. 34 10528 – 10540 . 10.1523/JNEUROSCI.0416-14.2014 25100587 PMC4200107

Faas M. M. Sáez T. De Vos P. ( 2017 ). Extracellular ATP and adenosine: the Yin and Yang in immune responses? Mol. Aspects Med. 55 9 – 19 . 10.1016/j.mam.2017.01.002 28093236

Fabiyi A. C. Brading A. F. ( 2006 ). The use of the isolated mouse whole bladder for investigating bladder overactivity. J. Pharmacol. Exp. Ther. 319 1386 – 1394 . 10.1124/jpet.106.108902 16943254

Falk S. Schwab S. D. Frosig-Jorgensen M. Clausen R. P. Dickenson A. H. Heegaard A. M. ( 2015 ). P2X7 receptor-mediated analgesia in cancer-induced bone pain. Neuroscience 291 93 – 105 . 10.1016/j.neuroscience.2015.02.011 25686524

Fan Y. Kong H. Ye X. Ding J. Hu G. ( 2016 ). ATP-sensitive potassium channels: uncovering novel targets for treating depression. Brain Struct. Funct. 221 3111 – 3122 . 10.1007/s00429-015-1090-z 26289962

Fang J. Chen X. Wang S. Xie T. Du X. Liu H. ( 2015 ). The expression of P2X7 receptors in EPCs and their potential role in the targeting of EPCs to brain gliomas. Cancer Biol. Ther. 16 498 – 510 . 10.1080/15384047.2015.1016663 25839324 PMC4623375

Faria M. Timóteo M. A. Lafuente-De-Carvalho M. Correia-De-Sá P. ( 2010 ). P2 purinoceptor subtyope changes in patients with vasculogenic erectile dysfunction. Purinergic Signal. 6 S115 .

Fasullo M. Endres L. ( 2015 ). Nucleotide salvage deficiencies, DNA damage and neurodegeneration. Int. J. Mol. Sci. 16 9431 – 9449 . 10.3390/ijms16059431 25923076 PMC4463597

Fathalla A. M. Soliman A. M. Ali M. H. Moustafa A. A. ( 2016 ). Adenosine A2A receptor blockade prevents rotenone-induced motor impairment in a rat model of Parkinsonism. Front. Behav. Neurosci. 10 : 35 10.3389/fnbeh.2016.00035 PMC4770055 26973484

Fausther M. Sheung N. Saiman Y. Bansal M. B. Dranoff J. A. ( 2012 ). Activated hepatic stellate cells upregulate transcription of ecto-5′-nucleotidase/CD73 via specific SP1 and SMAD promoter elements. Am. J. Physiol. Gastrointest. Liver Physiol. 303 G904 – G914 . 10.1152/ajpgi.00015.2012 22899823 PMC3469697

Fehm T. Zwirner M. Wallwiener D. Seeger H. Neubauer H. ( 2012 ). Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay. BMC Cancer 12 : 308 10.1186/1471-2407-12-308 PMC3416722 22824103

Feng L. Sun X. Csizmadia E. Han L. Bian S. Murakami T. ( 2011 ). Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. Neoplasia 13 206 – 216 . 10.1593/neo.101332 21390184 PMC3050864

Feng Y. H. Li X. Wang L. Zhou L. Gorodeski G. I. ( 2006 ). A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization. J. Biol. Chem. 281 17228 – 17237 . 10.1074/jbc.M602999200 16624800 PMC2409001

Fern R. F. Matute C. Stys P. K. ( 2014 ). White matter injury: ischemic and nonischemic. Glia 62 1780 – 1789 . 10.1002/glia.22722 25043122

Fernando S. L. Saunders B. M. Sluyter R. Skarratt K. K. Goldberg H. Marks G. B. ( 2007 ). A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 175 360 – 366 . 10.1164/rccm.200607-970OC 17095747

Ferrante A. Martire A. Pepponi R. Varani K. Vincenzi F. Ferraro L. ( 2014 ). Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington’s disease. Neurobiol. Dis. 71 k193 – 204 . 10.1016/j.nbd.2014.08.013 25132555

Ferrari D. Bianchi N. Eltzschig H. K. Gambari R. ( 2016a ). MicroRNAs modulate the purinergic signaling network. Trends Mol. Med. 22 905 – 918 . 10.1016/j.molmed.2016.08.006 27623176

Ferrari D. Mcnamee E. N. Idzko M. Gambari R. Eltzschig H. K. ( 2016b ). Purinergic signaling during immune cell trafficking. Trends Immunol. 37 399 – 411 . 10.1016/j.it.2016.04.004 27142306

Ferrari D. Vitiello L. Idzko M. La Sala A. ( 2015 ). Purinergic signaling in atherosclerosis. Trends Mol. Med. 21 184 – 192 . 10.1016/j.molmed.2014.12.008 25637413

Ferré S. Bonaventura J. Tomasi D. Navarro G. Moreno E. Cortés A. ( 2016 ). Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer. Neuropharmacology 104 154 – 160 . 10.1016/j.neuropharm.2015.05.028 26051403 PMC5754196

Ferrée S. ( 2016 ). Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders. Psychopharmacology 233 1963 – 1979 . 10.1007/s00213-016-4212-2 26786412 PMC4846529

Festugato M. ( 2015 ). Adenosine: an endogenous mediator in the pathogenesis of psoriasis. An. Bras. Dermatol. 90 862 – 867 . 10.1590/abd1806-4841.20153689 26734868 PMC4689075

Fiebich B. L. Akter S. Akundi R. S. ( 2014 ). The two-hit hypothesis for neuroinflammation: role of exogenous ATP in modulating inflammation in the brain. Front. Cell Neurosci. 8 : 260 10.3389/fncel.2014.00260 PMC4150257 25225473

Figliuolo V. R. Chaves S. P. Savio L. E. B. Thorstenberg M. L. P. Machado Salles E. Takiya C. M. ( 2017a ). The role of the P2X7 receptor in murine cutaneous leishmaniasis: aspects of inflammation and parasite control. Purinergic Signal. 13 143 – 152 . 10.1007/s11302-016-9544-1 27866341 PMC5432475

Figliuolo V. R. Savio L. E. B. Safya H. Nanini H. Bernardazzi C. Abalo A. ( 2017b ). P2X7 receptor promotes intestinal inflammation in chemically induced colitis and triggers death of mucosal regulatory T cells. Biochim. Biophys. Acta 1863 1183 – 1194 . 10.1016/j.bbadis.2017.03.004 28286160

Figueiredo A. B. Souza-Testasicca M. C. Afonso L. C. ( 2016 ). Purinergic signaling and infection by Leishmania : a new approach to evasion of the immune response. Biomed. J. 39 244 – 250 . 10.1016/j.bj.2016.08.004 27793266 PMC6139394

Fischer T. Rotermund N. Lohr C. Hirnet D. ( 2012 ). P2Y1 receptor activation by photolysis of caged ATP enhances neuronal network activity in the developing olfactory bulb. Purinergic Signal. 8 191 – 198 . 10.1007/s11302-011-9286-z 22187118 PMC3350580

Fish R. S. Klootwijk E. Tam F. W. K. Kleta R. Wheeler D. C. Unwin R. J. ( 2013 ). ATP and arterial calcification. Eur. J. Clin. Invest. 43 405 – 412 . 10.1111/eci.12055 23398250

Fishman P. Ochaion A. Cohen S. Patoka R. Barer F. Bar-Yehuda S. ( 2008 ). The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin. Investig. Drugs 16 1601 – 1613 . 10.1517/13543784.16.10.1601 17922624

Fonseca B. Martinez-Aguila A. De Lara M. J. P. Pintor J. ( 2017 ). Diadenosine tetraphosphate as a potential therapeutic nucleotide to treat glaucoma. Purinergic Signal. 13 171 – 177 . 10.1007/s11302-016-9547-y 27848070 PMC5432477

Ford A. P. Cockayne D. A. ( 2011 ). ATP and P2X purinoceptors in urinary tract disorders. Handb. Exp. Pharmacol. 202 485 – 526 . 10.1007/978-3-642-16499-6_22 21290240

Ford A. P. Undem B. J. ( 2013 ). The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders. Front. Cell Neurosci. 7 : 267 10.3389/fncel.2013.00267 PMC3867694 24391544

Ford A. P. Undem B. J. Birder L. A. Grundy D. Pijacka W. Paton J. F. ( 2015 ). P2X3 receptors and sensitization of autonomic reflexes. Auton. Neurosci. 191 16 – 24 . 10.1016/j.autneu.2015.04.005 25956567

Förster D. Reiser G. ( 2015 ). Supportive or detrimental roles of P2Y receptors in brain pathology?—The two faces of P2Y receptors in stroke and neurodegeneration detected in neural cell and in animal model studies. Purinergic Signal. 11 441 – 454 . 10.1007/s11302-015-9471-6 26407872 PMC4648799

Fotino C. Vergani A. Fiorina P. Pileggi A. ( 2015 ). P2X receptors and diabetes. Curr. Med. Chem. 22 891 – 901 . 10.2174/0929867321666141012173520 25312216

Fragakis N. Antoniadis A. P. Saviano M. Vassilikos V. Pappone C. ( 2015 ). The use of adenosine and adenosine triphosphate testing in the diagnosis, risk stratification and management of patients with syncope: current evidence and future perspectives. Int. J. Cardiol. 183 267 – 273 . 10.1016/j.ijcard.2015.01.089 25725201

Franco M. Bautista-Perez R. Cano-Martinez A. Pacheco U. Santamaria J. Del Valle-Mondragon L. ( 2017 ). Physiopathological implications of P2X1 and P2X7 receptors in regulation of glomerular hemodynamics in angiotensin II-induced hypertension. Am. J. Physiol. Renal Physiol. 313 F9 – F19 . 10.1152/ajprenal.00663.2016 28404593

Franklin K. M. Asatryan L. Jakowec M. W. Trudell J. R. Bell R. L. Davies D. L. ( 2014 ). P2X4 receptors (P2X4Rs) represent a novel target for the development of drugs to prevent and/or treat alcohol use disorders. Front. Neurosci. 8 : 176 10.3389/fnins.2014.00176 PMC4068020 25009459

Fransson A. Järlebark L. E. Ulfendahl M. ( 2009 ). In vivo infusion of UTP and uridine to the deafened guinea pig inner ear: effects on response thresholds and neural survival. J. Neurosci. Res. 87 1712 – 1717 . 10.1002/jnr.21969 19115418

Frenguelli B. G. Wall M. J. ( 2016 ). Combined electrophysiological and biosensor approaches to study purinergic regulation of epileptiform activity in cortical tissue. J. Neurosci. Methods 260 202 – 214 . 10.1016/j.jneumeth.2015.09.011 26381061

Friebe D. Yang T. Schmidt T. Borg N. Steckel B. Ding Z. ( 2014 ). Purinergic signaling on leukocytes infiltrating the LPS-injured lung. PLOS ONE 9 : e95382 10.1371/journal.pone.0095382 PMC3991673 24748324

Frontini A. V. Cd D. L. V. E. Nicolorich M. V. Naves A. Schwarzbaum P. Venera G. D. ( 2011 ). In vivo effects of adenosine 5′-triphosphate on rat preneoplastic liver. Medicina 71 139 – 145 . 21550930

Fu S. Davies K. P. ( 2015 ). Opiorphin-dependent upregulation of CD73 (a key enzyme in the adenosine signaling pathway) in corporal smooth muscle cells exposed to hypoxic conditions and in corporal tissue in pre-priapic sickle cell mice. Int. J. Impot. Res. 27 140 – 145 . 10.1038/ijir.2015.5 25833166 PMC4504813

Fu W. Mccormick T. Qi X. Luo L. Zhou L. Li X. ( 2009 ). Activation of P2X7-mediated apoptosis Inhibits DMBA/TPA-induced formation of skin papillomas and cancer in mice. BMC Cancer 9 : 114 10.1186/1471-2407-9-114 PMC2676299 19379509

Fuller S. J. Stokes L. Skarratt K. K. Gu B. J. Wiley J. S. ( 2009 ). Genetics of the P2X7 receptor and human disease. Purinergic Signal. 5 257 – 262 . 10.1007/s11302-009-9136-4 19319666 PMC2686826

Fumagalli M. Lecca D. Abbracchio M. P. ( 2016 ). CNS remyelination as a novel reparative approach to neurodegenerative diseases: the roles of purinergic signaling and the P2Y-like receptor GPR17. Neuropharmacology 104 82 – 93 . 10.1016/j.neuropharm.2015.10.005 26453964

Füredi R. Bölcskei K. Szolcsányi J. Pethö G. ( 2010 ). Comparison of the peripheral mediator background of heat injury- and plantar incision-induced drop of the noxious heat threshold in the rat. Life Sci. 86 244 – 250 . 10.1016/j.lfs.2009.12.010 20036261

Furlan-Freguia C. Marchese P. Gruber A. Ruggeri Z. M. Ruf W. ( 2011 ). P2X7 receptor signaling contributes to tissue factor-dependent thrombosis in mice. J. Clin. Invest. 121 2932 – 2944 . 10.1172/JCI46129 21670495 PMC3127437

Furlong T. M. Supit A. S. Corbit L. H. Killcross S. Balleine B. W. ( 2015 ). Pulling habits out of rats: adenosine 2A receptor antagonism in dorsomedial striatum rescues meth-amphetamine-induced deficits in goal-directed action. Addict. Biol. 22 172 – 183 . 10.1111/adb.12316 26515740 PMC4851927

Gan M. Moussaud S. Jiang P. Mclean P. J. ( 2015 ). Extracellular ATP induces intracellular alpha-synuclein accumulation via P2X1 receptor-mediated lysosomal dysfunction. Neurobiol. Aging 36 1209 – 1220 . 10.1016/j.neurobiolaging.2014.10.037 25480524 PMC4315767

Gandelman M. Levy M. Cassina P. Barbeito L. Beckman J. S. ( 2013 ). P2X7 receptor-induced death of motor neurons by a peroxynitrite/FAS-dependent pathway. J. Neurochem. 126 382 – 388 . 10.1111/jnc.12286 23646980 PMC3716845

Gao L. Cao L. Qui Y. Su Z. Burnstock G. Xiang Z. ( 2010 ). Blocking P2X receptors can inhibit the injury-induced proliferation of olfactory epithelium progenitor cells in adult mouse. Int. J. Pediatr. Otorhinolaryngol. 74 747 – 751 . 10.1016/j.ijporl.2010.03.030 20394994

Gao Y. Xu C. Yu K. Li G. Wan F. Liu S. ( 2010 ). Effect of tetramethylpyrazine on DRG neuron P2X3 receptor involved in transmitting pain after burn. Burns 36 127 – 134 . 10.1016/j.burns.2009.04.032 19726132

Gariboldi V. Vairo D. Guieu R. Marlingue M. Ravis E. Lagier D. ( 2017 ). Expressions of adenosine A2A receptors in coronary arteries and peripheral blood mononuclear cells are correlated in coronary artery disease patients. Int. J. Cardiol. 230 427 – 431 . 10.1016/j.ijcard.2016.12.089 28041708

Gazzerro E. Baldassari S. Assereto S. Fruscione F. Pistorio A. Panicucci C. ( 2015 ). Enhancement of muscle T regulatory cells and improvement of muscular dystrophic process in mdx mice by blockade of extracellular ATP/P2X axis. Am. J. Pathol. 185 3349 – 3360 . 10.1016/j.ajpath.2015.08.010 26465071

Gehring M. P. Kipper F. Nicoletti N. F. Sperotto N. D. Zanin R. Tamajusuku A. S. ( 2015 ). P2X7 receptor as predictor gene for glioma radiosensitivity and median survival. Int. J. Biochem. Cell Biol. 68 92 – 100 . 10.1016/j.biocel.2015.09.001 26358881

Gendaszewska-Darmach E. Kucharska M. ( 2011 ). Nucleotide receptors as targets in the pharmacological enhancement of dermal wound healing. Purinergic Signal. 7 193 – 206 . 10.1007/s11302-011-9233-z 21519856 PMC3146642

Gendaszewska-Darmach E. Szustak M. ( 2016 ). Thymidine 5′-O-monophosphorothioate induces HeLa cell migration by activation of the P2Y6 receptor. Purinergic Signal. 12 199 – 209 . 10.1007/s11302-015-9492-1 26746211 PMC4854834

Gentile D. Natale M. Lazzerini P. E. Capecchi P. L. Laghi-Pasini F. ( 2015 ). The role of P2X7 receptors in tissue fibrosis: a brief review. Purinergic Signal. 11 435 – 440 . 10.1007/s11302-015-9466-3 26318434 PMC4648791

Geraghty N. J. Watson D. Adhikary S. R. Sluyter R. ( 2016 ). P2X7 receptor in skin biology and diseases. World J. Dermatol. 5 72 – 83 . 10.5314/wjd.v5.i2.72

Ghanbari H. Jani R. Hussain-Amin A. Al-Assad W. Huether E. Ansari S. ( 2016 ). Role of adenosine after antral pulmonary vein isolation of paroxysmal atrial fibrillation: a randomized controlled trial. Heart Rhythm 13 407 – 415 . 10.1016/j.hrthm.2015.10.016 26455342

Giannuzzo A. Saccomano M. Napp J. Ellegaard M. Alves F. Novak I. ( 2016 ). Targeting of the P2X7 receptor in pancreatic cancer and stellate cells. Int. J. Cancer 139 2540 – 2552 . 10.1002/ijc.30380 27513892 PMC5095874

Gicquel T. Le Dare B. Boichot E. Lagente V. ( 2017 ). Purinergic receptors: new targets for the treatment of gout and fibrosis. Fundam. Clin. Pharmacol. 31 136 – 146 . 10.1111/fcp.12256 27885718

Gidlöf O. Sathanoori R. Magistri M. Faghihi M. A. Wahlestedt C. Olde B. ( 2015 ). Extracellular uridine triphosphate and adenosine triphosphate attenuate endothelial inflammation through miR-22-mediated ICAM-1 inhibition. J. Vasc. Res. 52 71 – 80 . 10.1159/000431367 26088024

Gill A. Wortham K. Costa D. Davis W. Ticho B. Whalley E. ( 2009 ). Protective effect of tonapofylline (BG9928), an adenosine A1 receptor antagonist, against cisplatin-induced acute kidney injury in rats. Am. J. Nephrol. 30 521 – 526 . 10.1159/000248762 19828940

Giniatullin R. Nistri A. ( 2013 ). Desensitization properties of P2X3 receptors shaping pain signaling. Front. Cell Neurosci. 7 : 245 10.3389/fncel.2013.00245 PMC3854565 24367291

Giorgi V. S. Witkin S. S. Bannwart-Castro C. F. Sartori M. S. Romao-Veiga M. Borges V. T. ( 2016 ). Elevated circulatingadenosine deaminase activity in women with preeclampsia: association with pro-inflammatory cytokine production and uric acid levels. Pregnancy Hypertens. 6 400 – 405 . 10.1016/j.preghy.2016.09.004 27939490

Giuliani A. L. Colognesi D. Ricco T. Roncato C. Capece M. Amoroso F. ( 2014 ). Trophic activity of human P2X7 receptor isoforms A and B in osteosarcoma. PLOS ONE 9 : e107224 10.1371/journal.pone.0107224 PMC4165768 25226385

Giuliani A. L. Sarti A. C. Falzoni S. Di Virgilio F. ( 2017 ). The P2X7 receptor-interleukin-1 liaison. Front. Pharmacol. 8 : 123 10.3389/fphar.2017.00123 PMC5353276 28360855

Giuliani P. Zuccarini M. Buccella S. Pena-Altamira L. E. Polazzi E. Virgili M. ( 2017 ). Evidence for purine nucleoside phosphorylase (PNP) release from rat C6 glioma cells. J. Neurochem. 141 208 – 221 . 10.1111/jnc.14004 28251649

Glass R. Bardini M. Robson T. Burnstock G. ( 2001 ). Expression of nucleotide P2X receptor subtypes during spermatogenesis in the adult rat testis. Cells Tissues Org. 169 377 – 387 . 10.1159/000047905 11490117

Gloria-Bottini F. Saccucci P. Ammendola M. Neri A. Magrini A. Bottini E. ( 2016 ). Genetic variability within Adenosine Deaminase gene and uterine leiomyomas. Eur. J. Obstet. Gynecol. Reprod. Biol. 199 108 – 109 . 10.1016/j.ejogrb.2016.02.002 26918693

Gnad T. Scheibler S. Von Kügelgen I. Scheele C. Kilic A. Glode A. ( 2014 ). Adenosine activates brown adipose tissue and recruits beige adipocytes via A2A receptors. Nature 516 395 – 399 . 10.1038/nature13816 25317558

Go G. Sung J.-S. Jee S.-C. Kim M. Jang W.-H. Kang K.-Y. ( 2017 ). In vitro anti-obesity effects of sesamol mediated by adenosine monophosphate-activated protein kinase and mitogen-activated protein kinase signaling in 3T3-L1 cells. Food Sci. Biotechnol. 26 195 – 200 . 10.1007/s10068-017-0026-1 PMC6049478 30263528

Gölöncsér F. Sperlágh B. ( 2014 ). Effect of genetic deletion and pharmacological antagonism of P2X7 receptors in a mouse animal model of migraine. J. Headache Pain 15 : 24 10.1186/1129-2377-15-24 PMC4016653 24885962

Gomez-Villafuertes R. Garcia-Huerta P. Diaz-Hernandez J. I. Miras-Portugal M. T. ( 2015 ). PI3K/Akt signaling pathway triggers P2X7 receptor expression as a pro-survival factor of neuroblastoma cells under limiting growth conditions. Sci. Rep. 5 : 18417 10.1038/srep18417 PMC4685307 26687764

Gonçalves F. M. Neis V. B. Rieger D. K. Lopes M. W. Heinrich I. A. Costa A. P. ( 2017 ). Signaling pathways underlying the antidepressant-like effect of inosine in mice. Purinergic Signal. 13 203 – 214 . 10.1007/s11302-016-9551-2 27966087 PMC5432480

Goonetilleke L. Ralevic V. Dunn W. R. ( 2013 ). Influence of pressure on adenosine triphosphate function as a sympathetic neurotransmitter in small mesenteric arteries from the spontaneously hypertensive rat. J. Hypertens. 31 312 – 320 . 10.1097/HJH.0b013e32835bd74d 23263239

Gorodeski G. I. ( 2009 ). P2X7-mediated chemoprevention of epithelial cancers. Expert. Opin. Ther. Targets 13 1313 – 1332 . 10.1517/14728220903277249 19845494

Gorodeski G. I. ( 2015 ). Purinergic signalling in the reproductive system. Auton. Neurosci. 191 82 – 101 . 10.1016/j.autneu.2015.04.008 25981553

Graubardt N. Fahrner R. Trochsler M. Keogh A. Breu K. Furer C. ( 2013 ). Promotion of liver regeneration by natural killer cells in a murine model is dependent on extracellular adenosine triphosphate phosphohydrolysis. Hepatology 57 1969 – 1979 . 10.1002/hep.26008 22898900

Greene S. J. Sabbah H. N. Butler J. Voors A. A. Abrecht-Küpper B. E. Düngen H. D. ( 2016 ). Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. Heart Fail. Rev. 21 95 – 102 . 10.1007/s10741-015-9522-7 26701329

Greer S. Page C. W. Joshi T. Yan D. Newton R. Giembycz M. A. ( 2013 ). Concurrent agonism of adenosine A2B and glucocorticoid receptors in human airway epithelial cells cooperatively induces genes with anti-inflammatory potential: a novel approach to treat chronic obstructive pulmonary disease. J. Pharmacol. Exp. Ther. 346 473 – 485 . 10.1124/jpet.113.206284 23820127

Grenz A. Kim J.-H. Bauerle J. D. Tak E. Eltzschig H. K. Clambey E. T. ( 2012 ). Adora2b adenosine receptor signaling protects during acute kidney injury via inhibition of neutrophil-dependent TNF-α release. J. Immunol. 189 4566 – 4573 . 10.4049/jimmunol.1201651 23028059 PMC3651815

Greve A. S. Skals M. Fagerberg S. K. Tonnus W. Ellermann-Eriksen S. Evans R. J. ( 2017 ). P2X1, P2X4, and P2X7 receptor knock out mice expose differential outcome of sepsis induced by α-haemolysin producing Escherichia coli . Front. Cell Infect. Microbiol. 7 : 113 10.3389/fcimb.2017.00113 PMC5382212 28428949

Gu B. J. Field J. Dutertre S. Ou A. Kilpatrick T. J. Lechner-Scott J. ( 2015 ). A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis. Hum. Mol. Genet. 24 5644 – 5654 . 10.1093/hmg/ddv278 26188005

Gualix J. León-Otegui M. Recuero M. Bullido M. J. Valdivieso F. Miras-Portugal M. T. ( 2015 ). Functional characterization of P2Y1 and P2X4 receptors in human neuroblastoma SK-N-MC cells. An. Real Acad. Farm. 81 247 – 257 .

Gubert C. Fries G. R. Wollenhaupt De Aguiar B. Ribeiro A. R. Busnello J. V. Ribeiro L. ( 2013 ). The P2X7 purinergic receptor as a molecular target in bipolar disorder. Neuropsychiatry Neuropsychol. 8 1 – 7 .

Gubert C. Jacintho Moritz C. E. Vasconcelos-Moreno M. P. Quadros Dos Santos B. T. Sartori J. Fijtman A. ( 2016 ). Peripheral adenosine levels in euthymic patients with bipolar disorder. Psychiatry Res. 246 421 – 426 . 10.1016/j.psychres.2016.10.007 27788463

Guixà-González R. Javanainen M. Gómez-Soler M. Cordobilla B. Domingo J. C. Sanz F. ( 2016 ). Membrane omega-3 fatty acids modulate the oligomerisation kinetics of adenosine A2A and dopamine D2 receptors. Sci. Rep. 6 : 19839 10.1038/srep19839 PMC4726318 26796668

Guo J. Fu X. Cui X. Fan M. ( 2015 ). Contributions of purinergic P2X3 receptors within the midbrain periaqueductal gray to diabetes-induced neuropathic pain. J. Physiol. Sci. 65 99 – 104 . 10.1007/s12576-014-0344-5 25367719 PMC10717477

Gupta S. Sharma B. ( 2014 ). Protective effects of phosphodiesterase-1 (PDE1) and ATP sensitive potassium (KATP) channel modulators against 3-nitropropionic acid induced behavioral and biochemical toxicities in experimental Huntington×s disease. Eur. J. Pharmacol. 732 111 – 122 . 10.1016/j.ejphar.2014.03.032 24690258

Gür S. Kadowitz P. J. Abdel-Mageed A. S. Kendirci M. Sikka S. C. Burnstock G. ( 2009 ). Management of erectile function by penile purinergic P2 receptors in the diabetic rat. J. Urol. 181 2375 – 2382 . 10.1016/j.juro.2009.01.002 19303093

Gur S. Kadowitz P. J. Hellstrom W. J. ( 2007 ). Purinergic (P2) receptor control of lower genitourinary tract function and new avenues for drug action: an overview. Curr. Pharm. Des. 13 3236 – 3244 . 10.2174/138161207782341277 18045173

Guzman S. J. Gerevich Z. ( 2016 ). P2Y receptors in synaptic transmission and plasticity: therapeutic potential in cognitive dysfunction. Neural Plast. 2016 : 1207393 10.1155/2016/1207393 PMC4812485 27069691

Guzman-Aranguez A. Gasull X. Diebold Y. Pintor J. ( 2014 ). Purinergic receptors in ocular inflammation. Mediators Inflamm. 2014 : 320906 10.1155/2014/320906 PMC4123590 25132732

Guzmán-Aránguez A. Irazu M. Yayon A. Pintor J. ( 2008 ). P2Y receptors activated by diadenosine polyphosphates reestablish Ca 2+ transients in achondroplasic chondrocytes. Bone 42 516 – 523 . 10.1016/j.bone.2007.10.023 18093889

Haanes K. A. Edvinsson L. ( 2014 ). Expression and characterization of purinergic receptors in rat middle meningeal artery-potential role in migraine. PLOS ONE 9 : e108782 10.1371/journal.pone.0108782 PMC4180922 25265286

Hafner S. Wagner K. Weber S. Gröger M. Wepler M. Mccook O. ( 2017 ). Role of the purinergic receptor P2XR4 after blunt chest trauma in cigarette smoke-exposed mice. Shock 47 193 – 199 . 10.1097/SHK.0000000000000726 27559703

Hamidpour R. Hamidpour S. Hamidpour M. Zarabi M. Sohraby M. Shalari M. ( 2016 ). Antipurinergic therapy with suramin as a treatment for autism spectrum disorder. J. Biomed. Sci. 5 14 10.4172/2254-609X.100028

Hansen R. R. Nasser A. Falk S. Baldvinsson S. B. Ohlsson P. H. Bahl J. M. ( 2012 ). Chronic administration of the selective P2X3, P2X2/3 receptor antagonist, A-317491, transiently attenuates cancer-induced bone pain in mice. Eur. J. Pharmacol. 688 27 – 34 . 10.1016/j.ejphar.2012.05.008 22634164

Hansen R. R. Nielsen C. K. Nasser A. Thomsen S. I. Eghorn L. F. Pham Y. ( 2011 ). P2X7 receptor-deficient mice are susceptible to bone cancer pain. Pain 152 1766 – 1776 . 10.1016/j.pain.2011.03.024 21565445 PMC6463294

Hansson E. Werner T. Björklund U. Skiöldebrand E. ( 2016 ). Therapeutic innovation: inflammatory-reactive astrocytes as targets of inflammation. IBRO Rep. 1 1 – 9 . 10.1016/j.ibror.2016.06.001 PMC6084881 30135924

Hao Y. Liang J. F. Chow A. W. Cheung W. T. Ko W. H. ( 2014 ). P2Y6 receptor-mediated proinflammatory signaling in human bronchial epithelia. PLOS ONE 9 : e106235 10.1371/journal.pone.0106235 PMC4171090 25243587

Hao Y. Zhou G. Wu W. Zhang Y. Tao L. Yao J. ( 2017 ). Synthesis and antiviral evaluation of novel N-6 substituted adenosine analogues. Tetrahedron Lett. 58 190 – 193 . 10.1016/j.tetlet.2016.11.059

Harmse R. Van Der Walt M. M. Petzer J. P. Terre’blanche G. ( 2016 ). Discovery of 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine derivatives as novel adenosine A1 and A2A receptor antagonists. Bioorg. Med. Chem. Lett. 26 5951 – 5955 . 10.1016/j.bmcl.2016.10.086 27836398

Hasebe H. Yoshida K. Iida M. Hatano N. Muramatsu T. Aonuma K. ( 2016 ). Right-to-left frequency gradient during atrial fibrillation initiated by right atrial ectopies and its augmentation by adenosine triphosphate: implications of right atrial fibrillation. Heart Rhythm 13 354 – 363 . 10.1016/j.hrthm.2015.09.030 26432585

Hattori F. Ohshima Y. Seki S. Tsukimoto M. Sato M. Takenouchi T. ( 2012 ). Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7. Eur. J. Pharmacol. 695 20 – 26 . 10.1016/j.ejphar.2012.09.001 22981895

Hayoz S. Jia C. Hegg C. ( 2012 ). Mechanisms of constitutive and ATP-evoked ATP release in neonatal mouse olfactory epithelium. BMC Neurosci. 13 : 53 10.1186/1471-2202-13-53 PMC3444318 22640172

He W. Mazumder A. Wilder T. Cronstein B. N. ( 2012 ). Adenosine regulates bone metabolism via A 1 , A 2A and A 2B receptors in bone marrow cells from normal humans and patients with multiple myeloma. FASEB J. 27 3446 – 3454 . 10.1096/fj.13-231233 PMC3752544 23682121

Headrick J. P. Ashton K. J. Rose’meyer R. B. Peart J. N. ( 2013 ). Cardiovascular adenosine receptors: expression, actions and interactions. Pharmacol. Ther. 140 92 – 111 . 10.1016/j.pharmthera.2013.06.002 23764371

Higgins G. Buchanan P. Perriere M. Al-Alawi M. Costello R. W. Verriere V. ( 2014 ). Activation of P2RY11 and ATP release by lipoxin A4 restores the airway surface liquid layer and epithelial repair in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 51 178 – 190 . 10.1165/rcmb.2012-0424OC 24588705

Ho M. F. Low L. M. Rose’meyer R. B. ( 2016 ). Pharmacology of the adenosine A3 receptor in the vasculature and essential hypertension. PLOS ONE 11 : e0150021 10.1371/journal.pone.0150021 PMC4764345 26907173

Ho T. Aplin F. P. Jobling A. I. Phipps J. A. De Iongh R. U. Greferath U. ( 2016 ). Localization and possible function of P2X receptors in normal and diseased retinae. J Ocul. Pharmacol. Ther. 32 509 – 517 . 10.1089/jop.2015.0158 27266716

Hoegl S. Brodsky K. S. Blackburn M. R. Karmouty-Quintana H. Zwissler B. Eltzschig H. K. ( 2015 ). Alveolar epithelial A2B adenosine receptors in pulmonary protection during acute lung injury. J. Immunol. 195 1815 – 1824 . 10.4049/jimmunol.1401957 26188061 PMC4530072

Hofer M. Pospisil M. Dusek L. Hoferova Z. Weiterova L. Komurkova D. ( 2013 ). Erythropoiesis- and thrombopoiesis-characterizing parameters in adenosine A3 receptor knock-out mice. Physiol. Res. 62 305 – 311 . 23489188 10.33549/physiolres.932489

Hofman P. Cherfils-Vicini J. Bazin M. Ilie M. Juhel T. Hébuterne X. ( 2015 ). Genetic and pharmacological inactivation of the purinergic P2RX7 receptor dampens inflammation but increases tumor incidence in a mouse model of colitis-associated cancer. Cancer Res. 75 835 – 845 . 10.1158/0008-5472.CAN-14-1778 25564520

Holst S. C. Valomon A. Landolt H. P. ( 2016 ). Sleep pharmacogenetics: personalized sleep-wake therapy. Annu. Rev. Pharmacol. Toxicol. 56 577 – 603 . 10.1146/annurev-pharmtox-010715-103801 26527070

Hooper J. S. Hadley S. H. Morris K. F. Breslin J. W. Dean J. B. Taylor-Clark T. E. ( 2016 ). Characterization of cardiovascular reflexes evoked by airway stimulation with allylisothiocyanate, capsaicin, and ATP in Sprague-Dawley rats. J. Appl. Physiol. 120 580 – 591 . 10.1152/japplphysiol.00944.2015 26718787 PMC4868373

Hoque R. Sohail M. A. Salhanick S. Malik A. F. Ghani A. Robson S. C. ( 2012 ). P2X7 receptor-mediated purinergic signaling promotes liver injury in acetaminophen hepatotoxicity in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 302 G1171 – G1179 . 10.1152/ajpgi.00352.2011 22383490 PMC3362096

Horckmans M. Esfahani H. Beauloye C. Clouet S. Di Pietrantonio L. Robaye B. ( 2015 ). Loss of mouse P2Y4 nucleotide receptor protects against myocardial infarction through endothelin-1 downregulation. J. Immunol. 194 1874 – 1881 . 10.4049/jimmunol.1401364 25595790

Houchi H. Persyn W. Legastelois R. Naassila M. ( 2013 ). The adenosine A2A receptor agonist CGS 21680 decreases ethanol self-administration in both non-dependent and dependent animals. Addict. Biol. 18 812 – 825 . 10.1111/adb.12032 23301633

Housley G. D. Bringmann A. Reichenbach A. ( 2009 ). Purinergic signaling in special senses. Trends Neurosci. 32 128 – 141 . 10.1016/j.tins.2009.01.001 19232752

Howarth A. R. Conway B. R. Bailey M. A. ( 2015 ). Vascular and inflammatory actions of P2X receptors in renal injury. Auton. Neurosci. 191 135 – 140 . 10.1016/j.autneu.2015.05.001 25998687

Hu F. Hui Z. Wei W. Yang J. Chen Z. Guo B. ( 2017 ). Hypotonic stress promotes ATP release, reactive oxygen species production and cell proliferation via TRPV4 activation in rheumatoid arthritis rat synovial fibroblasts. Biochem. Biophys. Res. Commun. 486 108 – 115 . 10.1016/j.bbrc.2017.03.008 28274876

Hu H. Yang B. Li Y. Zhang S. Li Z. ( 2016 ). Blocking of the P2X7 receptor inhibits the activation of the MMP-13 and NF-κB pathways in the cartilage tissue of rats with osteoarthritis. Int. J. Mol. Med. 38 1922 – 1932 . 10.3892/ijmm.2016.2770 27748894

Hu J. Ye F. Cui M. Lee P. Wei C. Hao Y. ( 2016 ). Protein profiling of bladder urothelial cell carcinoma. PLOS ONE 11 : e0161922 10.1371/journal.pone.0161922 PMC5023150 27626805

Hu S. J. Calippe B. Lavalette S. Roubeix C. Montassar F. Housset M. ( 2015 ). Upregulation of P2RX7 in Cx3cr1-deficient mononuclear phagocytes leads to increased interleukin-1β secretion and photoreceptor neurodegeneration. J. Neurosci. 35 6987 – 6996 . 10.1523/JNEUROSCI.3955-14.2015 25948251 PMC6605270

Hu X. Liou A. K. Leak R. K. Xu M. An C. Suenaga J. ( 2014 ). Neurobiology of microglial action in CNS injuries: receptor-mediated signaling mechanisms and functional roles. Prog. Neurobiol. 11 60 – 84 . 10.1016/j.pneurobio.2014.06.002 PMC4121732 24923657

Hua X. Naselsky W. C. Bennett W. D. Ledent C. Senior B. A. Tilley S. L. ( 2013 ). Adenosine increases nasal mucociliary clearance rate in mice through A2A and A2B adenosine receptors. Laryngoscope 123 306 – 310 . 10.1002/lary.23586 22965898

Huang J. Zhang M. Zhang P. Liang H. Ouyang K. Yang H. T. ( 2016 ). Coupling switch of P2Y-IP3 receptors mediates differential Ca 2+ signaling in human embryonic stem cells and derived cardiovascular progenitor cells. Purinergic Signal. 12 465 – 478 . 10.1007/s11302-016-9512-9 27098757 PMC5023627

Huang T. C. Chang H. Y. Hsu C. H. Kuo W. H. Chang K. J. Juan H. F. ( 2008 ). Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B. J. Proteome Res. 7 1433 – 1444 . 10.1021/pr700742h 18275135

Huang Z. L. Liu R. Bai X. Y. Zhao G. Song J. K. Wu S. ( 2014 ). Protective effects of the novel adenosine derivative WS0701 in a mouse model of posttraumatic stress disorder. Acta Pharmacol. Sin. 35 24 – 32 . 10.1038/aps.2013.143 24335837 PMC4075746

Huber S. M. ( 2012 ). Purinoceptor signaling in malaria-infected erythrocytes. Microbes Infect. 14 779 – 786 . 10.1016/j.micinf.2012.04.009 22580091

Huete F. Guzmán-Aránguez A. Ortin J. Hoyle C. H. Pintor J. ( 2011 ). Effects of diadenosine tetraphosphate on FGF9-induced chloride flux changes in achondroplastic chondrocytes. Purinergic Signal. 7 243 – 249 . 10.1007/s11302-011-9234-y 21559786 PMC3146644

Hullugundi S. K. Ansuini A. Ferrari M. D. Van Den Maagdenberg A. M. Nistri A. ( 2014 ). A hyperexcitability phenotype in mouse trigeminal sensory neurons expressing the R192Q Cacna1a missense mutation of familial hemiplegic migraine type-1. Neuroscience 266 244 – 254 . 10.1016/j.neuroscience.2014.02.020 24583041

Hupertan V. Neuzillet Y. Stücker O. Pons C. Leammel E. Lebret T. ( 2012 ). Effects of nucleotides adenosine monophosphate and adenosine triphosphate in combination with L-arginine on male rabbit corpus cavernosum tissue. Int. J. Androl. 35 860 – 866 . 10.1111/j.1365-2605.2012.01290.x 22709341

Hur H. Kim N. K. Kim H. G. Min B. S. Lee K. Y. Shin S. J. ( 2012 ). Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis. Br. J. Cancer 106 53 – 60 . 10.1038/bjc.2011.469 22068817 PMC3251844

Hurtado-Alvarado G. Domínguez-Salazar E. Velázquez-Moctezuma J. Gómez-González B. ( 2016 ). A2A adenosine receptor antagonism reverts the blood-brain barrier dysfunction induced by sleep restriction. PLOS ONE 11 : e0167236 10.1371/journal.pone.0167236 PMC5125701 27893847

Husted L. B. Harsløf T. Stenkjær L. Carstens M. Jørgensen N. R. Langdahl B. L. ( 2013 ). Functional polymorphisms in the P2X7 receptor gene are associated with osteoporosis. Osteoporos. Int. 24 949 – 959 . 10.1007/s00198-012-2035-5 22707062

Iba K. Yamashita T. ( 2016 ). “Osteoclast-mediated pain in osteoporosis,” in Osteoporosis in Orthopedics: Assessment and Therapeutic Options , eds Shimada Y. Miyakoshi N. ( Tokyo : Springer ), 23 – 34 . 10.1007/978-4-431-55778-4_2

Ibrahim A. S. El-Shishtawy M. M. Zhang W. Caldwell R. B. Liou G. I. ( 2011 ). A2A adenosine receptor (A2AAR) as a therapeutic target in diabetic retinopathy. Am. J. Pathol. 178 2136 – 2145 . 10.1016/j.ajpath.2011.01.018 21514428 PMC3081155

Ikeda N. Murata S. Maruyama T. Tamura T. Nozaki R. Kawasaki T. ( 2012 ). Platelet-derived adenosine 5′-triphosphate suppresses activation of human hepatic stellate cell: in vitro study. Hepatol. Res. 42 91 – 102 . 10.1111/j.1872-034X.2011.00893.x 21988364

Ikeda Y. Zabbarova I. V. Birder L. A. De Groat W. C. Mccarthy C. J. Hanna-Mitchell A. T. ( 2012 ). Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder. Eur. Urol. 62 1157 – 1164 . 10.1016/j.eururo.2012.03.031 22480459 PMC5515465

Ilatovskaya D. V. Palygin O. Staruschenko A. ( 2016 ). Functional and therapeutic importance of purinergic signaling in polycystic kidney disease. Am. J. Physiol. Renal Physiol. 311 F1135 – F1139 . 10.1152/ajprenal.00406.2016 27654892 PMC5210209

Illes P. Rubini P. ( 2017 ). Regulation of neural stem/progenitor cell functions by P2X and P2Y receptors. Neural Regen. Res. 12 395 – 396 . 10.4103/1673-5374.202937 28469648 PMC5399711

Illes P. Verkhratsky A. Burnstock G. Sperlagh B. ( 2016 ). Purines in neurodegeneration and neuroregeneration. Neuropharmacology 104 1 – 3 . 10.1016/j.neuropharm.2016.01.020 26775822

Imarisio C. Alchera E. Sutti S. Valente G. Boccafoschi F. Albano E. ( 2012 ). Adenosine A 2A receptor stimulation prevents hepatocyte lipotoxicity and non-alcoholic steatohepatitis (NASH) in rats. Clin. Sci. 123 323 – 332 . 10.1042/CS20110504 22439844

Ingwersen J. Wingerath B. Graf J. Lepka K. Hofrichter M. Schröter F. ( 2016 ). Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation. J. Neuroinflammation 13 48 10.1186/s12974-016-0512-z PMC4768407 26920550

Inoue Y. Yoshimura K. Kurabe N. Kahyo T. Kawase A. Tanahashi M. ( 2017 ). Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. Oncotarget 8 8738 – 8751 . 10.18632/oncotarget.14434 28060732 PMC5352437

Iriyama T. Sun K. Parchim N. F. Li J. Zhao C. Song A. ( 2015 ). Elevated placental adenosine signaling contributes to the pathogenesis of preeclampsia. Circulation 131 730 – 741 . 10.1161/CIRCULATIONAHA.114.013740 25538227 PMC4751998

Ishikawa T. Miyagi M. Ohtori S. Aoki Y. Ozawa T. Doya H. ( 2005 ). Characteristics of sensory DRG neurons innervating the lumbar facet joints in rats. Eur. Spine J. 14 559 – 564 . 10.1007/s00586-004-0834-x 15690212 PMC3489236

Ishimaru M. Tsukimoto M. Harada H. Kojima S. ( 2013 ). Involvement of P2Y11 receptor in IFN-γ-induced IL-6 production in human keratinocytes. Eur. J. Pharmacol. 703 67 – 73 . 10.1016/j.ejphar.2013.02.020 23461851

Iskandarov E. Kadaba Srinivasan P. Xin W. Bleilevens C. Afify M. Hamza A. ( 2016 ). Protective effects of adenosine receptor agonist in a cirrhotic liver resection model. Hepat. Mon. 16 : e36821 10.5812/hepatmon.36821 PMC5075226 27799962

Iwata M. Ota K. T. Li X. Y. Sakaue F. Li N. Dutheil S. ( 2016 ). Psychological stress activates the inflammasome via release of adenosine triphosphate and stimulation of the purinergic type 2X7 receptor. Biol. Psychiatry 80 12 – 22 . 10.1016/j.biopsych.2015.11.026 26831917

Jacob F. Novo C. P. Bachert C. Crombruggen K. ( 2013 ). Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses. Purinergic Signal. 9 285 – 306 . 10.1007/s11302-013-9357-4 23404828 PMC3757148

Jacobs B. Dussor G. ( 2016 ). Neurovascular contributions to migraine: moving beyond vasodilation. Neuroscience 338 130 – 144 . 10.1016/j.neuroscience.2016.06.012 27312704 PMC5083225

Jacobson K. A. Muller C. E. ( 2016 ). Medicinal chemistry of adenosine, P2Y and P2X receptors. Neuropharmacology 104 31 – 49 . 10.1016/j.neuropharm.2015.12.001 26686393 PMC4871727

Jajoo S. Mukherjea D. Watabe K. Ramkumar V. ( 2009 ). Adenosine A3 receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity. Neoplasia 11 1132 – 1145 . 10.1593/neo.09744 19881949 PMC2767215

Jalkanen J. Yegutkin G. G. Hollmén M. Aalto K. Kiviniemi T. Salomaa V. ( 2015 ). Aberrant circulating levels of purinergic signaling markers are associated with several key aspects of peripheral atherosclerosis and thrombosis. Circ. Res. 116 1206 – 1215 . 10.1161/CIRCRESAHA.116.305715 25645301

Jameel M. N. Xiong Q. Mansoor A. Bache R. J. Zhang J. ( 2016 ). ATP sensitive K + channels are critical for maintaining myocardial perfusion and high energy phosphates in the failing heart. J. Mol. Cell. Cardiol. 92 116 – 121 . 10.1016/j.yjmcc.2016.02.005 26854629 PMC4789110

Janes K. Symons-Liguori A. M. Jacobson K. A. Salvemini D. ( 2016 ). Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics. Br. J. Pharmacol. 173 1253 – 1267 . 10.1111/bph.13446 26804983 PMC4940822

Jared Bunch T. ( 2015 ). One drug, two outcomes after atrial fibrillation ablation: the situational irony of adenosine. Eur. Heart J. 36 3288 – 3290 . 10.1093/eurheartj/ehv473 26377401

Jastrzebska J. Nowak E. Smaga I. Bystrowska B. Frankowska M. Bader M. ( 2014 ). Adenosine A2A receptor modulation of nicotine-induced locomotor sensitization. A pharmacological and transgenic approach. Neuropharmacology 81 318 – 326 . 10.1016/j.neuropharm.2014.03.002 24632528

Jelassi B. Anchelin M. Chamouton J. Cayuela M. L. Clarysse L. Li J. ( 2013 ). Anthraquinone emodin inhibits human cancer cell invasiveness by antagonizing P2X7 receptors. Carcinogenesis 34 1487 – 1496 . 10.1093/carcin/bgt099 23524196

Jenner P. ( 2014 ). An overview of adenosine A2A receptor antagonists in Parkinson’s disease. Int. Rev. Neurobiol. 119 71 – 86 . 10.1016/B978-0-12-801022-8.00003-9 25175961

Jeong J. Y. Kim J. Kim B. Kim J. Shin Y. Kim J. ( 2016 ). IL-1ra secreted by ATP-induced P2Y2 negatively regulates MUC5AC overproduction via PLCβ3 during airway inflammation. Mediators Inflamm. 2016 : 7984853 10.1155/2016/7984853 PMC4789511 27034593

Ji X. Naito Y. Hirokawa G. Weng H. Hiura Y. Takahashi R. ( 2012 ). P2X7 receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertens. Res. 35 173 – 179 . 10.1038/hr.2011.153 21918525

Jia C. Sangsiri S. Belock B. Iqbal T. R. Pestka J. J. Hegg C. C. ( 2011 ). ATP mediates neuroprotective and neuroproliferative effects in mouse olfactory epithelium following exposure to satratoxin G in vitro and in vivo. Toxicol. Sci. 124 169 – 178 . 10.1093/toxsci/kfr213 21865290 PMC3196654

Jia X. Naito H. Yetti H. Tamada H. Kitamori K. Hayashi Y. ( 2012 ). The modulation of hepatic adenosine triphosphate and inflammation by eicosapentaenoic acid during severe fibrotic progression in the SHRSP5/Dmcr rat model. Life Sci. 90 934 – 943 . 10.1016/j.lfs.2012.04.029 22569299

Jian R. Sun Y. Wang Y. Yu J. Zhong L. Zhou P. ( 2012 ). CD73 protects kidney from ischemia-reperfusion injury through reduction of free radicals. APMIS 120 130 – 138 . 10.1111/j.1600-0463.2011.02827.x 22229268

Jiang S. Zhang Y. Zheng J. H. Li X. Yao Y. L. Wu Y. L. ( 2017 ). Potentiation of hepatic stellate cell activation by extracellular ATP is dependent on P2X7R-mediated NLRP3 inflammasome activation. Pharmacol. Res. 117 82 – 93 . 10.1016/j.phrs.2016.11.040 27940204

Jiménez M. Clavé P. Accarino A. Gallego D. ( 2014 ). Purinergic neuromuscular transmission in the gastrointestinal tract; functional basis for future clinical and pharmacological studies. Br. J. Pharmacol. 171 4360 – 4375 . 10.1111/bph.12802 24910216 PMC4209144

Jiménez M. De Diego M. Martínez-Cutillas M. Mañé Reed N. Gallego D. Ojanguren M. ( 2015 ). Purinergic and nitrergic inhibitory neuromuscular transmission in ganglionic, transitional and aganglionic segments from Hirschsprung’s disease patients. Neurogastroenterol. Motil. 27 71 .

Jimenez-Mateos E. M. Arribas-Blazquez M. Sanz-Rodriguez A. Concannon C. Olivos-Ore L. A. Reschke C. R. ( 2015 ). microRNA targeting of the P2X7 purinoceptor opposes a contralateral epileptogenic focus in the hippocampus. Sci. Rep. 5 : 17486 10.1038/srep17486 PMC4668358 26631939

Jin F. ( 2016 ). Analysis on mechanism of ATP-sensitive K + channel opener natakalim improving congestive heart failure after myocardial infarction. Exp. Ther. Med. 12 3993 – 3997 . 10.3892/etm.2016.3853 28101177 PMC5228084

Jin H. Seo J. Eun S. Y. Joo Y. N. Park S. W. Lee J. H. ( 2014 ). P2Y2R activation by nucleotides promotes skin wound-healing process. Exp. Dermatol. 23 480 – 485 . 10.1111/exd.12440 24816122

Jin W. Xu W. Chen J. Zhang X. Shi L. Ren C. ( 2016 ). Adenosine kinase facilitated astrogliosis-induced cortical neuronal death in traumatic brain injury. J. Mol. Histol. 47 259 – 271 . 10.1007/s10735-016-9670-7 26983602

Jörg M. Scammells P. J. Capuano B. ( 2014 ). The dopamine D2 and adenosine A2A receptors: past, present and future trends for the treatment of Parkinson’s disease. Curr. Med. Chem. 21 3188 – 3210 . 10.2174/1389200215666140217110716 24533801

Jørgensen N. R. Boeynaems J. M. Di Virgilio F. ( 2011 ). European meeting “P2 receptors: new targets for the treatment of osteoporosis”. Purinergic Signal. 7 275 – 276 . 10.1007/s11302-011-9223-1 21484088 PMC3146637

Jørgensen N. R. Grove E. L. Schwarz P. Vestergaard P. ( 2012 ). Clopidogrel and the risk of osteoporotic fractures: a nationwide cohort study. J. Intern. Med. 272 385 – 393 . 10.1111/j.1365-2796.2012.02535.x 22372976

Jørgensen N. R. Syberg S. Ellegaard M. ( 2015 ). The role of P2X receptors in bone biology. Curr. Med. Chem. 22 902 – 914 . 10.2174/0929867321666141215094749 25515517

Joseph E. K. Green P. G. Ferrari L. F. Levine J. D. ( 2015 ). Homocysteine-induced attenuation of vascular endothelium-dependent hyperalgesia in the rat. Neuroscience 284 678 – 684 . 10.1016/j.neuroscience.2014.10.056 25451284 PMC4267916

Junger W. G. ( 2011 ). Immune cell regulation by autocrine purinergic signalling. Nat. Rev. Immunol. 11 201 – 212 . 10.1038/nri2938 21331080 PMC4209705

Kaan T. K. Yip P. K. Patel S. Davies M. Marchand F. Cockayne D. A. ( 2010 ). Systemic blockade of P2X3 and P2X2/3 receptors attenuates bone cancer pain behaviour in rats. Brain 133 2549 – 2564 . 10.1093/brain/awq194 20802203

Kaiser M. Penk A. Franke H. Krügel U. Norenberg W. Huster D. ( 2016 ). Lack of functional P2X7 receptor aggravates brain edema development after middle cerebral artery occlusion. Purinergic Signal. 12 453 – 463 . 10.1007/s11302-016-9511-x 27048203 PMC5023626

Kao Y. H. Lin M. S. Chen C. M. Wu Y. R. Chen H. M. Lai H. L. ( 2017 ). Targeting ENT1 and adenosine tone for the treatment of Huntington’s disease. Hum. Mol. Genet. 26 467 – 478 . 10.1093/hmg/ddw402 28069792

Kapila N. Higa J. T. Longhi M. S. Robson S. C. ( 2013 ). Autoimmune hepatitis: clinical review with insights into the purinergic mechanism of disease. J. Clin. Transl. Hepatol. 1 79 – 86 . 10.14218/JCTH.2013.00015 26356124 PMC4521285

Karmakar M. Katsnelson M. A. Dubyak G. R. Pearlman E. ( 2016 ). Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP. Nat. Commun. 7 : 10555 10.1038/ncomms10555 PMC4756306 26877061

Kaster M. P. Machado N. J. Silva H. B. Nunes A. Ardais A. P. Santana M. ( 2015 ). Caffeine acts through neuronal adenosine A2A receptors to prevent mood and memory dysfunction triggered by chronic stress. Proc. Natl. Acad. Sci. U.S.A 112 7833 – 7838 . 10.1073/pnas.1423088112 26056314 PMC4485143

Katz N. K. Ryals J. M. Wright D. E. ( 2015 ). Central or peripheral delivery of an adenosine A1 receptor agonist improves mechanical allodynia in a mouse model of painful diabetic neuropathy. Neuroscience 285 312 – 323 . 10.1016/j.neuroscience.2014.10.065 25451280 PMC4286141

Kavanagh K. A. Schreiner D. C. Levis S. C. O’neill C. E. Bachtell R. K. ( 2015 ). Role of adenosine receptor subtypes in methamphetamine reward and reinforcement. Neuropharmacology 89 265 – 273 . 10.1016/j.neuropharm.2014.09.030 25301277 PMC4250385

Kawai Y. Kaidoh M. Ohhashi T. ( 2008 ). MDA-MB-231 produces ATP-mediated ICAM-1-dependent facilitation of the attachment of carcinoma cells to human lymphatic endothelial cells. Am. J. Physiol. Cell Physiol. 295 C1123 – C1132. 10.1152/ajpcell.00247.2008 18768924

Kawamura H. Aswad F. Minagawa M. Govindarajan S. Dennert G. ( 2006 ). P2X7 receptors regulate NKT cells in autoimmune hepatitis. J. Immunol. 176 2152 – 2160 . 10.4049/jimmunol.176.4.2152 16455971

Ke J. Yao B. Li T. Cui S. Ding H. ( 2015 ). A2 adenosine receptor-mediated cardioprotection against reperfusion injury in rat hearts is associated with autophagy downregulation. J. Cardiovasc. Pharmacol. 66 25 – 34 . 10.1097/FJC.0000000000000239 25706370

Keay S. K. Birder L. A. Chai T. C. ( 2014 ). Evidence for bladder urothelial pathophysiology in functional bladder disorders. Biomed Res. Int. 2014 : 865463 10.1155/2014/865463 PMC4034482 24900993

Kehasse A. Rich C. B. Lee A. Mccomb M. E. Costello C. E. Trinkaus-Randall V. ( 2013 ). Epithelial wounds induce differential phosphorylation changes in response to purinergic and EGF receptor activation. Am. J. Pathol. 183 1841 – 1852 . 10.1016/j.ajpath.2013.08.015 24095926 PMC5745543

Keystone E. C. Wang M. M. Layton M. Hollis S. Mcinnes I. B. ( 2012 ). Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann. Rheum. Dis. 71 1630 – 1635 . 10.1136/annrheumdis-2011-143578 22966146

Khalid M. Brisson L. Tariq M. Hao Y. Guibon R. Fromont G. ( 2017 ). Carcinoma-specific expression of P2Y11 receptor and its contribution in ATP-induced purinergic signalling and cell migration in human hepatocellular carcinoma cells. Oncotarget 8 37278 – 37290 . 10.18632/oncotarget.16191 28418839 PMC5514908

Khoja S. Shah V. Garcia D. Asatryan L. Jakowec M. W. Davies D. L. ( 2016 ). Role of purinergic P2X4 receptors in regulating striatal dopamine homeostasis and dependent behaviors. J. Neurochem. 139 134 – 148 . 10.1111/jnc.13734 27402173 PMC5037001

Kilinc E. Koroleva K. Guerrero Toro C. Töre F. Giniatullin R. ( 2015 ). The role of adenosine triphosphate and its receptors in migraine pathophysiology. Acta Physiol. 215 44 .

Killeen M. E. Ferris L. Kupetsky E. A. Falo L. Jr. Mathers A. R. ( 2013 ). Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis. J. Immunol. 190 4324 – 4336 . 10.4049/jimmunol.1202045 23479230 PMC3622186

Kim H. Walsh M. C. Takegahara N. Middleton S. A. Shin H. I. Kim J. ( 2017 ). The purinergic receptor P2X5 regulates inflammasome activity and hyper-multinucleation of murine osteoclasts. Sci. Rep. 7 196 10.1038/s41598-017-00139-2 PMC5427844 28298636

Kim M. J. Turner C. M. Hewitt R. Smith J. Bhangal G. Pusey C. D. ( 2014 ). Exaggerated renal fibrosis in P2X4 receptor-deficient mice following unilateral ureteric obstruction. Nephrol. Dial. Transplant. 29 1350 – 1361 . 10.1093/ndt/gfu019 24574541 PMC4071051

Kimbler D. E. Shields J. Yanasak N. Vender J. R. Dhandapani K. M. ( 2012 ). Activation of P2X7 promotes cerebral edema and neurological injury after traumatic brain injury in mice. PLOS ONE 7 : e41229 10.1371/journal.pone.0041229 PMC3398891 22815977

Kinnamon S. C. Finger T. E. ( 2013 ). A taste for ATP: neurotransmission in taste buds. Front. Cell Neurosci. 7 : 264 10.3389/fncel.2013.00264 PMC3866518 24385952

Kira S. Yoshiyama M. Tsuchiya S. Shigetomi E. Miyamoto T. Nakagomi H. ( 2017 ). P2Y6-deficiency increases micturition frequency and attenuates sustained contractility of the urinary bladder in mice. Sci. Rep. 7 771 10.1038/s41598-017-00824-2 PMC5429706 28396595

Kishore B. K. Carlson N. G. Ecelbarger C. M. Kohan D. E. Müller C. E. Nelson R. D. ( 2015 ). Targeting renal purinergic signalling for the treatment of lithium-induced nephrogenic diabetes insipidus. Acta Physiol. 214 176 – 188 . 10.1111/apha.12507 PMC4430398 25877068

Kitta T. Chancellor M. B. De Groat W. C. Kuno S. Nonomura K. Yoshimura N. ( 2012 ). Suppression of bladder overactivity by adenosine A2A receptor antagonist in a rat model of Parkinson disease. J. Urol. 187 1890 – 1897 . 10.1016/j.juro.2011.12.062 22425056

Kizilirmak F. Gunes H. M. Demir G. G. Gokdeniz T. Guler E. Cakal B. ( 2015 ). Impact of intracoronary adenosine on myonecrosis in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Cardiovasc. Drugs Ther. 29 519 – 526 . 10.1007/s10557-015-6631-4 26631392

Knight G. E. Bodin P. De Groat W. C. Burnstock G. ( 2002 ). ATP is released from guinea pig ureter epithelium on distension. Am. J. Physiol. Renal Physiol. 282 F281 – F288 . 10.1152/ajprenal.00293.2000 11788442

Kofoed K. Skov L. Zachariae C. ( 2015 ). New drugs and treatment targets in psoriasis. Acta Derm. Venereol. 95 133 – 139 . 10.2340/00015555-1931 25111317

Köhler D. Streienberger A. Morote-García J. C. Granja T. F. Schneider M. Straub A. ( 2016 ). Inhibition of adenosine kinase attenuates acute lung injury. Crit. Care Med. 44 e181 – e189 . 10.1097/CCM.0000000000001370 26491864 PMC4792660

Komai A. M. Brännmark C. Musovic S. Olofsson C. S. ( 2014 ). PKA-independent cAMP stimulation of white adipocyte exocytosis and adipokine secretion: modulations by Ca 2+ and ATP. J. Physiol. 592 5169 – 5186 . 10.1113/jphysiol.2014.280388 25194045 PMC4262332

Kornum B. R. Kawashima M. Faraco J. Lin L. Rico T. J. Hesselson S. ( 2011 ). Common variants in P2RY11 are associated with narcolepsy. Nat. Genet. 43 66 – 71 . 10.1038/ng.734 21170044 PMC3019286

Kowaluk E. A. Jarvis M. F. ( 2000 ). Therapeutic potential of adenosine kinase inhibitors. Expert Opin. Investig. Drugs 9 551 – 564 . 10.1517/13543784.9.3.551 11060695

Krasowska E. Róg J. Sinadinos A. Young C. N. Górecki D. C. Zablocki K. ( 2014 ). Purinergic receptors in skeletal muscles in health and in muscular dystrophy. Postepy Biochem. 60 483 – 489 . 25807827

Kretschmar C. Oyarzún C. Villablanca C. Jaramillo C. Alarcón S. Perez G. ( 2016 ). Reduced adenosine uptake and its contribution to signaling that mediates profibrotic activation in renal tubular epithelial cells: implication in diabetic nephropathy. PLOS ONE 11 : e0147430 10.1371/journal.pone.0147430 PMC4726618 26808537

Krizaj D. Ryskamp D. A. Tian N. Tezel G. Mitchell C. H. Slepak V. Z. ( 2014 ). From mechanosensitivity to inflammatory responses: new players in the pathology of glaucoma. Curr. Eye Res. 39 105 – 119 . 10.3109/02713683.2013.836541 24144321 PMC3946931

Krügel U. ( 2016 ). Purinergic receptors in psychiatric disorders. Neuropharmacology 104 212 – 225 . 10.1016/j.neuropharm.2015.10.032 26518371

Krügel U. Köles L. Illes P. ( 2013 ). Integration of neuronal and glial signalling by pyramidal cells of the rat prefrontal cortex; control of cognitive functions and addictive behaviour by purinergic mechanisms. Neuropsychopharmacol. Hung. 15 206 – 213 . 24380961

Kruglov E. A. Correa P. R. Arora G. Yu J. Nathanson M. H. Dranoff J. A. ( 2007 ). Molecular basis for calcium signaling in hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 292 G975 – G982 . 17204544 10.1152/ajpgi.00401.2006

Kuan Y. H. Shih H. C. Tang S. C. Jeng J. S. Shyu B. C. ( 2015 ). Targeting P2X7 receptor for the treatment of central post-stroke pain in a rodent model. Neurobiol. Dis. 78 134 – 145 . 10.1016/j.nbd.2015.02.028 25836422

Kuan Y. H. Shyu B. C. ( 2016 ). Nociceptive transmission and modulation via P2X receptors in central pain syndrome. Mol. Brain 9 58 10.1186/s13041-016-0240-4 PMC4880968 27230068

Kudira R. Malinka T. Kohler A. Dosch M. De Aguero M. G. Melin N. ( 2016 ). P2X1-regulated IL-22 secretion by innate lymphoid cells is required for efficient liver regeneration. Hepatology 63 2004 – 2017 . 10.1002/hep.28492 26853442

Kumahashi N. Naitou K. Nishi H. Oae K. Watanabe Y. Kuwata S. ( 2011 ). Correlation of changes in pain intensity with synovial fluid adenosine triphosphate levels after treatment of patients with osteoarthritis of the knee with high-molecular-weight hyaluronic acid. Knee 18 160 – 164 . 10.1016/j.knee.2010.04.013 20627733

Kumar V. Chapple C. R. Rosario D. Tophill P. R. Chess-Williams R. ( 2010 ). In vitro release of adenosine triphosphate from the urothelium of human bladders with detrusor overactivity, both neurogenic and idiopathic. Eur. Urol. 57 1087 – 1092 . 10.1016/j.eururo.2009.11.042 20022422

Kurashima Y. Kiyono H. ( 2016 ). “Physiological and pathological inflammation at the mucosal frontline,” in Chronic Inflammation: Mechanisms and Regulation , eds Miyasaka M. Takatsu K. ( Tokyo : Springer ), 567 – 590 .

Kurashima Y. Kiyono H. Kunisawa J. ( 2015 ). Pathophysiological role of extracellular purinergic mediators in the control of intestinal inflammation. Mediators Inflamm. 2015 : 427125 10.1155/2015/427125 PMC4405224 25944982

Kurlak L. O. Williams P. J. Bulmer J. N. Broughton Pipkin F. Mistry H. D. ( 2015 ). Placental expression of adenosine A2A receptor and hypoxia inducible factor-1 alpha in early pregnancy, term and pre-eclamptic pregnancies: interactions with placental renin-angiotensin system. Placenta 36 611 – 613 . 10.1016/j.placenta.2015.02.011 25745823

Kvist T. M. Schwarz P. Jørgensen N. R. ( 2014 ). The P2X7 receptor: a key player in immune-mediated bone loss? Sci. World J. 2014 : 954530 10.1155/2014/954530 PMC3915485 24574936

Kwon S. G. Roh D. H. Yoon S. Y. Moon J. Y. Choi S. R. Choi H. S. ( 2014 ). Blockade of peripheral P2Y1 receptors prevents the induction of thermal hyperalgesia via modulation of TRPV1 expression in carrageenan-induced inflammatory pain rats: involvement of p38 MAPK phosphorylation in DRGs. Neuropharmacology 79 368 – 379 . 10.1016/j.neuropharm.2013.12.005 24333674

Kyle B. D. ( 2014 ). Ion channels of the mammalian urethra. Channels 8 393 – 401 . 10.4161/19336950.2014.954224 25483582 PMC4594508

Labazi H. Teng B. Zhou Z. Mustafa S. J. ( 2016 ). Enhanced A2A adenosine receptor-mediated increase in coronary flow in type I diabetic mice. J. Mol. Cell. Cardiol. 90 30 – 37 . 10.1016/j.yjmcc.2015.11.033 26654777 PMC4729563

Lahmann C. Clark R. H. Iberl M. Ashcroft F. M. ( 2014 ). A mutation causing increased KATP channel activity leads to reduced anxiety in mice. Physiol. Behav. 129 79 – 84 . 10.1016/j.physbeh.2014.02.031 24582665 PMC5576528

Lajdova I. Oksa A. Chorvat J. D. Topor P. Spustova V. ( 2012 ). Purinergic P2X7 receptors participate in disturbed intracellular calcium homeostasis in peripheral blood mononuclear cells of patients with chronic kidney disease. Kidney Blood Press. Res. 35 48 – 57 . 10.1159/000330349 21860249

Laketa D. Savic J. Bjelobaba I. Lavrnja I. Vasic V. Stojiljkovic M. ( 2015 ). Brain injury alters ectonucleotidase activities and adenine nucleotide levels in rat serum. J. Med. Biochem. 34 215 – 222 . 10.2478/jomb-2014-0025 28356834 PMC4922325

Lau O. C. Samarawickrama C. Skalicky S. E. ( 2014 ). P2Y2 receptor agonists for the treatment of dry eye disease: a review. Clin. Ophthalmol. 8 327 – 334 . 10.2147/OPTH.S39699 24511227 PMC3915022

Lavrnja I. Laketa D. Savic D. Bozic I. Bjelobaba I. Pekovic S. ( 2015 ). Expression of a second ecto-5′-nucleotidase variant besides the usual protein in symptomatic phase of experimental autoimmune encephalomyelitis. J. Mol. Neurosci. 55 898 – 911 . 10.1007/s12031-014-0445-x 25326791

Layland J. Carrick D. Lee M. Oldroyd K. Berry C. ( 2014 ). Adenosine: physiology, pharmacology, and clinical applications. JACC Cardiovasc. Interv. 7 581 – 591 . 10.1016/j.jcin.2014.02.009 24835328

Ledderose C. Bao Y. Kondo Y. Fakhari M. Slubowski C. Zhang J. ( 2016 ). Purinergic signaling and the immune response in sepsis: a review. Clin. Ther. 38 1054 – 1065 . 10.1016/j.clinthera.2016.04.002 27156007 PMC4875817

Lee B. H. Hwang D. M. Palaniyar N. Grinstein S. Philpott D. J. Hu J. ( 2012 ). Activation of P2X7 receptor by ATP plays an important role in regulating inflammatory responses during acute viral infection. PLOS ONE 7 : e35812 10.1371/journal.pone.0035812 PMC3338466 22558229

Lee C. F. Chern Y. ( 2014 ). Adenosine receptors and Huntington’s disease. Int. Rev. Neurobiol. 119 195 – 232 . 10.1016/B978-0-12-801022-8.00010-6 25175968

Lee C. Y. ( 2015 ). Adenosine protects Sprague Dawley rats from high-fat diet and repeated acute restraint stress-induced intestinal inflammation and altered expression of nutrient transporters. J. Anim. Physiol. Anim. Nutr. 99 317 – 325 . 10.1111/jpn.12247 25196093

Lee D. Myers J. S. Katz L. J. ( 2016 ). The role of adenosine receptor agonists in ocular disorders. Drugs Future 41 547 – 552 . 10.1358/dof.2016.041.09.2533858

Lemaire A. Vanorlé M. Horckmans M. Di Pietrantonio L. Clouet S. Robaye B. ( 2016 ). Mouse P2Y4 nucleotide receptor is a negative regulator of cardiac adipose-derived stem cell differentiation and cardiac fat formation. Stem Cells Dev. 26 363 – 373 . 10.1089/scd.2016.0166 27855539

Lerman B. B. ( 2015 ). Ventricular tachycardia: mechanistic insights derived from adenosine. Circ. Arrhythm. Electrophysiol. 8 483 – 491 . 10.1161/CIRCEP.115.001693 25900991

Lertsuwan K. Peters W. Johnson L. Lertsuwan J. Marwa I. Sikes R. A. ( 2017 ). Purinergic receptor expression and cellular responses to purinergic agonists in human prostate cancer cells. Anticancer Res. 37 529 – 537 . 10.21873/anticanres.11345 28179298

Leyva-Grado V. H. Ermler M. E. Schotsaert M. Gonzalez M. G. Gillespie V. Lim J. K. ( 2017 ). Contribution of the purinergic receptor P2X7 to development of lung immunopathology during influenza virus infection. mBio 8 : e00229 – 17 10.1128/mBio.00229-17 PMC5371412 28351919

Li C. L. Yang X. L. Wang J. J. Du G. H. Yang W. M. Zhang H. P. ( 2015 ). Effects of intracavernous injection of P2X3 and NK1 receptor antagonists on erectile dysfunction induced by spinal cord transection in rats. Andrologia 47 25 – 29 . 10.1111/and.12217 24387161

Li H. Chen O. Ye Z. Zhang R. Hu H. Zhang N. ( 2017 ). Inhalation of high concentrations of hydrogen ameliorates liver ischemia/reperfusion injury through A2A receptor mediated PI3K-Akt pathway. Biochem. Pharmacol. 130 83 – 92 . 10.1016/j.bcp.2017.02.003 28188779

Li H. J. Wang L. Y. Qu H. N. Yu L. H. Burnstock G. Ni X. ( 2011 ). P2Y2 receptor-mediated modulation of estrogen-induced proliferation of breast cancer cells. Mol. Cell. Endocrinol. 338 28 – 37 . 10.1016/j.mce.2011.02.014 21356271

Li L. Huang L. Ye H. Song S. P. Bajwa A. Lee S. J. ( 2012 ). Dendritic cells tolerized with adenosine A2AR agonist attenuate acute kidney injury. J. Clin. Invest. 122 3931 – 3942 . 10.1172/JCI63170 23093781 PMC3484444

Li S. Geiger N. H. Soliman M. L. Hui L. Geiger J. D. Chen X. ( 2015 ). Caffeine, through adenosine A3 receptor-mediated actions, suppresses amyloid-β protein precursor internalization and amyloid-β generation. J. Alzheimers Dis. 47 73 – 83 . 10.3233/JAD-142223 26402756 PMC4609209

Li W. Li Y. Li G. Zhou Z. Chang X. Xia Y. ( 2017 ). Ectopic expression of the ATP synthase beta subunit on the membrane of PC-3M cells supports its potential role in prostate cancer metastasis. Int. J. Oncol. 50 1312 – 1320 . 10.3892/ijo.2017.3878 28259978

Li W. Silva H. B. Real J. Wang Y. M. Rial D. Li P. ( 2015 ). Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington’s disease models. Neurobiol. Dis. 79 70 – 80 . 10.1016/j.nbd.2015.03.030 25892655

Li X. Qi X. Zhou L. Catera D. Rote N. S. Potashkin J. ( 2007 ). Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells. Gynecol. Oncol. 106 233 – 243 . 10.1016/j.ygyno.2007.03.032 17482244 PMC2398694

Li X. Qi X. Zhou L. Fu W. Bdul-Karim F. W. Maclennan G. ( 2009 ). P2X7 receptor expression is decreased in epithelial cancer cells of ectodermal, uro-genital sinus, and distal paramesonephric duct origin. Purinergic Signal. 5 351 – 368 . 10.1007/s11302-009-9161-3 19399640 PMC2717318

Li Y. He Y. Chen M. Pu Z. Chen L. Li P. ( 2016 ). Optogenetic activation of adenosine A2A receptor signaling in the dorsomedial striatopallidal neurons suppresses goal-directed behavior. Neuropsychopharmacology 41 1003 – 1013 . 10.1038/npp.2015.227 26216520 PMC4748425

Li Y. Xue L. Miao Q. Mao F. Yao L. Yuan J. ( 2013 ). Expression and electrophysiological characteristics of P2X3 receptors in interstitial cells of Cajal in rats with partial bladder outlet obstruction. BJU Int. 111 843 – 851 . 10.1111/j.1464-410X.2012.11408.x 22882254

Lietsche J. Imran I. Klein J. ( 2016 ). Extracellular levels of ATP and acetylcholine during lithium-pilocarpine induced status epilepticus in rats. Neurosci. Lett. 611 69 – 73 . 10.1016/j.neulet.2015.11.028 26610905

Liñán-Rico A. Wunderlich J. E. Enneking J. T. Tso D. R. Grants I. Williams K. C. ( 2015 ). Neuropharmacology of purinergic receptors in human submucous plexus: involvement of P2X1, P2X2, P2X3 channels, P2Y and A3 metabotropic receptors in neurotransmission. Neuropharmacology 95 83 – 99 . 10.1016/j.neuropharm.2015.02.014 25724083 PMC4466061

Lindberg D. Shan D. Ayers-Ringler J. Oliveros A. Benitez J. Prieto M. ( 2015 ). Purinergic signaling and energy homeostasis in psychiatric disorders. Curr. Mol. Med. 15 275 – 295 . 10.2174/1566524015666150330163724 25950756 PMC5036858

Lioi A. B. Ferrari B. M. Dubyak G. R. Weinberg A. Sieg S. F. ( 2015 ). Human β defensin-3 increases CD86 expression on monocytes by activating the ATP-gated channel P2X7. J. Immunol. 195 4438 – 4445 . 10.4049/jimmunol.1401319 26416278 PMC4610865

Liu F. Tantry U. S. Gurbel P. A. ( 2015 ). P2Y12 receptor inhibitors for secondary prevention of ischemic stroke. Expert Opin. Pharmacother. 16 k1149 – 1165 . 10.1517/14656566.2015.1035256 25873127

Liu G. Li M. Daneshgari F. ( 2008 ). Temporal expression of muscarinic and purinergic receptors in diabetic rat bladder. Neurourol. Urodyn. 27 594 – 595 .

Liu H. Jiang Y. Kuo H. ( 2013 ). Increased suburothelial nerve fiber and purinergic P2X3 receptor expressions in patients with idiopathic detrusor overactivity and their relationship with botulinum toxin A therapeutic outcome. Neurourol. Urodyn. 32 733 – 735 .

Liu H. Xia Y. ( 2015 ). Beneficial and detrimental role of adenosine signaling in diseases and therapy. J. Appl. Physiol. 119 1173 – 1182 . 10.1152/japplphysiol.00350.2015 26316513 PMC4839494

Liu J. Prell T. Stubendorff B. Keiner S. Ringer T. Gunkel A. ( 2016 ). Down-regulation of purinergic P2X7 receptor expression and intracellular calcium dysregulation in peripheral blood mononuclear cells of patients with amyotrophic lateral sclerosis. Neurosci. Lett. 630 77 – 83 . 10.1016/j.neulet.2016.07.039 27453058

Liu K. Vergani A. Zhao P. Ben N. M. Wu X. Iken K. ( 2014 ). Inhibition of the purinergic pathway prolongs mouse lung allograft survival. Am. J. Respir. Cell Mol. Biol. 51 300 – 310 . 10.1165/rcmb.2013-0362OC 24661183

Liu M. Yang H. Fang D. Yang J. J. Cai J. Wan Y. ( 2013 ). Upregulation of P2X3 receptors by neuronal calcium sensor protein VILIP-1 in dorsal root ganglions contributes to the bone cancer pain in rats. Pain 154 1551 – 1568 . 10.1016/j.pain.2013.04.022 23707265

Liu P. S. Chen C. Y. ( 2010 ). Butyl benzyl phthalate suppresses the ATP-induced cell proliferation in human osteosarcoma HOS cells. Toxicol. Appl. Pharmacol. 244 308 – 314 . 10.1016/j.taap.2010.01.007 20114058

Liu R. Ma S. Lu Z. Shen H. Sun L. Wei M. ( 2015 ). The ADP antagonist MRS2179 regulates the phenotype of smooth muscle cells to limit intimal hyperplasia. Cardiovasc. Drugs Ther. 29 23 – 29 . 10.1007/s10557-014-6561-6 25528944

Liu R. Wang H. Xu B. Chen W. Turlova E. Dong N. ( 2016 ). Cerebrovascular safety of sulfonylureas: the role of KATP channels in neuroprotection and the risk of stroke in patients with type 2 diabetes. Diabetes Metab. Res. Rev. 65 2795 – 2809 . 10.2337/db15-1737 27207539

Liu S. Shi Q. Zhu Q. Zou T. Li G. Huang A. ( 2015 ). P2X7 receptor of rat dorsal root ganglia is involved in the effect of moxibustion on visceral hyperalgesia. Purinergic Signal. 11 161 – 169 . 10.1007/s11302-014-9439-y 25527178 PMC4425718

Liu S. Zou L. Xie J. Xie W. Wen S. Xie Q. ( 2016 ). LncRNA NONRATT021972 siRNA regulates neuropathic pain behaviors in type 2 diabetic rats through the P2X 7 receptor in dorsal root ganglia. Mol. Brain 9 44 10.1186/s13041-016-0226-2 PMC4841959 27107575

Liu W. Ao Q. Guo Q. He W. Peng L. Jiang J. ( 2017 ). miR-9 mediates CALHM1-activated ATP-P2X7R signal in painful diabetic neuropathy rats. Mol. Neurobiol. 54 922 – 929 . 10.1007/s12035-016-9700-1 26781424

Liu X. Wang C. Fujita T. Malmstrom H. S. Nedergaard M. Ren Y. F. ( 2015 ). External dentin stimulation induces ATP release in human teeth. J. Dent. Res. 94 1259 – 1266 . 10.1177/0022034515592858 26130258 PMC4547316

Liu Z. Liu Y. Xu L. An H. Chang Y. Yang Y. ( 2015 ). P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma. Cancer Sci. 106 1224 – 1231 . 10.1111/cas.12736 26179886 PMC4582993

Liverani E. ( 2017 ). Lung injury during LPS-induced inflammation occurs independently of the receptor P2Y1. Purinergic Signal. 13 119 – 125 . 10.1007/s11302-016-9543-2 27815804 PMC5334203

Liverani E. Rico M. C. Tsygankov A. Y. Kilpatrick L. E. Kunapuli S. P. ( 2016 ). P2Y12 receptor modulates sepsis-induced inflammation. Arterioscler. Thromb. Vasc. Biol. 36 961 – 971 . 10.1161/ATVBAHA.116.307401 27055904 PMC4850113

Loma P. Guzman-Aranguez A. Perez De Lara M. J. Pintor J. ( 2015 ). Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency. Exp. Eye Res. 134 141 – 147 . 10.1016/j.exer.2015.02.014 25701803

Lu J. Cui J. Li X. Wang X. Zhou Y. Yang W. ( 2016 ). An anti-Parkinson’s disease drug via targeting adenosine A2A receptor enhances amyloid-β generation and γ-secretase activity. PLOS ONE 11 : e0166415 10.1371/journal.pone.0166415 PMC5106031 27835671

Lu W. Hu H. Sévigny J. Gabelt B. T. Kaufman P. L. Johnson E. C. ( 2015 ). Rat, mouse, and primate models of chronic glaucoma show sustained elevation of extracellular ATP and altered purinergic signaling in the posterior eye. Invest. Ophthalmol. Vis. Sci. 56 3075 – 3083 . 10.1167/iovs.14-15891 26024091 PMC4439132

Luo F. Le N. B. Mills T. Chen N. Y. Karmouty-Quintana H. Molina J. G. ( 2016 ). Extracellular adenosine levels are associated with the progression and exacerbation of pulmonary fibrosis. FASEB J. 30 874 – 883 . 10.1096/fj.15-274845 26527068 PMC4714555

Luo Y. Feng C. Wu J. Wu Y. Liu D. Wu J. ( 2016 ). P2Y1, P2Y2, and TRPV1 receptors are increased in diarrhea-predominant irritable bowel syndrome and P2Y2 correlates with abdominal pain. Dig. Dis. Sci. 61 k2878 – 2886 . 10.1007/s10620-016-4211-5 27250983

Ma B. Jiang Q. Li W. Li Z. ( 2016 ). Estrogen receptor beta (ERβ) activation plays a therapeutic role in murine models of inflammatory bowel disease (IBD) via inhibiting P2X3 and P2X7 receptors. FASEB J. 30 1023 – 1023 .26625903

Ma D. F. Kondo T. Nakazawa T. Niu D. F. Mochizuki K. Kawasaki T. ( 2010 ). Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells. Hum. Pathol. 41 1550 – 1557 . 10.1016/j.humpath.2010.04.008 20619442

Ma M. Ren Q. Zhang J. C. Hashimoto K. ( 2014 ). Effects of brilliant blue G on serum tumor necrosis factor-α levels and depression-like behavior in mice after lipopolysaccharide administration. Clin. Psychopharmacol. Neurosci. 12 31 – 36 . 10.9758/cpn.2014.12.1.31 24851118 PMC4022763

Ma X. Pan X. Wei Y. Tan B. Yang L. Ren H. ( 2016 ). Chemotherapy-induced uridine diphosphate release promotes breast cancer metastasis through P2Y6 activation. Oncotarget 7 29036 – 29050 . 10.18632/oncotarget.8664 27074554 PMC5045376

Ma X. Xu T. Xu H. Jiang W. ( 2015 ). Blockade and reversal of spinal morphine tolerance by P2X3 receptor antagonist. Behav. Pharmacol. 26 k260 – 267 . 10.1097/FBP.0000000000000105 25350728

Mac Mullan P. A. Peace A. J. Madigan A. M. Tedesco A. F. Kenny D. Mccarthy G. M. ( 2010 ). Platelet hyper-reactivity in active inflammatory arthritis is unique to the adenosine diphosphate pathway: a novel finding and potential therapeutic target. Rheumatology 49 240 – 245 . 10.1093/rheumatology/kep377 19965976

Macle L. Khairy P. Weerasooriya R. Novak P. Verma A. Willems S. ( 2015 ). Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial. Lancet 386 672 – 679 . 10.1016/S0140-6736(15)60026-5 26211828

Magni G. Merli D. Verderio C. Abbracchio M. P. Ceruti S. ( 2015 ). P2Y2 receptor antagonists as anti-allodynic agents in acute and sub-chronic trigeminal sensitization: role of satellite glial cells. Glia 63 1256 – 1269 . 10.1002/glia.22819 25779655

Mahi N. Kumar A. Jaggi A. S. Singh N. Dhawan R. ( 2015 ). Possible role of pannexin 1/P2x7 purinoceptor in neuroprotective mechanism of ischemic postconditioning in mice. J. Surg. Res. 196 190 – 199 . 10.1016/j.jss.2015.02.050 25796110

Maminishkis A. Jalickee S. Blaug S. A. Rymer J. Yerxa B. R. Peterson W. M. ( 2002 ). The P2Y2 receptor agonist INS37217 stimulates RPE fluid transport in vitro and retinal reattachment in rat. Invest. Ophthalmol. Vis. Sci. 43 3555 – 3566 . 12407168

Manzoor S. Akhtar U. Naseem S. Khalid M. Mazhar M. Parvaiz F. ( 2016 ). Ionotropic purinergic receptors P2X4 and P2X7: proviral or antiviral? An insight into P2X receptor signaling and hepatitis C virus infection. Viral Immunol. 29 401 – 408 . 10.1089/vim.2016.0008 27526181

Marchenkova A. Van Den Maagdenberg A. M. Nistri A. ( 2016 ). Loss of inhibition by brain natriuretic peptide over P2X3 receptors contributes to enhanced spike firing of trigeminal ganglion neurons in a mouse model of familial hemiplegic migraine type-1. Neuroscience 331 197 – 205 . 10.1016/j.neuroscience.2016.06.034 27346147

Martinez C. G. Zamith-Miranda D. Da Silva M. G. Ribeiro K. C. Brandão I. T. Silva C. L. ( 2015 ). P2x7 purinergic signaling in dilated cardiomyopathy induced by auto-immunity against muscarinic M2 receptors: autoantibody levels, heart functionality and cytokine expression. Sci. Rep. 5 : 16940 10.1038/srep16940 PMC4655336 26592184

Martinez N. A. Ayala A. M. Martinez M. Martinez-Rivera F. J. Miranda J. D. Silva W. I. ( 2016 ). Caveolin-1 regulates the P2Y2 receptor signaling in human 1321N1 astrocytoma cells. J. Biol. Chem. 291 12208 – 12222 . 10.1074/jbc.M116.730226 27129210 PMC4933270

Martins J. P. Silva R. B. Coutinho-Silva R. Takiya C. M. Battastini A. M. Morrone F. B. ( 2012 ). The role of P2X7 purinergic receptors in inflammatory and nociceptive changes accompanying cyclophosphamide-induced haemorrhagic cystitis in mice. Br. J. Pharmacol. 165 183 – 196 . 10.1111/j.1476-5381.2011.01535.x 21675966 PMC3252976

Masahiro K. Nakamachi Y. Kosaka H. Nakazawa T. Tsuji G. Kumagai S. ( 2003 ). Modification of cytokine milieu in rheumatoid arthritis by signalling through A2A adenosine receptors. FASEB J. 17 C69 .

Masino S. A. Kawamura M. Jr. Cote J. L. Williams R. B. Ruskin D. N. ( 2013 ). Adenosine and autism: a spectrum of opportunities. Neuropharmacology 68 116 – 121 . 10.1016/j.neuropharm.2012.08.013 22940000 PMC3529135

Masuch A. Shieh C. H. Van Rooijen N. Van Calker D. Biber K. ( 2016 ). Mechanism of microglia neuroprotection: involvement of P2X7, TNFα, and valproic acid. Glia 64 76 – 89 . 10.1002/glia.22904 26295445

Matos M. Shen H. Y. Augusto E. Wang Y. Wei C. J. Wang Y. T. ( 2015 ). Deletion of adenosine A2A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: relevance to schizophrenia. Biol. Psychiatry 78 763 – 774 . 10.1016/j.biopsych.2015.02.026 25869810 PMC4714966

Matsumoto T. Goulopoulou S. Taguchi K. Tostes R. C. Kobayashi T. ( 2015 ). Constrictor prostanoids and uridine adenosine tetraphosphate: vascular mediators and therapeutic targets in hypertension and diabetes. Br. J. Pharmacol. 172 3980 – 4001 . 10.1111/bph.13205 26031319 PMC4543607

Matsumura Y. Yamashita T. Sasaki A. Nakata E. Kohno K. Masuda T. ( 2016 ). A novel P2X4 receptor-selective antagonist produces anti-allodynic effect in a mouse model of herpetic pain. Sci. Rep. 6 : 32461 10.1038/srep32461 PMC5006034 27576299

Matta C. Fodor J. Miosge N. Takács R. Juhász T. Rybaltovszki H. ( 2015 ). Purinergic signalling is required for calcium oscillations in migratory chondrogenic progenitor cells. Pflugers Arch. 467 429 – 442 . 10.1007/s00424-014-1529-8 24841338

Maynard J. P. Lee J. S. Sohn B. H. Yu X. Lopez-Terrada D. Finegold M. J. ( 2015 ). P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients. Oncotarget 6 41162 – 41179 . 10.18632/oncotarget.6240 26517690 PMC4747397

Mazzon E. Esposito E. Impellizzeri D. Di Paola R. Melani A. Bramanti P. ( 2011 ). CGS 21680, an agonist of the adenosine (A2A) receptor, reduces progression of murine type II collagen-induced arthritis. J. Rheumatol. 38 2119 – 2129 . 10.3899/jrheum.110111 21765105

McGovern A. E. Mazzone S. B. ( 2014 ). Neural regulation of inflammation in the airways and lungs. Auton. Neurosci. 182 95 – 101 . 10.1016/j.autneu.2013.12.008 24411267

McLarnon J. G. ( 2017 ). Roles of purinergic P2X7 receptor in glioma and microglia in brain tumors. Cancer Lett. 402 93 – 99 . 10.1016/j.canlet.2017.05.004 28536012

McPhee M. D. Whiting S. J. ( 1989 ). The effect of adenosine and adenosine analogues on methylxanthine-induced hypercalciuria in the rat. Can. J. Physiol. Pharmacol. 67 1278 – 1282 . 10.1139/y89-203 2611724

Mediavilla-Varela M. Luddy K. Noyes D. Khalil F. K. Neuger A. M. Soliman H. ( 2013 ). Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol. Ther. 14 860 – 868 . 10.4161/cbt.25643 23917542 PMC3909555

Mendieta-Condado E. Chagoya de Sanchez V. Hernandez-Munoz R. ( 2007 ). Adenosine can accelerate the cell cycle during rat liver regeneration induced by partial hepatectomy. J. Hepatol. 46 S142 – S143 . 10.1124/jpet.109.156620 19638569

Menezes C. B. Tasca T. ( 2016 ). Trichomoniasis immunity and the involvement of the purinergic signaling. Biomed. J. 39 234 – 243 . 10.1016/j.bj.2016.06.007 27793265 PMC6138788

Meng E. Lin W. Y. Lee W. C. Chuang Y. C. ( 2012 ). Pathophysiology of overactive bladder. LUTS 4 48 – 55 . 10.1111/j.1757-5672.2011.00122.x 26676700

Menzies R. I. Tam F. W. Unwin R. J. Bailey M. A. ( 2017 ). Purinergic signaling in kidney disease. Kidney Int. 91 315 – 323 . 10.1016/j.kint.2016.08.029 27780585

Menzies R. I. Unwin R. J. Bailey M. A. ( 2015 ). Renal P2 receptors and hypertension. Acta Physiol. 213 232 – 241 . 10.1111/apha.12412 25345692

Merighi S. Borea P. A. Gessi S. ( 2015 ). Adenosine receptors and diabetes: focus on the A2B adenosine receptor subtype. Pharmacol. Res. 99 229 – 236 . 10.1016/j.phrs.2015.06.015 26142494

Merighi S. Borea P. A. Varani K. Gessi S. ( 2017 ). Deregulation of adenosine receptors in psoriatic epidermis: an option for therapeutic treatment. J. Invest. Dermatol. 137 11 – 13 . 10.1016/j.jid.2016.08.001 28010756

Merighi S. Simioni C. Gessi S. Varani K. Mirandola P. Tabrizi M. A. ( 2009 ). A2B and A3 adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia 11 1064 – 1073 . 10.1593/neo.09768 19794965 PMC2745672

Metzger M. W. Walser S. M. Aprile-Garcia F. Dedic N. Chen A. Holsboer F. ( 2017 ). Genetically dissecting P2rx7 expression within the central nervous system using conditional humanized mice. Purinergic Signal. 13 153 – 170 . 10.1007/s11302-016-9546-z 27858314 PMC5432476

Meyer C. H. Hotta K. Peterson W. M. Toth C. A. Jaffe G. J. ( 2002 ). Effect of INS37217, a P2Y2 receptor agonist, on experimental retinal detachment and electroretinogram in adult rabbits. Invest. Ophthalmol. Vis. Sci. 43 3567 – 3574 . 12407169

Michalak A. Biala G. ( 2016 ). Alcohol dependence - neurobiology and treatment. Acta Pol. Pharm. 73 3 – 12 . 27008795

Micioni Di Bonaventura M. V. Cifani C. Lambertucci C. Volpini R. Cristalli G. Froldi R. ( 2012 ). Effects of A2A adenosine receptor blockade or stimulation on alcohol intake in alcohol-preferring rats. Psychopharmacology 219 945 – 957 . 10.1007/s00213-011-2430-1 21833502

Milicic I. Buckner S. A. Daza A. Coghlan M. Fey T. A. Brune M. E. ( 2006 ). Pharmacological characterization of urinary bladder smooth muscle contractility following partial bladder outlet obstruction in pigs. Eur. J. Pharmacol. 532 107 – 114 . 10.1016/j.ejphar.2005.12.076 16487510

Minns M. S. Teicher G. Rich C. B. Trinkaus-Randall V. ( 2016 ). Purinoreceptor P2X7 regulation of Ca 2+ mobilization and cytoskeletal rearrangement is required for corneal reepithelialization after injury. Am. J. Pathol. 186 285 – 296 . 10.1016/j.ajpath.2015.10.006 26683661 PMC4729273

Minns M. S. Trinkaus-Randall V. ( 2016 ). Purinergic signaling in corneal wound healing: a tale of 2 receptors. J. Ocul. Pharmacol. Ther. 32 498 – 503 . 10.1089/jop.2016.0009 27643999 PMC5069712

Miranda M. F. Hamani C. De Almeida A. C. Amorim B. O. Macedo C. E. Fernandes M. J. ( 2014 ). Role of adenosine in the antiepileptic effects of deep brain stimulation. Front. Cell. Neurosci. 8 : 312 10.3389/fncel.2014.00312 PMC4183090 25324724

Miras-Portugal M. T. Diaz-Hernandez J. I. Gomez-Villafuertes R. Diaz-Hernandez M. Artalejo A. R. Gualix J. ( 2015 ). Role of P2X7 and P2Y2 receptors on α-secretase-dependent APP processing: control of amyloid plaques formation “in vivo” by P2X7 receptor. Comput. Struct. Biotechnol. J. 13 176 – 181 . 10.1016/j.csbj.2015.02.005 25848496 PMC4372621

Mishra A. Guo Y. Zhang L. More S. Weng T. Chintagari N. R. ( 2016 ). A critical role for P2X7 receptor-induced VCAM-1 shedding and neutrophil infiltration during acute lung injury. J. Immunol. 197 2828 – 2837 . 10.4049/jimmunol.1501041 27559050 PMC5026933

Mittal R. Chan B. Grati M. Mittal J. Patel K. Debs L. H. ( 2016 ). Molecular structure and regulation of P2X receptors with a special emphasis on the role of P2X2 in the auditory system. J. Cell. Physiol. 231 1656 – 1670 . 10.1002/jcp.25274 26627116

Molck C. Ryall J. Failla L. M. Coates J. L. Pascussi J. M. Heath J. K. ( 2016 ). The A2b adenosine receptor antagonist PSB-603 promotes oxidative phosphorylation and ROS production in colorectal cancer cells via adenosine receptor-independent mechanism. Cancer Lett. 383 135 – 143 . 10.1016/j.canlet.2016.09.018 27693637

Molina C. E. Llach A. Herraiz-Martínez A. Tarifa C. Barriga M. Wiegerinck R. F. ( 2016 ). Prevention of adenosine A2A receptor activation diminishes beat-to-beat alternation in human atrial myocytes. Basic Res. Cardiol. 111 5 10.1007/s00395-015-0525-2 26611209

Molz S. Olescowicz G. Kraus J. R. Ludka F. K. Tasca C. I. ( 2015 ). Purine receptors are required for DHA-mediated neuroprotection against oxygen and glucose deprivation in hippocampal slices. Purinergic Signal. 11 117 – 126 . 10.1007/s11302-014-9438-z 25504554 PMC4336303

Monção-Ribeiro L. C. Faffe D. S. Santana P. T. Vieira F. S. Da Graca C. L. Marques-Da-Silva C. ( 2014 ). P2X7 receptor modulates inflammatory and functional pulmonary changes induced by silica. PLOS ONE 9 : e110185 10.1371/journal.pone.0110185 PMC4195726 25310682

Montesinos M. C. Desai-Merchant A. Cronstein B. N. ( 2015 ). Promotion of wound healing by an agonist of adenosine A2A receptor is dependent on tissue plasminogen activator. Inflammation 38 2036 – 2041 . 10.1007/s10753-015-0184-3 25991438

Morandini A. C. Savio L. E. Coutinho-Silva R. ( 2014 ). The role of P2X7 receptor in infectious inflammatory diseases and the influence of ectonucleotidases. Biomed. J. 37 169 – 177 . 10.4103/2319-4170.127803 25116711

Morello S. Sorrentino R. Montinaro A. Luciano A. Maiolino P. Ngkelo A. ( 2011 ). NK1.1 + cells and CD8 + T cells mediate the antitumor activity of Cl-IB-MECA in a mouse melanoma model. Neoplasia 13 365 – 373 . 10.1593/neo.101628 21472141 PMC3071085

Mori A. ( 2014 ). Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson’s disease. Int. Rev. Neurobiol. 119 k87 – 116 . 10.1016/B978-0-12-801022-8.00004-0 25175962

Morrone F. B. Gehring M. P. Nicoletti N. F. ( 2016 ). Calcium channels and associated receptors in malignant brain tumor therapy. Mol. Pharmacol. 90 403 – 409 . 10.1124/mol.116.103770 27418672

Mrazek F. Gallo J. Stahelova A. Petrek M. ( 2010 ). Functional variants of the P2RX7 gene, aseptic osteolysis, and revision of the total hip arthroplasty: a preliminary study. Hum. Immunol. 71 201 – 205 . 10.1016/j.humimm.2009.10.013 19891999

Mujoomdar M. Bennett A. Hoskin D. Blay J. ( 2004 ). Adenosine stimulation of proliferation of breast carcinoma cell lines: evaluation of the [3H]thymidine assay system and modulatory effects of the cellular microenvironment in vitro. J. Cell. Physiol. 201 429 – 438 . 10.1002/jcp.20089 15389546

Mulryan K. Gitterman D. P. Lewis C. J. Vial C. Leckie B. J. Cobb A. L. ( 2000 ). Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature 403 86 – 89 . 10.1038/47495 10638758

Mumtaz F. H. Lau D. H. Siddiqui E. J. Morgan R. J. Thompson C. S. Mikhailidis D. P. ( 2006 ). Changes in cholinergic and purinergic neurotransmission in the diabetic rabbit bladder. In Vivo 20 1 – 4 . 16433020

Munoz A. Romain Z. Munch E. Gangitano D. Boone T. Smith C. ( 2008 ). Changes in purinergic and nitrergic sensory signals in female rats during early diabetes. Neurourol. Urodyn. 28 110 – 111 .

Munoz A. Somogyi G. T. Boone T. B. Ford A. P. Smith C. P. ( 2012 ). Modulation of bladder afferent signals in normal and spinal cord-injured rats by purinergic P2X3 and P2X2/3 receptors. BJU Int. 110 E409 – E414 . 10.1111/j.1464-410X.2012.11189.x 22540742 PMC4537156

Munoz A. Yazdi I. K. Tang X. Rivera C. Taghipour N. Grossman R. G. ( 2017 ). Localized inhibition of P2X7R at the spinal cord injury site improves neurogenic bladder dysfunction by decreasing urothelial P2X3R expression in rats. Life Sci. 171 60 – 67 . 10.1016/j.lfs.2016.12.017 28039004

Murakami S. Yoshida M. Masunaga K. Maeda Y. Ueda S. ( 2008 ). Change in acetylcholine release from rat bladder with partial outlet obstruction. BJU Int. 101 633 – 639 . 10.1111/j.1464-410X.2007.07325.x 18070174

Muti M. Del Grande C. Musetti L. Marazziti D. Turri M. Cirronis M. ( 2015 ). Serum uric acid levels and different phases of illness in bipolar I patients treated with lithium. Psychiatry Res. 225 604 – 608 . 10.1016/j.psychres.2014.11.038 25547850

Nagahama M. Seike S. Shirai H. Takagishi T. Kobayashi K. Takehara M. ( 2015 ). Role of P2X7 receptor in Clostridium perfringens beta-toxin-mediated cellular injury. Biochim. Biophys. Acta 1850 2159 – 2167 . 10.1016/j.bbagen.2015.08.011 26299247

Nakagawa Y. Yoshioka M. Abe Y. Uchinami H. Ohba T. Ono K. ( 2012 ). Enhancement of liver regeneration by adenosine triphosphate-sensitive K+ channel opener (diazoxide) after partial hepatectomy. Transplantation 93 1094 – 1100 . 10.1097/TP.0b013e31824ef1d1 22466787

Nakamachi Y. Koshiba M. Nakazawa T. Hatachi S. Saura R. Kurosaka M. ( 2003 ). Specific increase in enzymatic activity of adenosine deaminase 1 in rheumatoid synovial fibroblasts. Arthritis Rheum. 48 668 – 674 . 10.1002/art.10956 12632419

Nam H. W. Bruner R. C. Choi D. S. ( 2013 ). Adenosine signaling in striatal circuits and alcohol use disorders. Mol. Cells 36 195 – 202 . 10.1007/s10059-013-0192-9 23912595 PMC3887972

Nascimento F. Pousinha P. A. Correia A. M. Gomes R. Sebastião A. M. Ribeiro J. A. ( 2014 ). Adenosine A2A receptors activation facilitates neuromuscular transmission in the pre-symptomatic phase of the SOD1(G93A) ALS mice, but not in the symptomatic phase. PLOS ONE 9 : e104081 10.1371/journal.pone.0104081 PMC4122437 25093813

Nascimento F. Sebastião A. M. Ribeiro J. A. ( 2015 ). Presymptomatic and symptomatic ALS SOD1(G93A) mice differ in adenosine A1 and A2A receptor-mediated tonic modulation of neuromuscular transmission. Purinergic Signal. 11 471 – 480 . 10.1007/s11302-015-9465-4 26335190 PMC4648802

Navarro G. Borroto-Escuela D. O. Fuxe K. Franco R. ( 2016 ). Purinergic signaling in Parkinson’s disease. Relevance for treatment. Neuropharmacology 104 161 – 168 . 10.1016/j.neuropharm.2015.07.024 26211977

Naviaux J. C. Schuchbauer M. A. Li K. Wang L. Risbrough V. B. Powell S. B. ( 2014 ). Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy. Transl. Psychiatry 4 e400 10.1038/tp.2014.33 PMC4080315 24937094

Naviaux J. C. Wang L. Li K. Bright A. T. Alaynick W. A. Williams K. R. ( 2015 ). Antipurinergic therapy corrects the autism-like features in the Fragile X ( Fmr1 knockout) mouse model. Mol. Autism 6 : 1 10.1186/2040-2392-6-1 PMC4334917 25705365

Nelson S. Kiyono H. Kurashima Y. ( 2017 ). Epithelial extracellular ATP: an initiator of immunity to parasitic infections. Immunol. Cell Biol. 95 117 – 118 . 10.1038/icb.2016.106 27874014

Neuhuber W. L. Tiegs G. ( 2004 ). Innervation of immune cells: evidence for neuroimmunomodulation in the liver. Anat. Rec. A Discov. Mol. Cell. Evol. Biol. 280 884 – 892 . 10.1002/ar.a.20093 15382013

Neves A. R. Castelo-Branco M. T. Figliuolo V. R. Bernardazzi C. Buongusto F. Yoshimoto A. ( 2014 ). Overexpression of ATP-activated P2X7 receptors in the intestinal mucosa is implicated in the pathogenesis of Crohn’s disease. Inflamm. Bowel Dis. 20 444 – 457 . 10.1097/01.MIB.0000441201.10454.06 24412990

Ng S. K. Higashimori H. Tolman M. Yang Y. ( 2015 ). Suppression of adenosine 2a receptor (A2aR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 267 115 – 122 . 10.1016/j.expneurol.2015.03.004 25779930 PMC5363273

Ni R. Zheng D. Xiong S. Hill D. J. Sun T. Gardiner R. B. ( 2016 ). Mitochondrial calpain-1 disrupts ATP synthase and induces superoxide generation in type 1 diabetic hearts: a novel mechanism contributing to diabetic cardiomyopathy. Diabetes Metab. Res. Rev. 65 255 – 268 . 10.2337/db15-0963 PMC4686953 26470784

Ning C. Wen J. Zhang Y. Blackburn M. Kellems R. Xia Y. ( 2012a ). Impaired adenosine signaling contributes to erectile dysfunction. J. Sex. Med. 9 183 – 298 . 10.1161/ATVBAHA.111.226803 22862844

Ning C. Zhang Y. Wen J. Blackburn M. Kellems R. Xia Y. ( 2012b ). Adenosine signaling in priapism and novel therapies. J. Sex. Med. 9 223 . 10.1111/j.1743-6109.2008.01187.x 19267852

Noronha-Matos J. B. Morais T. Trigo D. Timóteo M. A. Magalhães-Cardoso M. T. Oliveira L. ( 2011 ). Tetanic failure due to decreased endogenous adenosine A2A tonus operating neuronal Cav 1 (L-type) influx in Myasthenia gravis. J. Neurochem. 117 797 – 811 . 10.1111/j.1471-4159.2011.07216.x 21323926

Novitskaya T. Chepurko E. Covarrubias R. Novitskiy S. Ryzhov S. V. Feoktistov I. ( 2016 ). Extracellular nucleotide regulation and signaling in cardiac fibrosis. J. Mol. Cell. Cardiol. 93 47 – 56 . 10.1016/j.yjmcc.2016.02.010 26891859

Nylander S. Schulz R. ( 2016 ). Effects of P2Y12 receptor antagonists beyond platelet inhibition - comparison of ticagrelor with thienopyridines. Br. J. Pharmacol. 173 1163 – 1178 . 10.1111/bph.13429 26758983 PMC5341337

Ochoa-Cortes F. Liñán-Rico A. Jacobson K. A. Christofi F. L. ( 2014 ). Potential for developing purinergic drugs for gastrointestinal diseases. Inflamm. Bowel Dis. 20 1259 – 1287 . 10.1097/MIB.0000000000000047 24859298 PMC4340257

Ohshima Y. Tsukimoto M. Takenouchi T. Harada H. Suzuki A. Sato M. ( 2010 ). γ-Irradiation induces P2X7 receptor-dependent ATP release from B16 melanoma cells. Biochim. Biophys. Acta 1800 40 – 46 . 10.1016/j.bbagen.2009.10.008 19854240

Olatunji O. J. Feng Y. Olatunji O. O. Tang J. Ouyang Z. Su Z. ( 2016 ). Neuroprotective effects of adenosine isolated from Cordyceps cicadae against oxidative and ER stress damages induced by glutamate in PC12 cells. Environ. Toxicol. Pharmacol. 44 53 – 61 . 10.1016/j.etap.2016.02.009 27114365

Oliveira A. G. Marques P. E. Amaral S. S. Quintão J. L. Cogliati B. Dagli M. L. ( 2013 ). Purinergic signalling during sterile liver injury. Liver Int. 33 353 – 361 . 10.1111/liv.12109 23402607

Oliveira L. Correia A. Costa A. C. Guerra-Gomes S. Ferreirinha F. Magalhães-Cardoso M. T. ( 2015 ). Deficits in endogenous adenosine formation by ecto-5′-nucleotidase/CD73 impair neuromuscular transmission and immune competence in experimental autoimmune myasthenia gravis. Mediators Inflamm. 2015 : 460610 10.1155/2015/460610 PMC4322825 25691808

Olivier E. Dutot M. Regazzetti A. Leguillier T. Dargere D. Auzeil N. ( 2016 ). P2X7-pannexin-1 and amyloid β-induced oxysterol input in human retinal cell: role in age-related macular degeneration? Biochimie 127 70 – 78 . 10.1016/j.biochi.2016.04.014 27109381

Ondrakova M. Knot J. Ulman J. Maly M. Motovska Z. ( 2016 ). Efficacy of P2Y12 receptor antagonists in patients with atrial fibrillation according to the CHA2DS2VASc score. Int. J. Cardiol. 207 84 – 86 . 10.1016/j.ijcard.2016.01.039 26797336

Ongaro A. Varani K. Masieri F. F. Pellati A. Massari L. Cadossi R. ( 2012 ). Electromagnetic fields (EMFs) and adenosine receptors modulate prostaglandin E(2) and cytokine release in human osteoarthritic synovial fibroblasts. J. Cell. Physiol. 227 2461 – 2469 . 10.1002/jcp.22981 21830213

O’Reilly B. A. Kosaka A. H. Knight G. E. Chang T. K. Ford A. P. D. W. Rymer J. M. ( 2002 ). P2X receptors and their role in female idiopathic detrusor instability. J. Urol. 167 157 – 164 . 10.1016/S0022-5347(05)65403-1 11743296

Orriss I. R. Arnett T. R. Russell R. G. ( 2016 ). Pyrophosphate: a key inhibitor of mineralisation. Curr. Opin. Pharmacol. 28 57 – 68 . 10.1016/j.coph.2016.03.003 27061894

Orth S. R. Amann K. Strojek K. Ritz E. ( 2001 ). Sympathetic overactivity and arterial hypertension in renal failure. Nephrol. Dial. Transplant. 16(Suppl. 1) , 67 – 69 . 10.1093/ndt/16.suppl_1.67 11369825

Ortiz R. Ulrich H. Zarate C. A. Jr. Machado-Vieira R. ( 2015 ). Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics. Prog. Neuropsychopharmacol. Biol. Psychiatry 57 117 – 131 . 10.1016/j.pnpbp.2014.10.016 25445063 PMC4262688

Ou Z. Sun Y. Lin L. You N. Liu X. Li H. ( 2016 ). Olig2-targeted G-protein-coupled receptor Gpr17 regulates oligodendrocyte survival in response to lysolecithin-induced demyelination. J. Neurosci. 36 k10560 – 10573 . 10.1523/JNEUROSCI.0898-16.2016 PMC6601930 27733608

Oury C. Lecut C. Hego A. Wéra O. Delierneux C. ( 2015 ). Purinergic control of inflammation and thrombosis: role of P2X1 receptors. Comput. Struct. Biotechnol. J. 13 106 – 110 . 10.1016/j.csbj.2014.11.008 25709760 PMC4334884

Oyarzun C. Garrido W. Alarcon S. Yanez A. Sobrevia L. Quezada C. ( 2017 ). Adenosine contribution to normal renal physiology and chronic kidney disease. Mol. Aspects Med. 55 75 – 89 . 10.1016/j.mam.2017.01.004 28109856

Ozaki T. Muramatsu R. Sasai M. Yamamoto M. Kubota Y. Fujinaka T. ( 2016 ). The P2X4 receptor is required for neuroprotection via ischemic preconditioning. Sci. Rep. 6 : 25893 10.1038/srep25893 PMC4865734 27173846

Pacheco P. A. Faria R. X. Ferreira L. G. Paixão I. C. ( 2014 ). Putative roles of purinergic signaling in human immunodeficiency virus-1 infection. Biol. Direct 9 : 21 10.1186/1745-6150-9-21 PMC4218944 25351961

Pandolfi J. B. Ferraro A. A. Sananez I. Gancedo M. C. Baz P. Billordo L. A. ( 2016 ). ATP-induced inflammation drives tissue-resident Th17 cells in metabolically unhealthy obesity. J. Immunol. 196 3287 – 3296 . 10.4049/jimmunol.1502506 26951799

Panjehpour M. Hemati S. Forghani M. A. ( 2012 ). Expression of A1 and A3 adenosine receptors in human breast tumors. Tumori 98 137 – 141 . 10.1700/1053.11512 22495714

Parabucki A. Savic D. Laketa D. Pekovic S. Stojiljkovic M. Nedeljkovic N. ( 2014 ). Expression of major ectonucleotidases after cortical stab brain injury in rats: a real-time PCR study. Arch. Biol. Sci. Belgrade 66 149 – 155 . 10.2298/ABS1401148P

Patel A. Honoré E. ( 2010 ). Polycystins and renovascular mechanosensory transduction. Nat. Rev. Nephrol. 6 530 – 538 . 10.1038/nrneph.2010.97 20625375

Pedata F. Dettori I. Coppi E. Melani A. Fusco I. Corradetti R. ( 2016 ). Purinergic signalling in brain ischemia. Neuropharmacology 104 105 – 130 . 10.1016/j.neuropharm.2015.11.007 26581499

Pedata F. Pugliese A. M. Coppi E. Dettori I. Maraula G. Cellai L. ( 2014 ). Adenosine A2A receptors modulate acute injury and neuroinflammation in brain ischemia. Mediators Inflamm. 2014 : 805198 10.1155/2014/805198 PMC4138795 25165414

Pei H. Linden J. ( 2016 ). Adenosine influences myeloid cells to inhibit aeroallergen sensitization. Am. J. Physiol. Lung Cell. Mol. Physiol. 310 L985 – L992 . 10.1152/ajplung.00330.2015 27016586 PMC4896100

Pelleg A. Schulman E. S. Barnes P. J. ( 2016 ). Extracellular adenosine 5′-triphosphate in obstructive airway diseases. Chest 150 908 – 915 . 10.1016/j.chest.2016.06.045 27568579

Peng H. Zou L. Xie J. Wu H. Wu B. Zhu G. ( 2017 ). lncRNA NONRATT021972 siRNA decreases diabetic neuropathic pain mediated by the P2X3 receptor in dorsal root ganglia. Mol. Neurobiol. 54 511 – 523 . 10.1007/s12035-015-9632-1 26742527

Peng W. Cotrina M. L. Han X. Yu H. Bekar L. Blum L. ( 2009 ). Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. Proc. Natl. Acad. Sci. U.S.A. 106 12489 – 12493 . 10.1073/pnas.0902531106 19666625 PMC2718350

Pereira V. S. Casarotto P. C. Hiroaki-Sato V. A. Sartim A. G. Guimarães F. S. Joca S. R. ( 2013 ). Antidepressant- and anticompulsive-like effects of purinergic receptor blockade: involvement of nitric oxide. Eur. Neuropsychopharmacol. 23 1769 – 1778 . 10.1016/j.euroneuro.2013.01.008 23434291

Pérez de Lara M. J. Guzmán-Aránguez A. De La Villa P. Díaz-Hernández J. I. Miras-Portugal M. T. Pintor J. ( 2015 ). Increased levels of extracellular ATP in glaucomatous retinas: possible role of the vesicular nucleotide transporter during the development of the pathology. Mol. Vis. 21 1060 – 1070 . 26392744 PMC4558477

Perez-Aso M. Mediero A. Low Y. C. Levine J. Cronstein B. N. ( 2016 ). Adenosine A2A receptor plays an important role in radiation-induced dermal injury. FASEB J. 30 457 – 465 . 10.1096/fj.15-280388 26415936 PMC4684533

Pérez-Sen R. Queipo M. J. Morente V. Ortega F. Delicado E. G. Miras-Portugal M. T. ( 2015 ). Neuroprotection mediated by P2Y13 nucleotide receptors in neurons. Comput. Struct. Biotechnol. J. 13 160 – 168 . 10.1016/j.csbj.2015.02.002 25750704 PMC4348571

Persson P. Friederich-Persson M. Fasching A. Hansell P. Inagi R. Palm F. ( 2015 ). Adenosine A2 a receptor stimulation prevents proteinuria in diabetic rats by promoting an anti-inflammatory phenotype without affecting oxidative stress. Acta Physiol. 214 311 – 318 . 10.1111/apha.12511 25891445

Petrasek J. Iracheta-Vellve A. Saha B. Satishchandran A. Kodys K. Fitzgerald K. A. ( 2015 ). Metabolic danger signals, uric acid and ATP, mediate inflammatory cross-talk between hepatocytes and immune cells in alcoholic liver disease. J. Leukoc. Biol. 98 249 – 256 . 10.1189/jlb.3AB1214-590R 25934928 PMC4501673

Pettengill M. A. Abdul-Sater A. Coutinho-Silva R. Ojcius D. M. ( 2016 ). Danger signals, inflammasomes, and the intricate intracellular lives of chlamydiae. Biomed. J. 39 306 – 315 . 10.1016/j.bj.2016.07.001 27884377 PMC6138786

Phillips E. Carpenter C. Oates R. D. ( 2014 ). Ejaculatory dysfunction. Urol. Clin. North Am. 41 115 – 128 . 10.1016/j.ucl.2013.08.018 24286771

Pijacka W. Moraes D. J. A. Ratcliffe L. E. K. Nightingale A. K. Hart E. C. Da Silva M. P. ( 2016 ). Purinergic receptors in the carotid body as a new drug target for controlling hypertension. Nat. Med. 22 1151 – 1159 . 10.1038/nm.4173 27595323 PMC5750397

Pinna A. ( 2014 ). Adenosine A2A receptor antagonists in Parkinson’s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs 28 455 – 474 . 10.1007/s40263-014-0161-7 24687255

Pintsuk J. Borroto-Escuela D. O. Pomierny B. Wydra K. Zaniewska M. Filip M. ( 2016 ). Cocaine self-administration differentially affects allosteric A2A-D2 receptor-receptor interactions in the striatum. Relevance for cocaine use disorder. Pharmacol. Biochem. Behav. 144 85 – 91 . 10.1016/j.pbb.2016.03.004 26987369

Plemel J. R. Keough M. B. Duncan G. J. Sparling J. S. Yong V. W. Stys P. K. ( 2014 ). Remyelination after spinal cord injury: is it a target for repair? Prog. Neurobiol. 117 54 – 72 . 10.1016/j.pneurobio.2014.02.006 24582777

Pochmann D. Rucker B. Battastini A. M. Sarkis J. J. ( 2004 ). Ovariectomy and estradiol replacement therapy alters the adenine nucleotide hydrolysis in rat blood serum. Thromb. Res. 114 275 – 281 . 10.1016/j.thromres.2004.06.021 15381391

Portales-Cervantes L. Niño-Moreno P. Doníz-Padilla L. Baranda-Candido L. García-Hernández M. Salgado-Bustamante M. ( 2010 ). Expression and function of the P2X7 purinergic receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. Hum. Immunol. 71 818 – 825 . 10.1016/j.humimm.2010.05.008 20493226

Portales-Cervantes L. Niño-Moreno P. Salgado-Bustamante M. García-Hernández M. H. Baranda-Candido L. Reynaga-Hernández E. ( 2012 ). The His155Tyr (489C>T) single nucleotide polymorphism of P2RX7 gene confers an enhanced function of P2X7 receptor in immune cells from patients with rheumatoid arthritis. Cell. Immunol. 276 168 – 175 . 10.1016/j.cellimm.2012.05.005 22703695

Pritchard M. Mandal P. Chiang D. J. Ndum O. Nagy L. E. ( 2011 ). Adenosine and adenosine signaling contribute to the anti-inflammatory effect of globular adiponectin in macrophages. Hepatology 54 1099A – 1100A .

Puchalowicz K. Tarnowski M. Baranowska-Bosiacka I. Chlubek D. Dziedziejko V. ( 2014 ). P2X and P2Y receptors-role in the pathophysiology of the nervous system. Int. J. Mol. Sci. 15 23672 – 23704 . 10.3390/ijms151223672 25530618 PMC4284787

Qu W. Zhu Z. J. Sun L. Y. Wei L. Liu Y. Zeng Z. G. ( 2017 ). Correlation between survival interval and CD4+ T-cell intracellular ATP levels in liver transplant recipients. Transplant. Proc. 49 316 – 321 . 10.1016/j.transproceed.2016.11.044 28219591

Quezada C. Alarcón S. Jaramillo C. Muñoz D. Oyarzún C. San Martín R. ( 2013 ). Targeting adenosine signaling to treatment of diabetic nephropathy. Curr. Drug Targets 14 490 – 496 . 10.2174/1389450111314040010 23316933

Rai B. Kaur J. Jacobs R. Anand S. C. ( 2011 ). Adenosine deaminase in saliva as a diagnostic marker of squamous cell carcinoma of tongue. Clin. Oral Investig. 15 347 – 349 . 10.1007/s00784-010-0404-z 20379753

Ralevic V. ( 2015 ). P2X receptors in the cardiovascular system and their potential as therapeutic targets in disease. Curr. Med. Chem. 22 851 – 865 . 10.2174/0929867321666141215094050 25515516

Ralevic V. Burnstock G. ( 1998 ). Receptors for purines and pyrimidines. Pharmacol. Rev. 50 413 – 492 . 9755289

Rama Rao K. V. Kielian T. ( 2015 ). Neuron-astrocyte interactions in neurodegenerative diseases: role of neuroinflammation. Clin. Exp. Neuroimmunol. 6 245 – 263 . 10.1111/cen3.12237 26543505 PMC4629520

Ramos D. B. Muller G. C. Rocha G. B. Dellavia G. H. Almeida R. F. Pettenuzzo L. F. ( 2016 ). Intranasal guanosine administration presents a wide therapeutic time window to reduce brain damage induced by permanent ischemia in rats. Purinergic Signal. 12 149 – 159 . 10.1007/s11302-015-9489-9 26695181 PMC4749534

Ran H. Duan W. Gong Z. Xu S. Zhu H. Hou X. ( 2015 ). Critical contribution of adenosine A2A receptors in bone marrow-derived cells to white matter lesions induced by chronic cerebral hypoperfusion. J. Neuropathol. Exp. Neurol. 74 305 – 318 . 10.1097/NEN.0000000000000174 25756592

Rao S. Liu S. Zou L. Jia T. Zhao S. Wu B. ( 2017 ). The effect of sinomenine in diabetic neuropathic pain mediated by the P2X3 receptor in dorsal root ganglia. Purinergic Signal. 13 227 – 235 . 10.1007/s11302-016-9554-z 28054206 PMC5432482

Rassendren F. Audinat E. ( 2016 ). Purinergic signaling in epilepsy. J. Neurosci. Res. 94 781 – 793 . 10.1002/jnr.23770 27302739

Rau A. R. Ariwodola O. J. Weiner J. L. ( 2014 ). Presynaptic adenosine A1 receptors modulate excitatory transmission in the rat basolateral amygdala. Neuropharmacology 77 465 – 474 . 10.1016/j.neuropharm.2013.10.029 24212058 PMC3872110

Rayalam S. Yang J. Y. La-Fera M. A. Baile C. A. ( 2011 ). Novel molecular targets for prevention of obesity and osteoporosis. J. Nutr. Biochem. 22 k1099 – 1104 . 10.1016/j.jnutbio.2010.11.009 21429725

Rech J. C. Bhattacharya A. Letavic M. A. Savall B. M. ( 2016 ). The evolution of P2X7 antagonists with a focus on CNS indications. Bioorg. Med. Chem. Lett. 26 3838 – 3845 . 10.1016/j.bmcl.2016.06.048 27426304

Reichenbach A. Bringmann A. ( 2016 ). Purinergic signaling in retinal degeneration and regeneration. Neuropharmacology 104 194 – 211 . 10.1016/j.neuropharm.2015.05.005 25998275

Reigada D. Navarro-Ruiz R. M. Caballero-López M. J. Del Águila Á Muñoz-Galdeano T. Maza R. M. ( 2017 ). Diadenosine tetraphosphate (Ap4A) inhibits ATP-induced excitotoxicity: a neuroprotective strategy for traumatic spinal cord injury treatment. Purinergic Signal. 13 75 – 87 . 10.1007/s11302-016-9541-4 27761681 PMC5334201

Reiss A. B. Cronstein B. N. ( 2012 ). Regulation of foam cells by adenosine. Arterioscler. Thromb. Vasc. Biol. 32 879 – 886 . 10.1161/ATVBAHA.111.226878 22423040 PMC3306592

Ren C. Qiu C. Y. Gan X. Liu T. T. Qu Z. W. Rao Z. ( 2015 ). Prokineticin 2 facilitates mechanical allodynia induced by α,β-methylene ATP in rats. Eur. J. Pharmacol. 767 24 – 29 . 10.1016/j.ejphar.2015.09.047 26435025

Ren M. Liu Y. Zhao H. Dong S. Jiang Z. Li K. ( 2016 ). Adenosine triphosphate postconditioning is associated with better preserved global and regional cardiac function during myocardial ischemia and reperfusion: a speckle tracking imaging-based echocardiologic study. Cardiovasc. Ther. 34 343 – 351 . 10.1111/1755-5922.12205 27328167

Rial D. Lara D. R. Cunha R. A. ( 2014 ). The adenosine neuromodulation system in schizophrenia. Int. Rev. Neurobiol. 119 395 – 449 . 10.1016/B978-0-12-801022-8.00016-7 25175974

Ribeiro F. F. Xapelli S. Miranda-Lourenco C. Tanqueiro S. R. Fonseca-Gomes J. Diogenes M. J. ( 2016 ). Purine nucleosides in neuroregeneration and neuroprotection. Neuropharmacology 104 226 – 242 . 10.1016/j.neuropharm.2015.11.006 26577017

Richards J. P. Bowles E. A. Gordon W. R. Ellsworth M. L. Stephenson A. H. Sprague R. S. ( 2015 ). Mechanisms of C-peptide-mediated rescue of low O2-induced ATP release from erythrocytes of humans with Type 2 diabetes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 308 R411 – R418 . 10.1152/ajpregu.00420.2014 25552662

Riding A. Pullar C. E. ( 2016 ). ATP release and P2Y receptor signaling are essential for keratinocyte galvanotaxis. J. Cell. Physiol. 231 181 – 191 . 10.1002/jcp.25070 26058714

Ring S. Enk A. Mahnke K. ( 2011 ). A role for adenosine triphosphate in regulating immune responses during melanoma growth. J. Invest. Dermatol. 131 S91 .

Roberts V. Lu B. Rajakumar S. Cowan P. J. Dwyer K. M. ( 2013 ). The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury. Purinergic Signal. 9 135 – 143 . 10.1007/s11302-012-9342-3 23188420 PMC3646120

Roberts V. H. Webster R. P. Brockman D. E. Pitzer B. A. Myatt L. ( 2007 ). Post-translational modifications of the P2X4 purinergic receptor subtype in the human placenta are altered in preeclampsia. Placenta 28 270 – 277 . 10.1016/j.placenta.2006.04.008 16793133

Rockenbach L. Bavaresco L. Fernandes F. P. Cappellari A. R. Barrios C. H. Bueno M. F. ( 2013 ). Alterations in the extracellular catabolism of nucleotides are involved in the antiproliferative effect of quercetin in human bladder cancer T24 cells. Urol. Oncol. 31 1204 – 1211 . 10.1016/j.urolonc.2011.10.009 22137869

Rodrigues A. M. Bergamaschi C. T. Fernandes M. J. Paredes-Gamero E. J. Buri M. V. Ferreira A. T. ( 2014 ). P2X7 receptor in the kidneys of diabetic rats submitted to aerobic training or to N-acetylcysteine supplementation [corrected]. PLOS ONE 9 : e97452 10.1371/journal.pone.0097452 PMC4062402 24940871

Rodrigues L. Miranda I. M. Andrade G. M. Mota M. Cortes L. Rodrigues A. G. ( 2016 ). Blunted dynamics of adenosine A2A receptors is associated with increased susceptibility to Candida albicans infection in the elderly. Oncotarget 7 62862 – 62872 . 10.18632/oncotarget.11760 27590517 PMC5325332

Rodrigues R. J. Tomé A. R. Cunha R. A. ( 2015 ). ATP as a multi-target danger signal in the brain. Front. Neurosci. 9 : 148 10.3389/fnins.2015.00148 PMC4412015 25972780

Rodriguez-Alvarez N. Jimenez-Mateos E. M. Engel T. Quinlan S. Reschke C. R. Conroy R. M. ( 2017 ). Effects of P2X7 receptor antagonists on hypoxia-induced neonatal seizures in mice. Neuropharmacology 116 351 – 363 . 10.1016/j.neuropharm.2017.01.005 28082183

Rollini F. Franchi F. Angiolillo D. J. ( 2016 ). Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat. Rev. Cardiol. 13 11 – 27 . 10.1038/nrcardio.2015.113 26283269

Rollini F. Franchi F. Angiolillo D. J. ( 2017 ). Drug-drug interactions when switching between intravenous and oral P2Y12 receptor inhibitors: how real is it? JACC Cardiovasc. Interv. 10 130 – 132 . 10.1016/j.jcin.2016.11.021 28104205

Romagnoli R. Baraldi P. G. Cruz-Lopez O. Lopez-Cara C. Preti D. Borea P. A. ( 2008 ). The P2X7 receptor as a therapeutic target. Expert Opin. Ther. Targets 12 647 – 661 . 10.1517/14728222.12.5.647 18410246

Rong W. Burnstock G. ( 2004 ). Activation of ureter nociceptors by exogenous and endogenous ATP in guinea pig. Neuropharmacology 47 1093 – 1101 . 10.1016/j.neuropharm.2004.08.003 15555643

Rossi C. Santini E. Chiarugi M. Salvati A. Comassi M. Vitolo E. ( 2014 ). The complex P2X7 receptor/inflammasome in perivascular fat tissue of heavy smokers. Eur. J. Clin. Invest. 44 295 – 302 . 10.1111/eci.12232 24372548

Rotte A. Garmann D. Buss I. Jaehde U. ( 2010 ). Effect of extracellular ATP on cisplatin-induced cytotoxicity in human ovarian carcinoma cells. Chemotherapy 56 1 – 8 . 10.1159/000287351 20185910

Roy Chowdhury U. Bahler C. K. Holman B. H. Dosa P. I. Fautsch M. P. ( 2015 ). Ocular hypotensive effects of the ATP-sensitive potassium channel opener cromakalim in human and murine experimental model systems. PLOS ONE 10 : e0141783 10.1371/journal.pone.0141783 PMC4633217 26535899

Roy Chowdhury U. Viker K. B. Stoltz K. L. Holman B. H. Fautsch M. P. Dosa P. I. ( 2016 ). Analogs of the ATP-sensitive potassium (KATP) channel opener cromakalim with in vivo ocular hypotensive activity. J. Med. Chem. 59 6221 – 6231 . 10.1021/acs.jmedchem.6b00406 27367033 PMC5567990

Ru Q. Tian X. Wu Y. X. Wu R. H. Pi M. S. Li C. Y. ( 2014 ). Voltage-gated and ATP-sensitive K+ channels are associated with cell proliferation and tumorigenesis of human glioma. Oncol. Rep. 31 842 – 848 . 10.3892/or.2013.2875 24284968

Rubaiy H. N. ( 2016 ). The therapeutic agents that target ATP-sensitive potassium channels. Acta Pharm. 66 23 – 34 . 10.1515/acph-2016-0006 27029082

Ruzsnavszky O. Telek A. Gönczi M. Balogh A. Remenyik E. Csernoch L. ( 2011 ). UV-B induced alteration in purinergic receptors and signaling on HaCaT keratinocytes. J. Photochem. Photobiol. B 105 113 – 118 . 10.1016/j.jphotobiol.2011.07.009 21862341

Ryten M. Yang S. Y. Dunn P. M. Goldspink G. Burnstock G. ( 2004 ). Purinoceptor expression in regenerating skeletal muscle in the mdx mouse model of muscular dystrophy and in satellite cell cultures. FASEB J. 18 k1404 – 1406 . 10.1096/fj.03-1175fje 15231720

Sacco E. Recupero S. M. Bientinesi R. Palermo G. D’agostino D. Currò D. ( 2015 ). Pioneering drugs for overactive bladder and detrusor overactivity: ongoing research and future directions. World J. Obstet. Gynecol. 4 k24 – 39 .

Sachdeva S. Gupta M. ( 2013 ). Adenosine and its receptors as therapeutic targets: an overview. Saudi. Pharm. J. 21 245 – 253 . 10.1016/j.jsps.2012.05.011 23960840 PMC3744929

Sadovnick A. D. Gu B. J. Traboulsee A. L. Bernales C. Q. Encarnacion M. Yee I. M. ( 2017 ). Purinergic receptors P2RX4 and P2RX7 in familial multiple sclerosis. Hum. Mutat. 38 736 – 744 . 10.1002/humu.23218 28326637 PMC5429140

Sáez-Orellana F. Godoy P. A. Bastidas C. Y. Silva-Grecchi T. Guzmán L. Aguayo L. G. ( 2016 ). ATP leakage induces P2XR activation and contributes to acute synaptic excitotoxicity induced by soluble oligomers of β-amyloid peptide in hippocampal neurons. Neuropharmacology 100 116 – 123 . 10.1016/j.neuropharm.2015.04.005 25896766

Sakamoto K. Endo K. Suzuki T. Fujimura K. Kurauchi Y. Mori A. ( 2015 ). P2X7 receptor antagonists protect against N-methyl-D-aspartic acid-induced neuronal injury in the rat retina. Eur. J Pharmacol. 756 52 – 58 . 10.1016/j.ejphar.2015.03.008 25796199

Salgado-Puga K. Rodriguez-Colorado J. Prado-Alcala R. A. Pena-Ortega F. ( 2017 ). Subclinical doses of ATP-sensitive potassium channel modulators prevent alterations in memory and synaptic plasticity induced by amyloid-β. J. Alzheimers Dis. 57 205 – 226 . 10.3233/JAD-160543 28222502

Salvetti N. R. Panzani C. G. Gimeno E. J. Neme L. G. Alfaro N. S. Ortega H. H. ( 2009 ). An imbalance between apoptosis and proliferation contributes to follicular persistence in polycystic ovaries in rats. Reprod. Biol. Endocrinol. 7 : 68 10.1186/1477-7827-7-68 PMC2713246 19570211

Samuel S. S. Mani A. Tachett B. Desai M. Thevananther S. ( 2010 ). P2Y2 purinergic receptor activation is essential for endotoxin-induced acute liver injury in mice. Hepatology 52 : 608A .

Sanderson J. Dartt D. A. Trinkaus-Randall V. Pintor J. Civan M. M. Delamere N. A. ( 2014 ). Purines in the eye: recent evidence for the physiological and pathological role of purines in the RPE, retinal neurons, astrocytes, Muller cells, lens, trabecular meshwork, cornea and lacrimal gland. Exp. Eye Res. 127 270 – 279 . 10.1016/j.exer.2014.08.009 25151301 PMC4175147

Santana P. T. Benjamim C. F. Martinez C. G. Kurtenbach E. Takiya C. M. Coutinho-Silva R. ( 2015 ). The P2X7 receptor contributes to the development of the exacerbated inflammatory response associated with sepsis. J. Innate Immun. 7 417 – 427 . 10.1159/000371388 25675986 PMC6738781

Santiago A. R. Baptista F. I. Santos P. F. Cristóvão G. Ambrósio A. F. Cunha R. A. ( 2014 ). Role of microglia adenosine A2A receptors in retinal and brain neurodegenerative diseases. Mediators Inflamm. 2014 : 465694 10.1155/2014/465694 PMC4124703 25132733

Sarafoff N. Byrne R. A. Sibbing D. ( 2012 ). Clinical use of clopidogrel. Curr. Pharm. Des. 18 5224 – 5239 . 10.2174/138161212803251853 22724411

Sashindranath M. Dwyer K. M. Dezfouli S. Selan C. Crikis S. Lu B. ( 2017 ). Development of a novel strategy to target CD39 antithrombotic activity to the endothelial-platelet microenvironment in kidney ischemia-reperfusion injury. Purinergic Signal. 13 259 – 265 . 10.1007/s11302-017-9558-3 28343356 PMC5432485

Sauer A. V. Mrak E. Hernandez R. J. Zacchi E. Cavani F. Casiraghi M. ( 2009 ). ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency. Blood 114 3216 – 3226 . 10.1182/blood-2009-03-209221 19633200

Savio L. E. Andrade M. G. De Andrade Mello P. Santana P. T. Moreira-Souza A. C. Kolling J. ( 2016 ). P2X7 receptor signaling contributes to sepsis-associated brain dysfunction. Mol. Neurobiol. 54 6459 – 6470 . 10.1007/s12035-016-0168-9 27730511

Savio L. E. Coutinho-Silva R. ( 2016 ). Purinergic signaling in infection and autoimmune disease. Biomed. J. 39 304 – 305 . 10.1016/j.bj.2016.09.002 27884376 PMC6138793

Sawynok J. ( 2016 ). Adenosine receptor targets for pain. Neuroscience 338 1 – 18 . 10.1016/j.neuroscience.2015.10.031 26500181

Schepp C. P. Reutershan J. ( 2008 ). Bench-to-bedside review: adenosine receptors–promising targets in acute lung injury? Crit. Care 12 : 226 10.1186/cc6990 PMC2592730 18828873

Schneider G. Glaser T. Lameu C. Bdelbaset-Ismail A. Sellers Z. P. Moniuszko M. ( 2015 ). Extracellular nucleotides as novel, underappreciated pro-metastatic factors that stimulate purinergic signaling in human lung cancer cells. Mol. Cancer 14 : 201 10.1186/s12943-015-0469-z PMC4657356 26597723

Schulte am Esch J. Akyildiz A. Tustas R. Y. Ganschow R. Schmelzle M. Krieg A. ( 2010 ). ADP-dependent platelet function prior to and in the early course of pediatric liver transplantation and persisting thrombocytopenia are positively correlated with ischemia/reperfusion injury. Transpl. Int. 23 745 – 752 . 10.1111/j.1432-2277.2010.01054.x 20136783

Schulz N. Liu K. C. Charbord J. Mattsson C. L. Tao L. Tworus D. ( 2016 ). Critical role for adenosine receptor A2a in β-cell proliferation. Mol. Metab. 5 1138 – 1146 . 10.1016/j.molmet.2016.09.006 27818940 PMC5081418

Sebastián-Serrano A. Engel T. De Diego-García L. Olivos-Oré L. A. Arribas-Blázquez M. Martínez-Frailes C. ( 2016 ). Neurodevelopmental alterations and seizures developed by mouse model of infantile hypophosphatasia are associated with purinergic signalling deregulation. Hum. Mol. Genet. 25 4143 – 4156 . 10.1093/hmg/ddw248 27466191 PMC5291194

Seref-Ferlengez Z. Maung S. Schaffler M. B. Spray D. C. Suadicani S. O. Thi M. M. ( 2016 ). P2X7R-Panx1 complex impairs bone mechanosignaling under high glucose levels associated with Type-1 diabetes. PLOS ONE 11 : e0155107 10.1371/journal.pone.0155107 PMC4861344 27159053

Shabbir M. Burnstock G. ( 2009 ). Purinergic receptor-mediated effects of ATP in urogenital malignant diseases. Int. J. Urol. 16 143 – 150 . 10.1111/j.1442-2042.2008.02207.x 19183233

Shabbir M. Ryten M. Thompson C. S. Mikhailidis D. P. Burnstock G. ( 2008 ). Purinergic receptor-mediated effects of ATP in high-grade bladder cancer. BJU Int. 101 106 – 112 . 17941929 10.1111/j.1464-410X.2007.07286.x

Shaikh G. Cronstein B. ( 2016 ). Signaling pathways involving adenosine A2A and A2B receptors in wound healing and fibrosis. Purinergic Signal. 12 191 – 197 . 10.1007/s11302-016-9498-3 26847815 PMC4854836

Shcherbatko A. Foletti D. Poulsen K. Strop P. Zhu G. Hasa-Moreno A. ( 2016 ). Modulation of P2X3 and P2X2/3 receptors by monoclonal antibodies. J. Biol. Chem. 291 12254 – 12270 . 10.1074/jbc.M116.722330 27129281 PMC4933274

Shibukawa Y. Sato M. Kimura M. Sobhan U. Shimada M. Nishiyama A. ( 2015 ). Odontoblasts as sensory receptors: transient receptor potential channels, pannexin-1, and ionotropic ATP receptors mediate intercellular odontoblast-neuron signal transduction. Pflugers. Arch. 467 843 – 863 . 10.1007/s00424-014-1551-x 24939701

Shimizu Y. Calvert J. W. ( 2016 ). Recycling KATP channels for cardioprotection. Am. J. Physiol. Heart Circ. Physiol. 310 H1381 – H1382 . 10.1152/ajpheart.00309.2016 27199122

Shishikura Y. Koarai A. Sugiura H. Aizawa H. Hashimoto Y. Numakura T. ( 2016 ). Extracellular ATP involves in dsRNA-induced MUC5AC production via P2Y2R in human airway epithelium. Am. J. Respir. Crit. Care Med. 193 A5851 . 10.1186/s12931-016-0438-0 PMC5039824 27677339

Sillero M. A. De Diego A. Tavares J. E. Silva J. A. Pérez-Zúñiga F. J. Sillero A. ( 2009 ). Synthesis of ATP derivatives of compounds of the mevalonate pathway (isopentenyl di- and triphosphate; geranyl di- and triphosphate, farnesyl di- and triphosphate, and dimethylallyl diphosphate) catalyzed by T4 RNA ligase, T4 DNA ligase and other ligases Potential relationship with the effect of bisphosphonates on osteoclasts. Biochem. Pharmacol. 78 335 – 343 . 10.1016/j.bcp.2009.04.028 19414000

Silva C. L. ( 2016 ). Purinergic signaling in schistosomal infection. Biomed. J. 39 316 – 325 . 10.1016/j.bj.2016.06.006 27884378 PMC6138794

Silva-Ramos M. Silva I. Oliveira J. C. Correia-De-Sa P. ( 2016 ). Increased urinary adenosine triphosphate in patients with bladder outlet obstruction due to benign prostate hyperplasia. Prostate 76 1353 – 1363 . 10.1002/pros.23207 27418113

Silva-Ramos M. Silva I. Oliveira O. Ferreira S. Reis M. J. Oliveira J. C. ( 2013 ). Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome. PLOS ONE 8 : e64696 10.1371/journal.pone.0064696 PMC3669404 23741373

Silveira G. F. Buffon A. Bruno A. N. ( 2013 ). New approaches to thyroid hormones and purinergic signaling. J. Thyroid Res. 2013 : 434727 10.1155/2013/434727 PMC3730180 23956925

Silverman M. H. Strand V. Markovits D. Nahir M. Reitblat T. Molad Y. ( 2008 ). Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J. Rheumatol. 35 41 – 48 . 18050382

Sinadinos A. Young C. N. Al-Khalidi R. Teti A. Kalinski P. Mohamad S. ( 2015 ). P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy. PLOS Med. 12 : e1001888 10.1371/journal.pmed.1001888 PMC4604078 26461208

Singh S. Roy K. K. Khan S. R. Kashyap V. K. Sharma A. Jaiswal S. ( 2015 ). Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis . Bioorg. Med. Chem. 23 742 – 752 . 10.1016/j.bmc.2014.12.060 25614114

Sivak K. V. Vasin A. V. Egorov V. V. Tsevtkov V. B. Kuzmich N. N. Savina V. A. ( 2016 ). Adenosine A2A receptor as a drug target for treatment of sepsis. Mol. Biol. 50 231 – 245 . 10.7868/S0026898416020233 27239843

Sjuve Scott R. Uvelius B. Arner A. ( 2004 ). Changes in intracellular calcium concentration and P2X1 receptor expression in hypertrophic rat urinary bladder smooth muscle. Neurourol. Urodyn. 23 361 – 366 . 10.1002/nau.20047 15227655

Slater M. Danieletto S. Gidley-Baird A. Teh L. C. Barden J. A. ( 2004 ). Early prostate cancer detected using expression of non-functional cytolytic P2X7 receptors. Histopathology 44 206 – 215 . 10.1111/j.0309-0167.2004.01798.x 14987223

Smith C. P. Vemulakonda V. M. Kiss S. Boone T. B. Somogyi G. T. ( 2005 ). Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: effect of botulinum toxin A. Neurochem. Int. 47 291 – 297 . 10.1016/j.neuint.2005.04.021 15970360

Smith S. B. Xu Z. Novitskaya T. Zhang B. Chepurko E. Pu X. A. ( 2016 ). Impact of cardiac-specific expression of CD39 on myocardial infarct size in mice. Life Sci. 179 54 – 59 . 10.1016/j.lfs.2016.10.016 27756600

Soares A. F. Diniz C. Fresco P. ( 2012 ). A3-adenosine receptor effects on malignant melanoma cells. FEBS J. 279 : 547 .

Soares-Bezerra R. J. Pinho R. T. Bisaggio Rda C. Benevolo-De-Andrade T. C. Alves L. A. ( 2015 ). The search for new agonists to P2X7R for clinical use: tuberculosis as a possible target. Cell Physiol. Biochem. 37 409 – 418 . 10.1159/000430364 26314826

Solini A. Menini S. Rossi C. Ricci C. Santini E. Blasetti Fantauzzi C. ( 2013 ). The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet: possible role of NLRP3 inflammasome activation. J. Pathol. 231 342 – 353 . 10.1002/path.4237 23843215

Soma T. Kobayashi T. Nakagome K. Nagata M. ( 2016 ). Clinical implication of adenosine triphosphate in sputum in asthma. Am. J. Respir. Crit. Care Med. 193 A1394 .

Song H. Han Y. Pan C. Deng X. Dai W. Hu L. ( 2015 ). Activation of adenosine monophosphate-activated protein kinase suppresses neuroinflammation and ameliorates bone cancer pain: involvement of inhibition on mitogen-activated protein kinase. Anesthesiology 123 1170 – 1185 . 10.1097/ALN.0000000000000856 26378398

Song S. Jacobson K. N. Mcdermott K. M. Reddy S. P. Cress A. E. Tang H. ( 2016 ). ATP promotes cell survival via regulation of cytosolic [Ca2+] and Bcl-2/Bax ratio in lung cancer cells. Am. J. Physiol. Cell Physiol. 310 C99 – C114 . 10.1152/ajpcell.00092.2015 26491047 PMC4719033

Sousa J. B. Diniz C. ( 2017 ). The adenosinergic system as a therapeutic target in the vasculature: new ligands and challenges. Molecules 22 : E752 10.3390/molecules22050752 PMC6154114 28481238

Spaans F. Melgert B. N. Borghuis T. Klok P. A. De Vos P. Bakker W. W. ( 2014a ). Extracellular adenosine triphosphate affects systemic and kidney immune cell populations in pregnant rats. Am. J. Reprod. Immunol. 72 k305 – 316 . 10.1111/aji.12267 24807649

Spaans F. Melgert B. N. Chiang C. Borghuis T. Klok P. A. De Vos P. ( 2014b ). Extracellular ATP decreases trophoblast invasion, spiral artery remodeling and immune cells in the mesometrial triangle in pregnant rats. Placenta 35 587 – 595 . 10.1016/j.placenta.2014.05.013 24953164

Sperlagh B. Illes P. ( 2014 ). P2X7 receptor: an emerging target in central nervous system diseases. Trends Pharmacol. Sci. 35 537 – 547 . 10.1016/j.tips.2014.08.002 25223574

Squadrito F. Bitto A. Altavilla D. Arcoraci V. De Caridi G. De Feo M. E. ( 2014 ). The effect of PDRN, an adenosine receptor A2A agonist, on the healing of chronic diabetic foot ulcers: results of a clinical trial. J. Clin. Endocrinol. Metab. 99 E746 – E753 . 10.1210/jc.2013-3569 24483158

Stachon P. Heidenreich A. Merz J. Hoppe N. Bode C. Idzko M. ( 2016 ). Deficiency of purinergic receptor P2X7 reduces atherosclerosis in mice. Circulation 134(Suppl._1) , A16502 .

Stagg J. Beavis P. A. Divisekera U. Liu M. C. Moller A. Darcy P. K. ( 2012 ). CD73-deficient mice are resistant to carcinogenesis. Cancer Res. 72 2190 – 2196 . 10.1158/0008-5472.CAN-12-0420 22396496

Stagg J. Divisekera U. Mclaughlin N. Sharkey J. Pommey S. Denoyer D. ( 2010 ). Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl. Acad. Sci. U.S.A. 107 1547 – 1552 . 10.1073/pnas.0908801107 20080644 PMC2824381

Stamp L. K. Hazlett J. Roberts R. L. Frampton C. Highton J. Hessian P. A. ( 2012 ). Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action. Arthritis Res. Ther. 14 : R138 10.1186/ar3871 PMC3446521 22682496

Steculorum S. M. Timper K. Engström Ruud L. Evers N. Paeger L. Bremser S. ( 2017 ). Inhibition of P2Y6 signaling in AgRP neurons reduces food intake and improves systemic insulin sensitivity in obesity. Cell Rep. 18 1587 – 1597 . 10.1016/j.celrep.2017.01.047 28199831

Stemmer S. Silverman M. H. Kerns W. D. Bar-Yehuda S. Fishman S. Harpaz Z. ( 2010 ). Phase 1/2 trial of CF102, a selective A3 adenosine receptor (A3AR) agonist, in patients with hepatocellular carcinoma (HCC). Eur. J. Cancer 8 : 122 10.1634/theoncologist.2012-0211

Sterle I. Zupancic D. Romih R. ( 2014 ). Correlation between urothelial differentiation and sensory proteins P2X3, P2X5, TRPV1, and TRPV4 in normal urothelium and papillary carcinoma of human bladder. Biomed. Res. Int. 2014 : 805236 10.1155/2014/805236 PMC4020497 24868547

Stoll M. Kim Y. O. Bebich B. Robson S. C. Schuppan D. ( 2012 ). The selective adenosine 2B receptor antagonist MRS1754 mitigates hepatic collagen deposition during fibrosis progression and induces mild fibrosis regression. Gastroenterology 142 S974 – S975 . 10.1016/S0016-5085(12)63778-0

Straub R. H. Rauch L. Fassold A. Lowin T. Pongratz G. ( 2008 ). Neuronally released sympathetic neurotransmitters stimulate splenic interferon-γ secretion from T cells in early type II collagen-induced arthritis. Arthritis Rheum. 58 3450 – 3460 . 10.1002/art.24030 18975332

Suadicani S. O. Urban-Maldonado M. Tar M. T. Melman A. Spray D. C. ( 2009 ). Effects of ageing and streptozotocin-induced diabetes on connexin43 and P2 purinoceptor expression in the rat corpora cavernosa and urinary bladder. BJU Int. 103 1686 – 1693 . 10.1111/j.1464-410X.2008.08337.x 19154470 PMC3422638

Subramanian M. Kini R. Madasu M. Ohta A. Nowak M. Exley M. ( 2014 ). Extracellular adenosine controls NKT-cell-dependent hepatitis induction. Eur. J. Immunol. 44 1119 – 1129 . 10.1002/eji.201343866 24448964 PMC4482763

Sugiyama T. ( 2014 ). Role of P2X7 receptors in the development of diabetic retinopathy. World J. Diabetes 5 141 – 145 . 10.4239/wjd.v5.i2.141 24748927 PMC3990313

Sun H. S. Xu B. Chen W. Xiao A. Turlova E. Alibraham A. ( 2015 ). Neuronal KATP channels mediate hypoxic preconditioning and reduce subsequent neonatal hypoxic-ischemic brain injury. Exp. Neurol. 263 161 – 171 . 10.1016/j.expneurol.2014.10.003 25448006

Sun L. Gao J. Zhao M. Cui J. Li Y. Yang X. ( 2015 ). A novel cognitive impairment mechanism that astrocytic p-connexin 43 promotes neuronic autophagy via activation of P2X7R and down-regulation of GLT-1 expression in the hippocampus following traumatic brain injury in rats. Behav. Brain Res. 291 315 – 324 . 10.1016/j.bbr.2015.05.049 26031379

Sun X. Han L. Seth P. Bian S. Li L. Csizmadia E. ( 2013 ). Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/ENTPD1 null mice. Hepatology 57 k205 – 216 . 10.1002/hep.25989 PMC3505255 22859060

Sun X. Imai M. Nowak-Machen M. Guckelberger O. Enjyoji K. Wu Y. ( 2011 ). Liver damage and systemic inflammatory responses are exacerbated by the genetic deletion of CD39 in total hepatic ischemia. Purinergic Signal. 7 427 – 434 . 10.1007/s11302-011-9239-6 21656186 PMC3224647

Sunggip C. Nishimura A. Shimoda K. Numaga-Tomita T. Tsuda M. Nishida M. ( 2017 ). Purinergic P2Y6 receptors: A new therapeutic target of age-dependent hypertension. Pharmacol. Res. 120 51 – 59 . 10.1016/j.phrs.2017.03.013 28336370

Suriyaphol G. Sarikaputi M. Suriyaphol P. ( 2009 ). Differential responses of cells from human skin keratinocyte and bovine mammary epithelium to attack by pore-forming Staphylococcus aureus α-toxin. Comp. Immunol. Microbiol. Infect. Dis. 32 491 – 502 . 10.1016/j.cimid.2008.07.002 18757097

Swennen E. L. Dagnelie P. C. Van Den Beucken T. Bast A. ( 2008 ). Radioprotective effects of ATP in human blood ex vivo. Biochem. Biophys. Res. Commun. 367 383 – 387 . 10.1016/j.bbrc.2007.12.125 18164682

Swiatkowski P. Murugan M. Eyo U. B. Wang Y. Rangaraju S. Oh S. B. ( 2016 ). Activation of microglial P2Y12 receptor is required for outward potassium currents in response to neuronal injury. Neuroscience 318 22 – 33 . 10.1016/j.neuroscience.2016.01.008 26791526 PMC4753827

Szkudelski T. ( 2007 ). Intracellular mediators in regulation of leptin secretion from adipocytes. Physiol. Res. 56 503 – 512 . 17184148 10.33549/physiolres.931038

Szuster-Ciesielska A. Sztanke K. Kandefer-Szerszen M. ( 2012 ). A novel fused 1,2,4-triazine aryl derivative as antioxidant and nonselective antagonist of adenosine A2A receptors in ethanol-activated liver stellate cells. Chem. Biol. Interact. 195 18 – 24 . 10.1016/j.cbi.2011.10.004 22063920

Tai Y. H. Cheng P. Y. Tsai R. Y. Chen Y. F. Wong C. S. ( 2010 ). Purinergic P2X receptor regulates N-methyl-D-aspartate receptor expression and synaptic excitatory amino acid concentration in morphine-tolerant rats. Anesthesiology 113 1163 – 1175 . 10.1097/ALN.0b013e3181f11aa2 20938337

Tak E. Jun D. Y. Kim S. H. Park G. C. Lee J. Hwang S. ( 2016 ). Upregulation of P2Y2 nucleotide receptor in human hepatocellular carcinoma cells. J. Int. Med. Res. 44 1234 – 1247 . 10.1177/0300060516662135 27807254 PMC5536769

Tak E. Ridyard D. Kim J. H. Zimmerman M. Werner T. Wang X. X. ( 2014 ). CD73-dependent generation of adenosine and endothelial Adora2b signaling attenuate diabetic nephropathy. J. Am. Soc. Nephrol. 25 547 – 563 . 10.1681/ASN.2012101014 24262796 PMC3935577

Takai E. Tsukimoto M. Harada H. Kojima S. ( 2011 ). Involvement of P2Y6 receptor in p38 MAPK-mediated COX-2 expression in response to UVB irradiation of human keratinocytes. Radiat. Res. 175 358 – 366 . 10.1667/RR2375.1 21388279

Takai E. Tsukimoto M. Harada H. Kojima S. ( 2014 ). Autocrine signaling via release of ATP and activation of P2X7 receptor influences motile activity of human lung cancer cells. Purinergic Signal. 10 487 – 497 . 10.1007/s11302-014-9411-x 24627191 PMC4152450

Takenouchi T. Tsukimoto M. Hashimoto M. Kitani H. ( 2014 ). Inflammasome activation by danger signals: extracellular ATP and pH. Inflammasome 1 76 – 80 . 10.2478/infl-2014-0008

Tanaka S. Kudo H. Asari T. Ono A. Motomura S. Toh S. ( 2011 ). P2Y1 transient overexpression induced mineralization in spinal ligament cells derived from patients with ossification of the posterior longitudinal ligament of the cervical spine. Calcif. Tissue Int. 88 263 – 271 . 10.1007/s00223-010-9456-y 21210088

Tang J. Li M. P. Zhou H. H. Chen X. P. ( 2015 ). Platelet inhibition agents: current and future P2Y12 receptor antagonists. Curr. Vasc. Pharmacol. 13 566 – 577 . 10.2174/1570161112666141127162209 25440595

Tang L. M. Zhu J. F. Wang F. Qian J. Zhu J. Mo Q. ( 2010 ). Activation of adenosine A2A receptor attenuates inflammatory response in a rat model of small-for-size liver transplantation. Transplant. Proc. 42 1915 – 1920 . 10.1016/j.transproceed.2010.02.084 20620548

Tantry S. J. Markad S. D. Shinde V. Bhat J. Balakrishnan G. Gupta A. K. ( 2017 ). Discovery of imidazo[1,2-a]pyridine ethers and squaramides as selective and potent inhibitors of mycobacterial adenosine triphosphate (ATP) synthesis. J. Med. Chem. 60 1379 – 1399 . 10.1021/acs.jmedchem.6b01358 28075132

Tao Y. Liang G. ( 2015 ). Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson’s disease: a meta-analysis of randomized controlled trials. Cell Biochem. Biophys. 71 57 – 62 . 10.1007/s12013-014-0162-7 25096504

Taskiran E. Erbas O. Yigittürk G. Meral A. Akar H. Taskiran D. ( 2016 ). Exogenously administered adenosine attenuates renal damage in streptozotocin-induced diabetic rats. Ren. Fail. 38 1276 – 1282 . 10.1080/0886022X.2016.1207054 27418253

Taylor J. M. Han Z. ( 2010 ). Purinergic receptor functionality is necessary for infection of human hepatocytes by hepatitis delta virus and hepatitis B virus. PLOS ONE 5 : e15784 10.1371/journal.pone.0015784 PMC3004961 21187936

Taylor S. R. J. Turner C. M. Elliott J. I. Hewitt R. Pickering M. Cook H. T. ( 2009 ). P2X7-deficiency ameliorates accelerated nephrotoxic nephritis in mice. J. Am. Soc. Nephrol. 20 1275 – 1281 . 10.1681/ASN.2008060559 19389853 PMC2689903

Teixeira J. M. Bobinski F. Parada C. A. Sluka K. A. Tambeli C. H. ( 2016 ). P2X3 and P2X2/3 receptors play a crucial role in articular hyperalgesia development through inflammatory mechanisms in the knee joint experimental synovitis. Mol. Neurobiol. 10.1007/s12035-016-0146-2 [Epub ahead of print] . PMC5380594 27709491

Teramachi J. Kukita A. Li Y. J. Ushijima Y. Ohkuma H. Wada N. ( 2011 ). Adenosine abolishes MTX-induced suppression of osteoclastogenesis and inflammatory bone destruction in adjuvant-induced arthritis. Lab. Invest. 91 719 – 731 . 10.1038/labinvest.2011.9 21339747

Thevananther S. Sun H. Hernandez A. Awad S. S. Karpen S. J. ( 2008 ). Impaired hepatocellular proliferation in P2Y2 purinergic receptor knockout mice: mitogenic role of extracellular ATP. Hepatology 44 : 206A .

Thevananther S. Sun H. Li D. Arjunan V. Awad S. S. Wyllie S. ( 2004 ). Extracellular ATP activates c-jun N-terminal kinase signaling and cell cycle progression in hepatocytes. Hepatology 39 393 – 402 . 10.1002/hep.20075 14767992

Tian T. Zhou Y. Feng X. Ye S. Wang H. Wu W. ( 2016 ). MicroRNA-16 is putatively involved in the NF-κB pathway regulation in ulcerative colitis through adenosine A2a receptor (A2aAR) mRNA targeting. Sci. Rep. 6 : 30824 10.1038/srep30824 PMC4967855 27476546

Tian Y. Marshall M. French B. A. Linden J. Yang Z. ( 2015 ). The infarct-sparing effect of IB-MECA against myocardial ischemia/reperfusion injury in mice is mediated by sequential activation of adenosine A3 and A2A receptors. Basic Res. Cardiol. 110 : 16 10.1007/s00395-015-0473-x 25711314

Tian Y. Tian X. Han X. Chen Y. Song C. Y. Zhang Y. B. ( 2016 ). Expression of ATP binding cassette E1 enhances viability and invasiveness of lung adenocarcinoma cells in vitro. Mol. Med. Rep. 14 1345 – 1350 . 10.3892/mmr.2016.5388 27314749

Torres A. Vargas Y. Uribe D. Jaramillo C. Gleisner A. Salazar-Onfray F. ( 2016 ). Adenosine A3 receptor elicits chemoresistance mediated by multiple resistance-associated protein-1 in human glioblastoma stem-like cells. Oncotarget 7 67373 – 67386 . 10.18632/oncotarget.12033 27634913 PMC5341882

Torres B. T. Jimenez D. A. Budsberg S. C. ( 2016 ). Elevated synovial fluid concentration of adenosine triphosphate in dogs with osteoarthritis or sodium urate-induced synovitis of the stifle. Vet. Comp. Orthop. Traumatol. 29 344 – 346 . 10.3415/VCOT-15-06-0111 27432274

Torres-Fuentes J. L. Rios M. Moreno R. D. ( 2015 ). Involvement of a P2X7 receptor in the acrosome reaction induced by ATP in rat spermatozoa. J. Cell. Physiol. 230 3068 – 3075 . 10.1002/jcp.25044 25989529

Truong L. D. Trostel J. Mcmahan R. Chen J. F. Garcia G. E. ( 2016 ). Macrophage A2A adenosine receptors are essential to protect from progressive kidney injury. Am. J. Pathol. 186 2601 – 2613 . 10.1016/j.ajpath.2016.06.017 27520357 PMC5222981

Tsuda M. ( 2016 ). Microglia in the spinal cord and neuropathic pain. J. Diabetes Investig. 7 17 – 26 . 10.1111/jdi.12379 PMC4718109 26813032

Tsuda M. ( 2017 ). P2 receptors, microglial cytokines and chemokines, and neuropathic pain. J. Neurosci. Res. 95 1319 – 1329 . 10.1002/jnr.23816 27376880

Tsuda M. Inoue K. ( 2016 ). Neuron-microglia interaction by purinergic signaling in neuropathic pain following neurodegeneration. Neuropharmacology 104 76 – 81 . 10.1016/j.neuropharm.2015.08.042 26327676

Tsuda M. Koga K. Chen T. Zhuo M. ( 2017 ). Neuronal and microglial mechanisms for neuropathic pain in the spinal dorsal horn and anterior cingulate cortex. J. Neurochem. 141 486 – 498 . 10.1111/jnc.14001 28251660

Tu G. Zou L. Liu S. Wu B. Lv Q. Wang S. ( 2016 ). Long noncoding NONRATT021972 siRNA normalized abnormal sympathetic activity mediated by the upregulation of P2X7 receptor in superior cervical ganglia after myocardial ischemia. Purinergic Signal. 12 521 – 535 . 10.1007/s11302-016-9518-3 27215605 PMC5023633

Turcin A. Dolzan V. Porcelli S. Serretti A. Plesnicar B. K. ( 2016 ). Adenosine hypothesis of antipsychotic drugs revisited: pharmacogenomics variation in nonacute schizophrenia. OMICS 20 283 – 289 . 10.1089/omi.2016.0003 27195966

Uchida S. Soshiroda K. Okita E. Kawai-Uchida M. Mori A. Jenner P. ( 2015 ). The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets. Eur. J. Pharmacol. 747 160 – 165 . 10.1016/j.ejphar.2014.11.038 25499739

Uluçkan Ö. Eagleton M. C. Floyd D. H. Morgan E. A. Hirbe A. C. Kramer M. ( 2008 ). APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. J. Cell. Biochem 104 1311 – 1323 . 10.1002/jcb.21709 18260128 PMC2763643

Ursu D. Ebert P. Langron E. Ruble C. Munsie L. Zou W. ( 2014 ). Gain and loss of function of P2X7 receptors: mechanisms, pharmacology and relevance to diabetic neuropathic pain. Mol. Pain 10 : 37 10.1186/1744-8069-10-37 PMC4072620 24934217

Valladares D. Altamirano F. Henríquez-Olguín C. Díaz-Vegas A. Intriago G. Contreras-Ferrat A. ( 2014 ). ATP signaling complex is altered in muscular dystrophy and was partly recovered after nifedipine treatment. FASEB J. 28 762.3 .

Vandenbeuch A. Anderson C. B. Parnes J. Enjyoji K. Robson S. C. Finger T. E. ( 2013 ). Role of the ectonucleotidase NTPDase2 in taste bud function. Proc. Natl. Acad. Sci. U.S.A. 110 14789 – 14794 . 10.1073/pnas.1309468110 23959882 PMC3767538

Vandenbeuch A. Larson E. D. Anderson C. B. Smith S. A. Ford A. P. Finger T. E. ( 2015 ). Postsynaptic P2X3-containing receptors in gustatory nerve fibres mediate responses to all taste qualities in mice. J. Physiol. 593 1113 – 1125 . 10.1113/jphysiol.2014.281014 25524179 PMC4358674

Vanderstocken G. Van De Paar E. Robaye B. Di Pietrantonio L. Bondue B. Boeynaems J. M. ( 2012 ). Protective role of P2Y2 receptor against lung infection induced by pneumonia virus of mice. PLOS ONE 7 : e50385 10.1371/journal.pone.0050385 PMC3503929 23185614

Varani K. Padovan M. Govoni M. Vincenzi F. Trotta F. Borea P. A. ( 2010a ). The role of adenosine receptors in rheumatoid arthritis. Autoimmun. Rev. 10 61 – 64 . 10.1016/j.autrev.2010.07.019 20691813

Varani K. Vincenzi F. Targa M. Paradiso B. Parrilli A. Fini M. ( 2013 ). The stimulation of A3 adenosine receptors reduces bone-residing breast cancer in a rat preclinical model. Eur. J. Cancer 49 482 – 491 . 10.1016/j.ejca.2012.06.005 22770890

Varani K. Vincenzi F. Tosi A. Targa M. Masieri F. F. Ongaro A. ( 2010b ). Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes. Br. J. Pharmacol. 160 101 – 115 . 10.1111/j.1476-5381.2010.00667.x 20331607 PMC2860211

Vaughn B. P. Robson S. C. Longhi M. S. ( 2014 ). Purinergic signaling in liver disease. Dig. Dis. 32 516 – 524 . 10.1159/000360498 25034284 PMC6310169

Vazquez-Cuevas F. G. Martinez-Ramirez A. S. Robles-Martinez L. Garay E. Garcia-Carranca A. Perez-Montiel D. ( 2014 ). Paracrine stimulation of P2X7 receptor by ATP activates a proliferative pathway in ovarian carcinoma cells. J. Cell. Biochem. 115 1955 – 1966 . 10.1002/jcb.24867 24913779

Vergani A. Fotino C. D’addio F. Tezza S. Podetta M. Gatti F. ( 2013 ). Effect of the purinergic inhibitor oxidized ATP in a model of islet allograft rejection. Diabetes Metab. Res. Rev. 62 1665 – 1675 . 10.2337/db12-0242 PMC3636636 23315496

Veselá R. Aronsson P. Andersson M. Wsol V. Tobin G. ( 2012a ). The potential of non-adrenergic, non-cholinergic targets in the treatment of interstitial cystitis/painful bladder syndrome. J. Physiol. Pharmacol. 63 k209 – 216 . 22791634

Veselá R. Aronsson P. Tobin G. ( 2011 ). Functional and morphological examinations of P1A1 purinoceptors in the normal and inflamed urinary bladder of the rat. Auton. Neurosci. 159 26 – 31 . 10.1016/j.autneu.2010.07.008 20685181

Veselá R. Asklund H. Aronsson P. Johnsson M. Wsol V. Andersson M. ( 2012b ). Coupled nitric oxide and autonomic receptor functional responses in the normal and inflamed urinary bladder of the rat. Physiol. Res. 61 371 – 380 . 22670695 10.33549/physiolres.932282

Vieira F. S. Nanini H. F. Takiya C. M. Coutinho-Silva R. ( 2016 ). P2X7 receptor knockout prevents streptozotocin-induced type 1 diabetes in mice. Mol. Cell. Endocrinol. 419 148 – 157 . 10.1016/j.mce.2015.10.008 26483196

Vincent I. S. Okusa M. D. ( 2015 ). Adenosine 2A receptors in acute kidney injury. Acta Physiol. 214 303 – 310 . 10.1111/apha.12508 PMC4470817 25877257

Vincenzi F. Padovan M. Targa M. Corciulo C. Giacuzzo S. Merighi S. ( 2013 ). A2A adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats. PLOS ONE 8 : e54195 10.1371/journal.pone.0054195 PMC3543361 23326596

Vincenzi F. Ravani A. Pasquini S. Merighi S. Gessi S. Romagnoli R. ( 2016 ). Positive allosteric modulation of A1 adenosine receptors as a novel and promising therapeutic strategy for anxiety. Neuropharmacology 111 283 – 292 . 10.1016/j.neuropharm.2016.09.015 27639989

Vindeirinho J. Santiago A. R. Cavadas C. Ambrósio A. F. Santos P. F. ( 2016 ). The adenosinergic system in diabetic retinopathy. J. Diabetes Res. 2016 : 4270301 10.1155/2016/4270301 PMC4789509 27034960

Vlajkovic S. M. Ambepitiya K. Barclay M. Boison D. Housley G. D. Thorne P. R. ( 2017 ). Adenosine receptors regulate susceptibility to noise-induced neural injury in the mouse cochlea and hearing loss. Hear. Res. 345 43 – 51 . 10.1016/j.heares.2016.12.015 28034618

Vlaskovska M. Kasakov L. Rong W. Bodin P. Bardini M. Cockayne D. A. ( 2001 ). P2X3 knockout mice reveal a major sensory role for urothelially released ATP. J. Neurosci. 21 5670 – 5677 . 11466438 10.1523/JNEUROSCI.21-15-05670.2001 PMC6762653

Völkl T. Ogilvie A. Neuhuber W. Ogilvie A. ( 2008 ). Cell death induced by uridine 5′-triphosphate (UTP) in contrast to adenosine 5′-triphosphate (ATP) in human epidermoid carcinoma cells (A-431). Cell Physiol. Biochem. 22 441 – 454 . 10.1159/000185491 19088426

Volonté C. Apolloni S. Parisi C. Amadio S. ( 2016 ). Purinergic contribution to amyotrophic lateral sclerosis. Neuropharmacology 104 180 – 193 . 10.1016/j.neuropharm.2015.10.026 26514402

von Versen-Höynck F. Rajakumar A. Bainbridge S. A. Gallaher M. J. Roberts J. M. Powers R. W. ( 2009 ). Human placental adenosine receptor expression is elevated in preeclampsia and hypoxia increases expression of the A2A receptor. Placenta 30 434 – 442 . 10.1016/j.placenta.2009.02.004 19303140 PMC2674514

Vonend O. Turner C. Chan C. M. Loesch A. Dell’anna G. C. Srai S. K. ( 2004 ). Glomerular expression of the ATP-sensitive P2X7 receptor in diabetic and hypertensive rat models. Kidney Int. 66 157 – 166 . 10.1111/j.1523-1755.2004.00717.x 15200422

Voors A. A. Dungen H. D. Senni M. Nodari S. Agostoni P. Ponikowski P. ( 2017 ). Safety and tolerability of neladenoson bialanate, a novel oral partial adenosine A1 receptor agonist, in patients with chronic heart failure. J. Clin. Pharmacol. 57 440 – 451 . 10.1002/jcph.828 27624622

Vorovenci R. J. Antonini A. ( 2015 ). The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson’s disease. Expert Rev. Neurother. 15 1383 – 1390 . 10.1586/14737175.2015.1113131 26630457

Waeber C. Moskowitz M. A. ( 2003 ). Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology 61 S9 – S20 . 10.1212/WNL.61.8_suppl_4.S9 14581653

Walsh C. A. Cheng Y. Mansfield K. J. Parkin K. Mukerjee C. Moore K. H. ( 2013 ). Decreased intravesical adenosine triphosphate in patients with refractory detrusor overactivity and bacteriuria. J. Urol. 189 1383 – 1387 . 10.1016/j.juro.2012.10.003 23063632

Wan H. X. Hu J. H. Xie R. Yang S. M. Dong H. ( 2016 ). Important roles of P2Y receptors in the inflammation and cancer of digestive system. Oncotarget 7 28736 – 28747 . 10.18632/oncotarget.7518 26908460 PMC5053759

Wan P. Liu X. Xiong Y. Ren Y. Chen J. Lu N. ( 2016 ). Extracellular ATP mediates inflammatory responses in colitis via P2 x 7 receptor signaling. Sci. Rep. 6 : 19108 10.1038/srep19108 PMC4703960 26739809

Wang C. Hu S. M. Xie H. Qiao S. G. Liu H. Liu C. F. ( 2015 ). Role of mitochondrial ATP-sensitive potassium channel-mediated PKC-ε in delayed protection against myocardial ischemia/reperfusion injury in isolated hearts of sevoflurane-preconditioned rats. Braz. J. Med. Biol. Res. 48 528 – 536 . 10.1590/1414-431X20143876 25831209 PMC4470312

Wang L. Wan H. Tang W. Ni Y. Hou X. Pan L. ( 2016 ). Critical roles of adenosine A2A receptor in regulating the balance of Treg/Th17cells in allergic asthma. Clin. Respir. J. 10.1111/crj.12503 [Epub ahead of print] . 27216911

Wang N. Rumney R. M. Yang L. Robaye B. Boeynaems J. M. Skerry T. M. ( 2013 ). The P2Y13 receptor regulates extracellular ATP metabolism and the osteogenic response to mechanical loading. J. Bone Miner. Res. 28 1446 – 1456 . 10.1002/jbmr.1877 23362109

Wang X. Arcuino G. Takano T. Lin J. Peng W. G. Wan P. ( 2004 ). P2X7 receptor inhibition improves recovery after spinal cord injury. Nat. Med. 10 821 – 827 . 10.1038/nm1082 15258577

Wang X. H. Xie X. Luo X. G. Shang H. He Z. Y. ( 2017 ). Inhibiting purinergic P2X7 receptors with the antagonist brilliant blue G is neuroprotective in an intranigral lipopolysaccharide animal model of Parkinson’s disease. Mol. Med. Rep. 15 768 – 776 . 10.3892/mmr.2016.6070 28035410 PMC5364844

Wang Z. Cristofaro V. Cheng Z. Xiao X. Ge R. Sullivan M. ( 2013 ). Urothelium-released ATP contributes to bladder dysfunction in type 2 diabetes. J. Urol. 189 e116 10.1016/j.juro.2013.02.1668

Wei C. J. Augusto E. Gomes C. A. Singer P. Wang Y. Boison D. ( 2014 ). Regulation of fear responses by striatal and extrastriatal adenosine A2A receptors in forebrain. Biol. Psychiatry 75 855 – 863 . 10.1016/j.biopsych.2013.05.003 23820821 PMC4058554

Wei Q. Costanzi S. Liu Q. Z. Gao Z. G. Jacobson K. A. ( 2011 ). Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells. Biochem. Pharmacol. 82 418 – 425 . 10.1016/j.bcp.2011.05.013 21632028 PMC3140712

Wen J. Wang B. Du C. Xu G. Zhang Z. Li Y. ( 2015 ). A2B adenosine receptor agonist improves erectile function in diabetic rats. Tohoku J. Exp. Med. 237 141 – 148 . 10.1620/tjem.237.141 26447087

Wen J. Xia Y. ( 2012 ). Adenosine signaling: good or bad in erectile function? Arterioscler. Thromb. Vasc. Biol. 32 845 – 850 . 10.1161/ATVBAHA.111.226803 22423035

Wesselius A. Bours M. J. Jørgensen N. R. Wiley J. Gu B. Van Helden S. ( 2013 ). Non-synonymous polymorphisms in the P2RX4 are related to bone mineral density and osteoporosis risk in a cohort of Dutch fracture patients. Purinergic Signal. 9 123 – 130 . 10.1007/s11302-012-9337-0 23138503 PMC3568421

Wessels J. A. Kooloos W. M. De Jonge R. De Vries-Bouwstra J. K. Allaart C. F. Linssen A. ( 2006 ). Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 54 2830 – 2839 . 10.1002/art.22032 16947783

Wettstein M. S. Buser L. Hermanns T. Roudnicky F. Eberli D. Baumeister P. ( 2015 ). CD73 predicts favorable prognosis in patients with nonmuscle-invasive urothelial bladder cancer. Dis. Markers 2015 : 785461 10.1155/2015/785461 PMC4620269 26543299

White C. W. Choong Y. T. Short J. L. Exintaris B. Malone D. T. Allen A. M. ( 2013 ). Male contraception via simultaneous knockout of α1A-adrenoceptors and P2X1-purinoceptors in mice. Proc. Natl. Acad. Sci U.S.A. 110 20825 – 20830 . 10.1073/pnas.1318624110 24297884 PMC3870707

White N. Butler P. E. M. Burnstock G. ( 2005 ). Human melanomas express functional P2X7 receptors. Cell Tissue Res. 321 411 – 418 . 10.1007/s00441-005-1149-x 15991050

White N. Knight G. E. Butler P. E. M. Burnstock G. ( 2009 ). An in vivo model of melanoma: treatment with ATP. Purinergic Signal. 5 327 – 333 . 10.1007/s11302-009-9156-0 19347609 PMC2717314

Wiesler B. Zech A. Idzko M. ( 2016 ). The purinergic receptor P2X4 mediates acute airway inflammation by regulating dendritic cell function. Am. J. Respir. Crit. Care Med. 193 A7543 .

Wille A. Amort T. Singewald N. Sartori S. B. Lusser A. ( 2016 ). Dysregulation of select ATP-dependent chromatin remodeling factors in high trait anxiety. Behav. Brain Res. 311 141 – 146 . 10.1016/j.bbr.2016.05.036 27208790

Winerdal M. Winerdal M. E. Wang Y. Q. Fredholm B. B. Winqvist O. Ådén U. ( 2016 ). Adenosine A1 receptors contribute to immune regulation after neonatal hypoxic ischemic brain injury. Purinergic Signal. 12 89 – 101 . 10.1007/s11302-015-9482-3 26608888 PMC4749537

Wirsdörfer F. De Leve S. Cappuccini F. Eldh T. Meyer A. V. Gau E. ( 2016 ). Extracellular adenosine production by ecto-5′-nucleotidase (CD73) enhances radiation-induced lung fibrosis. Cancer Res. 76 3045 – 3056 . 10.1158/0008-5472.CAN-15-2310 26921334 PMC4960984

Wojcik M. Zieleniak A. Mac-Marcjanek K. Wozniak L. A. Cypryk K. ( 2014 ). The elevated gene expression level of the A2B adenosine receptor is associated with hyperglycemia in women with gestational diabetes mellitus. Diabetes Metab. Res. Rev. 30 42 – 53 . 10.1002/dmrr.2446 23956030

Woods L. T. Ajit D. Camden J. M. Erb L. Weisman G. A. ( 2016 ). Purinergic receptors as potential therapeutic targets in Alzheimer’s disease. Neuropharmacology 104 169 – 179 . 10.1016/j.neuropharm.2015.10.031 26519903 PMC4848184

Wright A. Mahaut-Smith M. Symon F. Sylvius N. Ran S. Bafadhel M. ( 2016 ). Impaired P2X1 receptor-mediated adhesion in eosinophils from asthmatic patients. J. Immunol. 196 4877 – 4884 . 10.4049/jimmunol.1501585 27183585

Wright S. R. Zanos P. Georgiou P. Yoo J. H. Ledent C. Hourani S. M. ( 2016 ). A critical role of striatal A2A R-mGlu R interactions in modulating the psychomotor and drug-seeking effects of methamphetamine. Addict. Biol. 21 811 – 825 . 10.1111/adb.12259 25975203

Wu B. Zhang C. Zou L. Ma Y. Huang K. Lv Q. ( 2016 ). LncRNA uc. 48 + siRNA improved diabetic sympathetic neuropathy in type 2 diabetic rats mediated by P2X7 receptor in SCG. Auton. Neurosci. 197 14 – 18 . 10.1016/j.autneu.2016.04.001 27118262

Wu H. Nie Y. Xiong H. Liu S. Li G. Huang A. ( 2015 ). P2X7 receptor expression in peripheral blood monocytes is correlated with plasma C-reactive protein and cytokine levels in patients with type 2 diabetes mellitus: a preliminary report. Inflammation 38 2076 – 2081 . 10.1007/s10753-015-0189-y 26021292

Wu J. X. Xu M. Y. Miao X. R. Lu Z. J. Yuan X. M. Li X. Q. ( 2012 ). Functional up-regulation of P2X3 receptors in dorsal root ganglion in a rat model of bone cancer pain. Eur. J. Pain 16 1378 – 1388 . 10.1002/j.1532-2149.2012.00149.x 22528605

Wu M. Sahbaie P. Zheng M. Lobato R. Boison D. Clark J. D. ( 2013 ). Opiate-induced changes in brain adenosine levels and narcotic drug responses. Neuroscience 228 235 – 242 . 10.1016/j.neuroscience.2012.10.031 23098802 PMC3525713

Wu W. He Y. Feng X. Ye S. Wang H. Tan W. ( 2017 ). MicroRNA-206 is involved in the pathogenesis of ulcerative colitis via regulation of adenosine A3 receptor. Oncotarget 8 705 – 721 . 10.18632/oncotarget.13525 27893428 PMC5352191

Xia H. Zhang D. Yang S. Wang Y. Xu L. Wu J. ( 2014 ). Role of ATP-sensitive potassium channels in modulating nociception in rat model of bone cancer pain. Brain Res. 1554 29 – 35 . 10.1016/j.brainres.2014.01.032 24480471

Xia J. Yu X. Tang L. Li G. He T. ( 2015 ). P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway. Oncol. Rep. 34 103 – 110 . 10.3892/or.2015.3979 25976617

Xiang H. J. Liu Z. C. Wang D. S. Chen Y. Yang Y. L. Dou K. F. ( 2006 ). Adenosine A2b receptor is highly expressed in human hepatocellular carcinoma. Hepatol. Res. 36 56 – 60 . 10.1016/j.hepres.2006.06.008 16844405

Xiao F. Waldrop S. L. Khimji A. K. Kilic G. ( 2012 ). Pannexin1 contributes to pathophysiological ATP release in lipoapoptosis induced by saturated free fatty acids in liver cells. Am. J. Physiol. Cell Physiol. 303 C1034 – C1044 . 10.1152/ajpcell.00175.2012 22972801 PMC3492830

Xiao H. Si L. Y. Liu W. Li N. Meng G. Yang N. ( 2013 ). The effects of adenosine A2A receptor knockout on renal interstitial fibrosis in a mouse model of unilateral ureteral obstruction. Acta Histochem. 115 315 – 319 . 10.1016/j.acthis.2012.09.002 23026406

Xie R. Xu J. Wen G. Jin H. Liu X. Yang Y. ( 2014 ). The P2Y2 nucleotide receptor mediates the proliferation and migration of human hepatocellular carcinoma cells induced by ATP. J. Biol. Chem. 289 19137 – 19149 . 10.1074/jbc.M113.540047 24847054 PMC4081950

Xie Y. Williams C. D. Mcgill M. R. Lebofsky M. Ramachandran A. Jaeschke H. ( 2013 ). Purinergic receptor antagonist A438079 protects against acetaminophen-induced liver injury by inhibiting P450 isoenzymes, not by inflammasome activation. Toxicol. Sci. 131 325 – 335 . 10.1093/toxsci/kfs283 22986947 PMC3537131

Xu J. Chu K. L. Brederson J. D. Jarvis M. F. Mcgaraughty S. ( 2012 ). Spontaneous firing and evoked responses of spinal nociceptive neurons are attenuated by blockade of P2X3 and P2X2/3 receptors in inflamed rats. J. Neurosci. Res. 90 1597 – 1606 . 10.1002/jnr.23042 22422599

Xu P. Xu Y. Hu B. Wang J. Pan R. Murugan M. ( 2015 ). Extracellular ATP enhances radiation-induced brain injury through microglial activation and paracrine signaling via P2X7 receptor. Brain Behav. Immun. 50 87 – 100 . 10.1016/j.bbi.2015.06.020 26122280

Xu X. Zheng S. Xiong Y. Wang X. Qin W. Zhang H. ( 2017 ). Adenosine effectively restores endotoxin-induced inhibition of human neutrophil chemotaxis via A1 receptor-p38 pathway. Inflamm. Res. 66 353 – 364 . 10.1007/s00011-016-1021-3 28074216

Yamada K. Kobayashi M. Kanda T. ( 2014 ). Involvement of adenosine A2A receptors in depression and anxiety. Int. Rev. Neurobiol. 119 373 – 393 . 10.1016/B978-0-12-801022-8.00015-5 25175973

Yamauchi T. Kadowaki T. ( 2013 ). Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab. 17 185 – 196 . 10.1016/j.cmet.2013.01.001 23352188

Yan D. Zhu Y. Walsh T. Xie D. Yuan H. Sirmaci A. ( 2013 ). Mutation of the ATP-gated P2X2 receptor leads to progressive hearing loss and increased susceptibility to noise. Proc. Natl. Acad. Sci. U.S.A. 110 2228 – 2233 . 10.1073/pnas.1222285110 23345450 PMC3568371

Yan H. Zhang E. Feng C. Zhao X. ( 2016 ). Role of A3 adenosine receptor in diabetic neuropathy. J. Neurosci. Res. 94 936 – 946 . 10.1002/jnr.23774 27319979

Yan S. Du F. Wu L. Zhang Z. Zhong C. Yu Q. ( 2016 ). F1F0 ATP synthase-cyclophilin D interaction contributes to diabetes-induced synaptic dysfunction and cognitive decline. Diabetes Metab. Res. Rev. 65 3482 – 3494 . 10.2337/db16-0556 PMC5079631 27554467

Yan Y. Bai J. Zhou X. Tang J. Jiang C. Tolbert E. ( 2015 ). P2X7 receptor inhibition protects against ischemic acute kidney injury in mice. Am. J. Physiol. Cell Physiol. 308 C463 – C472 . 10.1152/ajpcell.00245.2014 25588875 PMC4360025

Yang C. Xu H. Cai L. Du X. Jiang Y. Zhang Y. ( 2016 ). Donor pretreatment with adenosine monophosphate-activated protein kinase activator protects cardiac grafts from cold ischaemia/reperfusion injury. Eur. J Cardiothorac. Surg. 49 1354 – 1360 . 10.1093/ejcts/ezv413 26609046

Yang Z. Li L. Zheng J. Ma H. Tian S. Li J. ( 2016 ). Identification of a new series of potent adenosine A2A receptor antagonists based on 4-amino-5-carbonitrile pyrimidine template for the treatment of Parkinson’s disease. ACS Chem. Neurosci. 7 1575 – 1584 . 10.1021/acschemneuro.6b00218 27569066

Yang P. Wang Z. Zhan Y. Wang T. Zhou M. Xia L. ( 2013 ). Endogenous A1 adenosine receptor protects mice from acute ethanol-induced hepatotoxicity. Toxicology 309 100 – 106 . 10.1016/j.tox.2013.05.003 23692951

Yap S. C. Lee H. T. ( 2012 ). Adenosine and protection from acute kidney injury. Curr Opin. Nephrol. Hypertens 21 24 – 32 . 10.1097/MNH.0b013e32834d2ec9 22080856 PMC3278996

Yegutkin G. G. Guerrero-Toro C. Kilinc E. Koroleva K. Ishchenko Y. Abushik P. ( 2016 ). Nucleotide homeostasis and purinergic nociceptive signaling in rat meninges in migraine-like conditions. Purinergic Signal. 12 561 – 574 . 10.1007/s11302-016-9521-8 27369815 PMC5023636

Yegutkin G. G. Marttila-Ichihara F. Karikoski M. Niemela J. Laurila J. P. Elima K. ( 2011 ). Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur. J. Immunol. 41 1231 – 1241 . 10.1002/eji.201041292 21469131

Yelovitch S. Barr H. M. Camden J. Weisman G. A. Shai E. Varon D. ( 2012 ). Identification of a promising drug candidate for the treatment of type 2 diabetes based on a P2Y1 receptor agonist. J. Med. Chem. 55 7623 – 7635 . 10.1021/jm3006355 22873688 PMC4354947

Yetgin T. Uitterdijk A. Te Lintel Hekkert M. Merkus D. Krabbendam-Peters I. Van Beusekom H. M. ( 2015 ). Limitation of infarct size and no-reflow by intracoronary adenosine depends critically on dose and duration. JACC Cardiovasc. Interv. 8 1990 – 1999 . 10.1016/j.jcin.2015.08.033 26738671

Yip L. Taylor C. Whiting C. C. Fathman C. G. ( 2013 ). Diminished adenosine A1 receptor expression in pancreatic α-cells may contribute to the pathology of type 1 diabetes. Diabetes Metab. Res. Rev. 62 4208 – 4219 . 10.2337/db13-0614 PMC3837064 24264405

Yoneyama Y. Sawa R. Suzuki S. Shin S. Power G. G. Araki T. ( 1996 ). The relationship between uterine artery Doppler velocimetry and umbilical venous adenosine levels in pregnancies complicated by preeclampsia. Am. J. Obstet. Gynecol. 174 267 – 271 . 10.1016/S0002-9378(96)70406-4 8572019

Yoneyama Y. Suzuki S. Sawa R. Araki T. ( 2004 ). Plasma adenosine concentrations increase in women with hyperemesis gravidarum. Clin. Chim. Acta 342 99 – 103 . 10.1016/j.cccn.2003.12.004 15026270

Yoshida K. Ito M. Matsuoka I. ( 2015 ). P2X7 receptor antagonist activity of the anti-allergic agent oxatomide. Eur. J. Pharmacol. 767 41 – 51 . 10.1016/j.ejphar.2015.10.002 26463039

Young C. N. J. Sinadinos A. Gorecki D. C. ( 2013 ). P2X receptor signaling in skeletal muscle health and disease. Wiley Interdiscip. Rev. Membr. Transp. Signal. 2 265 – 274 . 10.1042/BJ20141551

Yu Q. Guo Z. Liu X. Ouyang Q. He C. Burnstock G. ( 2013 ). Block of P2X7 receptors could partly reverse the delayed neuronal death in area CA1 of the hippocampus after transient global cerebral ischemia. Purinergic Signal. 9 663 – 675 . 10.1007/s11302-013-9379-y 23877788 PMC3889395

Yu W. Sun X. Robson S. C. Hill W. G. ( 2013 ). Extracellular UDP enhances P2X-mediated bladder smooth muscle contractility via P2Y6 activation of the phospholipase C/inositol trisphosphate pathway. FASEB J. 27 1895 – 1903 . 10.1096/fj.12-219006 23362118 PMC3633826

Yu Y. ( 2015 ). Nucleotide modulates odor response through activation of purinergic receptor in olfactory sensory neuron. Biochem. Biophys. Res. Commun. 463 1006 – 1011 . 10.1016/j.bbrc.2015.06.050 26072377

Yu Y. Zhang C. ( 2014 ). Purinergic signaling negatively regulates activity of an olfactory receptor in an odorant-dependent manner. Neuroscience 275 89 – 101 . 10.1016/j.neuroscience.2014.05.055 24928349

Yu Y. C. Sohma Y. Hwang T. C. ( 2016 ). On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator. J. Physiol. 594 3227 – 3244 . 10.1113/JP271723 26846474 PMC4908022

Yuryeva K. Saltykova I. Ogorodova L. Kirillova N. Kulikov E. Korotkaya E. ( 2015 ). Expression of adenosine receptors in monocytes from patients with bronchial asthma. Biochem. Biophys. Res. Commun. 464 1314 – 1320 . 10.1016/j.bbrc.2015.07.141 26232643 PMC4558207

Zafrah H. A. Alotaibi M. F. ( 2017 ). The effect of extracellular ATP on rat uterine contraction from different gestational stages and its possible mechanisms of action. J. Basic Clin. Physiol. Pharmacol. 28 209 – 217 . 10.1515/jbcpp-2016-0118 28358713

Zakeri Z. Izadi S. Niazi A. Bari Z. Zendeboodi S. Shakiba M. ( 2012 ). Comparison of adenosine deaminase levels in serum and synovial fluid between patients with rheumatoid arthritis and osteoarthritis. Int. J. Clin. Exp. Med. 5 195 – 200 . 22567181 PMC3342715

Zanin R. F. Da Silva G. L. Erig T. Sperotto N. D. Leite C. E. Coutinho-Silva R. ( 2015 ). Decrease of serum adenine nucleotide hydrolysis in an irritant contact dermatitis mice model: potential P2X7R involvement. Mol. Cell. Biochem. 404 221 – 228 . 10.1007/s11010-015-2381-7 25772484

Zarjou A. Agarwal A. ( 2011 ). ATP as a death factor: purinergic signaling in renal epithelial-fibroblast cross talk. Am. J. Physiol. Renal Physiol. 300 F60 – F61 . 10.1152/ajprenal.00593.2010 20962119

Zempo H. Sugita Y. Ogawa M. Watanabe R. Suzuki J. Isobe M. ( 2015 ). A P2X7 receptor antagonist attenuates experimental autoimmune myocarditis via suppressed myocardial CD4+ T and macrophage infiltration and NADPH oxidase 2/4 expression in mice. Heart Vessels 30 527 – 533 . 10.1007/s00380-014-0527-2 24879505

Zhang B. Cheng B. Li F. S. Ding J. H. Feng Y. Y. Zhuo G. Z. ( 2015a ). High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma. Tumour. Biol. 36 9411 – 9419 . 10.1007/s13277-015-3683-9 26113408

Zhang C. Gao L. Yi Y. Han H. Cheng H. Ye X. ( 2016 ). Adenosine triphosphate regresses endometrial explants in a rat model of endometriosis. Reprod. Sci. 23 924 – 930 . 10.1177/1933719115625847 26887426

Zhang K. Liu J. You X. Kong P. Song Y. Cao L. ( 2016 ). P2X7 as a new target for chrysophanol to treat lipopolysaccharide-induced depression in mice. Neurosci. Lett. 613 60 – 65 . 10.1016/j.neulet.2015.12.043 26724370

Zhang X. Qin J. Zou J. Lv Z. Tan B. Shi J. ( 2016 ). Extracellular ADP facilitates monocyte recruitment in bacterial infection via ERK signaling. Cell Mol. Immunol. 10.1038/cmi.2016.56 [Epub ahead of print] . PMC5827171 27867196

Zhang Y. Guo Q. Li X. Gao J. Liu Y. Yang J. ( 2015b ). P2Y purinergic receptor-regulated insulin secretion is mediated by a cAMP/Epac/Kv channel pathway. Biochem. Biophys. Res. Commun. 460 850 – 856 . 10.1016/j.bbrc.2015.03.121 25839655

Zhang Y. Peti-Peterdi J. Müller C. E. Carlson N. G. Baqi Y. Strasburg D. L. ( 2015c ). P2Y12 receptor localizes in the renal collecting duct and its blockade augments arginine vasopressin action and alleviates nephrogenic diabetes insipidus. J. Am. Soc. Nephrol. 26 2978 – 2987 . 10.1681/ASN.2014010118 25855780 PMC4657822

Zhang Y. Yuan F. Cao X. Zhai Z. Ganghuang Du X. ( 2014 ). P2X7 receptor blockade protects against cisplatin-induced nephrotoxicity in mice by decreasing the activities of inflammasome components, oxidative stress and caspase-3. Toxicol. Appl. Pharmacol. 281 1 – 10 . 10.1016/j.taap.2014.09.016 25308879

Zhao H. Zhang X. Dai Z. Feng Y. Li Q. Zhang J. H. ( 2016 ). P2X7 receptor suppression preserves blood-brain barrier through inhibiting RhoA activation after experimental intracerebral hemorrhage in rats. Sci. Rep. 6 : 23286 10.1038/srep23286 PMC4793194 26980524

Zhao J. Wang H. Dai C. Wang H. Zhang H. Huang Y. ( 2013 ). P2X7 blockade attenuates lupus nephritis by inhibiting NLRP3/ASC/caspase-1 activation. Arthritis Rheum. 65 3176 – 3185 . 10.1002/art.38174 24022661 PMC4038356

Zhao R. Liang D. Sun D. ( 2016 ). Blockade of extracellular ATP effect by oxidized ATP effectively mitigated induced mouse experimental autoimmune uveitis (EAU). PLOS ONE 11 : e0155953 10.1371/journal.pone.0155953 PMC4873015 27196432

Zheng B. Lai R. Li J. Zuo Z. ( 2017 ). Critical role of P2X7 receptors in the neuroinflammation and cognitive dysfunction after surgery. Brain Behav. Immun. 61 365 – 374 . 10.1016/j.bbi.2017.01.005 28089560 PMC5316360

Zheng X. Li T. Chen Y. Pan H. Zhang Z. Dai Y. ( 2017 ). Genetic polymorphisms of the P2X7 gene associated with susceptibility to and prognosis of pulmonary tuberculosis. Infect. Genet. Evol. 53 24 – 29 . 10.1016/j.meegid.2017.05.003 28495473

Zhong H. Yang L. Belardinelli L. Zeng D. ( 2007 ). Pro-fibrotic roles of the A2B adenosine receptor in human primary hepatic stellate cells. J. Hepatol. 46 S135 – S135 . 10.1016/S0168-8278(07)61943-6

Zhong Y. Yang Z. Huang W. C. Luo X. ( 2013 ). Adenosine, adenosine receptors and glaucoma: an updated overview. Biochim. Biophys. Acta 1830 2882 – 2890 . 10.1016/j.bbagen.2013.01.005 23328492

Zhou Q. Xu C. Cheng X. Liu Y. Yue M. Hu M. ( 2016 ). Platelets promote cartilage repair and chondrocyte proliferation via ADP in a rodent model of osteoarthritis. Platelets 27 212 – 222 . 10.3109/09537104.2015.1075493 26325015

Zhou X. Ma L. M. Xiong Y. Huang H. Yuan J. X. Li R. H. ( 2016 ). Upregulated P2X3 receptor expression in patients with intractable temporal lobe epilepsy and in a rat model of epilepsy. Neurochem. Res. 41 1263 – 1273 . 10.1007/s11064-015-1820-x 26738991

Zhu J. Zeng Y. Li W. Qin H. Lei Z. Shen D. ( 2017 ). CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer. Mol. Cancer 16 : 34 10.1186/s12943-017-0591-1 PMC5291990 28158983

Zhu Y. Zhao H. B. ( 2012 ). ATP activates P2X receptors to mediate gap junctional coupling in the cochlea. Biochem. Biophys. Res. Commun. 426 528 – 532 . 10.1016/j.bbrc.2012.08.119 22982314 PMC3471361

Zhu Y. J. Lu T. J. ( 2010 ). A multi-scale view of skin thermal pain: from nociception to pain sensation. Philos. Trans. A Math. Phys. Eng. Sci. 368 521 – 559 . 10.1098/rsta.2009.0234 20047938

Zierhut M. Dyckhoff S. Masouris I. Klein M. Hammerschmidt S. Pfister H. W. ( 2017 ). Role of purinergic signaling in experimental pneumococcal meningitis. Sci. Rep. 7 : 44625 10.1038/srep44625 PMC5353597 28300164

Ziganshin A. U. Vafina Z. R. Fatkullin I. F. ( 2008 ). Contrasting effects of P2 receptor agonists on spontaneous contractility of human fallopian tubes with and without acute inflammation. Pharmacol. Res. 57 56 – 59 . 10.1016/j.phrs.2007.11.004 18155558